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Abstract  
Murine small intestinal CD103+ dendritic cells (DCs) produce retinoic acid (RA) through 
retinaldehyde dehydrogenase (RALDH) activity, thereby inducing ‘gut-homing’ α4β7 and 
CCR9 on T cells they activate, enhancing TGF-β-mediated induction of Foxp3+ 
regulatory T cells and suppressing induction of pro-inflammatory TH17 cells. RALDH 
activity of CD103+ DCs is reduced in mouse models of inflammatory bowel disease 
(IBD) but the role of RALDH activity in human intestinal DCs in the pathogenesis of IBD 
is undefined. This project aimed to determine the influence of inflammation on RALDH 
activity of antigen presenting cell (APC) subsets including CD103+ DCs within human 
distal intestinal mucosa. RALDH activity was identified by Aldefluor assay in intestinal 
DCs (CD103+ and CD103- subsets) alongside ALDH1A2 expression in healthy controls. 
In contrast with mouse models, RALDH activity was not reduced in CD103+ DCs from 
IBD patients. An increased frequency of CD14+ macrophages (MФ) of IBD patients 
displayed ALDH1A1-associated RALDH activity compared with healthy controls. Blood 
CD14+ monocytes, putative precursors of intestinal CD14+ MФ, of healthy controls and 
IBD patients displayed ALDH1A1-associated RALDH activity indicating RALDH is 
systemically acquired by monocytes and upregulated within the mucosa of IBD 
patients, or alternatively that RALDH+ monocytes are selectively recruited in IBD. In 
vitro, inhibition of RA receptor-α signalling blocked GM-CSF-mediated differentiation of 
TNFα-producing pro-inflammatory RALDH+ CD14+ MФ from monocytes, consistent with 
enhanced RALDH activity of intestinal CD14+ MФ in IBD supporting a pro-inflammatory 
phenotype. Soluble intestinal mediators including prostaglandin E2 suppressed RALDH 
activity of MoDCs in vitro, whilst mediators from inflamed IBD mucosa conditioned 
MoDCs to imprint enhanced levels of α4β7 expression on naive CD4+ T cells 
independent of RALDH activity. This study provides the first systematic analysis of 
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RALDH activity in human intestinal APCs and indicates important distinctions between 
mouse models and human IBD.  
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Chapter 1:  Introduction 
1:1 Overview 
The intestine must perform two basic functions critical for survival: release and uptake 
of nutrients from ingested material and the immunological defence of a large internal 
surface area. This second component is complicated by the fact that the intestine is 
colonized by a complex and abundant microbiota comprising bacteria, viruses, fungi 
and parasites. In general, the intestinal microbiota benefit the host e.g. through the 
break down and release of nutrients from otherwise non-digestible food molecules, and 
the restriction space for the access of pathogens (Backhed et al., 2005, Abraham and 
Medzhitov, 2011). Overall therefore, the intestinal immune system must exist in a 
balanced state between pro-inflammatory activity induced by pathogens entering the 
intestinal mucosa, and low or non-responsiveness to the microbiota and particles 
derived from the digestion of food. This careful balance in activities is disturbed in 
inflammatory bowel disease (IBD), where an inappropriate immune response is 
believed to propagate against microbiota-derived antigen in genetically susceptible 
individuals, resulting in a state of chronic inflammation, tissue damage and functional 
failure of the intestine (reviewed by Baumgart and Carding, 2007). The pathogenesis of 
IBD however remains incompletely understood. 
The questions central to this thesis relate to the role of a specific group of immune 
cells, the mononuclear phagocytes (macrophages and dendritic cells), in the 
pathogenesis of IBD in humans. In particular, this work seeks to determine the 
contribution of the vitamin A metabolite retinoic acid (RA) in the activity of these cells in 
the healthy and inflamed human intestine, which is involved in the intestinal immune 
system of mice through modulation of the intestinal adaptive response (see section 
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1:8), induction of lymphocyte gut-homing (see section 1:10) and the induction of 
secretory IgA production by B cells (see section 1:8.6).  
This introduction will provide a broad overview of the known activities of various 
dendritic cell and macrophage populations in the murine and human intestine and how 
these functions are influenced by RA. Attention will then turn to understanding 
contribution of these subsets to the pathogenesis of IBD in humans and experimental 
models of intestinal inflammation in mice. Finally, this introduction will finish with a 
discussion of the principal aims and hypothesis of this thesis. 
1:2 Anatomy of the intestine 
1:2.1  Small intestine 
The small and large intestine are distinguished by function and morphology. The small 
intestine is the principal site of food digestion and absorption. Beginning as the 
duodenum in direct contact with the pyloric sphincter, it is further sequentially divided 
into the jejunum and ileum, of which the most distal part is the terminal ileum (TI). The 
exterior surface of the small intestine is the serosa (visceral peritoneum), beneath 
which is the subserosa and then a sequentially longitudinal and circular muscle layer 
(muscularis externa). This is followed by the loose, moderately vascular connective 
tissue of the submucosa which contains blood vessels, lymphatics and nerves. A thin 
layer of longitudinal and circular smooth muscle fibres (muscularis mucosae) separates 
the submucosa from the mucosa, comprising the loose connective tissue of the lamina 
propria (LP) and a single layer of epithelial cells (reviewed by Moore et al., 2006, Day 
and Morson, 2003). The small intestinal mucosa is characterised by the presence of 
villi, finger-like structures that project into the intestinal lumen and significantly increase 
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the absorptive surface area (see Figure 1.1). There are between 10 and 40 villi per 
mm2 of mucosa, separated by crypts which extend down to the muscularis mucosae. 
The epithelium is continuous between crypt and villus, and is continually replenished by 
stem and committed progenitor cells towards the crypt base reviewed by Day and 
Morson, 2003).  
 
1:2.2  Large intestine 
The large intestine is primarily involved in absorption of water and electrolytes from 
indigestible material passed from the small intestine. It begins at the caecum which 
connects directly with the TI, and is also linked to the closed tubular structure of the 
appendix. From the caecum, the large intestine is divided into ascending, transverse, 
Figure 1.1: Structure of intestinal mucosa. Mucosa contains the surface epithelium and 
underlying connective tissue of the lamina propria. Small intestinal mucosa is arranged into 
finger-like villi projections separated by crypts containing stem cells which continually 
replenish the epithelium. Large intestinal mucosa is devoid of villi but contains crypts. The 
mucosa is separated from the submucosa by a thin layer of smooth muscle cells, the 
muscularis mucosae. Beneath the submucosa is the muscularis externa and serosa (not 
shown). 
Villus
Small intestine Large intestine
Crypt
Epithelium
Lamina propria
Submucosa
Muscularis mucosae
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descending and sigmoid colon, before ending at the rectum and anal canal. The 
arrangement of tissue layers is similar to the small intestine, though the longitudinal 
muscularis externa layer is narrow and shorter than the length of the large intestine, 
causing it to bunch into distinctive haustral clefts. Whilst the mucosa of the large 
intestine is devoid of villi, the epithelium is continuously replenished by crypt stem and 
committed progenitor cells as in the small intestine (reviewed by Day and Morson, 
2003). 
1:2.3  Gut-associated lymphoid tissue 
The gut associated lymphoid tissue (GALT) includes isolated lymphoid follicles (ILFs) 
which are regions of the duodenal and jejunal mucosa and/or submucosa 0.6 to 3.0 
mm in size (in humans) containing a high concentration of lymphocytes arranged into B 
cell follicles with T cell zones in the interfollicular areas, as well as macrophages (MФ) 
and dendritic cells (DCs).  ILFs aggregate in the distal ileum to form Peyer’s patches 
(PPs) up to 12 x 20 mm in size in humans (reviewed by Day and Morson, 2003). The 
follicle associated epithelium (FAE) overlying ILFs and PPs contains specialized 
epithelial microfold (M) cells which lack the brush border and mucus coverage of 
conventional enterocytes (reviewed by Mowat, 2003). M cells are highly specialized for 
phagocytosis and transcytosis of commensal and pathogenic bacteria as well as 
particulate antigen and macromolecules (reviewed by Mabbott et al., 2013). DCs in the 
extracellular space immediately below M cells collect antigen from these cells and 
present it directly to naive B cells inducing the formation of IgA+ plasma cells 
(Macpherson and Uhr, 2004) or present the antigen in a processed form to local T cell 
populations (discussed further in section 1:8). As discussed in section 1:4.4, secretory 
IgA provides an important component of intestinal barrier function. 
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1:2.4  Lymphoid tissue draining intestinal mucosa  
Extracellular fluid from the intestinal LP and GALT is collected by lymphatic vessels 
which then drain to a network of lymph nodes. In the human, jejunal and ileal 
lymphatics sequentially drain into juxta-intestinal lymph nodes close to the intestinal 
wall, then onto the mesenteric lymph nodes (MLNs), where the mesentery is a fan-
shaped fold of the peritoneum that holds the jejunum and ileum to the posterior 
abdominal wall (reviewed by Moore et al., 2006). MLNs then drain into superior MLNs 
and then into blood circulation via the thoracic duct. The section between the TI and up 
the ascending colon drains into ileocolic lymph nodes, whilst the transverse colon 
drains into middle colic lymph nodes. Both ileo- and middle colic lymph nodes drain into 
the superior MLN. The descending and sigmoid colon instead drain into the 
intermediate colic lymph nodes and then onto the inferior MLNs. The rectum and anal 
canal drain into the iliac nodes, which also drain the pelvic area. Throughout the colon 
are epicolic (attached to the intestinal wall) and pericolic (close to the intestinal wall) 
which first collect lymph before passing it on to the respective lymph nodes described 
above (reviewed by Moore et al., 2006).  
1:3 Nature of intestinal antigen 
The intestine harbours a complex microbial community of bacteria, fungi, parasites and 
viruses collectively termed the ‘microbiota’. This constitutes more than 100 trillion 
microorganisms in the human gastrointestinal tract, of which the majority are bacteria 
and are found in greatest density in the large intestine (reviewed by Kamada et al., 
2013). Such bacteria exist in a mutually beneficial symbiotic relationship with the host 
whereby bacteria are provided with an anaerobic environment and access to large 
quantities of dietary polysaccharides such as plant-derived pectin, cellulose and 
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resistant starches as a source of nutrients. In turn, bacteria degrade these otherwise 
indigestible products releasing nutrients for the benefit of the host (reviewed by 
Backhed et al., 2005). Symbiotic bacteria also out-compete many pathogenic bacteria 
for nutrients within the specialized environment of the intestine, as well as limiting the 
physical space available for colonisation by pathogens (reviewed by Hooper and 
Macpherson, 2010). The intestinal bacterial population is highly diverse at a species 
level and varies widely between individuals. The principal phyla however are the gram 
positive Firmicutes and gram negative Bacteroidetes (reviewed by Hooper and 
Macpherson, 2010). 
A wide range of immune cells as well as non-haematopoietic cells including epithelial 
cells express both cell surface and intracellular pathogen-associated molecular pattern 
(PAMP) receptors such as toll-like receptors (TLRs) and nucleotide oligomerization 
domain (NOD) proteins. Interaction of these receptors with their microbial ligand 
triggers dramatic changes in cell behaviour including the production of a range of pro-
inflammatory cytokines aimed at responding to microbial presence within the tissue 
(reviewed by (Akira et al., 2006). A key component of intestinal homeostasis is 
therefore the physical separation of the intestinal microbiota from the interior of the 
mucosa, so as to restrain uncontrolled inflammatory responses and thus prevent 
immunopathology. 
1:4 Restriction of access of lumenal antigen to the intestinal 
mucosa  
1:4.1  Mucus 
The lumenal epithelial surface of the murine large intestine is covered by two distinct 
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mucus layers. The inner layer is adherent to the epithelium, densely arranged and 
devoid of bacteria, whilst the outer layer is more loosely arranged and is penetrated by 
bacteria (Johansson et al., 2008). The main structural component of intestinal mucus is 
the heavily glycosylated protein MUC2. Produced by goblet cells, MUC2 forms a gel-
like polymeric net structure through disulphide bonds (reviewed in Johansson et al., 
2011). Murine small intestinal epithelium is covered by a single mucus layer which is 
penetrable by bacteria-sized particles (Ermund et al., 2013). The significance of the 
contrasting nature of mucus in the small and large intestine is not fully understood, but 
may reflect the more absorptive function of the small intestine and the need to protect 
the mucosa from the large bacterial burden of the large intestine. Antimicrobial peptides 
including the defensins HBD-1 and HBD-3, the cathelicidin LL37 and lysozyme are 
present within human rectal mucus, potentially further restricting bacterial 
encroachment (Antoni et al., 2013). Muc2-/- mice display bacterial encroachment 
directly onto the large intestinal epithelium (Johansson et al., 2008), associating with 
the onset of colitic symptoms including diarrhoea, rectal prolapse as well as severe 
growth retardation (Van der Sluis et al., 2006).  
It has been proposed that the pathogenic bacteria Campylobacter which causes 
diarrheal disease in humans is able to penetrate the viscous mucus layer and reach the 
epithelium due to high motility conferred by flagella (reviewed by Guerry, 2007).  
1:4.2  Epithelial barrier 
Beneath the mucus layer, the intestinal epithelium acts as a physical barrier between 
lumenal antigen and the interior of the mucosa. It is formed by a single and continuous 
layer of cells separated from the LP by a basement membrane. Neighbouring cells are 
held in close association through tight junction proteins such as zonula occludens 1 
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(ZO-1) and claudins which block the passage of from the apical to basal side of the 
epithelium (reviewed by Abreu, 2010). Four distinct cell types are found within the 
epithelium. Enterocytes are the most abundant, columnar in shape with a brush border 
lined with microvilli that assists in their absorptive function. Goblet cells produce large 
quantities of mucins which form the mucus layer as described in section 1:4.1 
(reviewed by Day and Morson, 2003). Paneth cells produce most of the anti-microbial 
peptides in the small intestine, including α-defensins, whilst most epithelial cells 
produce β-defensins (reviewed by Hooper and Macpherson, 2010). Enteroendocrine 
cells make up approximately 1 % of epithelial cells and produce a wide range of 
gastrointestinal hormones (Rehfeld, 1998). All four cell types originate from stem cells 
located within each crypt base. These cells asymmetrically divide and generate 
committed progenitor cells which push the cells above up the crypt wall. These 
progenitors then terminally differentiate before reaching the exposed surface 
epithelium. The continual upward motion of cells replenishes those sloughed off 
following the transit of lumenal material (reviewed by Humphries and Wright, 2008). 
1:4.3  Antimicrobial peptides 
As discussed, the intestinal epithelium also generates a range of antimicrobial peptides 
including defensins, cathelicidins, and C-type lectins which kill bacteria directly through 
enzymatic attack of the bacterial cell wall or inner membrane (reviewed by Hooper and 
Macpherson, 2010). Several of the α-defensins are generated constitutively by the 
murine intestinal epithelium independent of the presence of bacteria (Putsep et al., 
2000). In contrast, the presence of bacteria in the intestine induces production of the 
antibacterial C-type lectin regenerating islet-derived protein 3γ (REG3γ) in the murine 
small intestine (Cash et al., 2006, Brandl et al., 2007, Vaishnava et al., 2008). The vast 
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majority of antimicrobial activity in the murine small intestine is confined to the mucus 
layer as opposed to the intestinal lumen (Meyer-Hoffert et al., 2008). Targeted 
disruption of TLR signalling in murine intestinal epithelial cells through deletion of the 
MyD88 gene (a key signalling molecule in several TLR signalling pathways) leads to 
significantly increased levels of mucus-associated bacteria as well as translocation of 
bacteria to the interior of the mucosa, associated with reduced expression of REG3γ 
and MUC-2 (Frantz et al., 2012). Bacterial stimulation through epithelial TLRs also 
induces the production of factors which protect the intestinal epithelium from injury, 
including IL-6 (Rakoff-Nahoum et al., 2004). TLR2 signalling in epithelial cells helps to 
maintain epithelial integrity in mice during infection with Citrobacter rodentium through 
enhanced expression of the tight junction protein ZO-1 (Gibson et al., 2008). Overall, 
this demonstrates that in addition to acting as a physical barrier, the intestinal 
epithelium is able to sense and respond to bacterial encroachment directly. 
1:4.4  Secretory IgA 
Intestinal barrier function is further supported by secretory IgA (sIgA) produced by 
plasma cells (terminally differentiated B cells) within the LP. Expression of the J chain 
by plasma cells allows the formation of dimeric and larger polymers of IgA and 
facilitates transport of sIgA across the epithelium by polymeric Ig receptor (pIgR)-
mediated transcytosis (reviewed by Macpherson et al., 2008). sIgA in the intestinal 
lumen helps to limit bacterial association with the epithelial surface (Suzuki et al., 
2004). The polymeric nature of sIgA is likely to increase the avidity of antigen binding 
and promote agglutination of intestinal bacteria (reviewed by Macpherson et al., 2008). 
The induction of sIgA is discussed in greater detail in section 1:8.6. The overall features 
of the intestinal barrier are summarised in Figure 1.2. 
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1:5 Intestinal macrophages 
Whilst the combined action of the epithelial barrier and a mucus layer embedded with 
anti-microbial peptides and secretory IgA restricts access of the intestinal microbiota to 
the apical surface of the intestinal epithelium and the interior of the mucosa, the entry of 
microorganisms into the mucosa cannot be prevented entirely. M cells in the epithelium 
Figure 1.2: Barrier function of the epithelium in the large intestine. The inner mucus 
layer adjacent to the epithelium is densely packed and largely devoid of bacteria in the 
steady state. The outer layer is more loosely arranged and contains a large quantity of 
bacteria. Secretory IgA (sIgA) produced by IgA+ plasma cells in the LP is passed through 
epithelial cells by pIgR-mediated transcytosis and agglutinates bacteria, preventing 
encroachment. Antimicrobial peptides including defensins produced by epithelial cells further 
prevent bacterial encroachment into the crypts. 
IgA+ plasma cell
Antimicrobial peptides
Outer mucus layer Inner mucus layer
sIgA
Bacteria
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overlying gut-associated lymphoid (GALT) tissue promote bacterial encroachment 
through diminished mucus coverage and brush border, facilitating direct uptake of 
antigen including live bacteria by transcytosis into the interior of the tissue (reviewed by 
Mowat, 2003). Many bacterial pathogens including Salmonella, Yersinia and Shigella 
sub-species exploit M cells as an entry point into the intestinal mucosa (reviewed by 
Mowat, 2003). Bacteria may also enter the intestinal mucosa through damage to the 
intestinal epithelium. The intestinal immune system needs to rapidly clear bacterial 
presence from within the mucosa in order to prevent damaging chronic inflammatory 
responses. This section will focus on the distinct roles of human and murine 
mononuclear phagocytes in helping to maintain intestinal homeostasis. 
1:5.1  Human intestinal resident macrophages 
The human intestinal mucosa contains a large population of resident macrophages 
(MФ), members of the mononuclear phagocyte group, which efficiently phagocytose 
and kill bacteria including Escherichia coli and Salmonella typhimurium but do so 
without producing pro-inflammatory cytokines such as TNFα, IL-1β or IL-6 (Smythies et 
al., 2005). The majority of human intestinal resident MФ do not produce reactive 
oxygen species (ROS) such as superoxide anion (O2-) and hydrogen peroxide (H2O2), 
indicating that this killing mechanism is independent of ROS (Mahida et al., 1989).  
The low responsiveness of human intestinal MФs to microbial stimulation stems in part 
from lack of expression of a range of microbial ligand receptors including the 
lipopolysaccharide (LPS) co-receptor CD14 (Smythies et al., 2005, Schenk et al., 
2005). The LPS receptor TLR4 is also expressed at low levels by intestinal resident MФ 
when compared with non-intestinal cells such as circulating CD14+ monocytes 
(Smythies et al., 2010). An additional receptor which is expressed at high levels on 
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blood CD14+ monocytes but is very low or absent on human intestinal resident MФ is 
triggering receptor expressed on myeloid cells (TREM)-1 (Schenk et al., 2005). Whilst 
the physiological ligand of this receptor is unknown, stimulation of monocytes with 
TREM-1 agonistic antibodies synergistically enhances production of pro-inflammatory 
cytokines including TNFα and IL-1β in response to bacterial stimulation (Bouchon et al., 
2001).  
TLR3 recognises double stranded (ds)RNA which is an indicator of viral infection 
(Alexopoulou et al., 2001). Despite expressing TLR3, intestinal resident MФ do not 
respond to stimulation with the synthetic dsRNA molecule poly I:C (Smythies et al., 
2010). This indicates that the non-responsiveness of these cells to microbial stimulation 
extends beyond low expression of pattern recognition receptors (PRRs). A key 
downstream signalling consequence of the stimulation of TLRs is activation of the 
transcription factor NF-κB. In the steady state, NF- κB is retained in the cytosol due to 
an association with the protein IκBα. Signalling through TLRs leads to phosphorylation 
and degradation of IκBα, freeing NF-κB to translocate into the nucleus where it can 
direct the transcription of pro-inflammatory cytokines including TNFα (reviewed by 
Baldwin, 1996). The low inflammatory activity of human resident intestinal MФ is 
determined in part by a reduced ability to phosphorylate IκBα in response to microbial 
stimulation, leading to defective NF-κB signalling (Smythies et al., 2010). Furthermore, 
reduced expression of the TLR signalling adaptor proteins MyD88 and TRIF may also 
contribute to the weak responses of human intestinal resident MФ to microbial 
stimulation (Smythies et al., 2010). 
A small population of CD14+ MФ exists within the steady state human intestinal mucosa 
which is able to produce a range of pro-inflammatory cytokines including TNFα and IL-6 
in response to stimulation in vitro with both heat-killed E. coli and E. faecalis (Kamada 
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et al., 2008). The low numbers of these cells in comparison with intestinal resident MФ 
(which are CD14-) suggests that the overall response to bacterial encroachment into 
the human intestinal mucosa in the steady state is clearance by phagocytosis and 
intracellular killing without the induction of chronic inflammation. 
1:5.2  Murine intestinal resident macrophages 
Human intestinal resident MФ are marked by an absence of either pro or anti-
inflammatory cytokine production upon microbial stimulation (Smythies et al., 2005). In 
contrast, murine intestinal mucosa contains a large population of resident MФ that 
respond to microbial stimulation with production of the anti-inflammatory cytokine IL-10, 
as well as producing IL-10 constitutively (Denning et al., 2007, Bain et al., 2013, 
Rivollier et al., 2012). Moreover, murine resident intestinal MФ in the large intestinal 
mucosa do not express TLRs and do not produce pro-inflammatory cytokines in 
response to microbial stimulation (Platt et al., 2010).  
CX3CR1+ mononuclear phagocytes extend cellular protrusions through the intestinal 
epithelium of the murine terminal ileum (TI) (Niess et al., 2005, Rescigno et al., 2001). 
Demonstration of this activity requires Cx3cr1+/gfp mice in which one allele of the Cx3cr1 
gene is replaced with green fluorescent protein (GFP), allowing the direct visualization 
of CX3CR1-GFPhi cells (Jung et al., 2000). At this time, CX3CR1-GFPhi cells were 
identified as dendritic cells (DCs; see section 1:6) on the basis of a CD11c+ MHC II+ 
phenotype, and the activity was proposed as a method of sampling antigen directly 
from the intestinal lumen (Rescigno et al., 2001). However, more recent studies have 
determined that murine intestinal CX3CR1-GFPhi MФ in the steady state possess MФ 
as opposed to DC features, including a lack of migration from the LP in draining 
lymphatics, slow turnover, vacuolar morphology, high phagocytic activity (compared 
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with DCs) and low stimulatory capacity for naive T cells (Schulz et al., 2009, Rivollier et 
al., 2012).  They are identified as F4/80hi, CD11b+ and either CD11c+ or CD11c- (Bain 
et al., 2013, Rivollier et al., 2012). These and other phenotypic features of CX3CR1-
GFPhi MФ are listed in Table 1.1. 
Table 1.1: Phenotypic distinction of murine steady state intestinal mononuclear 
phagocytes 
Marker 
CD103+ CD11b+ 
DCs 
CD103+ CD11b- 
DCs 
CD103-  
DCs 
CX3CR1-GFPhi 
MФ 
CD11b + - + + 
CD11c + + + + or - 
CX3CR1-GFP - - + +++ 
MHC class II + + + + 
F4/80 + - + +++ 
CD172α + - + + 
CD8α - + or - - - 
CD103 + + - - 
CD64 - - - + 
Migration + + + - 
Naïve T cell 
stimulation 
+++ +++ +++ + 
 
The phenotypic features listed in the table above derive from the following publications: 
(Bogunovic et al., 2009, Schulz et al., 2009, Rivollier et al., 2012, Cerovic et al., 2012, Bain et 
al., 2013, Farache et al., 2013). 
 
The extension of transepithelial protrusions by CX3CR1-GFPhi MФ in mice requires the 
expression of CX3CR1 (Niess et al., 2005) which is the receptor for CX3CL1 (Imai et al., 
1997). CX3CL1 (fractalkine), is expressed on the basolateral surface of intestinal 
epithelial cells in mice and humans (Niess et al., 2005, Muehlhoefer et al., 2000). This 
process however is mouse strain-dependent, as it is observed in C57BL/6 but not in 
BALB/c mice (Vallon-Eberhard et al., 2006). The MLNs of Cx3cr1-/- mice contain 
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significantly increased bacterial density as composed to WT mice, and these bacteria 
are predominantly of commensal origin as members of the Firmicute phyla (Medina-
Contreras et al., 2011). This indicates that CX3CR1-GFPhi MФ support intestinal 
homeostasis through bacterial clearance, preventing dissemination of bacteria to the 
draining MLN. Moreover, CX3CR1+ cells  migrate through the small intestinal epithelium 
of mice upon stimulation with Salmonella, and are present within the intestinal lumen 
containing intracellular Salmonella (Arques et al., 2009). However, CX3CR1+ cells 
displaying this activity are CD11b-, and enter the intestinal lumen in BALB/c mice 
(Arques et al., 2009). The extent to which this represents CX3CR1+ MФ or a CX3CR1+ 
CD103- DC population (see section 1:6.2) remains controversial.  
Efficient bacterial killing is important in maintaining intestinal homeostasis in mice. Two 
important mechanisms of bacterial killing are the production of reactive oxygen species 
such as hydrogen peroxide (H2O2) and superoxide (O2-) by NAPDH oxidase (reviewed 
by Nathan and Cunningham-Bussel, 2013) and reactive nitrogen intermediates (RNI) 
including nitric oxide (NO) produced by inducible nitric oxide synthase (NOS2) 
(reviewed by Nathan and Hibbs, 1991). Mice genetically deficient in both pathways are 
highly susceptible to infection and the formation of large abdominal abscesses 
containing bacteria from the commensal microbiota (Shiloh et al., 1999). Peripheral MФ 
obtained from these mice have a significantly attenuated ability to kill bacteria in vitro, 
consistent with a role in maintaining control of the intestinal microbiota (Shiloh et al., 
1999). 
1:6 Intestinal dendritic cells 
The abundant population of resident intestinal MФ in mice and humans is likely to be 
able to clear non-pathogenic bacteria entering the intestinal mucosa. However, 
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pathogenic bacteria entering the intestinal mucosa have evolved virulence factors that 
allow them to evade killing by MФ, enabling them to cause infection. As an example, 
pathogenic bacteria of the genus Yersinia resist phagocytosis by intestinal MФ in mice 
through intracellular injection of the virulence factors YopE, YopH and YopT which 
inactivate the actin cytoskeleton (reviewed by Sansonetti, 2004). Pathogens are thus 
able to overwhelm the initial innate line of immune defence in the intestine. In order to 
contain the infection, the body mounts an adaptive immune response through which an 
enhanced level of microbial killing is targeted specifically to the antigens associated 
with infection (discussed in more detail in section 1:8). However, it is important that this 
adaptive immune response is not applied to harmless antigens such as those derived 
from food particles, or those associated with the commensal microbiota. The innate and 
adaptive immune systems are linked in the intestinal mucosa by dendritic cells (DCs).  
1:6.1  General features of dendritic cells 
DCs exist in peripheral tissues in an immature state characterised by high endocytic 
activity alongside a low capacity to activate naive T cells (reviewed by Cella et al., 
1997). Antigen sampling is performed by different forms of endocytosis including 
macropinocytosis whereby extracellular fluid containing soluble antigen is constitutively 
taken up at the cell membrane, and phagocytosis where large antigen including whole 
bacteria are internalized (Sallusto and Lanzavecchia, 1994). Uptake of antigen is 
facilitated by expression of a range of surface receptors including FcγRII which allows 
DCs to interact with and take up IgG-antigen immunocomplexes, and the mannose 
receptor which facilitates interaction with mannosylated antigen (Sallusto et al., 1995). 
Internalized antigen is degraded to constituent peptides within lysosomal compartments 
and the peptides are loaded on MHC class II molecules and presented at the cell 
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surface. Whilst in an immature state, MHC class II molecules undergo constitutive 
internalisation and recycling to endosomal compartments (Pinet et al., 1995). 
Antigen internalized by phagocytosis and macropinocytosis may also be passed into 
the cytosol, processed by the proteosome and derived peptides presented at the cell 
surface in conjunction with MHC class I (Kovacsovics-Bankowski and Rock, 1995, 
Norbury et al., 1995, Reis e Sousa and Germain, 1995). This ‘cross presentation’ 
pathway of antigen presentation is important in that MHC class I is used by all 
nucleated cells (i.e. including non-professional antigen presenting cells) primarily to 
present cytosol-derived peptides e.g. deriving from a viral infection (reviewed by Cella 
et al., 1997). Presentation of exogenously derived antigen by DCs in association with 
MHC class I allows priming of CD8+ cytotoxic T cells (discussed further in section 
1:8.4).  
Upon stimulation with inflammatory mediators including TNFα, IL-1β or LPS, DCs 
undergo CCR7-dependent migration to the T cell zones of draining lymph nodes as well 
as a process of maturation (reviewed by Alvarez et al., 2008). Maturation entails a 
simultaneous reduction in the endocytic capacity of cells and increased surface MHC 
expression through reduced MHC internalization (Pierre et al., 1997 and reviewed by 
Cella et al., 1997) alongside increased expression of co-stimulatory molecules such as 
CD80 and CD86 which interact with CD28 on naive T cells and promote T cell 
activation (reviewed by Sharpe and Freeman, 2002). Overall, this process renders DCs 
able to efficiently activate naive CD4+ and CD8+ T cells which express TCRs specific for 
the presented antigen. The distinct profile of cytokines produced during interaction of 
DCs and T cells also shapes the particular profile adopted by proliferating T cells 
(discussed further in section 1:8).  
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1:6.2  Murine intestinal dendritic cells 
Multiple DC subsets are present within murine intestinal mucosa. DCs expressing 
CD103 (αE integrin which forms a heterodimer with β7) are present in murine LP in 
close association with the epithelium of both the small and large intestine, and includes 
both CD11b+ and CD11b- CD8α+ subsets (Rivollier et al., 2012, Farache et al., 2013, 
Bogunovic et al., 2009). CD103+ CD11b- CD8α+ DCs are also present in greater 
concentration in murine PPs as compared with murine SI-LP (Bogunovic et al., 2009).  
The presence of lumenal Salmonella typhimurium draws murine SI-LP CD103+ DCs to 
the SI epithelium whereupon they extend dendrites between epithelial cells in order to 
take up bacteria by phagocytosis before returning to the LP (Farache et al., 2013). It 
has also recently been proposed that goblet cells provide a passage for low molecular 
weight soluble antigen e.g. ovalbumin through to the interior of mouse and human SI-
LP (goblet cell-associated antigen passages, or GAPs) for collection, at least in the 
mouse, by CD103+ DCs associated with the basolateral GAP surface (McDole et al., 
2012). Antigen sampling by murine CD103+ DCs in the small intestinal mucosa is 
summarised in Figure 1.3. 
CD103- DCs are also found within the large intestinal LP of mice (Rivollier et al., 2012), 
although it is unclear whether these cells can also pass dendrites through the 
epithelium to sample lumenal antigen. The ability of DCs to interact with the intestinal 
epithelium in response to Salmonella typhimurium is unaffected in Itgae-/- mice 
(deficient in CD103) (Diehl et al., 2013), indicating that expression of CD103 is not 
required for this process. The lack of CD103 expression by CD103- DCs would 
therefore not preclude Salmonella-induced sampling of lumenal antigen closely 
associated with the epithelium by this subset.  
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The identification of murine conventional CD103- DCs is made difficult by the fact that 
historically DCs were identified as CD11c+ MHC II+ cells. Murine intestinal resident 
CX3CR1-GFPhi MФ express MHC II and a significant fraction are CD11c+ (Schulz et al., 
2009, Rivollier et al., 2012, Bain et al., 2013). Therefore, murine studies referring to 
CD103- DCs may include CX3CR1+ MФ. To distinguish these groups, CD103- DCs 
express low to intermediate levels of F4/80, whilst CX3CR1-GFPhi MФ are F4/80hi 
(Schulz et al., 2009, Rivollier et al., 2012, Bain et al., 2013). CD103- DCs are also 
CD11b+, and are CX3CR1-GFPint in Cx3cr1+/gfp mice (Rivollier et al., 2012). Phenotypic 
distinction of these subsets is outlined in Table 1.1. 
In addition to sampling lumenal antigen directly, murine intestinal DCs also 
phagocytose apoptotic epithelial cells before migration into the draining MLNs. This 
behaviour is attributed to CD11c+ CD11b+ and CD11c+ CD11b- CD8α+ cells (Jang et al., 
2006). Whilst the CD11b subset may in fact contain both DCs and CX3CR1-GFPhi MФ, 
the CD11b- CD8α+ subset is likely to be entirely DCs as resident MФ are CD11b+ in the 
murine intestine (Bain et al., 2013, Rivollier et al., 2012). 
Expression of CCR7 allows murine intestinal CD103+ DCs to migrate from the SI-LP to 
the T cell zones of draining MLNs along a gradient of the chemokines CCL19 and 
CCL21 (Jang et al., 2006, Johansson-Lindbom et al., 2005). Murine CD103+ DCs (both 
CD11b+ and CD11b- CD8α+ subsets) and CD103- DCs from large intestinal LP 
upregulate CCR7 expression following stimulation with LPS (Rivollier et al., 2012). 
Furthermore, both CD103+ and CD103- DC subsets are identified in the afferent 
lymphatics draining the murine small intestine (Cerovic et al., 2012). Following oral 
inoculation of mice with Salmonella typhimurium, CD103+ DCs are the first cells present 
within the MLN to contain detectable bacteria, and the arrival of these cells is 
significantly reduced in Ccr7-/- mice (Bogunovic et al., 2009, Johansson-Lindbom et al., 
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2005). This is consistent with the ability of murine CD103+ DCs to collect Salmonella 
typhimurium directly from the epithelium and then migrate to the draining MLN (Farache 
et al., 2013). 
Migration of murine intestinal CD103+ DCs occurs constitutively at low levels in the 
steady state, and is enhanced by microbial stimulation (Schulz et al., 2009). This 
therefore allows a continuous surveillance of intestinal antigen in the steady state that 
may be augmented during a pathogenic challenge. Maturation may take place as DCs 
are en route to the MLNs as murine MLN DCs display elevated expression of CD40, 
CD80 and CD86 compared with their LP counterparts (Jang et al., 2006),  whilst 
CD103+ DCs in murine MLNs also display a more mature phenotype than SI-LP 
CD103+ DCs (Jaensson et al., 2008). Furthermore, CD103+ DCs collected from murine 
cannulated afferent lymphatics express intermediate levels of co-stimulatory molecules 
(Cerovic et al., 2012). 
Populations of DCs are present within GALT including PPs in mice. This includes a 
dense network of DCs in the subepithelial dome (SED) region immediately below the 
FAE (Kelsall and Strober, 1996). A subset of DCs within the SED expresses lysozyme, 
which damages bacterial peptidoglycan, and this cell population extends cellular 
protrusions through transcellular pores in M cells to internalize apical bacterial and 
particulate antigen (Lelouard et al., 2010, Lelouard et al., 2012). This population is 
CD11c+ CD11b+ F4/80- CD8α- and expresses CX3CR1, consistent with a CD103- DC 
phenotype (although CD103 expression is not defined in these studies). Lysozyme 
expressing DCs also capture apoptotic epithelial cells including M cells (Lelouard et al., 
2010).  
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DCs are also found in the T cell-rich interfollicular regions (IFRs) of murine PPs, which 
may include mature DCs originating from the SED or a distinct DC subset (Kelsall and 
Strober, 1996). Following intragastric administration of the commensal bacteria E. 
cloacae, bacteria are detected within both CD8α+ and CD8α- DC populations of the PP 
but not from SI-LP (Macpherson and Uhr, 2004), indicating that PPs are the primary 
route of sampling of commensal bacteria. Furthermore, these bacteria may be cultured 
in vitro following purification of DCs and so are retained alive within DCs following 
capture (Macpherson and Uhr, 2004). Following uptake of bacteria, PP DCs display 
CCR7-dependent migration to the draining MLNs and are retained there (see Figure 
1.3). This prevents the dissemination of live bacteria to the rest of the body 
(Macpherson and Uhr, 2004).  
Murine PP DCs may interact directly with B cells and induce T cell-independent IgA 
production, or else enlist the help of T cells to drive germinal centre formation and T 
cell-dependent IgA production (Macpherson et al., 2000, Macpherson and Uhr, 2004). 
This is discussed further in section 1:8.6. 
As discussed in section 1:5.2, murine intestinal CX3CR1-GFPhi MФ do not migrate in 
draining lymphatics in the steady state (Schulz et al., 2009). However, mice pre-treated 
with antibiotics followed by oral administration of invasion-deficient Salmonella 
typhimurium display significantly increased levels of bacteria in MLNs, and the 
migration of CX3CR1-GFPhi MФ is implicated in this process (Diehl et al., 2013). The 
intestinal microbiota may therefore suppress the migration of CX3CR1-GFPhi MФ in the 
steady state, though further studies are required to rule out a role for migratory 
CX3CR1-GFPint CD103- DCs. 
Chapter 1: Introduction 
39 
 
 
1:6.3  Human intestinal dendritic cells  
Conventional DCs in the human intestinal mucosa are identified as HLA-DR+ (MHC 
class II+), CD11c+ and by a lack of markers associated with other cell lineages (CD3 – T 
cells, CD14 – monocytes/MФ, CD19 – B cells, CD34 – haematopoietic and endothelial 
cells, CD56 – NK cells). Following extraction from large intestinal mucosa, DCs 
Figure 1.3: Antigen sampling by murine small intestinal DCs. CD103+ DCs interact with 
epithelial cells in response to lumenal Salmonella, and collect particulate antigen from goblet 
cell-associated antigen passages (GAPs). CD103- DCs extend dendrites through M cells in 
Peyer’s patches to sample lumenal bacteria. Following antigen sampling, both CD103+ and 
CD103- DCs migrate in draining lymphatics to the MLNs. Adapted from Mowat, 2003. 
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undergo maturation during overnight culture, up-regulating expression of CD40, CD80, 
CD83, CD86 and HLA-DR (Bell et al., 2001). 
Following removal of epithelial cells from human intestinal biopsies by EDTA treatment, 
a range of cells including lymphocytes and highly activated DCs exit the tissue and may 
be collected for analysis (Bell et al., 2001). At least some of this cell migration occurs 
through pores in the basement membrane (Mahida et al., 1997). It is possible that this 
DC migration is a parallel of the ability of murine intestinal CD103+ DCs to patrol the 
epithelium in response to the presence of lumenal Salmonella (Farache et al., 2013), 
although this activity has yet to be demonstrated in humans.  
DCs within the human large intestinal mucosa express significantly lower levels of 
TLR2 and TLR4 compared with blood DCs (Hart et al., 2005). This indicates that 
expression of these TLRs is down-modulated following entry of DCs into the intestinal 
mucosa. 
A subset of myeloid DCs expressing blood dendritic cell antigen (BDCA-1; CD1c) has 
been observed in the human large and small intestine (Dillon et al., 2010). These are a 
subset of Lin- HLA-DR+ CD11c+ cells and are predominantly CD103-. Furthermore, 
following overnight culture they upregulate the co-stimulatory molecules CD40 and 
CD86, the marker of mature human DCs CD83 as well as CCR7, suggesting they 
represent the human equivalent of murine CD103- DCs. CD1c+ DCs are unresponsive 
to TLR4 or TLR5 stimulation, but produce TNFα and IL-6 following stimulation with the 
TLR2 ligand bacterial lipoprotein or the TLR7/8 ligand single stranded (ss)RNA (Heil et 
al., 2004, Takeuchi et al., 1999, Dillon et al., 2010). The TLR7/8 agonist also induces 
IL-23 production by CD1c+ DCs, whereas the TLR2 agonist induces IL-10 production 
(Dillon et al., 2010). This indicates that whilst myeloid DCs within the human intestinal 
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mucosa tolerate low levels of bacterial products such as LPS, the presence of particular 
ligands including ssRNA which suggest the presence of a viral infection triggers rapid 
cytokine production which then shapes the immunological response. 
CD103+ DCs have been identified in human MLNs, and display increased expression of 
the maturation-associated markers CD40 and CD83 compared with their MLN CD103- 
DC counterparts (Jaensson et al., 2008). In addition, an increased proportion of human 
MLN CD103+ DCs are CCR7+ compared with CD103- DCs (Iliev et al., 2009). This is 
consistent with CD103+ DCs having migrated from the intestinal mucosa, with MLN 
CD103- DCs as potentially blood-derived.  
As in the mouse, a population of DCs expressing lysozyme is present in human PPs 
(Lelouard et al., 2010) and may therefore contribute to intestinal homeostasis through 
direct sampling of lumenal bacteria. 
A subset of myeloid DCs present in human blood defined by expression of CD141 
(BDCA-3) is efficient at cross presentation of soluble antigen as well as antigen derived 
from virus-infected necrotic cells to CD8+ T cells. It is therefore proposed as the human 
equivalent of murine CD103+ CD11b- CD8α+ DCs (Bachem et al., 2010, Jongbloed et 
al., 2010). Murine CD103+ CD11b- CD8α+ DCs have also been shown to express 
Clec9A, a C-type lectin that binds necrotic cells via interaction with filamentous actin 
(Zhang et al., 2012). CLEC9A+ DCs are present in human PP, as well as in the SI-LP, 
suggesting a degree of species overlap (Poulin et al., 2012).  
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1:7 Ontogeny of intestinal mononuclear phagocytes 
1:7.1  Ontogeny of murine intestinal mononuclear phagocytes 
Murine intestinal DCs and MФ populations originate from haematopoietic stem cells 
(HSCs) in the bone marrow following a complex process of differentiation. In mice, 
HSCs are self renewing and long-lived, generating short lived HSCs and then 
multipotent progenitor (MPP) cells. At this point, differentiation of these cells splits into 
the common lymphoid progenitor (CLP) which generates all lymphoid cells and the 
common myeloid progenitor (CMP). The CMP may differentiate into the megakaryocyte 
and erythrocyte progenitor (MEP) which ultimately generates erythrocytes and 
platelets, or alternatively the CMP becomes the granulocyte and macrophage 
progenitor (GMP) and subsequently all myeloid cell populations (reviewed by King and 
Goodell, 2011). GMPs may differentiate into the macrophage DC precursor (MDP) 
which in turn may then become a Ly6Chi or Ly6Clo monocyte, or alternatively the 
common DC precursor (CDP) (reviewed by Geissmann et al., 2010). The CDP may 
then differentiate into either a plasmacytoid DC (pDC) or a conventional DC precursor 
(pre-cDC), but will not become a monocyte (Liu et al., 2009, Naik et al., 2007, Onai et 
al., 2007). Intestinal CD103+ and CD103- DCs are classed as conventional DCs (cDCs), 
distinguishing this group from pDCs which produce large quantities of type I interferon 
(IFN) upon interaction with viral products as part of a potent anti-viral response but 
possess a significantly lower ability to activate T cells as compared with cDCs 
(reviewed by Colonna et al., 2004). These differentiation pathways are summarized in 
Figure 1.4. 
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The pre-cDC exits the bone marrow and enters blood circulation (Liu et al., 2009, Naik 
et al., 2006). Injection of MDPs, CDPs or pre-cDCs into mice generates both CD103+ 
CD11b+ and CD103+ CD11b- CD8α+ SI-LP DCs (Bogunovic et al., 2009). Differentiation 
of MDPs to intestinal CD103+ DCs is particularly apparent in mice in which CD11c+ 
cells (including DCs and some MФ populations) are first depleted (Bogunovic et al., 
2009). This requires transgenic mice in which the diphtheria toxin receptor (DTR) is 
Figure 1.4: Haematopoiesis of murine Ly6Chi monocytes and DCs in the murine bone 
marrow. Haematopoietic stem cells (HSCs) generate the common myeloid progenitor (CMP) 
and common lymphoid progenitor (CLP). CMP generates megakaryocyte and erythrocyte 
progenitor (MEP) which generates platelets and erythrocytes, the CMP also generates the 
granulocyte macrophage progenitor (GMP), which in turn generates all granulocyte 
populations and the macrophage DC progenitor (MDP). MDP generates Ly6Chi monocytes, 
which exit the bone marrow under the control of CCR2 and enter the intestinal mucosa in the 
steady state to give CX3CR1hi MФ. MDP also gives the common DC progenitor (CDP) which 
generates either plasmacytoid DCs (pDC) or the pre-conventional DC (pre-cDC) which 
enters blood circulation and ultimately generates conventional DCs (cDC) such as CD103 
DCs within peripheral tissues including the intestinal mucosa. 
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expressed by CD11c+ cells, such that administration of diphtheria toxin selectively 
ablates CD11c+ cells (Jung et al., 2002). This may promote differentiation of CD103+ 
DCs through the creation of a ‘niche’ which these cells may then fill, however it is also 
possible that this reflects a non-physiological response. 
Murine SI-LP CD103+ CD11b+ and CD103+ CD11b- CD8α+ DCs increase in number in 
response to fms-like tyrosine kinase receptor-3 ligand (Flt3L) administration (Bogunovic 
et al., 2009, Cerovic et al., 2012). This is consistent with increased numbers of pre-
cDCs in mice following Flt3L administration (Liu et al., 2009). GM-CSF also increases 
the numbers of murine SI-LP CD103+ DCs (Schulz et al., 2009). Intestinal CD103+ DC 
subsets do not however require M-CSF for their development (Bogunovic et al., 2009). 
Due to the difficulty of distinguishing conventional murine intestinal CD103- DCs from 
CD103- CD11c+ MФ in earlier studies in which DCs were defined as CD11c+ MHC II+ 
cells, less is known about the development of CD103- DCs. However, Flt3L 
administration increases the numbers of murine SI-LP CD103- DCs (Bain et al., 2013, 
Cerovic et al., 2012), indicating that they share a developmental pathway with CD103+ 
DCs.  
A small proportion of intestinal CD103+ DCs may be derived from Ly6Chi monocytes in 
CD11c-depleted mice in the steady state (Bogunovic et al., 2009, Rivollier et al., 2012). 
This may indicate further complexity in the differentiation pathway of these cells. In 
contrast, a large proportion of adoptively transferred Ly6Chi monocytes differentiate into 
intestinal CX3CR1-GFPhi MФ in mice in the steady state, although again the 
demonstration of this requires either prior depletion of CD11c+ cells or the use of CCR2-
/- mice (Rivollier et al., 2012, Bain et al., 2013, Tamoutounour et al., 2012, Zigmond et 
al., 2012). Differentiation of Ly6Chi monocytes into CX3CR1-GFPhi MФ within the 
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intestinal mucosa occurs in conjunction with upregulation of MHC II, F4/80, CX3CR1 
and CD64, with variable amounts of CD11c and concomitant loss of Ly6C (Rivollier et 
al., 2012, Bain et al., 2013, Tamoutounour et al., 2012, Zigmond et al., 2012). In 
contrast with DCs, murine intestinal CX3CR1hi MФ do not expand in response to or 
require Flt3L or GM-CSF for differentiation in mice, but are dependent on M-CSF 
(Schulz et al., 2009, Bogunovic et al., 2009).  
Expression of the transcription factor zDC (Zbtb46, Btbd4) was recently identified in 
murine pre-cDCs and cDCs but not MDPs or monocytes (Meredith et al., 2012a). 
Depletion of zDC+ cells using a zDC-DTR approach reduced numbers of CD103+ 
CD11b- DCs in the SI-LP to approximately 6 % of their level in wild-type mice. In 
contrast, CD103+ CD11b+ DCs were reduced to 38 % of their level in wild-type mice 
(Meredith et al., 2012a). This indicates that majority of murine intestinal CD103+ CD11b- 
DCs maintain significant levels of Zbtb46 expression, whereas expression of Zbtb46 is 
more variable within the murine intestinal CD103+ CD11b+ DC subset. However, the 
proportion of both DC subsets is not significantly different in Zbtb46-/- mice, indicating 
that zDC may be involved in DC function as opposed to being required for their 
differentiation (Meredith et al., 2012a). Indeed, zDC expression is associated with 
suppression of MHC class II expression in the immature DC state (Meredith et al., 
2012b). 
Murine SI-LP CD103+ CD11b+ and CD103+ CD11b- DCs are further distinguished by a 
range of transcription factors. For example, CD103+ CD11b- DCs express significantly 
greater levels DNA-binding protein inhibitor 2 (Id2), IRF8, and Batf3 compared with 
CD103+ CD11b+ DCs (reviewed by Persson et al., 2010). In contrast, murine SI-LP 
CD103+ CD11b+ DCs express elevated levels of IRF4 compared with CD103+ CD11b- 
DCs, and IRF4 expression appears to promote survival of CD103+ CD11b+ DCs 
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(Persson et al., 2013). IRF4 expression is also observed in myeloid DCs within the 
human intestinal mucosa, suggesting a transcriptional overlap between mouse and 
man within these cells (Schlitzer et al., 2013, Persson et al., 2013).  
Recent evidence indicates that RA may regulate the generation of a subset of pre-
cDCs within the murine bone marrow expressing α4β7 and which are predisposed to 
differentiate into intestinal CD103+ DCs (Zeng et al., 2012). Moreover, the differentiation 
of pre-cDCs into CD103+ CD11b+ DCs and CD103+ CD11b- CD8α+ DCs in the murine 
SI-LP is also regulated by the presence of RA, with RA favouring the CD103+ CD11b+ 
DC phenotype (Klebanoff et al., 2013). 
1:7.2  Ontogeny of human intestinal mononuclear phagocytes 
Human intestinal resident MФ are likely to derive from circulating CD14+ monocytes, 
which are the equivalent of murine Ly6Chi monocytes (Ziegler-Heitbrock et al., 2010). 
Indirect evidence of differentiation derives from in vitro experiments in which human 
CD14+ monocytes cultured in intestinal stromal cell-conditioned medium develop an 
intestinal resident MФ-like phenotype associated with loss of expression of CD14, low 
or non-responsiveness to microbial stimulation combined with strong phagocytic and 
bactericidal activity (Smythies et al., 2005). This differentiation process requires TGF-β, 
which is produced in by intestinal epithelial cells and mast cells (Smythies et al., 2005). 
Moreover, TREM-1 expression by human CD14+ monocytes is down-regulated in 
culture with TGF-β in the presence of IL-10 (Schenk et al., 2005). TGF-β signalling 
leads to phosphorylation of Smad2 and Smad3 proteins, which recruits Smad4 and the 
whole complex then translocates into the nucleus where it influences gene expression 
(reviewed by Massague, 1998). This process is inhibited by the presence of Smad7 in 
the cytosol, which inhibits Smad2/3 phosphorylation (reviewed by Massague, 1998). 
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Human intestinal resident MФ display reduced levels of cytosolic Smad7 compared with 
blood monocytes, indicating that they experience constitutive TGF-β signalling within 
the intestinal mucosa (Smythies et al., 2010). Overall, this indicates that human CD14+ 
monocytes arriving in the intestinal mucosa from circulation undergo a differentiation 
process mediated by TGF-β that generates a resident MФ phenotype specialised for 
the intestinal mucosa. 
This system therefore appears to be similar to the mouse, where circulating Ly6Chi 
monocytes enter the intestinal mucosa and differentiate into intestinal resident 
CX3CR1-GFPhi MФ in Cx3cr1+/GFP mice in the steady state (Bain et al., 2013, 
Tamoutounour et al., 2012, Rivollier et al., 2012).  
1:8 Lymphocyte activation by intestinal DCs 
Intestinal DCs interact with populations of naive T cells within draining MLN and 
present antigen obtained from within the intestinal mucosa in the context of MHC class 
I and MHC class II molecules. This process leads to expansion of T cells expressing 
TCRs specific for antigen derived from the intestinal mucosa. In addition, the 
subsequent activity of the responding T cells is also determined by cytokines produced 
by intestinal DCs during this activation event. This section will give an overview of the T 
cell subsets induced within GALT and MLNs by intestinal DCs (summarised in Figure 
1.5) as well as discussing the role of these cells within the intestinal mucosa. 
1:8.1  TH1 cells 
TH1 cells play an important role in the eradication of intracellular pathogens such as 
Listeria monocytogenes and Leishmania major, and are characterised by expression of 
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the cytokines IFNγ, TNFα and IL-2 (reviewed by Szabo et al., 2003). One essential role 
of IFNγ is to activate macrophages, resulting in increased phagocytosis, increased 
MHC class I and II expression, and induction of IL-12 and nitric oxide, and superoxide 
which are all important in the eradication of intracellular pathogens (reviewed by Boehm 
et al., 1997).  
Figure 1:5: Induction of CD4+ T cell lineages by dendritic cells. Activation of naive CD4+ 
T cells in the presence of IL-12 and IFNγ induces TH1 cells, which produce IFNγ, TNFα and 
IL-2 under the control of Tbet and mediate macrophage activation for defence against 
intracellular bacterial pathogens. IL-4 induces TH2 cells which produce IL-4, IL-5 and IL-13 
under the control of GATA-3, and support humoral responses and IgE class switching 
required for defence against extracellular pathogens e.g. helminths. TGF-β and IL-6 or IL-21 
in mice (TGF-β and IL-21 in humans) induces TH17 cells which produce IL-17A, IL-17F and 
IL-22 under the control of RORγt, and mediate defence against extracellular bacteria and 
fungal pathogens through neutrophil recruitment and increased neutrophil production in the 
bone marrow. RA enhances the TGF-β-mediated induction of Foxp3+ TREG in mice which 
mediate suppression of effector T cell responses for the maintenance of homeostasis and 
the induction of oral tolerance. 
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Naive CD4+ T cells are induced into the TH1 phenotype in the presence of IL-12, which 
signals through the IL-12 receptor composed of IL-12Rβ1 and IL-12Rβ2 chains (Chua 
et al., 1994, Presky et al., 1996). Naive CD4+ T cells upregulate the IL-12 receptor upon 
stimulation through the TCR, which renders them sensitive to IL-12 signalling (Presky 
et al., 1996). IFNγ plays an important role in supporting induction of the TH1 phenotype 
through induction of the transcription factor T box expressed in T cells (Tbet) (Lighvani 
et al., 2001, Afkarian et al., 2002). Tbet induces expression of IL-12Rβ2 and so 
promotes IL-12 signalling in naive CD4+ T cells (Mullen et al., 2001, Afkarian et al., 
2002).  IL-12 then supports the TH1 phenotype through promoting cell survival, division 
prolonging the production of IFNγ (Mullen et al., 2001). In addition, IL-12 signalling 
induces expression of the IL-18 receptor on TH1 cells (Yoshimoto et al., 1998). IL-18 
synergizes with IL-12 to promote IFNγ production by TH1 cells (Robinson et al., 1997). 
Murine CD103+ CD11b+ DCs collected from afferent lymphatics draining the SI-LP are 
poor inducers of IFNγ production in CD4+ T cells in vitro (Cerovic et al., 2012). 
However, stimulation of SI-LP CD103+ CD11b+ and CD103+ CD11b- CD8α+ DCs with 
CpG ODN leads to significant induction of IFNγ by CD4+ T cells (Fujimoto et al., 2011). 
In contrast, CD103+ DCs collected from the afferent lympatics draining the SI of rats 
efficiently induce IFNγ production by naive CD4+ T cells without prior stimulation (Milling 
et al., 2009). This may indicate that CD103+ DCs in rats are more pro-inflammatory in 
the steady state than in mice, or alternatively that they are more sensitive to cellular 
stress associated with the surgical procedure. 
CD103- DCs both from the murine large intestinal LP and in lymphatics draining the SI-
LP induce strong IFNγ production from CD4+ T cells in vitro, without the need for prior 
stimulation from TLR ligands (Rivollier et al., 2012, Cerovic et al., 2012). When 
stimulated with anti-CD40 in vitro to replicate a T cell interaction, murine CD103- DCs 
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from the afferent lymphatics draining the SI-LP express increased levels of L-12p35, IL-
12/23p40 and IL-23p19 required for expression of both IL-12 and IL-23, compared with 
both CD103+ CD11b+ and CD103+ CD11b- CD8α+ DCs collected from the same 
afferent lymphatics (Cerovic et al., 2012). 
Murine MLN CD103- DCs induce significantly greater levels of IFNγ production by naive 
CD4+ T cells compared with MLN CD103+ DCs (Laffont et al., 2010). This is also 
observed with human MLN CD103- and CD103+ DCs (Iliev et al., 2009), indicating that 
in the steady state CD103+ DCs have a less inflammatory phenotype than CD103- DCs 
in both mice and humans. 
1:8.2  TH2 cells  
TH2 cells are characterized by expression of a range of cytokines including IL-4, IL-5, 
IL-9, IL-13 and IL-25 (IL-17E) (reviewed by Paul and Zhu, 2010). They are primarily 
involved in defence against parasites through induction of IL-4 dependent B cell class 
switching to IgE. IgE immune complexes cross link high affinity FcεRI on innate cells 
including mast cells and basophils, leading to degranulation and the release of a wide 
range of cytokines, chemokines, histamine, serotonin and proteases involved in 
parasite clearance (reviewed by Paul and Zhu, 2010). Within the intestinal mucosa, TH2 
cells also recruit mast cells and eosinophils through production of IL-9 and IL-5, 
respectively (reviewed by Paul and Zhu, 2010). 
TH2 cells are induced from naive CD4+ T cells during T cell activation in the presence of 
IL-4, which signals through the transcription factor STAT6 and upregulates GATA-
binding protein 3 (GATA-3), the master transcription factor for the TH2 lineage (Zheng 
and Flavell, 1997, Zhang et al., 1997). IL-2 signalling through STAT5 also plays an 
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important role in this process (Zhu et al., 2003, Cote-Sierra et al., 2004), although 
phosphorylation of STAT5 by IL-7 or thymic stromal lymphopoietin (TSLP) can replace 
IL-2 in mice (reviewed by Rochman et al., 2009). 
The extent to which DCs regulate IL-4-mediated induction of TH2 cells from naive CD4+ 
T cells remains controversial. Basophils in mice may act as antigen presenting cells 
and present antigen derived from IgE complexes to naive CD4+ T cells and promote the 
induction of TH2 cells (Yoshimoto et al., 2009). Furthermore, basophils migrate to skin-
draining lymph nodes in mice following stimulation with the cysteine protease papain 
and produce IL-4 and TSLP (Sokol et al., 2008a). Basophils may also play a key role in 
inducing an effective TH2 response in mice to clear infection with the intestinal helminth 
Trichuris muris (Perrigoue et al., 2009). However, depletion of CD11c+ cells (including 
DCs and some MФ subsets) in mice significantly reduces the induction of an effective 
TH2 response to the helminth Schistosoma mansoni, whilst depletion of basophils has 
no effect on TH2 induction (Phythian-Adams et al., 2010). Furthermore, adoptive 
transfer of bone-marrow derived DCs pulsed with antigen derived from the intestinal 
nematode Nippostrongylus brasiliensis induces a TH2 response in naive mice (Balic et 
al., 2004). Production of TSLP by intestinal epithelial cells may condition intestinal DCs 
to make reduced levels of IL-12p40, favouring the induction of TH2 cells in Trichuris 
muris infection (Taylor et al., 2009). Intestinal DCs are therefore likely to play a key role 
in the induction of TH2 responses to helminth infection, however the nature of this 
induction remains to be defined in a greater level of detail (reviewed by Allen and 
Maizels, 2011). 
1:8.3  TH17 cells  
Activation of murine naive CD4+ T cells in the presence of TGF-β and IL-6 induces a 
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TH17 helper T cell phenotype based on production the cytokines IL-17A and IL-17F 
(Bettelli et al., 2006, Veldhoen et al., 2006, Mangan et al., 2006). In addition, TH17 cells 
may be differentiated from naive CD4+ T cells with TGF-β in the presence of IL-21 
(Korn et al., 2007, Nurieva et al., 2007, Zhou et al., 2007). TH17 differentiation is under 
the transcriptional control of RORγt (Ivanov et al., 2006), which synergizes with RORα 
(Yang et al., 2008d). TH17 cells cultured with only TGF-β and IL-6 develop a non-
inflammatory IL-17A+ IL-10+ phenotype, whilst secondary stimulation with IL-23 
promotes commitment to the TH17 lineage, expansion in cell numbers and a loss of IL-
10 production (McGeachy et al., 2007, McGeachy et al., 2009).  
TH17 cells display a reciprocal relationship with Foxp3+ TREG (discussed in section 
1:8.5). Induction of TH17 cells is suppressed by IL-2, whilst induction and expansion of 
Foxp3+ TREG is enhanced (Setoguchi et al., 2005, Davidson et al., 2007, Zheng et al., 
2007). Furthermore, induction of TH17 cells is suppressed by retinoic acid (RA) whilst 
that of Foxp3+ TREG is enhanced (Mucida et al., 2007, Schambach et al., 2007, Elias et 
al., 2008). Consistent with a high ability to produce RA, CD103+ CD11b+ DCs collected 
from the afferent lymphatics draining the SI-LP of mice are poor inducers of TH17 cells 
in vitro (Cerovic et al., 2012). However, prior stimulation of SI-LP CD103+ CD11b+ DCs 
with flagellin or CpG ODN significantly enhances induction of TH17 cells through 
enhanced production of IL-23 (Fujimoto et al., 2011). Moreover, murine SI-LP CD103+ 
CD11b+ DCs display a significantly greater ability to induce TH17 cells compared with 
CD103+ CD11b- DCs (Denning et al., 2011). As discussed in section 1:7.1, murine SI-
LP CD103+ CD11b+ DCs express IRF4 which mediates survival of these cells (Persson 
et al., 2013). Mice deficient in IRF4 specifically in CD11c+ cells are deficient for CD103+ 
CD11b+ DCs leading to significantly reduced levels of TH17 cells within the intestinal 
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mucosa (Persson et al., 2013). This indicates that murine intestinal CD103+ DCs play a 
key role in inducing TH17 cells in vivo. 
Activation of human naive CD4+ T cells in the presence TGF-β and IL-6 does not 
however induce a TH17 phenotype (Acosta-Rodriguez et al., 2007, van Beelen et al., 
2007, Wilson et al., 2007), which instead requires TGF-β and IL-21 (Yang et al., 
2008a). The human TH17 phenotype is also under the transcriptional control of RORγt 
(Wilson et al., 2007). Furthermore, RA suppresses induction of human TH17 cells from 
naive CD4+ T cells (Kamada et al., 2009). 
TH17 cells in both mice and humans produce IL-17A, IL-17F, IL-22 and GM-CSF 
(Annunziato et al., 2007, Wilson et al., 2007). IL-17A and IL-17F play important roles in 
defence against extracellular bacterial and fungal pathogens in mice through indirect 
recruitment of neutrophils via induction of neutrophil chemokines including CXCL8 (IL-
8) by stromal cells as well as induction of the production of further neutrophils from the 
bone marrow by inducing release of G-CSF from stromal cells (reviewed by Witowski et 
al., 2004). IL-22 production promotes the production of antimicrobial peptides by 
epithelial cells and therefore may help to enhance epithelial barrier function during an 
infection (Zheng et al., 2008). 
The induction of TH17 cells within the intestinal mucosa may be influenced by particular 
members of the microbiota. Mice harbouring segmented filamentous bacteria  (SFB) 
possess significantly increased levels of TH17 cells within the intestinal mucosa 
compared to mice without it (Ivanov et al., 2009). This increased presence of TH17 cells 
associates with an increased ability to cope with Citrobacter rodentium infection (Ivanov 
et al., 2009). 
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1:8.4  Cytotoxic T lymphocytes  
DCs present peptides derived from extracellular antigen in the context of MHC class I 
to naive CD8+ T cells as part of a process termed ‘cross presentation’ (reviewed by 
Joffre et al., 2012). The presence of IL-12 during this activation induces the 
differentiation of naive CD8+ T cells into cytotoxic T lymphocytes (CTLs) which have the 
ability to induce apoptosis of virally infected or malignant cells expressing their cognate 
peptide-MHC class I target through the release of granzyme and perforin reviewed by 
Kaech and Cui, 2012). Induction of the transcription factors Tbet and eomesodermin 
(EOMES) induces expression of IFNγ, TNFα, granzyme B, perforin and the chemokine 
receptors CXCR3 and CXCR4 as part of the CTL differentiation process (Intlekofer et 
al., 2005, Joshi et al., 2007). 
CD103+ CD11b- DCs collected from the murine large intestinal LP display a superior 
ability to induce activation of CD8+ T cells as compared with CD103+ CD11b+ DCs 
(Rivollier et al., 2012). Furthermore, murine CD103+ CD11b- CD8α+ DCs collected from 
intestinal afferent lymphatics are also superior to CD103+ CD11b+ DCs in this regard 
(Cerovic et al., 2012). However, one study has demonstrated that CD103+ CD11b+ and 
CD103+ CD11b- CD8α+ DCs collected from SI-LP have equivalent ability to activate 
CD8+ T cells following stimulation with the TLR9 ligand CpG oligodeoxynucleotides 
ODN (Fujimoto et al., 2011). Whether stimulation overcomes differences in CD8+ T cell 
activation or if collecting the cells from different compartments influences this activity is 
unclear.  
Murine CD103+ CD11b+ DCs collected from afferent lymphatics draining the SI-LP are 
poor inducers of IFNγ production in CD8+ T cells in vitro. However, prior stimulation of 
these CD103+ CD11b+ DCs with the TLR2 ligand bacterial lipoprotein significantly 
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increases their ability to induce IFNγ production by CD8+ T cells (Cerovic et al., 2012). 
In contrast, CD103- DCs from both the murine large intestinal LP and in lymphatics 
draining the SI-LP induce strong IFNγ production from CD8+ T cells in vitro without the 
need for prior stimulation (Rivollier et al., 2012, Cerovic et al., 2012). Injection of OVA-
pulsed and CpG ODN-stimulated SI-LP CD103+ CD11b+ DCs into the murine 
peritoneum leads  to efficient induction of OVA-specific IFNγ+ CD8+ T cells in vivo 
(Fujimoto et al., 2011). 
Targeting ovalbumin (OVA) to murine CD103+ DCs by conjunction of the antigen to an 
anti-CD103 monoclonal antibody and then administration by IP injection leads to 
proliferation of OVA-specific CD4+ and CD8+ T cells with low cytokine production in 
MLNs. However co-administration of anti-CD40 monoclonal antibody leads to efficient 
induction of OVA-specific IFNγ+ CD8+ T cells which are cytotoxic for OVA peptide-
presenting splenocytes (Semmrich et al., 2011). 
1:8.5  Regulatory T cells 
A significant proportion of effector T cells in the steady state human intestinal mucosa 
possess a TH1 phenotype with the potential to produce IFNγ upon stimulation 
(Rovedatti et al., 2009). Furthermore, during an acute gastrointestinal infection TH1 
cells are generated with specificity for microbiota-derived antigen and persist in the 
intestinal mucosa of mice for an extended period of time (Hand et al., 2012). The 
activity of these effector T cell populations is likely to be restrained in order to maintain 
intestinal homeostasis and prevent immunopathology. Subsets of regulatory T cells 
(TREG) play important roles in restraining the activity of these cells (reviewed by Barnes 
and Powrie, 2009). 
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A major subset of TREG in mice are defined by expression of the transcription factor 
Forkhead winged helix P3 (Foxp3) (Hori et al., 2003) and high expression of the IL-2 
receptor-α chain CD25 (reviewed by Barnes and Powrie, 2009). Foxp3+ TREG mediate 
suppression of T cell proliferation and cytokine production through a range of 
mechanisms. Contact-dependent mechanisms of suppression include surface 
expression of cytotoxic T lymphocyte associated antigen 4 (CTLA-4) which interacts 
with and down-regulates the co-stimulatory molecules CD80 and CD86 on APCs 
(Takahashi et al., 2000, Read et al., 2000), whilst contact-independent mechanisms 
include production of IL-10 (reviewed by Barnes and Powrie, 2009). 
CD25hi Foxp3+ TREG are divided into natural TREG (nTREG) which develop in the thymus 
and are believed to express TCRs with specificities for self antigen, and inducible TREG 
(iTREG) which develop in the periphery from naive CD4+ T cells and therefore allow 
expansion of repertoire of antigens which may be subject TREG responses (reviewed by 
Barnes and Powrie, 2009). Naive CD4+ T cells are induced into Foxp3+ iTREG during T 
cell activation in mice in the presence of TGF-β (Chen et al., 2003), which is further 
enhanced with RA (Coombes et al., 2007, Sun et al., 2007, Mucida et al., 2007). Murine 
CD103+ DCs from both the SI-LP and MLN possess a specialised ability to induce 
Foxp3+ iTREG in vitro through expression of the integrin αvβ8 which activates latent TGF-
β (Travis et al., 2007, Paidassi et al., 2011, Worthington et al., 2011). This is further 
supported by the provision of RA through enhanced expression of Aldh1a2, encoding 
RALDH2 (Coombes et al., 2007, Sun et al., 2007).  
Murine CD103+ CD11b+ DCs but not CD103+ CD11b- CD8α+ DCs from SI-LP induce 
Foxp3+ TREG from naive CD4+ T cells in the presence of exogenous TGF-β (Fujimoto et 
al., 2011). This may reflect the low ability of murine SI-LP CD103+ CD11b- CD8α+ DCs 
to produce RA (Fujimoto et al., 2011). Furthermore, murine large intestinal LP CD103+ 
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CD11b+ DCs induce Foxp3+ TREG from naive CD4+ T cells but in this study a further 
population of CD103+ CD11b- CD8α- DCs and CD103- DCs were unable to do so 
(Rivollier et al., 2012). In comparison with CD103+ DCs, murine resident MФ have a 
reduced ability to produce RA. They do however express Aldh1a1 (encoding RALDH1), 
of which expression is greatest in the CD11c- subset (Denning et al., 2011). Their ability 
to induce Foxp3+ TREG is suppressed when RA signalling is inhibited, suggesting that 
this may contribute to a regulatory phenotype (Denning et al., 2007).  
The combined action of TGF-β and RA exert complex epigenetic regulation of Foxp3 
expression in murine CD4+ T cells. RA enhances TGF-β-mediated induction of murine 
Foxp3+ iTREG acts through phosphorylation of ERK1/2, leading to increased histone 
methylation and acetylation at the Foxp3 promoter (Lu et al., 2011). RA and TGF-β 
induce expression of a particular profile of micro RNA molecules (miRNA) which 
increase the stability of the Foxp3+ TREG phenotype (Takahashi et al., 2012). It has also 
been proposed that RA does not act on iTREG directly, but inhibits the production of 
cytokines such as IFNγ by neighbouring effector cells which normally suppress the 
induction of Foxp3 (Hill et al., 2008). 
Murine SI-LP and MLN CD103+ DCs also express the enzyme indoleamine 2,3-
dioxygenase (IDO), which is involved in tryptophan catabolism (Matteoli et al., 2010). 
This enzyme activity contributes to the induction of Foxp3+ iTREG in mice in vivo, 
indicating that IDO acts to complement TGF-β and RA in the induction of these cells 
(Matteoli et al., 2010). 
Murine Foxp3+ nTREG and iTREG are distinguished in the literature by expression of the 
transcription factor Helios, such that Foxp3+ nTREG are Helios+ (Sugimoto et al., 2006, 
Thornton et al., 2010). However, subsequent reports indicate that Helios is transiently 
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upregulated during the activation and proliferation of murine CD4+ T cells, including 
Foxp3+ iTREG, indicating that expression of Helios is insufficient to distinguish murine 
nTREG and iTREG (Akimova et al., 2011, Gottschalk et al., 2012). There is controversy as 
to whether the population of Foxp3+ TREG in murine intestinal LP is predominantly of 
nTREG or iTREG origin. Germ-free mice contain equivalent proportions of MLN and 
colonic TREG populations when compared with mice containing intestinal microbiota 
(Min et al., 2007, Round and Mazmanian, 2010). However, a subset of colonic Foxp3+ 
TREG in microbiota-containing mice express TCRs specific for microbiota-derived 
antigen (Lathrop et al., 2011). Furthermore, these specific TCR sequences do not 
support nTREG formation when expressed in Rag-/- thymocytes, and adoptive transfer of 
CD4+ T cells expressing such TCRs into Rag-/- mice recapitulates T-cell transfer colitis 
(see 1:14.5.2) (Lathrop et al., 2011). Overall, this indicates that at least some of the 
murine colonic Foxp3+ TREG population is induced in the periphery, potentially under the 
influence of CD103+ DCs. It is therefore proposed that the murine intestinal mucosa 
comprises a TREG ‘niche’, such that in absence of microbiota-derived antigen leading to 
induction of Foxp3+ iTREG, it is instead filled with nTREG (Lathrop et al., 2011). 
However, this has recently been challenged by a report in which the TCR was 
sequenced from large numbers of Foxp3+ and Foxp3- CD4+ T cells in the murine 
intestine and thymus. This indicates that the majority of Foxp3+ TREG in the murine 
intestine express TCR sequences that are identified within Foxp3+ TREG in the thymus, 
suggesting that they represent thymus-derived nTREG (Cebula et al., 2013). Modulation 
of intestinal microbiota through antibiotic treatment significantly alters the frequency of 
specific Foxp3+ TREG TCR clones within the murine intestine, indicating a close 
association between antigen and respective TREG population. However, these TCRs are 
again present in the thymus (Cebula et al., 2013). This therefore challenges the notion 
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that nTREG recognise only self-antigen, and suggests a crucial role for Foxp3+ nTREG in 
maintaining tolerance to microbiota-derived antigen. Murine MLN CD103+ DCs support 
the maintenance of CD25hi Foxp3+ TREG in addition to inducing this phenotype from 
naive CD4+ T cells (Coombes et al., 2007), and so may provide the link between 
microbiota-derived antigen and the relative abundance of specific Foxp3+ nTREG 
populations within the intestinal mucosa.  
The induction of Foxp3+ iTREG by murine MLN CD103+ DCs is implicated in oral 
tolerance, in which mice develop systemic peripheral tolerance to a fed antigen e.g. 
ovalbumin (OVA) (reviewed by Mayer and Shao, 2004). This is a multi-step process 
that requires sampling of OVA from the intestinal lumen and CCR7-dependent 
migration of CD103+ DCs into the MLNs (Worbs et al., 2006). Furthermore, the gut-
homing of Foxp3+ iTREG is then required as this does not develop in mice deficient in 
Ccr9-/- or Itb7--/ mice (Cassani et al., 2011, Hadis et al., 2011). Finally, the arrival of 
Foxp3+ iTREG is followed by a process of expansion within the intestinal mucosa under 
the influence of IL-10 derived from resident CX3CR1-GFPhi MФ (Hadis et al., 2011). 
Administration of the human commensal bacterium Bacteroides fragilis into germ-free 
mice leads to the induction of IL-10-producing Foxp3+ TREG. Furthermore, this 
conversion requires expression of polysaccharide A (PSA) by these bacteria (Round 
and Mazmanian, 2010). Deletion of IL-10 specifically in Foxp3+ T cells renders mice 
susceptible to spontaneous large intestinal inflammation, particularly in the caecum 
(Rubtsov et al., 2008). This indicates that production of IL-10 is an important 
mechanism by which Foxp3+ TREG maintain intestinal homeostasis in the steady state in 
mice. This is supported by the large presence of Foxp3+ IL-10+ and Foxp3- IL-10+ CD4+ 
T cells in the murine small and large intestinal mucosa in the steady state which are not 
apparent in other peripheral tissues (Maynard et al., 2007). Furthermore, mice lacking 
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IL-10 expression in Foxp3+ T cells do not display the systemic auto-immunity of Scurfy 
mice indicating that distinct mechanisms prevent the activation and expansion of self-
reactive effector T cells outside the intestine (Rubtsov et al., 2008). 
Type 1 regulatory T cells (TR1) represents an alternative regulatory T cell population in 
mice and humans and are defined by low proliferative capacity, high expression of IL-
10 and low expression of TGF-β, IFNγ and IL-2 upon activation (Groux et al., 1997). 
They are induced in the presence of high concentrations of IL-10 and efficiently 
suppress the proliferation of T cells in a contact-independent mechanism involving both 
IL-10 and TGF-β (Groux et al., 1997). Murine TR1 cells do not express Foxp3, and are 
therefore distinct from both Foxp3+ nTREG and iTREG (Vieira et al., 2004). The 
relationship between these subsets is controversial, however human peripheral blood 
CD25+ TREG induce an IL-10 producing TR1-like phenotype in naive CD4+ T cells during 
suppression assays (Dieckmann et al., 2002), indicating that Foxp3+ TREG may support 
the induction of further regulatory T cell phenotypes. 
In the presence of exogenous TGF-β, murine MLN CD103+ DCs efficiently induce 
Foxp3+ iTREG but fail to induce the IL-10+ TR1 phenotype from naive CD4+ T cells 
(Maynard et al., 2009). Inhibition of RA signalling during this stimulation however leads 
to efficient induction of IL-10+ TR1 cells, whilst suppressing Foxp3+ iTREG induction 
(Maynard et al., 2009).This indicates that the production of RA by MLN CD103+ DCs 
exerts reciprocal regulation of Foxp3+ iTREG and TR1 induction.  
The importance of FOXP3+ TREG in humans is indicated by the fatal autoimmunity of 
patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked 
syndrome (IPEX) which is caused by mutations in the FOXP3 gene (Bennett et al., 
2001, Wildin et al., 2001). However, the identification of TREG in humans is more difficult 
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in humans than in mice. This is due to transient expression of FOXP3 by activated 
human CD4+ T cells (Gavin et al., 2006, Allan et al., 2007, Pillai et al., 2007, Merlo et 
al., 2008) which does not associate with suppressive activity. Furthermore, induction of 
FOXP3 in naive CD4+ T cells with exogenous TGF-β does not induce suppressive 
activity (Tran et al., 2007). Additional markers including a lack of the IL-7 receptor 
(CD127) have been proposed to indentify FOXP3+ TREG in human blood (Liu et al., 
2006). This complexity means that identification of TREG in humans requires careful 
demonstration of regulatory properties. 
Studies have identified populations of TREG within the steady state human intestinal 
mucosa on the basis of high level expression of CD25  which are able to suppress the 
proliferation of CD25- cells in vitro (Makita et al., 2004). Furthermore myofibroblasts 
within human colonic LP support expansion of FOXP3+ TREG and the induction of 
FOXP3+ TREG from naive CD4+ T cells (Pinchuk et al., 2011). Stimulation of human 
blood TREG with flagellin through TLR5 increases suppressive activity, suggesting that 
interactions with microbial products in the intestinal mucosa may enhance the ability of 
TREG to maintain homeostasis in the steady state (Crellin et al., 2005). 
Nevertheless, human MLN CD103+ DCs induce a significantly greater number of 
FOXP3+ TREG compared with CD103- DCs (Iliev et al., 2009), which is consistent with 
the properties of murine MLN CD103+ DCs described above.  
1:8.6  B cells 
GALT is an important site of induction of IgA production by B cells. Murine DCs carrying 
live bacteria induce bacteria-specific IgA without T cell help (Macpherson et al., 2000). 
This process may recapitulated in vitro with murine PP DCs and requires the production 
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of RA as well as IL-5 or IL-6 by these DCs (Mora et al., 2006). Whilst specific for 
bacterial antigen, this IgA is of relatively low affinity as compared with that generated by 
B cells with the help of T cells in the GALT. In this case, activated T cells interact with 
or help B cells which have identified a component of the same antigen through the 
surface B cell receptor (BCR). Co-stimulation provided as a result of this interaction 
results in the formation of a germinal centre, wherein the B cell undergoes class switch 
recombination from IgM to IgA and also somatic hypermutation in which multiple clones 
of the original B cell are generated but with a range of mutations in the variable region 
of their antibody. Those mutants expressing an antibody of greater affinity are positively 
selected, resulting in the expansion of a clone generating a high affinity IgA (reviewed 
by Pabst, 2012). 
Activated B cells producing IgA differentiate into plasma cells and exit the GALT 
through draining lymphatics and enter the circulation via the thoracic duct. Following 
selective homing of these cells back into the gut (discussed in more detail in section 
1:9.3), they remain there for an extended period of time and generate large quantities 
of sIgA which is passed through the epithelium by pIgR-mediated transcytosis 
(reviewed by Pabst, 2012). 
Murine SI-LP CD103+ CD11b+ DCs efficiently induce the differentiation of naive B cells 
into IgA+ plasma cells in vitro following stimulation with CpG (ODN) through T cell-
independent class switching (Fujimoto et al., 2011). In contrast, SI-LP CD103+ CD11b- 
CD8α+ DCs do not efficiently induce this differentiation. IgA class-switching may be 
induced in the presence of RA and cytokines including IL-5 or IL-6 (Mora et al., 2006). 
The ability of CD103+ CD11b+ DCs to induce IgA class-switching may therefore relate 
to a superior ability to generate RA through enhanced Aldh1a2 (encoding RALDH2) 
expression (Fujimoto et al., 2011).  
Chapter 1: Introduction 
63 
 
Intraperitoneal (IP) injection of murine SI-LP CD103+ CD11b+ DCs pulsed with the 
model antigen ovalbumin (OVA) and stimulated with CpG (ODN) into mice followed by 
immunization with OVA leads to the generation of OVA-specific serum IgG and also 
sIgA as detected in faeces. In contrast, repeating this experiment with SI-LP CD103+ 
CD11b- CD8α+ DCs generates only serum IgG, consistent the reduced ability of 
CD103+ CD11b- CD8α+ DCs to generate the RA required for IgA class-switching. 
However, murine CD103+ CD11b- CD8α+ DCs and CD103+ CD11b+ DCs collected from 
lymphatics draining the murine small intestine possess equivalent levels of RALDH 
activity, and induce a similar level of CCR9 expression on CD8+ T cells (Cerovic et al., 
2012). They may therefore generate a similar degree of IgA class-switching upon 
interaction with B cells in the draining MLN. The reason for this difference in RA-
producing ability is unclear, but may relate to whether cells are collected directly from 
the mucosa or en route to the draining MLN.  
1:9 Lymphocyte migration 
1:9.1  Migration of naive lymphocytes into GALT and MLN 
DCs present within GALT and also those entering the draining MLNs interact with local 
populations of naive T cells. However, these lymphocyte populations are not static but 
actively circulate between lymphoid tissue and the blood stream in order to maximise 
the probability of an interaction with an antigen presenting cell presenting their cognate 
peptide-MHC ligand (reviewed by Agace, 2006).  
The mechanism of entry of naive T cells into murine PP has been elucidated in detail, 
and follows the ‘multi-step adhesion cascade model’ (reviewed by Butcher and Picker, 
1996). Naive T cells express CD62L (L-selectin), a glycoprotein of the C-type lectin 
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group which bind to specific carbohydrate moieties on selectin ligands. CD62L interacts 
with oligosaccharides containing sialyl-LewisX residues expressed on high endothelial 
venules (HEV) in lymph nodes (reviewed by (Butcher and Picker, 1996). Furthermore, 
CD62L interacts with sulphated glycans present on mucosal addressin cell adhesion 
molecule 1 (MAdCAM-1) (Berg et al., 1993), an immunoglobulin gene superfamily 
member which is expressed constitutively by endothelial cells throughout the 
gastrointestinal tract of mice and humans including associated lymphoid tissue and 
MLNs (Briskin et al., 1997). In addition, naive T cells express low to intermediate levels 
of the integrin α4β7 which is the principal receptor mediating interaction with MAdCAM-1 
(Berlin et al., 1993). Low affinity interactions between L-selectin and MAdCAM-1 with 
support from α4β7-MAdCAM-1 interactions facilitate tethering and rolling of circulating 
naive T cells along the PP endothelial surface (Bargatze et al., 1995). Naive T cells are 
then exposed to additional factors including the chemokine CCL21 which is present on 
HEV within T cell zones of PPs and MLNs, and which signals through the chemokine 
receptor CCR7 expressed by naive T cells. CCL21-CCR7 signalling triggers a 
conformational change or activation of the integrin αLβ2 on naive T cells, enhancing the 
ability of αLβ2 to interact with intercellular adhesion molecule 1 (ICAM-1) (reviewed by 
Sigmundsdottir and Butcher, 2008). The result of these interactions is the complete 
arrest of naive T cells in the PP and MLN HEVs, followed by a process of 
transendothelial migration (diapedesis) which is not fully understood. This process is 
summarized in Figure 1.6.  
1:9.2  Migration of effector T cells into intestinal mucosa 
Following activation in GALT and MLNs, effector T cells display a significant shift in 
their migratory capacity. This includes downregulation of CD62L and CCR7, consistent 
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which a diminished ability to enter lymphoid tissue (reviewed by Masopust and 
Schenkel, 2013). Simultaneously, they are induced to express a gut-homing phenotype 
that allows them to home specifically into the intestinal mucosa once they enter blood 
CCL25
MAdCAM-1
α4β7
CCR9
L-selectin
MAdCAM-1
CCR7
CCL21
Sialyl-LewisX
ICAM-1
αLβ2
Tethering/rolling Adhesion Transendothelial 
migration
PP and MLN
Intestinal mucosa
Endothelium
Figure 1.6: Migration of naive T cells and effector T cells into intestinal mucosa. Upper 
panel: Naive T cells express L-selectin which interacts with sialyl-LewisX residues expressed 
on high endothelial venules (HEVs) in PPs and MLNs, as well as with glycans of MAdCAM-1, 
leading to tethering and rolling along the endothelium. Low expression of α4β7 by naive T 
cells contributes to tethering through interaction with MAdCAM-1 (not shown).Signalling by 
CCL21 present on HEVs through CCR7 on naive T cells induces activation of the αLβ2 
integrin of naive T cells and increases affinity of this integrin for HEV-associated ICAM-1, 
bringing the cell to a stop. Transendothelial migration then transports the naive T cell to the 
interior of the tissue in a process which remains poorly understood. Lower panel: Naive T 
cells activated in GALT express high levels of α4β7 which is sufficient to interact with 
MAdCAM-1 on vascular endothelial cells in the intestinal mucosa and induce tethering and 
rolling behaviour. Signalling of CCL25 through CCR9 promotes recruitment of lymphocytes to 
the small intestinal mucosa, and may act through modulation of α4β7-MAdCAM-1 
interactions. 
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circulation via the thoracic duct (reviewed by Agace, 2006). This selective migration is a 
key part of the compartmentalisation of intestinal immune responses, where antigen 
sampled in a gut-specific context requires a gut-specific response. A subset of 
activated cells retain expression of both CD62L and CCR7, and so are able to continue 
to circulate through secondary lymphoid organs as central memory cells (TCM) 
(reviewed by Masopust and Schenkel, 2013). 
The first component of the T cell gut-homing profile is high level surface expression of 
the integrin α4β7, facilitating expression of MAdCAM-1 present on endothelial cells 
throughout the gastrointestinal tract (Briskin et al., 1997). In murine PP HEVs, high 
level expression of α4β7 is sufficient to induce rapid arrest of T cells through interaction 
with MAdCAM-1 (Bargatze et al., 1995). Mice treated with anti-MAdCAM-1 monoclonal 
antibodies have suppressed recruitment of adoptively transferred T cells into SI-LP and 
PPs (Haddad et al., 2003, Cassani et al., 2011). 
The second component of the lymphocyte gut-homing profile is the chemokine receptor 
CCR9, a 7 transmembrane spanning G protein-coupled receptor (Zaballos et al., 1999). 
The ligand for CCR9 is CCL25 which is expressed by small intestinal epithelial cells in 
mice and humans (Kunkel et al., 2000), but is not detected in cells within the murine 
intestinal LP (Stenstad et al., 2007). This indicates that CCL25 diffuses through the LP 
and becomes embedded on the endothelial vasculature. Adoptive transfer of Ccr9-/- 
CD4+ T cells into mice leads to significantly reduced migration of these cells into the SI-
LP compared with adoptively transferred wild-type CD4+ T cells (Stenstad et al., 2006).  
The mechanism of T cell entry into the small intestinal mucosa is likely to proceed 
through initial tethering and rolling via α4β7-MAdCAM-1 interactions, allowing interaction 
between CCR9 and CCL25 which may activate or cluster α4β7 to further enhance 
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interaction and induce arrest (see Figure 1.6). This is followed by transendothelial 
migration into the mucosa which remains incompletely understood. 
In addition to facilitating migration of lymphocytes into the intestinal LP, CCR9 is 
involved in recruitment of T cells directly into the epithelium where they are classed as 
intra-epithelial lymphocytes (reviewed by Agace, 2006). Accordingly, there is a striking 
reduction in the number of adoptively transferred Ccr9-/- CD8+ T cells in the small 
intestinal epithelium of recipient mice as compared with adoptively transferred wild-type 
CD8+ T cells (Johansson-Lindbom et al., 2003, Johansson-Lindbom et al., 2005). 
The expression of CCL25 follows a diminishing gradient along the length of the small 
intestine, with high level expression observed in murine duodenal epithelium and low 
level expression in ileal epithelium (Stenstad et al., 2007). This indicates that entry of 
lymphocytes into the LP of the proximal small intestine is more reliant on CCR9-CCL25 
signalling. Accordingly, the majority of CD4+ and CD8+ T cells in the human jejunal 
mucosa are CCR9+ (Kunkel et al., 2000), whilst this proportion falls to 60% in human 
ileal mucosa and just 20 and 10% in  human colonic mucosa for CD4+ and CD8+ T 
cells, respectively (Papadakis et al., 2001). 
The G protein coupled receptor GPR15 has recently been identified in mice as a 
putative chemokine receptor mediating recruitment of lymphocytes specifically to the 
large intestinal mucosa and acting in association with α4β7 (Kim et al., 2013). In contrast 
with CCR9, GPR15 did not influence recruitment of lymphocytes into small intestinal 
mucosa. Elevated expression of GPR15 is also observed in human large intestinal 
mucosa, suggesting that this system may be shared between mice and humans (Kim et 
al., 2013). 
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1:9.3  Migration of IgA+ activated B cells into the intestinal mucosa 
IgA+ activated B cells also home to the small intestinal mucosa in mice through 
expression of CCR9 (Pabst et al., 2004). Furthermore, the majority of IgA+ plasma cells 
within human intestinal mucosa are α4β7+ (Farstad et al., 1995). In contrast, migration of 
murine IgA+ B cells to the large intestinal mucosa as well as a range of other mucosal 
sites is mediated by expression of CCR10, which responds to CCL28 produced by 
epithelial cells (Pan et al., 2000, Wang et al., 2000).  
1:9.4  Migration of effector T cells to extraintestinal sites 
In contrast to lymphocytes primed in the GALT and PPs, lymphocytes primed in skin-
draining lymph nodes in mice express a range of receptors that facilitate homing into 
inflamed skin. This includes E-selectin ligands and P-selectin ligands which interact 
with E-selectin and P-selectin, respectively, expressed on endothelial cells, and CCR4 
which interacts with the chemokine CCL17 (reviewed by Sigmundsdottir and Butcher, 
2008). In mice, E-selectin and P-selectin expression by cutaneous endothelial cells are 
required to induce rolling of lymphocytes in the steady state (Weninger et al., 2000).  
In mice, RA suppresses the induction of E-selectin ligands whilst enhancing induction 
of α4β7 and CCR9 (Iwata et al., 2004). Vitamin D receptor, a nuclear receptor which 
pairs with RXR also induces a ‘skin-homing’ CCR10+ phenotype on T cells during 
activation in vitro whilst suppressing induction of α4β7 and CCR9 (Sigmundsdottir et al., 
2007). This allows T cells to home toward CCL27 preferentially expressed in murine 
inflamed skin (Reiss et al., 2001). 
In humans, a significant proportion of T cells present in inflamed and healthy human 
skin express cutaneous lymphocyte antigen (CLA) (Picker et al., 1990, Clark et al., 
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2006), an inducible carbohydrate modification of P-selectin glycoprotein ligand-1 
(PSGL-1) (Fuhlbrigge et al., 1997). CLA interacts with E-selectin (Berg et al., 1991) 
which is a lectin preferentially expressed by human cutaneous endothelial cells during 
chronic inflammation (Picker et al., 1991). CLA is therefore likely to mediate the 
migration of circulating human effector T cells into inflamed skin. Furthermore, a 
significantly greater proportion of effector/memory T cells in human skin draining lymph 
nodes express are CLA+ as compared with lymphoid tissue in the appendix, indicating 
that CLA is induced in humans during T cell activation (Picker et al., 1993). In contrast 
with mice, treatment of human T cells with both RA and vitamin D result in suppression 
of CLA expression (Yamanaka et al., 2008). 
1:10 RA-mediated regulation of lymphocyte gut homing  
The induction of a gut-homing α4β7+ CCR9+ profile on lymphocytes in mice is mediated 
by exposure of the cells to RA during activation in vitro (Iwata et al., 2004). The 
specialized ability of murine intestinal and MLN CD103+ DCs to induce α4β7 and CCR9 
expression on lymphocytes (Johansson-Lindbom et al., 2003, Stagg et al., 2002, 
Jaensson et al., 2008) is therefore dependent on the capacity of these DCs to generate 
RA. This may be complemented within MLNs by RA produced by stromal cells 
(Hammerschmidt et al., 2008). 
Furthermore, it has been demonstrated in OT-I cells in which RAR signalling induces 
expression of luciferase that MLN CD103+ but not CD103- DCs induce RAR signalling 
early during a T cell interaction, and prior to the first cell division (Jaensson et al., 2008, 
Svensson et al., 2008).  
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Human MLN CD103+ but not CD103- DCs induce RA-dependent CCR9 expression on 
CD8+ T cells (Jaensson et al., 2008). This indicates that as in the mouse, CD103+ DCs 
in the MLN have a specialised ability to generate RA. In contrast, both subsets induced 
α4β7 expression on CD8+ T cells. Their ability to imprint gut-homing on CD4+ T cells 
was not addressed in this work. 
As discussed in section 1:11, many studies identify an enhanced ability to produce RA 
through RALDH enzyme activity exclusively in CD103+ DCs. However, CD103- DCs 
collected from afferent lymphatics display equivalent RALDH activity and ability to 
induce CCR9 expression on naive CD8+ T cells (Cerovic et al., 2012). This discrepancy 
may result from confusion over the earlier ‘CD103- DC phenotype’, which would 
certainly contain CD11c+ CX3CR1-GFPhi MФ which do not possess enhanced RALDH 
activity (Schulz et al., 2009). By collecting cells from afferent lymphatics, only migratory 
conventional CD103- DCs are analysed as the CX3CR1-GFPhi MФ do not migrate in 
the steady state (Schulz et al., 2009).  
1:10.1  RA-mediated induction of α4β7 
The α4 and β7 integrin chains are produced independently in cells before binding and 
moving to the cell surface (reviewed by Hynes, 2002). In murine CD4+ and CD8+ T cells 
the α4 gene (Itga4) is under direct transcriptional control by RA whilst the β7 gene 
(Itgb7) is expressed constitutively (Kang et al., 2011). The basic leucine zipper 
transcription factor, ATF-like (BATF) facilitates interaction of RARα with the Itga4 
promoter and is required for the acetylation of histones in the regulatory region of this 
promoter (Wang et al., 2013). In BATF-/- mice, there is reduced mRNA expression of 
Itga4 and surface α4β7, but Itgb7 mRNA levels are unchanged. This results in reduced 
numbers of CD4+ and CD8+ T cells in the colon, SI-LP and PPs (Wang et al., 2013). 
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In addition to β7, α4 may also combine with β1. The α4β1 integrin binds to vascular cell 
adhesion molecule (VCAM)-1, which is expressed in non-intestinal sites including 
inflamed skin (reviewed by Agace, 2010). Whilst both β7 and β1 act in competition for 
the binding of α4, β1 is the dominant binding partner to α4 in mice (DeNucci et al., 2010). 
The presence of RA during T cell activation therefore results in increased α4 
expression, allowing β7 to overcome competition from β1 to create α4β7 at the cell 
surface. In mice deficient for β1, antigen-specific T cells uniformly express α4β7 
following infection with Listeria monocytogenes and selectively home into PPs 
(DeNucci et al., 2010). 
Beyond RA, induction of α4β7 on OT-I cells by murine CD103+ DCs pulsed with OVA 
peptide is influenced by antigen dose (Svensson et al., 2008).  Smaller doses associate 
with greater induction of α4β7, and enhanced migration of CD8+ T cells into the SI-LP 
following IP administration of OVA to mice. This effect is independent of the level of RA 
signalling that the CD8+ T cell experiences, indicating that additional factors overlap in 
the regulation of α4β7 expression.   
Induction of α4β7 by RA may also be counteracted by vitamin D receptor (VDR) 
signalling (Sigmundsdottir et al., 2007). This mechanism may involve sequestering of 
RXR into VDR-RXR complexes, reducing the level of RAR signalling. VDR signalling 
has also been proposed as an inducer of skin-homing markers such as E-selectin 
ligands and CCR10  
1:10.2  RA-mediated regulation of CCR9 
In contrast with α4β7, CCR9 expression facilitates migration of lymphocytes into the SI-
LP and epithelium but not into the LI in mice (reviewed by Agace, 2010). Like α4, CCR9 
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is under direct transcriptional control by RA (Kang et al., 2011). Following CD4+ and 
CD8+ T cell activation there is increased expression of Nfatc1 and Nfatc2, and both 
proteins are recruited into the nucleus. NFATc2 promotes CCR9 expression through 
enhanced recruitment of RARα/RXRα to the CCR9 promoter, whilst NFATc1 
suppresses this induction. In the period following T cell activation, nuclear levels of 
NFATc1 fall whilst nuclear NFATc2 is increased. The presence of RA therefore 
supports NFATc2-mediated induction of CCR9 expression, leading to increased 
surface CCR9 (Ohoka et al., 2011). 
Induction of CCR9 on naive CD4+ T cells by RA may also be further enhanced by direct 
stimulation of RXR. Naive OT-II cells adoptively transferred into mice injected IP with 
ova display enhanced homing into the SI-LP when administered in conjunction with the 
RXR agonist PA024 (Takeuchi et al., 2010). 
Murine naive CD8+, but not CD4+ T cells express CCR9 on their surface which is lost 
during stimulation in the absence of additional RA (Svensson et al., 2002). This may 
indicate a differential relationship between these subsets and the induction of CCR9 by 
RA. In support of this, CCR9 is efficiently induced on transferred OT-I but not OT-II 
cells in mice injected IP with OVA (Semmrich et al., 2011). 
Regulation of α4β7 and CCR9 expression in humans is also regulated by exposure to 
RA (Jaensson et al., 2008). The extent to which the mechanisms of RA-mediated 
induction for α4β7 and CCR9 in humans compares with mice is however unclear. 
1:11 Regulation of RA production by intestinal CD103+ DCs 
A key feature of murine intestinal CD103+ DCs, particularly those found within the small 
intestine and MLNs, is an ability to generate the vitamin A metabolite retinoic acid (RA) 
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via expression of retinaldehyde dehydrogenase (RALDH). This enables MLN CD103+ 
DCs to induce a gut-homing α4β7+ CCR9+ phenotype on activated T cells (see section 
1:9.2), and can influence the induction of distinct T cell profiles (see section 1:8). RA 
metabolism and RA-mediated regulation of T cell gut-homing by CD103+ DCs are 
discussed further in sections 1:12 and 1:10, respectively. 
Murine CD103+ DCs within the SI-LP and MLN possess an enhanced ability to 
generate RA through the activity of RALDH enzymes, as compared with CX3CR1-GFPhi 
resident MФ in the SI-LP which display 3 fold reduced expression of Aldh1a2 (Schulz et 
al., 2009). RALDH activity of intestinal DCs correlates closely with tissue concentration 
of retinol and RA, which is greatest in the duodenum and decreases along the length of 
the intestine (Villablanca et al., 2011b). This indicates that exposure of CD103+ DCs to 
RA in the intestinal mucosa may be key to the generation of RALDH activity. Vitamin A-
deficient (VAD) mice display significantly reduced RALDH2 activity in their MLN and SI-
LP CD103+ DCs (Molenaar et al., 2011, Jaensson-Gyllenback et al., 2011). 
Furthermore, RALDH activity of MLN CD103+ DCs is enhanced following oral 
administration of RA to VAD mice (Villablanca et al., 2011b). Finally, intrarectal 
administration of RA enhances RALDH activity of colonic CD103+ DCs, suggesting that 
reduced tissue RA is responsible for their relatively diminished RALDH activity 
(Jaensson-Gyllenback et al., 2011).  
The intestinal epithelium may act as a source of RA for the induction of RALDH activity 
in CD103+ DCs. As an important site of uptake of dietary retinol (discussed further in 
section 1:12), small intestinal enterocytes but not LP cells express cellular retinol 
binding protein II (CRBPII) (Crow and Ong, 1985). SI-LP CD103+ DCs from CRBPII-/- 
mice have significantly reduced RALDH activity which suggests that the ability of 
Chapter 1: Introduction 
74 
 
enterocytes to contain and process retinol in some way is critical for the subsequent 
induction of RALDH activity in CD103+ DCs (McDonald et al., 2012).  
Retinoids derive from the diet (see section 1:12), and their persistence within the 
intestinal lumen is prolonged through their presence in bile salts which further support 
induction of RALDH activity in murine CD103+ DCs (Jaensson-Gyllenback et al., 2011, 
McDonald et al., 2012). 
The upregulation of RALDH activity in murine CD103+ DCs is rapid given the absence 
of activity in circulating pre-DCs (Jaensson-Gyllenback et al., 2011) and  the relatively 
fast turnover of these cells within the LP compared with resident CX3CR1-GFPhi MФ 
(Rivollier et al., 2012, Schulz et al., 2009). The inability of CX3CR1-GFPhi MФ to 
upregulate RALDH activity to the same extent as CD103+ DCs despite persisting in the 
tissue for long periods of time (Schulz et al., 2009) could  indicate the presence of 
negative RALDH factors which restrain this activity in some cells. Indeed, prostaglandin 
E2 (PGE2) suppresses the induction of RALDH activity in both murine and human 
monocyte-derived DCs via induction of cyclic adenosine monophosphate (cAMP)-
regulated proteins (Stock et al., 2011). Interestingly, MLN DCs have reduced 
expression of the E-prostanoid-2 (EP2) receptor, suggesting that RALDH activity 
develops through absence of restriction by PGE2 signalling. Whether suppression of 
RALDH activity in CX3CR1-GFPhi MФ is mediated through PGE2 remains to be 
determined.  
RA alone is sufficient to induce Aldh1a2 expression and RALDH activity in murine 
splenic DCs, and this induction is blocked with inhibition of the mitogen associated 
protein kinase (MAPK) ERK (Villablanca et al., 2011b). Furthermore, mice fed an oral 
ERK antagonist display reduced RALDH activity in their MLN CD103+ DCs, indicating 
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that this pathway is important in the in vivo induction of RALDH activity by RA in the 
intestine (Villablanca et al., 2011b). Induction of RALDH activity in splenic DCs is also 
reduced in MyD88-/- mice, suggesting an involvement of TLR signalling in this process 
(Villablanca et al., 2011b). Consistent with this view, stimulation of murine splenic DCs 
with the TLR1/2 agonist Pam3CSK4 (a bacterial lipoprotein) of the fungal TLR2 ligand 
zymosan, is sufficient to induce RALDH activity (Wang et al., 2011b). This process 
requires JNK/MAPK signalling, as opposed to ERK/MAPK, suggesting that JNK and 
ERK may regulate TLR and RA-induced Aldh1a2 expression, respectively. In contrast, 
stimulation of murine splenic DCs with the fungal TLR2 ligand zymosan induces 
RALDH activity in a ERK-dependent manner (Manicassamy et al., 2009), suggesting 
further complexity. TLR2-/- mice also display reduced RALDH activity of MLN CD103+ 
DCs, with reduced imprinting of α4β7 and CCR9 on CD8+ T cells (Wang et al., 2011b). 
This further implicates microbial recognition through TLR1/2 in the development of 
RALDH activity in intestinal CD103+ DCs. 
Culturing murine splenic DCs with the zymosan induces expression of CD137 (also 
known as 4-1BB), a member of the TNF receptor superfamily. Stimulation of this 
receptor enhances induction of RALDH activity in these cells in an ERK-dependent 
manner (Lee et al., 2012). Furthermore, the majority of murine MLN CD103+ DCs are 
CD137+ (Lee et al., 2012), indicating that this pathway may also be active in promoting 
upregulation of RALDH activity in vivo.  
Infection of mice with adenovirus 5 leads to gut-homing of antigen-specific CD8+ T 
cells. This is caused by GM-CSF-mediated upregulation of RALDH activity in non-
intestinal DCs, leading to the induction of α4β7 on CD8+ T cells (Ganguly et al., 2011a). 
GM-CSF also induces Aldh1a2 expression in murine bone marrow (BM)-derived DCs, 
and mice deficient in GM-CSF display significantly reduced RALDH activity in intestinal 
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DCs (Yokota et al., 2009). The DC-specific cytokine Flt3L alone did not induce Aldh1a2 
expression in BM-DCs, but did in the presence of either IL-4 or IL-13 (Yokota et al., 
2009). The factors influencing RALDH activity of murine intestinal CD103+ DCs are 
summarized in Figure 1.7. 
 
1:12 RA metabolism  
RA is derived from dietary vitamin A (retinol), ingested as retinyl esters from animal 
tissue and carotenoids from vegetables. Most retinyl esters are enzymatically converted 
to retinol in the intestinal lumen before being absorbed by enterocytes. Some 
carotenoids are converted to retinol within the enterocytes (Blomhoff et al., 1990). 
Figure 1.7: Factors regulating RALDH activity of murine SI-LP CD103+ DCs. Retinoids 
derived from the diet and present within bile provide the main signals promoting RALDH 
activity within murine SI-LP CD103+ DCs. GM-CSF and TLR2 ligands such as zymosan 
induce RALDH activity in murine splenic DCs in vitro and so may also influence RALDH in 
intestinal CD103+ DCs. PGE2 is a negative regulatory of RALDH in DCs; it may suppress 
RALDH activity in cells other than CD103+ DCs. 
GM-CSF
PGE2
Dietary retinoids Bile retinoids
TLR2 ligands
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Retinol is then converted back into retinyl esters and packaged into chylomicrons which 
enter circulation via the lymphatics and are processed in the liver. A steady release of 
retinol associated with retinol binding protein (RBP) into the circulation ensures that 
retinol is distributed to target sites around the body (Blomhoff et al., 1990). 
Transfer of retinol into cells occurs either via the transporter STRA6 (Kawaguchi et al., 
2007), or by passive diffusion. Inside the cell, retinol is bound by cellular retinol binding 
protein (CRBP)-I and is converted into retinoic acid by a two stage oxidation process. 
The first is reversible, catalysed predominantly by the microsomal short chain 
dehydrogenase/reductase enzymes (SDR) and generates retinal. Well established 
members of this enzyme family include RDH10 (Rdh1 in mice), RDH16 and DHRS9. 
Retinal is then irreversibly oxidised to RA by members of the cytosolic retinaldehyde 
dehydrogenase (RALDH) family, of which RALDH1 (ALDH1A1), RALDH2 (ALDH1A2) 
and RALDH3 (ALDH1A3) are the best studied. Whilst both oxidations require the 
cofactor nicotinamide adenosine dinucleotide (NAD), the first is stage is rate limiting in 
the presence of CRBP-I (reviewed by Napoli, 2012). The production of RA is 
summarized in Figure 1.8. 
Different retinoid isoforms exist based on whether the functional groups of the molecule 
are on different sides (trans) or on the same side (cis) of the four double bonds present 
in the side chain of the structure. The all-trans form predominates, and is the most 
biologically active. The different enzymes have varying affinities for 9-cis and all-trans 
retinoids, but an in vivo role for 9-cis RA remains controversial (reviewed by Napoli, 
2012). 
The net level of RA within a cell is determined by the rate of degradation as well as 
synthesis. The cytochrome P450 (CYP)26 family of enzymes are known to convert RA 
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into the polar and much less biologically active metabolites 4-hydroxy RA and 4-oxo RA 
(Niederreither and Dolle, 2008). Members of this family include CYP26a1 and 
CYP26b1, which has been implicated in regulating CCR9 expression in murine T cells 
(Takeuchi et al., 2011). 
1:13 RA signalling 
The retinoic acid receptor (RAR) exists as 3 isoforms (α, β, and γ) and forms a 
heterodimer with the one of the 3 isoforms of the retinoid X receptor (RXR; α, β, and γ). 
NAD(P)+
NAD(P)H + H+
NAD+ + H2O
NADH + H+
RDH10
RDH16
DHRS9
RALDH1 (ALDH1A1)
RALDH2 (ALDH1A2)
RALDH3 (ALDH1A3)
NAD(P)+
NAD(P)H + H+
RRD
H3C
CH3
CH3 CH3 CH3
OH
H3C
CH3
CH3 CH3 CH3 O
H
H3C
CH3
CH3 CH3 CH3 O
OH All-trans retinoic acid
All-trans retinol
All-trans retinal
Figure 1.8: Generation of RA from retinol. All-trans retinol is derived from dietary β-
carotene and retinyl esters e.g. retinyl palmitate. This is reversibly oxidised by members of 
the short chain dehydrogenase/reductase (SDR) family of enzymes including RDH10, 
RDH16 and DHRS9. Retinol reductase enzymes (RRD) catalyse the reduction of retinal back 
to retinol. Retinal is then irreversibly oxidised to retinoic acid by the ALDH1A (RALDH) family 
of enzymes including RALDH1, RALDH2 and RALDH3. 
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RAR/RXR is a member of the superfamily of nuclear receptors, and is a ligand-
activated transcription factor. In absence of RA, RAR/RXR recognises and occupies a 
short sequence of DNA known as a RA response element (RARE) and associates with 
transcription co-repressors. These include histone deacetylases and methyl transferase 
complexes that render the DNA inaccessible. Binding of RA to RAR/RXR leads to a 
conformational shift in a ligand binding domain, releasing co-repressors and recruiting 
activators involved in chromatin remodelling and actvation of transciption machinery 
(Niederreither and Dolle, 2008). 
RA is associated with cellular retinoic acid bindinig proteins (CRABPs), which mediate 
transfer of RA onto RAR/RXR (Napoli, 2012). Alternative binding proteins such as  fatty 
acid binding protein (FABP)-5 have been associated with transfer of RA to separate 
nuclear receptors such as PPARγ (Schug et al., 2007). 
Hundreds of genes have been identified as being regulated by RA. However, only 
relatively few have been shown to possess RARE indicating direct regulation (Balmer 
and Blomhoff, 2002). This implies the vast majority of RA-regulated genes are 
regulated in an indirect manner. 
1:14 Inflammatory bowel disease 
1:14.1  General features of IBD 
Patients with inflammatory bowel disease (IBD) experience relapsing and remitting 
episodes of intestinal inflammation. This has a significantly detrimental impact on 
quality of life, with symptoms including abdominal pain, diarrhoea with blood and/or 
mucus, vomiting and nausea. IBD is believed to be the result of a complex interplay 
between an exaggerated immune response to the commensal microbiota, genetic 
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predisposition and a range of environmental factors which are not fully understood 
(reviewed by Baumgart and Carding, 2007).  
IBD is divided into two separate diseases, Crohn’s disease (CD) and ulcerative colitis 
(UC). Early inflammatory events in CD typically manifest as ulcers overlying lymphoid 
follicles and PPs. Inflammation affects multiple layers of the intestine (transmural), 
extending beyond the submucosa as far as the serosa. Isolated areas are affected and 
may be surrounding by apparently normal mucosa (focal inflammation). Furthermore, 
inflammation may affect any part of the gastrointestinal tract (reviewed by Day and 
Morson, 2003). A cohort study of 306 CD patients in the US identified inflammation in 
the TI in 45%, the colon in 32% and both the TI and colon (ileocolonic) in 18.6 % of 
patients at diagnosis (Thia et al., 2010). Patients may develop stricturing where the 
intestine narrows causing bowel obstruction, or fistulae where transmural inflammation 
forms a passageway into a new area of the body (e.g. between the colon and skin). 
The cumulative risk for developing either a stricturing or penetrating disease 20 years 
after diagnosis is approximately 50% (Thia et al., 2010). Non-caseating granulomas are 
present in approximately 50% of CD patients, and may be located in the mucosa, 
submucosa and in lymphoid tissue (reviewed by Day and Morson, 2003). The varying 
location and severity of inflammation as well as the presence or absence of stricturing 
fistulae in CD patients demonstrates the highly heterogeneous nature of this disease. 
Inflammation in UC is present almost universally in the rectum, and extends to varying 
extents along the large intestine in a continuous manner. Where the entire large 
intestine is inflamed (pan colitis), inflammation may also be present in the TI. 
Furthermore, the inflammation is more superficial than in CD, largely limited to the 
mucosa and submucosa (reviewed by Day and Morson, 2003). Pathological features of 
UC include leukocyte infiltration into the LP. Mucosal architecture also becomes 
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distorted with a shortening of crypts, mucin depletion and ulceration (reviewed by 
Ordas et al., 2012).  
There are a number of associations between IBD and additional extra-intestinal 
manifestations. For example, there is increased incidence in arthropathy and the skin 
conditions pyoderma gangrenosum and erythema nodosum in both CD and UC 
patients (reviewed by Day and Morson, 2003). There is also an association between 
liver pathology and chronic UC. Between 5 and 10 % of UC patients develop primary 
sclerosing cholangitis (PSC), where fibrosis causes inflammation and obstruction of the 
bile ducts (cholangitis). Up to 70% of PSC patients also have UC (reviewed by Day and 
Morson, 2003).  
1:14.2  Genetic predisposition to IBD 
IBD manifests in genetically susceptible individuals, however the nature of this 
susceptibility is complex and known genetic variants account for only approximately 
13.6 % of CD cases and 7.5 % of UC cases (Jostins et al., 2012). 
Early studies identified frameshift and missense variants in nucleotide oligomerization 
domain (NOD)-2 in CD patients (Hugot et al., 2001, Ogura et al., 2001). NOD2 acts as 
an intracellular receptor for muramyl dipeptide (MDP), a component of bacterial 
peptidoglycan, leading to activation of NF-κB and the production of pro-inflammatory 
cytokines (Inohara et al., 2003, Girardin et al., 2003). Human monocyte-derived DCs 
(MoDCs) derived from CD patients with NOD2 mutations display a significantly reduced 
ability to process bacterial antigen and to present bacteria-derived peptides (Cooney et 
al., 2010). These genetic studies therefore underscore the importance of ability of the 
intestinal innate immune system to respond to bacterial encroachment appropriately.  
Chapter 1: Introduction 
82 
 
Genome wide association studies (GWAS) have identified 163 genetic loci implicated in 
IBD (Jostins et al., 2012). Of these 163 loci, 30 are specific for CD and 23 are specific 
for UC, and the so the majority are common to both diseases (Jostins et al., 2012). 
Whilst these loci refer to specific areas of the genome, the identity and function of the 
genes within these areas are not always known (reviewed by Graham and Xavier, 
2013). The magnitude of risk associated with each polymorphism is very small, but 
provides a potential insight into the particular pathways that may involved in the 
pathogenesis of IBD. This includes autophagy, a lysosomal degradation pathway 
whereby cell components are degraded for re-use, and by which internalized bacteria 
may also be degraded (reviewed by Levine and Kroemer, 2008). Variants in ATG16L1 
are implicated in CD through impaired Paneth cell function, as with diminished 
autophagy these highly secretory cells are less able to manage an accumulation of mis-
folded protein (Cadwell et al., 2008). This may lead to increased bacterial 
encroachment due reduced output of anti-microbial peptides. In addition, stimulation of 
NOD2 promotes recruitment of ATG16L1 to the cell membrane for the internalization of 
bacteria and subsequent destruction in the autophagosome (Travassos et al., 2010). 
In contrast to CD, NOD2 variants are not associated with UC (Anderson et al., 2011). 
UC-specific variants include CDH1 which encodes E-cadherin and is expressed by 
intestinal epithelial cells (Anderson et al., 2011). In addition, variants in the region 
encoding HNFA have been associated with UC (Barrett et al., 2009). HNF4A encodes 
the transcription factor hepatocytes nuclear factor 4 which regulates expression of tight 
junction proteins in epithelium of the liver and intestine (Battle et al., 2006). This 
specifically implicates the barrier function of the intestinal epithelium in UC as a source 
of predisposition to disease. 
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Both CD and UC are associated with variants in genes associated with TH17-mediated 
immunity, including IL23R, IL12B (encoding IL-12/23p40), JAK2 and STAT3 (Anderson 
et al., 2011). Furthermore, both CD and UC are associated with variants in IL10 
(Franke et al., 2008, Franke et al., 2010). Overall therefore, individuals with IBD are 
genetically predisposed to some extent to have a dysregulated immune response which 
may be due to genetically predisposed barrier function as in UC, or a genetically 
predisposed inability to cope with bacterial encroachment as in CD. As described 
previously, known genetic variants account for only approximately 13.6% of CD cases 
and 7.5% of UC cases (Jostins et al., 2012). One study observed that in a group of 
monozygotic twins where at least one sibling had CD, the second also had CD in 35 % 
of cases compared with just 3 % for dizygotic twins. For UC, the figures were 16 and 2 
%, respectively (Spehlmann et al., 2008). Whilst this indicates a clear role for genetic 
pre-disposition in both CD and UC, the fact that in the majority of cases only one of the 
identical twins had IBD indicates the role that additional environmental factors play in 
the pathogenesis of disease. It has been proposed that epigenetics, or non-coding 
DNA modifications that influence gene expression and may be mitotically inherited 
bridge the ‘missing heritability’ gap between known disease variants and environmental 
factors (reviewed by Ventham et al., 2013). 
1:14.3  Environmental factors 
IBD incidence varies according to geographical location, with high incidence areas 
including North America, northern Europe and Australia. Low incidence areas include 
southern and eastern Europe, Asia and many developing countries. The incidence of 
IBD is however steadily increasing in these low incidence areas (reviewed by Ng et al., 
2013). This variation has been linked to a range of environmental factors associated 
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with the ‘western lifestyle’ including urbanisation of society, improved sanitation, diet, 
antibiotic use, microbial exposure and pollution (reviewed by Ng et al., 2013). Tobacco 
smoking is a clearly defined environmental factor associated with modifications in IBD 
incidence. Smoking is associated with increased severity of CD (Seksik et al., 2009), 
and is protective against UC (Mahid et al., 2006). 
IBD is believed to result from a breakdown in the relationship between intestinal 
microbiota and the host immune system (reviewed by Baumgart and Carding, 2007). 
An important environmental factor in IBD is therefore the nature of the microbiota itself. 
IBD associates with reduced proportions of Bifidobacteria, Lactobacilli, Bacteroides and 
Firmicutes (reviewed by Sartor, 2008). An increased prevalence of an adherent 
invasive E. coli (AIEC) has been observed specifically in ileal CD and may contribute to 
disease pathogenesis through invasion of the intestinal epithelium (Boudeau et al., 
1999, Darfeuille-Michaud et al., 2004, Martin et al., 2004b). Furthermore, a reduction in 
the numbers of the Firmicute Faecalibacterium prausnitzii associates with increased 
risk of post-operative CD recurrence (Sokol et al., 2008b). There is also a significant 
association between acute gastrointestinal infection and the onset or exacerbation of 
IBD (García Rodríguez et al., 2006, Porter et al., 2008, Gradel et al., 2009). This is 
consistent with infection triggering a breakdown in the host-microbiota relationship in a 
subset of genetically susceptible individuals. 
As discussed in section 1:4.2, the intestinal epithelium is required to provide a physical 
barrier between the luminal microbiota and the interior of the mucosa. Increased 
intestinal permeability is associated with both CD and UC, indicating that the intestinal 
immune system is exposed to microbiota-derived antigen to a significantly greater 
extent in IBD patients compared with healthy controls (reviewed by Baumgart and 
Sandborn, 2012, Ordas et al., 2012). The structure of the epithelium itself is modified in 
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CD, which reduced expression of tight junction proteins in inflamed areas (Zeissig et 
al., 2007).  
In CD, reduced expression of the mucin gene MUC1 is observed in the inflamed ileum 
of CD patients (Buisine et al., 1999), indicating that defective mucin production may 
contribute to bacterial encroachment. Furthermore, a genetic variant of MUC1 is 
associated with CD (Franke et al., 2010). Active UC associates with reduced production 
of MUC2 (Van Klinken et al., 1999), supporting defective separation of the intestinal 
microbiota from the interior of the mucosa in the pathogenesis of disease. As discussed 
in section 1:4.1, Muc2-/- mice display bacterial encroachment directly onto the large 
intestinal epithelium (Johansson et al., 2008), associating with the onset of colitic 
symptoms including diarrhoea, rectal prolapse as well as severe growth retardation 
(Van der Sluis et al., 2006).  
1:14.4  Immune-mediated inflammation in IBD  
As described in section 1:12.1, IBD is believed to result from an inappropriate immune 
response to commensal microbiota in genetically susceptible individuals. Inflammation 
in the intestine is driven by a range of pro-inflammatory mediators including cytokines 
with a broad range of effects. The prototypical pro-inflammatory cytokine is TNFα, 
which is produced in significantly elevated quantities by mononuclear cells, including 
MФ and T cells, in the inflamed mucosa of both CD and UC patients compared with 
healthy controls alongside IL-6 and IL-1β (Reinecker et al., 1993). Subepithelial MФ are 
the predominant source of TNFα in UC, whilst TNFα+ cells are evenly distributed 
throughout the LP in CD and beyond into the submucosa where they cluster around 
arterioles and venules (Murch et al., 1993). This distribution of TNFα+ cells therefore 
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parallels the differing nature of intestinal inflammation between UC and CD patients as 
discussed in section 1:12.1. 
Therapies which specifically target TNFα such as the neutralising monoclonal 
antibodies infliximab and adalimumab are significantly more effective in inducing clinical 
remission in patients with active CD (reviewed by Akobeng and Zachos, 2004) and UC 
(reviewed by Lawson et al., 2006) than placebo. However, the soluble TNF receptor-Fc 
fusion protein etanercept is ineffective in the treatment of CD (Sandborn et al., 2001). 
Whilst both infliximab and etanercept effectively neutralise soluble TNFα, Infliximab 
alone is able to bind surface TNFα on activated T cells and induce apoptosis in 
peripheral blood and intestinal LP activated T cells (ten Hove et al., 2002, Van Den 
Brande et al., 2003). Infliximab also induces apoptosis in blood monocytes from CD 
patients (Lugering et al., 2001). As discussed in section 1:15.5, human CD14+ 
monocytes are implicated in the pathogenesis of IBD. Overall, this indicates that 
neutralisation of soluble TNFα is insufficient to resolve intestinal inflammation in IBD, 
which instead requires removal of cells which are important sources of TNFα and other 
pro-inflammatory cytokines. 
As discussed in section 1:14.5.3, over-expression of TNFα in mice leads to 
inflammation of the ileum with several features of human CD (Kontoyiannis et al., 
1999). A key target of TNFα signalling in this model are intestinal myofibroblasts, which 
are stromal cells in the LP, and respond by producing a range of matrix 
metalloproteinases (MMPs) which degrade the tissue and propagate inflammation 
(Armaka et al., 2008). 
Inflammation in CD is associated with high levels of production of IFNγ by LP T cells 
(Fuss et al., 1996), and antigen presenting cells in CD patients produce greater 
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amounts of IL-12 compared with UC patients and healthy controls (Hart et al., 2005, 
Fuss et al., 2006). There is also an accumulation of Tbet+ T cells in the inflamed 
intestinal LP of CD patients compared with UC and healthy controls (Neurath et al., 
2002). Such observations led to the classification of CD as a TH1-mediated disorder 
(reviewed by Strober and Fuss, 2011). Elevated IFNγ is likely to contribute to disease 
pathogenesis through a diverse range of activities including the activation of endothelial 
cells promoting recruitment of neutrophils and monocytes into the inflammatory foci, 
activation of neutrophils and MФ, leading to the production of further pro-inflammatory 
cytokines, ROS and RNI, as well as upregulation of MHC molecules and promotion of 
antigen presentation (reviewed by Boehm et al., 1997). 
However, monoclonal antibodies to IFNγ are not effective in inducing a clinical 
response in CD patients when compared with placebo, suggesting that whilst IFNγ may 
contribute to disease pathogenesis, transient reduction in IFNγ is not sufficient to halt 
an ongoing intestinal inflammatory response (Reinisch et al., 2006, Reinisch et al., 
2010). 
Increased expression of IL-17A by intestinal LP T cells is observed in both CD and UC 
patients compared with healthy controls (Fujino et al., 2003). This has led to the 
proposal that inflammation in CD is mediated by a mixed TH1/TH17 response (reviewed 
by Strober and Fuss, 2011). IL-17A may contribute to intestinal inflammation as it 
synergizes with TNFα in inducing the production of the neutrophil chemokines IL-8 
(CXCL8) and CXCL1 by human intestinal epithelial cells in vitro (Lee et al., 2008). A 
population of IFNγ+/IL-17A+ T cells is present in peripheral blood and inflamed intestinal 
LP in CD patients which produces both IFNγ and IL-17A upon stimulation with IL-23 
(Kleinschek et al., 2009). In contrast, peripheral blood IFNγ+/IL-17A+ T cells in healthy 
controls require prior activation with IL-1β in order to respond to IL-23 with IFNγ and IL-
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17A production (Kleinschek et al., 2009). The role of IL-17A in the pathogenesis of CD 
remains controversial however as monoclonal antibodies against IL-17A are ineffective 
in CD, and associate with increased susceptibility to bacterial and fungal infections 
(Hueber et al., 2012). This suggests that IL-17A may exert both protective as well as 
pro-inflammatory effects in CD. This is supported by the T cell transfer colitis mouse 
model of intestinal inflammation (see section 1:12.5.2) whereby adoptive transfer of T 
cells from Il17a-/- mice into Rag-/- recipients causes a more severe intestinal 
inflammation than transfer of WT cells (O'Connor et al., 2009). Furthermore in the DSS 
colitis mouse model of intestinal inflammation (see section 1:12.5.1) Il17a-/- mice 
display a more severe colitis upon administration of DSS than WT mice (Yang et al., 
2008b). In contrast, in Il17f-/- mice this colitis is attenuated (Yang et al., 2008b), 
indicating contrasting protective and inflammatory roles within the IL-17 cytokine family. 
The transition from normal mucosa to macroscopically inflamed mucosa in the neo TI of 
CD patients following surgical removal of the original TI is associated with abundant 
levels of TNFα and IFNγ alongside a marked increase in IL-17A, IL-6 and IL-23 
expression (Zorzi et al., 2013). Established lesions contain a mixed TH1/TH17 response, 
with relatively low levels of TNFα (Zorzi et al., 2013). 
High levels of IL-6 and IL-1β produced by stromal cells in the intestinal mucosa of CD 
patients compared with healthy controls promote the proliferation of T cells in vitro, 
whilst IL-1β enhances production of both IFNγ and IL-17A (Huff et al., 2011). 
UC is associated with elevated concentrations of the TH2 cytokines IL-13 and IL-5, but 
not elevated expression of the classic TH2 cytokine IL-4 (Fuss et al., 1996, Fuss et al., 
2004). Such observations led to UC being defined as a ‘TH2-like’ immunopathology 
(reviewed by Strober and Fuss, 2011), although this remains controversial. It has been 
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proposed that IL-13 produced by a lymphocyte which shares features of NK and T cells 
(NK T cell) damages the intestinal epithelium in UC through modulation of tight junction 
proteins (Heller et al., 2005). Recent studies however have indicated that CD4+ T cells 
in both CD and UC display elevated production of IFNγ and IL-17A as compared with 
healthy controls (Rovedatti et al., 2009). Furthermore, the overall gene expression in 
CD and UC is remarkably similar, with a rare exception being elevated expression of IL-
23 in UC relative to CD intestinal mucosa (Granlund et al., 2013). This therefore 
challenges the notion that CD and UC are distinguished by the nature of the ongoing 
adaptive immune response, and indicates that distinct initiation events converge on a 
TH1/TH17-mediated intestinal inflammation. 
Inflammation associated with IBD may be the result of a failure of TREG populations 
within the intestinal mucosa to restrict the activity of effector T cells. However, 
identifying TREG within the human intestinal mucosa is made difficult by the transient 
expression of FOXP3 in activated T cells (Gavin et al., 2006, Allan et al., 2007, Pillai et 
al., 2007, Merlo et al., 2008). Regardless, CD25hi FOXP3+ T cells are present at low 
density in the intestinal mucosa of healthy controls, and at increased densities in UC 
and CD patients (Makita et al., 2004, Maul et al., 2005, Uhlig et al., 2006). CD4+ CD25hi 
T cells obtained from the colonic mucosa of healthy controls and IBD patients also 
suppress the proliferation of autologous peripheral blood T cells (Makita et al., 2004, 
Kelsen et al., 2005, Maul et al., 2005), consistent with a TREG phenotype. The presence 
of putative TREG populations within the inflamed mucosa of IBD patients indicates that 
these cells are unable to suppress effector T cells within this context. This is supported 
by observations that effector T cells in the inflamed mucosa of IBD patients express 
SMAD7, and so are resistant to TGF-β-mediated suppression by TREG (Fantini et al., 
2009). SMAD7 prevents TGF-β-dependent formation of SMAD2 and SMAD3, 
Chapter 1: Introduction 
90 
 
preventing association with SMAD4 and nuclear accumulation and transcriptional 
activity of SMAD2/3 (Hayashi et al., 1997, Nakao et al., 1997).   
Inflamed intestinal mucosa of CD patients contains a population of FOXP3+ CD4+ T 
cells with the capacity to produce IL-17A, and which are not observed in UC patients or 
healthy controls (Hovhannisyan et al., 2011). These FOXP3+ IL-17A+ cells display 
features overlapping TREG, TH17 and TH1 phenotypes as they suppress proliferation of 
peripheral blood CD4+ T cells in vitro, express IL-17A and RORγt, as well as expressing 
IFNγ and Tbet (Hovhannisyan et al., 2011). However these cells are not observed in 
peripheral circulation, and so may be induced within the intestinal mucosa under the 
influence of local mediators specific to CD patients. Treatment of CD4+ T cells from UC 
patients but not healthy controls with TGF-β is sufficient to induce IL-17A production 
from FOXP3+ T cells, suggesting that TGF-β as well as other factors induce this 
phenotype in CD (Hovhannisyan et al., 2011). It is unclear to what extent these distinct 
cell phenotypes negate each other, and whether overall they exert a pro or anti-
inflammatory effect. 
1:14.5  Mouse models of IBD 
Due to the limitations of studying disease mechanisms in humans, a diverse array of 
experimental mouse models of IBD have been generated and continue to provide key 
insights into how inflammation alters cellular behaviour within the intestinal mucosa 
(reviewed by Strober et al., 2002). This section will provide an overview of the models 
that have been used to conduct work relevant to the subject of this thesis. 
Chapter 1: Introduction 
91 
 
1:14.5.1 DSS colitis 
Dextran sodium sulphate (DSS) is a sulphated polysaccharide that when given to mice 
in drinking water induces inflammation in the large intestine within 7 days. This is 
associated with increased intestinal permeability, increasing exposure of the interior of 
the intestinal mucosa to intestinal microbiota. Inflammation manifests in a loss of crypts, 
infiltration of inflammatory cells including neutrophils and MФ into the mucosa and 
submucosa, oedema of the submucosa and ulceration (Okayasu et al., 1990). The 
molecular weight of DSS influences inflammation, with 5 kDa DSS primarily affecting 
the cecum and proximal colon in contrast with 40 kDa DSS which produces a more 
severe inflammation of the distal colon (Kitajima et al., 2000). The cytokine profile of 
DSS colitis is dominated by TNFα and IL-6. Inflammation is also induced in Rag2-/- mice 
which lack T and B cells, indicating that this is a model of innate inflammation in which 
MФ and neutrophil-derived pro-inflammatory cytokines play a key role in promoting 
tissue damage (Dieleman et al., 1994) . DSS colitis may also be induced in germ-free 
mice, indicating that the presence of intestinal inflammation is not absolutely required 
for the onset of inflammation (Bylundfellenius et al., 1994, Kitajima et al., 2001). 
1:14.5.2 T cell transfer colitis 
The CD45RBhi subset of CD4+ T cells is enriched for naive CD4+ T cells. Adoptive 
transfer of these cells into immunodeficient mice (Rag-/-, lacking mature T and B cells) 
induces a severe colitis within 3 to 5 weeks. Inflammation is restricted to the large 
intestine, and associates with ulceration, epithelial hyperplasia and a loss of mucus 
production. There is extensive infiltration of mononuclear cells (primarily CD4+ T cells 
and MФ), with increased production of IFNγ and TNFα which is consistent with a TH1-
dominated T cell response (Powrie et al., 1994b, Powrie et al., 1994a). Administration 
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of neutralising antibodies to either IFNγ or TNFα significantly attenuates disease 
(Powrie et al., 1994b). Furthermore, T cells from mice deficient in the TH1 transcription 
factor Tbet fail to induce inflammation in the T cell transfer model (Neurath et al., 2002). 
Co-transfer of CD45RBlo CD4+ T cells which contains mature T cells suppresses the 
induction of colitis. This is attributed to the presence of CD25+ regulatory T cells (TREG) 
within this subset that restrict activation and expansion of IFNγ+ CD4+ T cells via TGF-β 
and/or IL-10 production (reviewed by Strober et al., 2002). The microbiota plays a key 
role in the induction of T cell transfer colitis as the severity of inflammation is 
significantly attenuated in mice with reduced intestinal bacteria (Aranda et al., 1997). 
The TH1-mediated immune response of T cell transfer colitis resembles CD in humans, 
whilst restriction of inflammation to the large intestine parallels inflammation in UC. T 
cell transfer colitis is associated with a greater number of transcriptional changes that 
are observed in human IBD as compared with DSS colitis (te Velde et al., 2007). 
In a slightly modified version of T cell transfer colitis, naive CD4+ T cells are adoptively 
transferred into Cd3eΔ5/Δ5 mice which lack T cells but not B cells (Malissen et al., 1995), 
leading to rapid expansion of IFNγ+ T cells in the large intestine and chronic 
inflammation typified by weight loss, diarrhoea and rectal prolapse (Martin et al., 
2004a).  
1:14.5.3 TNFΔARE ileitis 
Expression of the pro-inflammatory cytokine TNFα is regulated at multiple levels, but 
critically at the level of mRNA stability. This is determined by a region in the 3’ 
untranslated region (UTR) of the TNFα mRNA which contains adenosine-uracil (AU) 
multimers which together form AU rich elements (ARE). By removing these ARE the 
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TNFα mRNA is stabilised, leading to increased production of TNFα protein by both MФ, 
lymphocytes, as well as non-haematopoietic cells including synovial fibroblasts 
(Kontoyiannis et al., 1999). TNFΔARE/ΔARE mice spontaneously develop intestinal 
pathology resembling CD at 2 to 4 weeks of age. Inflammation primarily affects the TI, 
but may also occur in the proximal colon. This includes villous blunting and broadening, 
mucosal and submucosal infiltration of mononuclear leukocytes, plasma cells and 
neutrophils, as well increased numbers of lymphoid aggregates and follicles. Over time, 
inflammation extends deep into the muscular layer of the intestinal wall, reflecting the 
transmural inflammation of CD. Older mice also display rudimental granulomata which 
resemble the non-caseating granulomas often observed in CD. 
In addition to intestinal pathology, TNFΔARE/ΔARE mice also develop severe inflammatory 
arthritis. Interestingly, intestinal inflammation is significantly suppressed in TNFΔARE/+ 
mice crossed onto a RAG-1-/- background, indicating a critical role for T and B cells in 
intestinal inflammation. In contrast, this has no effect on arthritic pathology which 
indicates a different mechanism of pathogenesis. This may relate to the observed 
production of TNFα by synovial MФ in TNFΔARE mice (Kontoyiannis et al., 1999). 
1:15 Role of mononuclear phagocytes in the pathogenesis of IBD 
As initiators of the adaptive immune response in IBD, intestinal DCs could potentially 
play a pivotal role in the pathogenesis of disease through driving imbalanced immune 
responses. This section will focus on the contribution of intestinal APC populations 
including CD103+ DCs in the pathogenesis of IBD. 
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1:15.1   Murine intestinal CD103+ DCs in models of IBD 
In the T cell transfer model of colitis (as discussed in section 1:12.5.2), murine CD103+ 
DCs within MLNs have significantly reduced expression of Aldh1a2 compared with their 
steady-state counterparts, indicating a reduced ability to produce RA (Laffont et al., 
2010). In addition, they have reduced expression of Tgfb2, associating with a reduced 
ability to induce Foxp3+ TREG from naive CD4+ T cells. Beyond this loss of regulatory 
properties, they also produce more IL-12p35 and induce greater production of IFNγ and 
IL-17A by naive CD4+ T cells (Laffont et al., 2010). This indicates that in this model, 
modifications to CD103+ DC behaviour including a reduced ability to make RA may 
contribute to the pathogenesis of disease. It is however difficult to determine whether 
these modulations are caused by the presence of intestinal inflammation as opposed to 
being the cause of inflammation. 
MLN CD103+ DCs in mice with control and inflamed intestinal mucosa express the 
Flt3L receptor (CD135), indicating that they are following a similar process of 
differentiation (as discussed in section 1:17.2).This suggests that their origins are 
constant before and during inflammation, but their behaviour is modified. BrdU 
experiments also indicate that the turnover of MLN CD103+ DCs is more rapid during 
inflammation (Laffont et al., 2010). If the ability to produce RA is the result of 
conditioning within the intestinal mucosa, CD103+ DCs may spend less time within this 
environment in inflammation before migrating onto the MLNs. 
In the TNFΔARE model of ileitis (see section 1:14.5.3) murine CD103+ DCs in the MLN 
and in the inflamed ileal mucosa display reduced Aldh1a2 expression compared with 
their steady-state counterparts (Collins et al., 2011). This correlates with reduced 
induction of Foxp3+ TREG and enhanced induction of TH17 cells, and again suggests that 
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a reduced ability of CD103+ DCs to produce RA may be involved in the pathogenisis of 
disease. As with the T cell transfer model, it is difficult to determine the extent to which 
these effects are the cause of intestinal inflammation or secondary to it. Overall, these 
reports indicate that CD103+ DCs may contribute to intestinal inflammation in mouse 
models of IBD through changes in the balance of effector T cell and TREG induction. 
1:15.2 Murine CD103- DCs and Ly6Chi monocyte-derived APCs in models 
of IBD 
Both DSS and T cell transfer colitic mice display a significant increase in the proportion 
of CX3CR1-GFPint cells in the inflamed large intestinal mucosa of Cx3cr1+/gfp mice 
(Rivollier et al., 2012, Bain et al., 2013, Tamoutounour et al., 2012, Zigmond et al., 
2012, Weber et al., 2011a). This CX3CR1-GFPint population displays considerable 
heterogeneity, and the presence of conventional CD103- DCs in this group is 
controversial. In T cell transfer colitis, a significant proportion of CX3CR1-GFPint cells 
are CD11c+ F4/80lo CD103- and E-cadherin+ and so are identified as CD103- DCs. They 
express increased levels of IL-12, IL-23, TNFα and IL-6 compared with their steady-
state CD103- DC counterparts (Rivollier et al., 2012). CD103- E-cadherin+ DCs 
simultaneously appear in inflamed intestinal mucosa and MLNs of T cell transfer colitis 
mice, but do not express CCR7. Despite an apparent lack of migration, they do 
however activate naive OT-II cells in vitro when extract from MLNs (Siddiqui et al., 
2010). 
The lack of migration into MLNs distinguishes CD103- DCs in T cell transfer colitic mice 
from those in the steady state (Rivollier et al., 2012, Cerovic et al., 2012). One study 
identifies an influx of CX3CR1-GFPint cells simultaneously in the MLN and intestinal 
mucosa of T cell colitic mice and which stimulate naive OT-II cells, but instead identifies 
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them as ‘inflammatory MФ’ (Tamoutounour et al., 2012). This identification is based on 
a MФ morphology with vacuolar cytoplasm, contrasting with the non-vacuolar and 
dendritic morphology of migratory CD103- DCs in the steady state (Cerovic et al., 
2012).  
Importantly, the CX3CR1-GFPint populations arriving in the inflamed intestinal mucosa 
of both T cell transfer and DSS colitic mice derive from circulating Ly6Chi monocytes 
(Bain et al., 2013, Tamoutounour et al., 2012, Zigmond et al., 2012, Rivollier et al., 
2012). Following differentiation within the mucosa, Ly6Chi monocytes upregulate CD64 
(FcγRI) expression, whilst conventional CD103+ and CD103- DCs are CD11c+ CD64-. 
CD64 expression has therefore been proposed as a means of distinguishing 
conventional CD103- DCs from the LyChi monocyte-derived CD103- antigen presenting 
cells (APCs) which accumulate in inflammation (Tamoutounour et al., 2012). 
Furthermore, CD11chi CD103- CD64- cells in large intestinal mucosa expand in the 
presence of Flt3L in the steady state, consistent with a conventional DC phenotype 
(Bain et al., 2013).  
In DSS colitic mice there is also an accumulation of Ly6Chi monocyte-derived CX3CR1-
GFPint cells in the inflamed intestinal mucosa (Zigmond et al., 2012, Bain et al., 2013). 
One study identifies increased lymphatic migration of CX3CR1-GFPint cells in DSS 
colitic mice (Zigmond et al., 2012). However it is not possible to determine whether this 
represents CD103- Ly6Chi monocyte-derived APCs which have become migratory in the 
presence of a DSS colitis-specific environment, or conventional CD103- DCs which 
have known migratory capacity and are also CX3CR1-GFPint. A separate study using 
DSS colitis refers to the Ly6Chi monocyte-derived CD64+ APCs as inflammatory MФ, 
based on TNFα production in response to LPS and MФ morphology (Bain et al., 2013).  
The considerable heterogeneity of the ‘CD103- DC’ phenotype makes clear 
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characterisation of subsets difficult, whilst the disparate naming preferences of different 
groups further adds to the confusion.  
The extent to which conventional CD103- DCs and CD103- Ly6Chi monocyte-derived 
APCs contribute to pathogenesis in models of IBD is unclear. Both subsets induce IFNγ 
production following activation of naive OT-II cells (Rivollier et al., 2012, Tamoutounour 
et al., 2012). The importance of the arrival of Ly6Chi monocytes into the intestinal 
mucosa in DSS colitis in the pathogenesis of disease is demonstrated in CCR2-/- mice 
in which inflammation is significantly attenuated compared with WT mice (Platt et al., 
2010). CCR2 expression by Ly6Chi monocytes promotes both exit from the bone 
marrow (Serbina and Pamer, 2006) and entry into bacterially-infected peripheral tissues 
(Jia et al., 2008). Depletion of CCR2+ Ly6Chi monocytes with a CCR2 monoclonal 
antibody also reduces the severity of DSS colitis (Zigmond et al., 2012). 
Ly6Chi monocytes entering acutely inflamed tissues including the spleen during 
bacterial infection differentiate into TNF/iNOS producing (Tip)-DCs (Serbina et al., 
2003). In both DSS colitis and the adoptive T cell transfer model of colitis, CX3CR1-
GFPint cells express iNOS (Weber et al., 2011a, Tamoutounour et al., 2012, Zigmond et 
al., 2012), indicating a possible overlap between the Ly6Chi-monocyte derived APC and 
TipDC phenotype. Recruitment of Ly6Chi monocytes through CCR2 signalling into the 
intestinal mucosa is required for the clearance of Citrobacter rodentium infection in 
mice (Kim et al., 2011). Nod2-/- mice display reduced expression of the CCR2 ligand 
CCL2, leading to reduced recruitment of LyChi monocytes and reduced pathogen 
clearance (Kim et al., 2011). This may provide further explanation of the role of NOD2 
mutations in susceptibility to CD as discussed in section 1:14.2. 
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Overall therefore, the arrival of Ly6Chi monocytes and differentiation into CD103- Ly6Chi 
monocyte-derived APCs as opposed to the steady-state CX3CR1-GFPhi resident MФ 
phenotype is an important step in the pathogenesis of T cell transfer and DSS colitis. 
This phenotype may overlap with previous designations of ‘CD103- DCs’ due to the lack 
of sufficient phenotypic detail. The human equivalent of the Ly6Chi monocyte-derived 
DC population is the CD14+ monocyte-derived CD14+ MФ and is discussed further in 
section 1:15.5. 
1:15.3  Murine resident MФ in models of IBD 
CX3CR1-GFPhi MФ in the inflamed large intestinal mucosa of DSS-treated mice have a 
similar gene expression to that of their counterparts in non-treated healthy mice, 
indicating a resistance to changes within the inflammatory milieu (Zigmond et al., 
2012). In the adoptive transfer model of colitis, CX3CR1-GFPhi MФ retain expression of 
IL-10, with a small increase in expression of pro-inflammatory IL-6, TNFα and iNOS 
compared with their counterparts in non-inflamed large intestine (Weber et al., 2011a). 
They also remain TREM-1- and TLR2- indicating low sensitivity to microbial stimulation 
even in the inflamed mucosa (Weber et al., 2011a). The absolute numbers of CX3CR1-
GFPhi MФ increase in the large intestine of T cell transfer colitic mice, suggesting 
continued arrival and differentiation of Ly6Chi monocytes or expansion of the local 
CX3CR1-GFPhi MФ population (Weber et al., 2011a).  
1:15.4  Human intestinal DCs in IBD 
Human intestinal DCs display significant phenotypic differences in IBD patients which 
may contribute to the pathogenesis of disease. When extracted from MLNs draining 
inflamed intestinal mucosa, DCs from CD patients induce a significantly greater level of 
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IFNγ production by CD4+ T cells compared with those derived from UC patients or from 
non-inflamed healthy controls (Sakuraba et al., 2009). The ability of intestinal DCs in 
CD patients to induce an enhanced TH1 response is consistent with the increased 
production of IFNγ by LP T cells in CD (Fuss et al., 1996). The TH1-favouring 
phenotype of MLN DCs in CD results from a combined increase in expression of IL-23 
and reduced expression of IL-10, however IL-12 expression is unchanged compared 
with MLN DCs from healthy controls and UC patients (Sakuraba et al., 2009). In 
contrast, a significantly elevated proportion of DCs within human large intestinal 
mucosa contain intracellular IL-12 in CD compared with DCs in healthy controls and UC 
patients (Hart et al., 2005), which would promote induction of TH1 cells. 
Human DCs extracted from the large intestine of CD and UC patients express 
significantly increased levels of TLR2 and TLR4 compared with healthy controls. 
Furthermore, this expression is also increased in inflamed compared with paired non-
inflamed mucosa in UC patients (Hart et al., 2005). This may indicate that DCs are 
more sensitive to stimulation by microbial products including LPS lipoproteins in IBD 
patients. Whether this reflects retention of TLR2 and TLR4 expression of blood DCs or 
de novo induction within the mucosa is unknown.  
Expression of the co-stimulatory markers CD80, CD83 and CD86 are not significantly 
different on mDCs in healthy control and CD patients (Bell et al., 2001). CD40 
expression is however significantly increased on mDCs in inflamed areas of CD 
patients compared with non-inflamed areas from the same patients and healthy 
controls (Hart et al., 2005). Furthermore, administration of anti-TNFα therapy to CD 
patients induced a significant decrease in CD40 expression on mDCs, irrespective of 
resolution of inflammation. This may suggest that TNFα in the intestinal mucosa of 
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active CD patients directly or indirectly upregulates CD40, but is insufficient to induce 
full maturation of mDCs.   
One study has focussed on the CD1c+ human intestinal DC subset in IBD and confirms 
earlier observations of DCs. This includes an enhanced expression of TLR4 on these 
cells in both CD and UC patients compared with healthy controls, as well as increased 
production of TNFα and IL-8 following stimulation with LPS. They also display 
enhanced expression of CD40 which suggests a partially mature state (Baumgart et al., 
2009). This study did not determine expression of CD103 on this subset; however 
CD1c+ DCs were predominantly CD103- in a different study (Dillon et al., 2010). This 
suggests that they reflect CD103- DC behaviour in CD and UC. Whether their ability to 
produce RA and induce a gut-homing or regulatory phenotype in IBD is modified is 
unknown. Human MLN CD103+ DCs in CD patients retain the ability to induce α4β7 and 
CCR9 expression on naive CD8+ T cells (Jaensson et al., 2008), indicating that the 
production of RA by RALDH activity in human intestinal CD103+ DCs is conserved 
between healthy controls and CD patients. Whether production of RA by human 
CD103+ DCs is modified to the extent that other features, including the induction of 
Foxp3+ TREG, are altered in CD whilst induction of imprinting is maintained is unclear. 
1:15.5 Human intestinal MФ in IBD 
The inflamed intestinal mucosa of CD and UC patients contains a significantly 
increased frequency of CD14+ MФ as a proportion of myeloid cells compared with 
healthy controls (Bain et al., 2013, Kamada et al., 2008, Tamoutounour et al., 2012, 
Grimm et al., 1995a). As with healthy controls, stimulation of the CD14+ MФ population 
derived from the inflamed intestinal mucosa of CD and UC patients with heat-killed 
bacteria leads to the production of a range of pro-inflammatory cytokines including 
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TNFα and IL-6 (Kamada et al., 2008). In addition, stimulation of intestinal CD14+ MФ 
from the inflamed mucosa of CD patients with heat-killed E. faecalis leads to the 
generation of significantly greater quantities of TNFα and IL-23 as compared with 
CD14+ MФ from healthy controls or the inflamed intestinal mucosa of UC patients 
(Kamada et al., 2008). It has been proposed that the IL-23 produced by CD14+ MФ in 
the inflamed intestinal mucosa of CD patients enhances IFNγ production by a subset of 
natural killer (NK) cells (Takayama et al., 2010), and that IL-23 also synergizes with 
TNFα to enhance production of IFNγ by CD4+ T cells in the intestinal mucosa (Kamada 
et al., 2008). Finally, CD14+ MФ in the inflamed intestinal mucosa of CD patients 
express high levels of TNF-like factor (TL1A) (Kamada et al., 2010). TL1A acts as a co-
stimulator molecule and induces secretion of pro-inflammatory cytokines by T cells 
(Migone et al., 2002). Synergy between IL-23 and TL1A expressed by CD14+ MФ 
enhances induction of both IFNγ and IL-17 by intestinal mucosal T cells in CD patients 
(Kamada et al., 2010).  
Human intestinal CD14+ MФ share several phenotypic features with blood CD14+ 
monocytes including expression of the LPS co-receptor CD14 and the high affinity IgG 
receptor CD64 (FcγRI) (Kamada et al., 2008, Bain et al., 2013). Stimulation of CD14+ 
MФ from the inflamed intestinal mucosa of CD and UC patients with immobilised IgG, 
which models IgG-immune complexes, through CD64 induces abundant TNFα and IL-
1β production as well as TL1A expression (Uo et al., 2012). In addition, both human 
CD14+ monocytes and CD14+ MФ in inflamed intestinal mucosa of CD and UC patients 
express TREM-1 (Schenk et al., 2005, Schenk et al., 2007). Whilst the physiological 
ligand of TREM-1 is unknown, stimulation of intestinal CD14+ MФ from CD and UC 
patients with TREM-1 monoclonal antibodies significantly increases production of a 
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range of pro-inflammatory cytokines including TNFα, IL-6 and IL-1β (Schenk et al., 
2007). 
There is evidence of direct uptake of CD14+ monocytes into the inflamed intestinal 
mucosa of IBD patients (Grimm et al., 1995b). Furthermore, intestinal CD14+ MФ are 
observed in close proximity to blood vessels within the inflamed intestinal mucosa of 
CD and UC patients (Rugtveit et al., 1994), indicating recent entry from circulation. 
Overall, this is consistent with the elevated proportion of CD14+ MФ in inflamed 
intestinal mucosa of IBD patients compared with healthy controls as resulting from 
increased recruitment of CD14+ monocytes from circulation. As CD14+ blood 
monocytes have also been proposed as precursors to human intestinal resident MФ 
(Smythies et al., 2005, Smythies et al., 2006), this suggests two distinct differentiation 
fates depending on the context in which the CD14+ monocyte arrives in the intestinal 
mucosa from circulation. In support of this model, the hyper IL-23-producing phenotype 
following stimulation with E. faecalis of CD14+ MФ from the inflamed intestinal mucosa 
of CD patients can be generated by in vitro culture of CD14+ monocytes with M-CSF in 
the presence of IFNγ (Kamada et al., 2008). 
MФ from the inflamed large intestinal mucosa of CD and UC patients display elevated 
production of ROS as compared with healthy controls (Rugtveit et al., 1995). As 
circulating human monocytes produce ROS including hydrogen peroxide and 
superoxide (Nakagawara et al., 1981), this further supports the arrival of CD14+ 
monocytes into the intestinal mucosa in IBD. ROS produce by these cells may 
contribute to inflammation in the intestine by damaging the epithelium (reviewed by 
Nathan and Cunningham-Bussel, 2013) 
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CD14+ MФ obtained from intestinal mucosa of healthy controls and CD patients are 
able to activate naive CD4+ T cells in vitro (Kamada et al., 2009). This is consistent with 
expression of the co-stimulatory markers CD40, CD80 and CD86 (Kamada et al., 
2008).  A significant proportion (> 30%) of proliferating CD4+ T cells activated in vitro by 
human intestinal CD14+ MФ express IFNγ (TH1) whilst a small proportion (< 0.5%) 
express IL-17A (TH17). However, the absolute output of both IFNγ and IL-17A cytokine 
by CD4+ T cells activated by intestinal CD14+ MФ from CD patients is significantly 
higher than T cells activated by intestinal CD14+ MФ from healthy controls (Kamada et 
al., 2009). The increased ability of CD14+ MФ from CD patients to induce IL-17A 
production by CD4+ T cells associates with reduced expression of the retinol 
dehydrogenase RDH10 (see section 1:12) in CD14+ MФ, potentially resulting in 
reduced output of RA and so less suppression of IL-17A production (Kamada et al., 
2009). 
As human intestinal CD14+ MФ do not express CCR7 (Kamada et al., 2008), they are 
unlikely to migrate into draining lymph nodes and interact with naive T cells. It is 
unclear whether they present antigen to local populations of effector T cells within the 
intestinal mucosa or simply influence cytokine production by these T cells through their 
own ability to produce cytokines (Kamada et al., 2008). Based on the assumption that 
CD14+ MФ do present antigen to effector T cells, the increased proportion of CD14+ 
MФ, particularly in CD, provides an increase range of targets for TH1 cells to activate 
through the production of IFNγ. This would further support release of pro-inflammatory 
cytokines by CD14+ MФ and contribute to the perpetuation of inflammation. 
The behaviour of the human intestinal resident MФ population (Smythies et al., 2005) 
within the inflamed mucosa of IBD patients is unknown. However, depletion of CD14+ 
cells from a mixed LP mononuclear cell (LPMC) preparation derived from the inflamed 
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intestinal mucosa of CD patients significantly reduces production of TNFα following 
stimulation with heat killed E. faecalis compared with stimulation of non-depleted 
LPMCs (Kamada et al., 2008). This indicates that the intestinal resident MФ population 
within CD14+ cell-depleted LPMCs retains low or absent ability to produce pro-
inflammatory cytokines upon microbial stimulation.  
1:16 Lymphocyte gut-homing in the pathogenesis of IBD 
1:16.1 α4β7-MAdCAM-1 and CCR9-CCL25 interactions in intestinal 
inflammation 
Human CD103+ DCs obtained from MLNs draining inflamed TI of CD patients display 
an equivalent ability to induce α4β7 and CCR9 as compared with those obtained from 
healthy control patients (Jaensson et al., 2008). This indicates that the level of RA 
output by human CD103+ DCs in this tissue during intestinal inflammation remains 
sufficient for the induction of these markers. Importantly, it also suggests that these 
pathways of lymphocyte migration remain active during intestinal inflammation. 
Recruitment of CD4+ T cells into the colonic mucosa of mice in the adoptive T cell 
transfer model of colitis is significantly attenuated by administration of neutralising β7 
and MAdCAM-1 monoclonal antibodies (Picarella et al., 1997). This treatment also 
leads to significant histological improvement, underscoring the role of α4β7-MAdCAM-1 
interactions in allowing entry of inflammatory CD4+ T cells into the intestinal mucosa in 
this model. In addition, migration of α4β7+ T and B cells into the distal colon of DSS-
colitic mice is significantly attenuated by neutralising MAdCAM-1 antibodies (Kato et al., 
2000). This correlates with reduced inflammation and improved colonic crypt 
architecture. In this model there is significant upregulation of MAdCAM-1 expression on 
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vascular endothelial cells in both the LP and sub-mucosa, indicating a key role during 
disease progression. 
In humans, expression of MAdCAM-1 is also increased on vascular endothelial cells in 
inflamed intestinal mucosa in both UC and CD patients (Briskin et al., 1997, Souza et 
al., 1999). This suggests that activation of the endothelium during inflammation 
promotes α4β7-MAdCAM-1-mediated entry of lymphocytes into the human intestinal 
mucosa. 
The proportion of α4β7+ T cells in the blood of CD and UC patients is reduced compared 
with healthy controls (Meenan et al., 1997, Hart et al., 2004). Potential explanations for 
this observation include increased uptake of α4β7+ T cells into the inflamed intestinal 
mucosa mediated by increased endothelial MAdCAM-1 expression, or reduced 
induction of α4β7 during T cell activation. 
Endothelial cells in the inflamed intestinal mucosa of IBD patients also express 
increased levels of ICAM-1 (Souza et al., 1999). This suggests that in addition to the 
steady-state pathways of lymphocyte migration into the gut, additional factors including 
expression of the ICAM-1-binding integrin αLβ2 (reviewed by Sigmundsdottir and 
Butcher, 2008) may mediate lymphocyte entry into the inflamed intestinal mucosa in 
humans. Migration of activated CD4+ T cells into the ileal mucosa drives spontaneous 
inflammation in the SAMP/Fit mouse model of CD (Kosiewicz et al., 2001). In addition 
to α4β7-MAdCAM-1, this recruitment requires L-selectin and α4β1 (Rivera-Nieves et al., 
2005), which interacts with VCAM-1 on activated vascular endothelium (reviewed by 
Sigmundsdottir and Butcher, 2008). This further implicates a role for non-conventional 
gut-homing of lymphocytes during intestinal inflammation. 
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The frequency of CCR9+ T cells within the inflamed TI mucosa of CD patients is 
reduced compared with non-inflamed TI mucosa of these patients (Papadakis et al., 
2001). The extent to which this is due to downregulation of CCR9 following entry into 
the tissue is difficult to determine, however it may reflect CCR9-CCL25-independent 
entry into of lymphocytes into the inflamed TI mucosa. This could be due to enhanced 
α4β7-MAdCAM-1 or αLβ2-ICAM-1-mediated entry as described above. The reduced 
frequency of CCR9+ T cells in MLN draining inflamed TI of CD patients (Papadakis et 
al., 2001) may indicate reduced induction of CCR9 during T cell activation in MLN in 
these patients. In vitro, CD103+ DCs from MLN draining inflamed terminal ileum in CD 
patients induce similar levels of RA-dependent CCR9 on CD8 T+ cells compared with 
healthy control-derived cells (Jaensson et al., 2008). However there may be increased 
T cell activation by blood-derived CD103- DC populations in these MLN that do not 
induce CCR9 (Jaensson et al., 2008). Patients with CD affecting the TI actually display 
increased proportions of CCR9+ T cells in peripheral blood compared with patients with 
colonic inflammation only (Papadakis et al., 2001). This suggests a counter argument 
that induction of CCR9 is actually increased in CD patients. Ultimately the key 
mechanisms of uptake and how this is regulated are not fully understood.  
Gut-homing of T cells is likely to be key to the arrival both effector and regulatory T 
cells to the site of inflammation. However, there is evidence that in IBD lesions, effector 
T cells have resistance to TGF-β mediated regulation via expression of SMAD-7 
(Fantini et al., 2009) Therefore the arrival of effector T cells is likely to be an important 
factor in driving the ongoing inflammatory episode. 
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1:16.2  Lymphocyte gut-homing in extra-intestinal manifestations in IBD 
As discussed in section 1:14.1, up to 10 % of UC patients develop primary sclerosing 
cholangitis (PSC), where fibrosis causes inflammation and obstruction of the bile ducts 
(reviewed by Day and Morson, 2003). This may be due to aberrant expression of 
CCL25 and MAdCAM-1 on vascular endothelial cells leading to recruitment of α4β7+ 
CCR9+ T cells originally destined for the intestinal mucosa (Eksteen et al., 2004).  
1:16.3  Gut-homing as a therapeutic target in IBD 
The recruitment of lymphocytes into the intestinal mucosa in IBD has attracted 
considerable interest as a potential therapeutic target. This section will discuss the 
various targets and their respective stages of development, which is summarized in 
Figure 1.9) 
Natalizumab is a humanised monoclonal antibody against α4 integrin; it disrupts both 
α4β7-MAdCAM-1 as well as α4β1-VCAM-1 interactions. Clinical trials have demonstrated 
natalizumab performs significantly better than placebo at inducing remission in patients 
with moderate to severe CD (reviewed by MacDonald and McDonald, 2007). Patients 
on natalizumab also displayed significantly increased levels of circulating T and B cells 
consistent with impeded lymphocyte migration into peripheral tissues (Gordon et al., 
2001).  Compared with CD, much less is known about the efficacy of natalizumab in 
UC. An non placebo-controlled open label trial has however suggested that 
natalizumab may be of benefit in active UC (Gordon et al., 2002). 
Safety concerns have been raised following cases of progressive multifocal 
leukoencephalopathy (PML) in CD and multiple sclerosis patients treated with 
natalizumab (Van Assche et al., 2005).  In these cases interference with α4β1-VCAM-1 
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interactions may have impaired immunosurveillance of the central nervous system, 
leading to reactivation of latent John Cunningham (JC) virus. However, concomitant 
medication with other immunosuppressive drugs complicates the picture. Whilst this 
adverse reaction is relatively rare, it has caused fatalities. This may be avoided in future 
by screening patient plasma for presence of JC virus (MacDonald and McDonald, 
2007). 
Vedolizumab (MLN-02) is a humanized monoclonal antibody specific to α4β7. In a 
phase II clinical trial it performed significantly better than placebo in inducing remission 
in active UC patients (Feagan et al., 2005). In a phase II trial, differences in clinical 
response for CD patients on vedolizumab were not significantly different from placebo 
(Feagan et al., 2008). Phase III trials for vedolizumab are ongoing for both CD and UC 
(Thomas and Baumgart, 2012). Vedolizumab has been shown to significantly reduce 
Figure 1.9: T cell gut-homing markers as therapeutic targets. Therapeutics in various 
stages of development include monoclonal antibodies to α4β7 (Vedolizumab) and MAdCAM-1 
(PF-00547659), as well as small molecule inhibitors of CCL25 (CCX282). Neutralising 
antibodies to α4 are effective in CD but associated with rare fatalities including reactivation of 
latent JC virus in the central nervous system. 
CCL25
MAdCAM-1
α4β7CCR9
CCX282
PF-00547659
Vedolizumab
Natalizumab (α4) 
Endothelium
T cell
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the frequency of β7+ T cells in the intestinal mucosa of healthy cynomolgus monkeys, 
with a concurrent increase in peripheral blood β7+ T cells (Fedyk et al., 2012). 
Current studies targeting MAdCAM-1 directly with a monoclonal antibody (PF-
00547659) have shown some improvements upon endoscopic investigation in UC 
patients (Vermeire et al., 2009). This antibody is undergoing multiple trials to determine 
safety in humans (reviewed by Thomas and Baumgart, 2012). 
CCX282 is an orally bio-available antagonist for CCR9, and has shown promise in 
reducing CD severity in a phase II trial (Eksteen and Adams, 2010). This approach is 
desirable as immune surveillance in the colon should remain unaffected. However, 
further trials are required before clear therapeutic benefit is demonstrated.  The 
therapeutic targets based on lymphocyte homing to the intestinal mucosa are 
summarized in Figure 1.9. 
1:17 RA in intestinal inflammation 
RA was originally considered to be a universally pro-regulatory molecule in the murine 
intestine. This viewpoint derived from the involvement of RA in the induction of oral 
tolerance through enhancing the induction of Foxp3+ iTREG in the murine MLN 
(Coombes et al., 2007, Sun et al., 2007, Mucida et al., 2007) (as discussed in section 
1:8.5) and the loss of RALDH activity in CD103+ DCs in mouse models of intestinal 
inflammation (as discussed in section 1:15.1). However, RA signalling is also intimately 
involved in effector T cell responses which may contribute to inflammation. VAD mice 
display reduced clearance of the intracellular parasite Toxoplasma gondii following oral 
infection, which is mediated by a suppressed IFNγ+ CD4+ T cell response (Hall et al., 
2011a). A key component of this defective response is a failure of CD4+ T cells to 
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proliferate in response to the presentation of T. gondii antigen. This stems from the key 
role of RARα in T cell activation through modulation of intracellular Ca2+ signalling (Hall 
et al., 2011a). 
In addition to be being necessary for effector T cell responses in the intestinal mucosa, 
there is also evidence that RA enhances pro-inflammatory responses under certain 
conditions. IL-15 promotes IL-12p70 production by murine intestinal DCs, and this 
production is further enhanced in the presence of RA (DePaolo et al., 2011). This is 
based on a synergistic phosphorylation of the MAPK JNK. The additional IL-12p70 
suppresses induction of Foxp3+ TREG, even in the presence of exogenous TGF-β. This 
has been proposed as a mechanism for the pathogenisis of Coeliac disease, where 
patients develop IFNγ+ CD4+ T cell responses to the gluten-derived peptide gliadin 
(DePaolo et al., 2011).  
There is currently an ongoing controversy as to whether isotretinoin (13-cis retinoic 
acid), prescribed for cystic acne, is causative in a small subset of IBD cases. However, 
population studies have found no significant association between isotretinoin use and 
IBD (Bernstein et al., 2009). This strongly suggests that this form of retinoic acid does 
not cause IBD, but cannot rule out that it may act as an IBD trigger in a small number of 
individuals. 
The overall effects of RA on immune responses within steady state and inflamed 
intestinal mucosa may be determined by the particular profile of cytokines present, as 
well as the concentration of RA itself. In vitro, RA induces expression of α4β7 and CCR9 
on murine T cells from 0.1 nM (Iwata et al., 2004, Takeuchi et al., 2010). At 1 nM, RA 
promotes induction of TH17 cells in the presence of IL-6 and TGF-β, (Takahashi et al., 
2012), but does not support efficient induction of Foxp3+ TREG in the presence of TGF-β 
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(Mucida et al., 2007, Takahashi et al., 2012). At 100 nM however, RA efficiently 
induces Foxp3+ TREG in the presence of TGF-β whilst suppressing induction of TH17 
cells in the presence of IL-6 and TGF-β (Mucida et al., 2007, Takahashi et al., 2012). 
RA supports induction of IL-22 from γδ T cells at 100 nM, but only in the presence of 
both IL-1β and IL-23 (Mielke et al., 2013). These effects are summarised in Figure 1.10. 
Any potential role for RA in the pathogenesis of IBD in humans is therefore likely to 
result from a complex interplay of factors.  
 
Figure 1.10: Concentration-dependence of RA effects in intestinal immunity. RA 
induces expression of gut-homing markers α4β7 and CCR9 on T cells in mice from 0.1 nM. At 
100 nM, RA enhances TGF-β mediated induction of Foxp3+ TREG but suppresses induction of 
TGF-β and IL-6-mediated TH17 induction in vitro. RA promotes TH17 induction at 1 nM 
however, whilst at this concentration has no significant effect on induction of Foxp3+ TREG in 
vitro. RA also enhances IL-22 production by innate lymphoid cells and γδ T cells at 100 nM 
in the presence of in the presence of IL-1β and IL-23. In the presence of IL-15, 10 to 100 nM 
RA also promotes IL-12p70 production by murine DCs. 
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1:18 Hypothesis and aims 
RA production by APCs, in particular CD103+ DCs, has emerged as an important 
contributor to immune regulation in the murine intestine. However, the role of RA 
production by APCs in the human intestine and whether this is involved in the 
pathogenesis of IBD is unknown. The overall hypothesis for this project is that the 
production of RA through RALDH enzyme activity by APCs including CD103+ DCs in 
the human intestinal mucosa is an important component of homeostasis in healthy 
individuals. Loss of this enzyme activity will associate with inflammation in the intestinal 
mucosa of IBD patients, and may contribute to the overall pathogenesis of disease. 
Restoration of this activity may therefore be an attractive therapeutic target. 
The aims of this project will therefore be to validate a methodology for determining 
RALDH enzyme activity in APCs within human intestinal mucosa and then use this 
methodology to determine whether this activity is different in the healthy and inflamed 
human intestinal mucosa. The next aim will be to convert these observations into 
functional understanding of the ways in which these modifications may contribute to the 
pathogenesis of disease. 
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Chapter 2:  Materials and methods 
2:1 Reagents  
Table 2.1: Reagents used in project 
Reagent Solvent Stock conc. (mM) Supplier 
all-trans retinoic acid (RA) DMSO 80  Sigma Aldrich 
all-trans retinal DMSO 80  Sigma Aldrich 
AH6809 DMSO 16.8 Sigma Aldrich 
Indomethacin DMSO 1.68 Sigma Aldrich 
Ro41-5253 DMSO 100 Enzo Life Sciences 
CFSE DMSO 40 Invitrogen 
 
Reagents were stored at -80 °C; aliquots were discarded following the second 
freeze/thaw cycle to minimize degradation. Retinoids were stored in tubes covered with 
aluminium foil to minimize UV-induced degradation. 
Complete medium: RPMI1640 Dutch Modification supplemented with 2 mM L-
glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin (all Sigma-Aldrich) and 10% 
heat-treated (56 °C for 30 minutes) foetal calf serum (FCS; PAA). 
FACS buffer: Phosphate-buffered saline solution (PBS) containing 2 %FCS, 1 mM 
ethylenediaminetetraacetic acid (EDTA) and 0.2% (w/v) sodium azide. 
MiniMACS buffer: PBS with BSA (0.5 %, w/v) and EDTA (2 mM) 
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2:2 Intestinal tissue and blood collection  
2:2.1  Intestinal tissue 
Up to 8 colonic and ileal biopsies were obtained at colonoscopy from patients with 
inflammatory bowel disease (IBD) or from control subjects, consisting of patients with 
macroscopically and histologically normal intestine who had been referred with 
symptoms of rectal bleeding or change in bowel habit with normal colonoscopic 
findings. Intestinal mucosa was also derived from surgically-resected tissue from IBD 
patients and from macroscopically unaffected areas of patients with colon cancer. The 
diagnosis for each patient was made using clinical parameters, radiographic studies 
and histological criteria. Tissue was collected in ice cold base medium (RPMI1640 
Dutch Modification; Sigma-Aldrich). 
Patient details are summarized in Appendix. 
2:2.2  Blood 
Blood was obtained by venepuncture from volunteer donors in 10 ml sodium heparin 
tubes (Becton Dickinson).  
2:2.3  Ethics 
All tissue and blood donors gave informed written consent and the study was approved 
by the local ethics committee (refs 05/Q0405/71, 08/H0702/33 and P/01/023). 
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2:3 Cell extraction from intestinal tissue 
2:3.1  Lamina propria cells (LPCs) 
Surgical resection specimens were cut into biopsy-sized pieces prior to tissue 
processing. LPCs were extracted from intestinal biopsies by enzymatic digestion as 
previously described (Bell et al., 2001, Hart et al., 2005). Biopsies were incubated for 
20 minutes at room temperature with 1 mM DTT (Sigma-Aldrich) in calcium and 
magnesium-free Hank’s balanced salt solution (HBSS; Sigma-Aldrich) in a T25 tissue 
culture flask (Becton Dickinson) to remove faeces and mucus. HBSS was removed 
from the flask with a Pasteur pipette and biopsies were washed in 10 ml additional 
HBSS which was then removed as previously. Biopsies were then incubated in 25 ml of 
1 mM EDTA (Sigma-Aldrich) in HBSS at 37 ºC under vigorous mechanical agitation for 
30 minutes to remove the epithelium. Spent HBSS was removed followed by two 
washes and a further EDTA incubation as previously. Biopsies were incubated in 1 
mg/ml collagenase D (Roche Applied Science) in pre-warmed HEPES buffered RPMI 
1640 medium (Sigma-Aldrich) containing 2% heat inactivated (30 minutes at 56 °C) 
foetal calf serum (PAA) and 20 μg/ml deoxyribonuclease I (Roche Applied Science) in a 
fresh T25 flask at 37 ºC under mechanical agitation. After 1 hour, the flask was shaken 
vigorously at 5 minute intervals until biopsies were fully digested. Cell suspension was 
passed through a 40 μm cell strainer (Becton Dickinson) and washed in base medium 
(RPMI1640). 
2:3.2  ‘Walk out’ cells 
‘Walk out’ cells were derived from biopsies for use in T cell stimulation assays as 
described previously (Bell et al., 2001). Biopsies were treated with DTT and EDTA as 
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described in section 2:3.1, then cultured overnight at 37 ºC in 1 ml complete medium 
(RPMI1640 Dutch Modification supplemented with 2 mM L-glutamine, 100 U/ml 
penicillin, 100 g/ml streptomycin (all Sigma-Aldrich) and 10% foetal calf serum (PAA)) 
in 24 well plates (Becton Dickinson) at one biopsy per well.  
APC-enriched cells present in the culture medium were recovered by centrifugation 
following removal of residual biopsy tissue.  
2:3.3  Flow-sorted APC populations  
LPCs were washed into filter sterilised modified FACS buffer (lacking sodium azide) 
and incubated with relevant monoclonal antibodies (see Table 2.1). APC populations 
within LPCs were isolated by flow-sorting with a FACS Aria (Becton Dickinson). DCs 
were isolated as CD45+ Lin- HLA-DR+ cells, and CD14+ MФ were isolated as CD33+ 
CD14+ cells. The discrete nature of antibody staining for these populations allowed for 
cell identification without the need for isotype controls. Cells were sorted at the lowest 
speed possible to minimise sort-associated cell damage, and were collected in sterile 
1.5 ml TubeOne Microcentrifuge Tubes (Star Lab) containing 0.5 ml complete medium. 
Technical assistance for cell sorting was provided by Gary Warnes, Flow Cytometry 
Core Facility, Blizard Institute. 
2:4 Purification of blood cell populations 
2:4.1  Peripheral blood mononuclear cells (PBMCs)  
Peripheral blood was diluted 2:1 with RPMI1640 Dutch Modification base medium, then 
layered over 15 ml Ficoll-Paque PLUS (GE Healthcare) in 15 ml falcon tubes using a 
Pasteur pipette and centrifuged at 650 x g for 20 minutes with the brake at its lowest 
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setting or deactivated. PBMCs were collected from the interface between Ficoll and 
serum with a Pasteur pipette, pooled into 15 ml Falcon tubes (Becton Dickinson) and 
centrifuged at 650 x g for 10 minutes. Supernatant was discarded and pellets were 
resuspended in residual volume, pooled into a 5 ml FACS tube (Becton Dickinson) and 
washed twice into complete medium by centrifugation at 400 x g for 5 minutes. 
2:4.2  Naive CD4+ T cells 
PBMCs were washed into sterile filtered miniMACS buffer and resuspended in 40 μl 
miniMACS buffer for every 10 ml blood originally used. Naive CD4+ T cells were then 
purified by negative selection using Human Naive CD4+ T Cell kit (Miltenyi Biotec). 
Briefly, PBMCs were incubated with 10 μl antibody cocktail II per 10 ml of blood for 15 
minutes on ice. This cocktail contains antibodies targeting antigens associated with all 
haematopoietic cell lineages except CD4+ T cells including CD8, CD14, CD15, CD16, 
CD19, CD34, CD36, CD56, CD123, TCRγ/δ, HLA-DR and CD235a. Effector/memory 
CD4+ T cells are excluded by antibodies to CD45RO and CD25. After labelling with the 
antibody cocktail, cells were washed by adding 2 ml of miniMACS buffer followed by 
centrifugation at 400 x g for 5 minutes. Cell pellet was resuspended in 80 μl miniMACS 
buffer per 10 ml blood and then incubated with 20 μl anti-biotin microbeads per 10 ml of 
blood for a further 10 minutes on ice. Cells were then washed by adding 2 ml of 
miniMACS buffer followed by centrifugation at 400 x g for 5 minutes resuspended in 
500 μl miniMACS buffer. An LS column was used for the separation to allow for the 
high level of non-target cell binding in negative selection. The column was also pre-
chilled to increase the stability of antibody binding. The LS column was attached to the 
magnet and separation apparatus and 3 ml miniMACS buffer added and allowed to run 
through the column completely. The labelled PBMC suspension was then added to the 
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column, allowed to run in and washed through the column by 3 sequential additions of 
3 ml miniMACS buffer. The eluted fraction enriched for naive CD4+ T cells was 
collected and was enriched for naive CD4+ T cells. Purity was verified by flow cytometry 
and was routinely >96 %. Cells magnetically attached the column were released by 
adding a further 5 ml miniMACS buffer with the column removed from the magnet, and 
depressing the plunger. This fraction contained PBMCs depleted of naive CD4+ T cells 
and was used for compensation control staining in flow cytometry (see below).  
2:4.3  CD14+ monocytes  
PBMCs were centrifuged at 400 x g for 5 minutes, supernatant discarded and 
resuspended in 2 ml miniMACS buffer before being centrifuged again at 400 x g for 5 
minutes. Cell pellet was resuspended in 100 μl miniMACS buffer, labelled with 10 μl 
anti-CD14 microbeads (Miltenyi Biotec) per 10 ml of blood and incubated for 15 
minutes on ice. An MS column was used for the purification of CD14+ monocytes as the 
number of labelled cells was not great enough to warrant use of the greater capacity LS 
column. The MS column was also pre-chilled to increase the stability of antibody 
binding, and assembled with the appropriate magnet onto the separation apparatus. 
MiniMACS buffer (0.5 ml) was added to the column and allowed to run through 
completely before the labelled cell suspension was added. This was followed by 3 
sequential additions of 500 ml miniMACS buffer. Eluted cells contained PBMCs 
depleted of CD14+ monocytes. Cells magnetically attached to the column were eluted 
by removing the column from the magnet and adding a further 500 μl miniMACS buffer 
and depressing the plunger. This fraction was enriched for CD14+ monocytes; purity 
was verified by flow cytometry and was routinely >98 %. Monocytes were washed twice 
into complete medium by centrifugation at 400 x g for 5 minutes. 
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2:4.4  Cell counts 
Cell counts were performed by mixing 50 μl cell suspension with 50 μl Trypan Blue 
Solution (0.4%, Invitrogen) and 150 μl RPMI-Dutch modification. A small sample of this 
mixture was applied to a haemocytometer (Neubauer) and cells counted within a 4 x 4 
grid. An average count was taken from at least 2 grids and this number was converted 
to the cell concentration by the following formula: 
 
 
 
2:5 In vitro cell culture 
2:5.1  Monocyte-derived DCs (MoDCs) 
CD14+ monocytes were obtained from PBMCs as described above. They were then 
cultured in the presence of GM-CSF (100 ng/ml) and IL-4 (100 ng/ml; both Peprotech) 
at 5 x 105 cells/ml in 1 ml of complete medium in 24 well plates at 37 ºC, 5 % CO2 in a 
humidified incubator. Half of the spent culture medium was removed on day 4 and 
replaced with fresh medium, GM-CSF and IL-4 to the same final concentration of 100 
ng/ml. Cells were collected for functional analysis on day 7.  
In experiments where MoDCs were conditioned with intestinal biopsy conditioned 
medium (CM), the final culture volume was reduced to 600 μl and CM introduced from 
the beginning of culture at 20% (v/v). The culture volume was reduced so as to 
conserve the CM samples. The total number of CD14+ monocytes was kept at 5 x 105 
whilst the concentration of GM-CSF and IL-4 was maintained (100 ng/ml). 
Average number of cells 
in each 4 x 4 grid 
 
x     5     x    104 
 
=      cells/ml 
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Intestinal biopsy conditioned medium (CM) was generated with DTT-treated intestinal 
biopsies (as described in section 2:3.1) by culturing one biopsy per well in a 24 well 
plate in 1 ml of complete medium for 6 hours in a humidified incubator at 37 ºC with 5 % 
CO2. Biopsies were then removed and CM pooled for each condition, filter sterilized 
and stored at -80 ºC. 
Maturation of MoDCs was induced in vitro in some experiments by culturing MoDCs (1 
x 105) in the presence or absence of LPS (1 μg/ml) in 0.5 ml complete medium 
overnight in a humidified incubator at 37 °C with 5% CO2. 
2:5.2  Inflammatory CD14+ MФ 
CD14+ monocytes were purified from PBMCs as described above. They were then 
cultured in the presence of GM-CSF (100 ng/ml) at 5 x 105 cells/ml in 1 ml complete 
medium in 24 well plates (Becton Dickinson) at 37 ºC, 5 % CO2 in a humidified 
incubator. Half of the spent culture medium was removed on day 3 and replaced with 
fresh medium and GM-CSF (to a final concentration of 100 ng/ml). CD14+ MФ were 
then cultured on day 6 at 1 x 105 cells/ml in the presence or absence of LPS (1 μg/ml, 
Escherichia coli 0111:B4, Sigma-Aldrich) in 1 ml complete medium in the presence of 
Brefeldin A (10 μg/ml, Sigma-Alrich). Cells were then prepared for intracellular cytokine 
staining and analysis by flow cytometry as described below.  
2:5.3  Activation of naïve CD4+ T cells 
2:5.3.1  CFSE labelling 
Naïve CD4+ T cells were purified from PBMCs as described above. They were then 
resuspended in serum-free PBS filter sterilised with a 0.2 μm syringe filter (VWR) at 
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approximately 2 x 107 cells/ml and stained with carboxyfluorescein succinimidyl ester 
(CFSE; Invitrogen) at a final concentration of 5 μM for 3 minutes at room temperature. 
Labelling was quenched the addition of one volume of FCS and then cells were washed 
twice by centrifugation (400 x g, 5 minutes) in complete medium.  
2:5.3.2  Activation of allogeneic naive CD4+ T cells  
CFSE-labelled allogeneic naive CD4+ T cells (2 x 105) were cultured with either 5 x 104 
‘walk out’ cells or alternatively 2 x 104 sorted intestinal APCs or MoDCs for 5 days in 
200 μl complete medium in round bottom 96 well plates (Becton Dickinson) at 37 ºC, 5 
% CO2 in a humidified incubator. Cells were recovered on day 5 or 6 and proliferating 
CFSElo cells identified and analysed by flow cytometry as described below. 
2:5.3.3  Activation of naive CD4+ T cells with activation beads 
In some experiments naive CD4+ T cells were activated with activation beads (Miltenyi 
Biotec). Activation beads were prepared according to manufacturer’s instructions. In 
brief, 62.5 μl of anti-biotin MACSi beads were mixed with 12.5 μl each of biotinylated 
anti-CD2, CD3 and CD28 and 25 μl of miniMACS buffer. This suspension was 
incubated under mechanical rotation for 2 hours at 4 °C. A sample (25 μl) of this 
suspension was then transferred to a 1.5 ml sterile screw cap tube (Star Lab) with the 
addition of 200 μl of complete medium. Following centrifugation (400 x g, 5 minutes), 
the supernatant was removed by pipetting and the bead pellet resuspended in 100 μl 
complete medium. CFSE-labelled naive CD4+ T cells (2 x 105) were cultured in the 
presence of 5 μl of this activation bead suspension in complete medium at a final 
volume of 200 μl and analysed by flow cytometry on day 5 or 6 as described below. 
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2:6 Aldefluor assay  
Flow cytometric analysis of cellular RALDH activity was performed with the 
Aldefluorassay (Stemcell Technologies). The reaction mechanism is described in detail 
in Chapter 3 (section 3:2). LPCs (4 x 106) and PBMCs or MФ (1 x 106) were washed in 
PBS by centrifugation (400 x g, 5 minutes) and resuspended in 1 ml Aldefluor assay 
buffer in a 5 ml tube labelled ‘test’. Elevated numbers of LPCs were used to facilitate 
identification of RALDH activity in rare DC populations. 5 μl of the ALDH inhibitor 
diethylaminobenzaldehyde (DEAB) was placed into a second 5 ml tube labelled 
‘control’. Aldefluor reagent (5 μl) was then added to ‘test’ (final concentration 1.5 μM); 
the cells were mixed and half the sample (500 μl) was transferred and mixed in the 
‘control’ tube. The tubes were then incubated at 37ºC for 45 minutes wrapped in 
aluminium foil, then prepared for flow cytometry (see below). Aldefluorhi cells were 
determined during data analysis by gating for cells at a fixed separation (2 cm on 
screen in all samples) from the leading edge of the DEAB-inhibited ‘control’ sample. 
Each cell subpopulation was defined in this way relative to its specific DEAB-inhibited 
‘control’ sample. 
2:7 Flow cytometry 
2:7.1  Antibodies 
Table 2.2: Antibodies used for flow cytometry 
Antigen Fluorochrome Clone Isotype  Supplier 
CD33 APC WM53 Mouse IgG1 Biolegend 
CD11c APC 3.9 Mouse IgG1 Biolegend 
CD4 APC RPA-T4 Mouse IgG1 Biolegend 
CD45  Pacific blue HI30 Mouse IgG1 Biolegend 
CD14  Pacific blue M5E2 Mouse IgG2a Biolegend 
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CCR7 Pacific blue G043H7 Mouse IgG2a Biolegend 
CD103 PE LF61 Mouse IgG1 Biolegend 
CD70 PE 113-16 Mouse IgG1 Biolegend 
E-Cadherin PE 67A4 Mouse IgG1 Biolegend 
Beta7 PE FIB504 Rat IgG2a Biolegend 
CD19 PE HIB19 Mouse IgG1 Biolegend 
TNFα PE MAb11 Mouse IgG1 Biolegend 
Goat anti-mouse 
IgG 
PE Poly4053  Biolegend 
HLA-DR PE/Cy7 L243 Mouse IgG2a Biolegend 
CD209 FITC 9E9A8 Mouse IgG2a Biolegend 
Lineage* PE/Cy5   AbD Serotec 
CX3CR1 FITC FAB5204F Mouse IgG1 R&D Systems 
CD8 PerCP/Cy5.5 SK-1 Mouse IgG1 BD Biosciences 
pSTAT5 Alexafluor 647 47/Stat5(pY694) Mouse IgG1 BD Biosciences 
 
* Lineage cocktail: anti-CD3, CD14, CD16, CD19 and CD34 
Isotype-matched control antibodies were obtained from the appropriate manufacturer. 
Act-1 (anti-human α4β7) was a kind gift from Eugene Butcher, Stanford University. 
LP34 (anti human cytokeratin 8/16) was a kind gift from Kristin Braun, Barts and the 
London School of Medicine and Dentistry. 
2:7.2  Antibody labelling  
Cells were transferred into 5 ml FACS tubes (Becton Dickinson) and washed by 
centrifugation (400 x g, 5 minutes) in cold FACS buffer. Supernatant was removed by 
inversion, and monoclonal antibodies were added to the residual volume 
(approximately 100 μl) containing the cell pellet at 5 μl antibody per test. Cells were 
vortexed and incubated on ice for 15 minutes and washed twice by centrifugation (400 
x g, 5 minutes) and supernatant removed by inversion. 
For detection of intracellular antigen e.g. cytokines and cytokeratins, cells were fixed 
following extracellular labelling by addition of 100 μl Leucoperm A solution (AbD 
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Serotec) and vortexed, then incubated in the dark for 15 minutes at room temperature. 
Cells were then washed by the centrifugation (400 x g, 5 minutes) with ice cold FACS 
buffer, supernatant removed entirely by inversion of the tube onto paper towel to 
remove residual volume. Cells were permeabilised with 100 μl Leucoperm B solution 
(AbD Serotec) in the presence of relevant monoclonal antibodies (5 μl/test), vortexed 
and incubated at room temperature in the dark for 30 minutes. Cells were then washed 
in cold FACS buffer by centrifugation (400 x g, 5 minutes) and fixed in 
paraformaldehyde (1 % w/v).  
Viability was assessed in some unfixed cell populations by the addition of 3 μl 7-amino-
actinomycin D (7-AAD; Biolegend) in 300 μl FACS buffer. Samples were vortexed, 
incubated for 5 minutes at room temperature and then analysed by flow cytometry (see 
below). 7-AAD enters cells with a damaged cell membrane (i.e. dead cells) and 
complexes with DNA, but is restricted to the exterior of cells with a viable membrane 
(i.e. live cells), providing a clear distinction between live and dead cells upon data 
analysis. 
2:7.3  Flow cytometry 
Labelled cells were acquired on a Canto II or LSR II (Becton Dickinson) using 
CellQuest software (Becton Dickinson). Single fluorophore compensation controls were 
generated by labelling compensation beads (Becton Dickinson) with the individual 
antibodies used in a particular experiment. These contain a population of beads that 
non-specifically binds to mouse IgG, generating a positively stained population, and 
beads to do not bind to mouse IgG and so create a negatively stained population. In 
cases where rat IgG was used (e.g. staining for β7), PBMCs labelled with only this 
antibody were used as the compensation control. In the case of 7-AAD staining, 1 x 106 
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PBMCs were cultured at 60 °C in PBS for 5 minutes and then placed on ice, and then 
combined with 1 x 106 PBMCs in PBD at room temperature. The combined cell 
population contained equal amounts of live and dead cells, and so when stained with 7-
AAD immediately prior to flow cytometry provides a single fluorophore compensation 
control for 7-AAD.  
At least 10,000 events were acquired for each sample, except in the analysis of 
Aldefluor activity in LPCs in which up to 300,000 events were acquired due to the rarity 
of DC populations within these samples. Data were exported and analysed using 
WinList 6.0 software (Verity). Compensation was applied prior to data analysis using 
the single fluorophore controls described above. Positive staining was determined by 
comparison with populations within samples stained with matched isotype control 
antibodies. Alternatively, for some populations this distinction was made on the basis of 
discrete staining characteristics e.g. CD45, where there is a clear distinction between 
positive and negatively stained populations. The level of staining was quantified as the 
mean fluorescence intensity (MFI), and geometric mean was used throughout so that 
the mean values were not distorted by the high levels of fluorescence of positively 
stained populations.  
2:7.4  PhosFlow analysis of STAT5 in MoDCs 
CD14+ monocytes were cultured in the presence of GM-CSF and IL-4 (100 ng/ml) in 
complete medium in the presence or absence of intestinal biopsy-derived CM. 
Phosphorylation of STAT5 was determined using a methodology developed in house. 
Briefly, cells were fixed in PFA (4 %) following 0, 0.25, 1, 4 or 24 hours of culture and 
permeabilised in ice cold methanol (70 %), labelled with monoclonal anti-phospho-
STAT5 antibody and analysed by flow cytometry.  
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2:8 Quantitative real-time PCR 
2:8.1  RNA extraction 
Cells were washed in PBS by centrifugation (400 x g, 5 minutes), then supernatant was 
removed entirely by careful pipetting. RNA extraction was performed using the RNeasy 
Micro Kit (Qiagen) as per manufacturer’s instruction. In brief, samples with low numbers 
of cells (<1 x 105) were lysed with 75 μl RLT buffer by vortexing for 1 minute. 
Alternatively, samples with (>1 x 105 cells) were lysed in 350 μl RLT buffer by vortexing 
for 1 minute. RNA extraction was either performed immediately after this point, or 
alternatively the cell lysate was stored at -80 ºC and thawed at a later date in a water 
bath at 37 ºC before continuing RNA extraction. One volume of 70 % ethanol (i.e. either 
75 or 350 μl) was added to the cell lysate and mixed by repeated pipetting. The entire 
volume was then transferred onto an RNeasy MinElute spin column placed in a 2 ml 
collection tube and centrifuged (8,000 x g, 15 seconds). Flow-through liquid in the 
collection tube was discarded and the collection tube re-used. RNA trapped on the 
column membrane was washed by the addition of 700 μl RWI buffer, and centrifugation 
(8,000 x g, 15 seconds). The RNeasy MinElute spin column was then placed in a fresh 
2 ml collection tube, then 500 μl RPE buffer was added followed by centrifugation 
(8,000 x g, 15 seconds) to was the spin column membrane. The flow-through liquid was 
then discarded and 2 ml collection tube re-used. 500 μl of 80 % ethanol was then 
added to the column to wash the membrane, followed by centrifugation (8,000 x g, 2 
minutes). The spin column was then placed in a fresh 2 ml collection tube and 
centrifuged at full speed for 5 minutes with the lid of the spin column open to completely 
remove all ethanol from the membrane. Finally, the spin column was transferred to a 
1.5 ml collection tube, 14 μl if RNase-free water was added directly to the membrane 
and then spin column was centrifuged at full speed for 1 minute to elute the RNA. 
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Purified RNA was used either immediately for reverse transcription to cDNA (see 
below) or stored at -20 °C for processing at a later date. 
2:8.2  Reverse transcription 
Reverse transcription was performed using the QuantiTect Reverse Transcription Kit 
(Qiagen) as per manufacturer’s instruction. In brief, the entire RNA sample 
(approximately 12 μl) was incubated with 2 μl gDNA Wipeout Buffer for 2 minutes at 42 
°C to degrade genomic DNA. The 14 μl gDNA elimination reaction was then mixed with 
Quantiscript Reverse Transcriptase (1 μl), Quantitect RT Buffer (4 μl) and RT primer 
mix (1 μl) and incubated at 42 °C for minutes allowing reverse transcription of all RNA 
molecules present into cDNA. The sample was then incubated at 95 °C for 3 minutes to 
inactivate Quantiscript Reverse Transcriptase. The cDNA sample was then either used 
for real-time PCR or stored at -20 °C until required. 
2:8.3  Real-time PCR with SYBR Green 
Quantitative real-time PCR was performed using QuantiFast SYBR Green PCR Kit 
(Qiagen) as per manufacturer’s instruction. In brief, master mixes containing 2x 
QuantiFast SYBR Green PCR Master Mix (12.5 μl), specific forward and reverse 
primers (primers listed in Table 2.3; 2.5 μl each or 2.5 μl of custom primers in which 
forward and reverse primers are combined for a final concentration of 1 μM), and 
sufficient RNase-free water to bring the volume up to 24 μl for each amplification. This 
master mix was then pipetted into the wells of a 96 well PCR plate (24 μl/well; Star 
Lab). cDNA (1 μl) was added to the top of relevant wells, then the plate was covered 
with Advanced Polyolefin StarSeal (Star Lab) and briefly centrifuged to draw the cDNA 
droplet into the master mix at the base of the well. The plate was then run on a 7500 
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Real-Time PCR System (Applied Biosystems). The program used for all amplifications 
is displayed in Table 2.4. 
Table 2.3: Primers used in real-time PCR 
Target Forward primer Reverse primer Company 
Cat. 
number 
ALDH1A1 GTTGATCAAAGAAGCTGCCG CAACAGCATTGTCCAAGTCG Invitrogen N/A 
ALDH1A2 CACTGATGATATGCGGATTGC TAAAGACAGCTGCTACGAGTC Invitrogen N/A 
ALDH1A3 GAATAGCACCGACTATGGAC AGCAGTTGATCCAGACCGTT Invitrogen N/A 
DHRS9 TCAGAGAGACTTCGTACTGTG TGTAGTCCTCTAGTGTCAGCC Invitrogen N/A 
GAPDH TGCACCACCAACTGCTTAGC GCATGGACTGTGGTCATGAG Invitrogen N/A 
RDH10   Qiagen QT00029176 
RDH16   Qiagen QT00493024 
MN1   Qiagen  QT00043414 
RPL30   Qiagen QT00056651 
 
Table 2.4: PCR program 
Step Time Temperature 
1. Activation step 5 min 95 °C 
2. Denaturation 10 sec 95 °C 
3. Annealing / extension 33 sec 60 °C 
 
Data was collected at step 3, and steps 2 to 3 were cycled 40 times. Following 
amplification, a threshold was placed across the beginning of the log-linear phase of 
amplification and the cycle number at which the individual amplifications crossed this 
threshold (Ct value) were collected. Expression of the target gene (e.g. ALDH1A1) was 
normalized to the reference genes GAPDH or RPL30 using the 2-ΔCt method (Pfaffl, 
2001) where ΔCt is the difference in threshold cycle number for target and reference 
gene. RPL30 is a newly identified reference gene encoding a ribosomal protein with 
exceptionally stable expression across a wide range of human tissues and following 
different drug treatments (de Jonge et al., 2007). Where indicated in the text, a 
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geometric mean value of expression relative to both GAPDH and RPL30 is reported. 
An example of an amplification plot (ALDH1A1) is displayed in Figure 2.1A. All 
amplifications were run in the presence of a no template control (NTC) containing water 
instead of cDNA to ensure that any amplification was not the result of contamination of 
the reagents. 
Purity of amplified product and the presence of primer dimers were determined by 
running a melt curve analysis with every experiment. This step involves incremental 
increases in temperature and analysis of fluorescence at each increase. SYBR green is 
fluorescent in the presence of double stranded DNA, and the dissociation of double 
stranded DNA therefore leads to a loss of this fluorescence. The temperature at which 
double stranded DNA dissociates or ‘melts’ results from the size of the molecule, and 
the composition of GC and AT base pairs. If the amplified PCR product is pure, all the 
DNA molecules will melt at the same temperature, leading to a large loss of 
fluorescence at a specific temperature. However, where multiple products have been 
non-specifically generated, SYBR green fluorescence is lost at a range of temperatures 
associated with the distinct melting points of these various products. Primer dimers also 
produce a characteristic melt curve profile with a lower melting temperature than the 
desired product. Therefore, if amplification is detected but only primer dimers are 
observed by melt curve analysis, this may be taken as a negative result. An example of 
melt curve analysis for ALDH1A1 amplification is displayed in Figure 2.1B.  
Primers used were either custom made from Qiagen, or were designed in house. In all 
cases, primers were exon spanning so as to prevent amplification of contaminating 
genomic DNA versions of the target gene. 
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Figure 2.1: Example of real time PCR amplification. A: CD14+ monocytes were cultured in 
GM-CSF and IL-4 (100 ng/ml) for 6 days, then RNA was extracted and reverse transcribed to 
cDNA. Real time PCR with SYBR green was performed using primers specific for ALDH1A1. 
Amplification was also performed with ALDH1A1 primers either in absence of cDNA (no 
template control; NTC) or with a sample in which reverse transcriptase was omitted from the 
reverse transcription step (i.e. no cDNA present; -RT). A threshold was placed at the 
beginning of the log-linear phase of amplification, with the cycle number at which the 
fluorescence crosses this line as the Ct value. B: Purity of the amplified produce was verified 
by melt curve analysis. For the ALDH1A1 amplified product there is a single discrete change 
in fluorescence at a specific temperature indicating a pure product. The NTC and –RT 
controls display the classic melt curve profile of primer dimers, indicating that the low level 
amplification observed for these samples in A is the result of primer dimer formation. 
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2:9 Analysis of retinoid concentrations 
2:9.1  MoDC cultures 
MoDCs were differentiated from CD14+ monocytes as described in Section 2:2.1, in the 
presence or absence of intestinal biopsy CM. Cells were washed twice by 
centrifugation in complete medium (400 x g, 5 minutes) and cultured at 5 x 105 
cells/well in a 24 well plate for 4 hours in the presence or absence of all-trans retinal 
(100 nM; Sigma-Aldrich). Cells were then collected and centrifuged (400 x g, 5 
minutes), supernatant was removed and then both supernatant and cell pellet were 
snap frozen in liquid nitrogen for analysis of retinoid concentration as described below. 
2:9.2  Intestinal biopsies 
Intestinal biopsies were collected from patients in absence of RPMI and snap frozen in 
liquid nitrogen as soon as possible to limit degradation of retinoids. Retinoid 
concentration was determined as described below. 
2:9.3  Retinoid quantification 
Retinoic acid, retinol and retinyl esters were quantified by high performance liquid 
chromatography (HPLC) with tandem mass spectrometry (MS/MS) in the laboratory of 
Maureen Kane, University of Maryland, Baltimore, as described previously (Kane et al., 
2005).   
2:10 Statistics 
Statistical analyses were performed using Sigmaplot 11.0 (Systat Software, London, 
UK). Comparisons between two groups of normally distributed data were analysed 
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using t-tests, paired where appropriate. Datasets containing more than two groups 
were compared by analysis of variance (ANOVA) with pair-wise comparisons using the 
Tukey test to correct for multiple comparisons. Non-normally distributed data were log10 
transformed and then analysed by ANOVA and Tukey test where indicated in the text. 
P-values were regarded as statistically significant when p<0.05. Significance of 
correlations for non-normally distributed data assessed by Spearman’s Rank.  
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Chapter 3: Validation of Aldefluor assay for determining 
RALDH activity in human dendritic cells 
 
3:1 Chapter summary 
This Chapter focuses on determining the suitability of the Aldefluor assay for assessing 
RALDH activity in human DCs by exploring the regulation of Aldefluor staining and 
RALDH gene expression in MoDCs as a model. MoDCs demonstrate Aldefluor activity 
with elevated expression of multiple ALDH1A isoforms in Aldefluorhi cells. This activity 
is also competitively inhibited by retinal, indicating a close association between 
Aldefluor and RALDH activity. Consistent with our understanding of the regulation of 
RALDH activity in other cells, RARα signalling during differentiation of MoDCs is 
required for ALDH1A expression and Aldefluor/RALDH activity, whilst exogenous RA 
enhances Aldefluor/RALDH activity through increased ALDH1A2 expression. 
Interestingly, Aldefluor/RALDH is greatest in MoDCs with a mature phenotype and 
consequently may be enhanced following LPS stimulation as the frequency of mature 
MoDCs increases. GM-CSF alone is a potent inducer of Aldefluor/RALDH activity in 
human monocytes, whereas IL-4 appears to act as a negative RALDH regulator which 
attenuates GM-CSF-mediated induction. In conclusion, the Aldefluor assay is suitable 
for analysis of RALDH activity in human MoDCs, and is therefore a valid approach for 
the analysis of RA generation in human intestinal DCs.  
3:2 Introduction 
The production of RA through RALDH enzyme activity is critical for the ability of murine 
small intestinal and MLN CD103+ DCs to imprint a gut-homing α4β7+ and CCR9+ 
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phenotype during T cell activation (Iwata et al., 2004 and reviewed by Agace, 2010). 
RA also supports the TGF-β mediated induction of Foxp3+ TREG from naive CD4+ T cells 
and suppresses induction of TH17 cells (Mucida et al., 2007, Sun et al., 2007, Coombes 
et al., 2007, Schambach et al., 2007). The loss of RALDH activity by intestinal CD103+ 
DCs is implicated in the pathogenesis of experimental intestinal inflammation of mice 
(Collins et al., 2011, Laffont et al., 2010). It has been demonstrated that human CD103+ 
but not CD103- MLN DCs induce high levels of CCR9 expression on CD8+ T cells, 
consistent with an enhanced ability to generate RA via the activity of RALDH enzymes 
(Jaensson et al., 2008). However, the role of RALDH activity in human intestinal DCs 
and whether modification of this activity plays a role in IBD remains poorly defined.  
RALDH activity in murine intestinal CD103+ DCs has been demonstrated by Aldefluor 
assay (Yokota et al., 2009, Denning et al., 2011, Jaensson-Gyllenback et al., 2011, 
Cerovic et al., 2012). The assay reagent comprises an aminoacetaldehyde moiety 
bound to a boron-dipyromethene (BODIPY) fluorochrome, which passively diffuses into 
cells. As a member of the aldehyde dehydrogenase (ALDH) family of enzymes, RALDH 
oxidises the aminoacetaldehyde moiety and converts it to aminoacetate. The net 
negative charge of the aminoacetate moiety then prevents exit by diffusion, leading to 
an accumulation of intracellular BODIPY and increased cellular fluorescence which is 
detectable by flow cytometry (Storms et al., 1999). Furthermore, the assay is performed 
in the presence of the efflux inhibitor verapamil in order to prevent loss of fluorescence 
by active efflux of the oxidised reagent. The Aldefluor reaction mechanism is 
summarised in Figure 3.1.   
The Aldefluor assay was originally developed for the identification and isolation of 
hematopoietic stem cells based on high aldehyde dehydrogenase (ALDH) activity and a 
Chapter 3: Validation of Aldefluor assay for determining RALDH activity in human DCs 
135 
 
low side scatter profile (Storms et al., 1999). It has since been used to study cancer 
stem cells in a range of different contexts, where high ALDH activity is an indicator of 
poor prognosis (Alison et al., 2010). However, its use in identifying RALDH activity in 
human intestinal DCs has not yet been reported.  
This chapter focuses on determining the suitability of the Aldefluor assay in determining 
RALDH activity within human intestinal DCs. These cells are obtained at relatively low 
frequencies following collagenase digestion of intestinal mucosa, therefore these 
experiments were performed on monocyte-derived DCs (MoDCs) generated in vitro 
with GM-CSF and IL-4 (Sallusto and Lanzavecchia, 1994). Aldefluor activity of human 
Figure 3.1: Mechanism of the Aldefluor assay. BODIPY aminoacetaldehyde (BAAA) 
diffuses into ‘Test’ cells and is oxidised by ALDH enzymes including the RALDH family to 
BODIPY aminoacetate (BAA-), which is prevented from exiting the cell by passive diffusion 
due to its net negative charge. Active efflux is also inhibited by the presence of verapamil in 
the assay buffer. This leads to an accumulation of fluorescence (520 – 540 nm) which is 
detectable by flow cytometry. In ‘Control’ cells, DEAB prevents the oxidation of BAAA to 
BAA- by RALDH, preventing the accumulation of fluorescence. Dotted arrows indicate 
movement of reagents across the cell membrane, solid arrows indicate oxidation. 
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MoDCs has been reported (Villablanca et al., 2011b), whilst expression of ALDH1A2 
has also been identified in these cells (Kamada et al., 2009). However, the relationship 
between RALDH and Aldefluor activity in MoDCs remains unaddressed.  
The MoDC system also allows the influence of exogenous factors on RALDH activity to 
be studied. RA has been proposed as a key inducer of RALDH activity in intestinal DCs 
(Molenaar et al., 2011, Villablanca et al., 2011b). Furthermore, TLR stimulation exerts 
some influence over RALDH activity (Wang et al., 2011b, Villablanca et al., 2011b). 
Following validation of the Aldefluor assay in MoDCs, this system therefore allows the 
nature of this regulation to be explored in more detail. 
3:3 Aims 
1. Determine whether the Aldefluor assay specifically identifies RALDH activity in 
human DCs  
 
2. Identify ALDH1A isoforms that drive Aldefluor activity in human DCs 
 
3. Identify factors which influence RALDH activity in human DCs 
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3:4 Results 
3:4.1  Human MoDCs have RALDH-specific Aldefluor activity 
MoDCs were differentiated from CD14+ monocytes in the presence of GM-CSF and IL-
4. Following the Aldefluor assay, a variable proportion of MoDCs displayed enhanced 
fluorescence consistent with intracellular accumulation of the acetate form of the 
Aldefluor reagent. In contrast, the accumulation of fluorescence (Aldefluor activity) was 
reduced in the presence of the ALDH inhibitor diethylaminobenzaldehyde (DEAB, 
Figure 3.2A). This indicates activity of the ALDH family of enzymes within human 
MoDCs. 
Aldefluor activity of MoDCs was inhibited in the presence of 10 μM retinal. However, 
this inhibition was also present with concentration-matched vehicle control (DMSO; 
Figures 3.2B and C), indicating a suppressive effect by DMSO. Almost complete 
suppression of Aldefluor activity was observed with 100 μM retinal which was not 
observed with concentration-matched DMSO (Figures 3.2B and C). This indicates that 
at sufficient molar excess (100 μM versus 1.5 μM for retinal and Aldefluor reagent, 
respectively) retinal competes with the Aldefluor reagent for access to the active site of 
ALDH enzymes. This strongly suggests that the observed Aldefluor activity in MoDCs is 
due to the RALDH (ALDH1A) sub-group of ALDH enzymes which specifically convert 
retinal into RA. 
The specific RALDH isoforms responsible for the observed Aldefluor activity in human 
MoDCs were unknown. To address this, Aldefluorhi and Aldefluorlo MoDCs were sorted 
by flow cytometry immediately following the Aldefluor assay and ALDH1A expression in 
each subset was determined by real-time PCR. To determine the sorting efficiency, 
aliquots of both subsets were also analysed by flow cytometry post-sorting (Figure 
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Figure 3.2: Human MoDCs possess Aldefluor activity that is specifically inhibited by 
retinal. A: CD14+ monocytes were cultured in the presence of GM-CSF and IL-4 (100 ng/ml) 
for 7 days to generate MoDCs which were then analysed by Aldefluor assay. Representative 
Aldefluor activity of MoDCs (n=16); the proportion of Aldefluorhi cells is indicated and is 
defined relative to a DEAB-inhibited control sample (right). B: Representative example of 
Aldefluor assay performed on MoDCs in the presence or absence of retinal. C: Summary 
data of MoDC Aldefluor data from two independent experiments performed in duplicate with 
concentration–matched vehicle control (DMSO). Mean values displayed ± SD; one way 
ANOVA with pair-wise comparison by Tukey test.  
 
A 
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3.3A). The Aldefluorlo subset was highly pure; however the Aldefluorhi subset contained 
both Aldefluorhi and Aldefluorlo cells. This most likely reflects loss of the Aldefluor 
reagent over time during the sorting process rather than a low sorting efficiency for this 
subset.  
ALDH1A1, ALDH1A2 and ALDH1A3 were expressed at approximately 2, 9 and 10 fold 
greater levels in Aldefluorhi compared with Aldefluorlo MoDCs, respectively (Figure 
3.3B). ALDH1A3 was expressed at levels considerably lower than those of ALDH1A1 
or ALDH1A2. This observation indicates that all three major RALDH isoforms could 
contribute to the observed Aldefluor activity of human MoDCs. At the level of 
transcription, RALDH2 appears to be the predominant enzyme in this context. 
B 
Figure 3.3: Human MoDCs with high levels of Aldefluor activity have enhanced 
ALDH1A expression. A: CD14+ monocytes were cultured in the presence of GM-CSF and 
IL-4 (100 ng/ml) for 7 days to generate MoDCs and then sorted by flow cytometry on the 
basis of Aldefluor activity. Representative example (n=3) of post-sort Aldefluorlo and 
Aldefluorhi MoDCs. B: Summary data of ALDH1A expression in flow-sorted Aldefluorlo and 
Aldefluorhi MoDCs as determined by real-time PCR (n=3); data normalized to GAPDH; mean 
values displayed + SD.  
 
 
A 
100 101 102 103 104 105
FITC-A
1
0
0
1
0
1
1
0
2
1
0
3
1
0
4
1
0
5
S
S
C
-A
R2
100 101 102 103 104 105
FITC-A
1
0
0
1
0
1
1
0
2
1
0
3
1
0
4
1
0
5
S
S
C
-A
R2
23.9 %
AldefluorhiAldefluorlo
0.3 %
Aldefluor
S
S
C
0
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
1A1 1A2 1A3
A
L
D
H
1
A
e
x
p
re
s
s
io
n
(A
rb
it
ra
ry
 u
n
it
s
)
ALDH isoform
Aldefluor lo
Aldefluor hi
Chapter 3: Validation of Aldefluor assay for determining RALDH activity in human DCs 
140 
 
3:4.2 RA is both required for and enhances RALDH activity of human 
MoDCs 
It has been demonstrated that dietary vitamin A (retinol) contributes significantly to the 
RALDH activity of murine intestinal CD103+ DCs (Molenaar et al., 2011, Jaensson-
Gyllenback et al., 2011). Furthermore, exogenous RA boosts Aldefluor activity in 
human MoDCs (Villablanca et al., 2011b). This likely represents a positive feedback 
loop, although the mechanism behind this remains undetermined. It is also currently 
unknown how the presence or absence of RA during the differentiation process 
influences RALDH activity of human MoDCs. Monocytes were therefore cultured in 
GM-CSF and IL-4 with the addition of exogenous RA or the RARα antagonist Ro41-
5253 (Apfel et al., 1992) in order to block endogenous RA present in FCS or generated 
by DC themselves. The Aldefluor/RALDH activity of control MoDCs was consistently 
enhanced by the presence of 10 nM RA across 3 independent experiments, although 
this did not reach statistical significance (Figures 3.4A and B). Furthermore, Ro41-5253 
suppressed the Aldefluor/RALDH activity of MoDCs (Figures 3.4A and B). Overall there 
was a statistically significant increase in the RALDH/Aldefluor activity of RA versus 
Ro41-5253-treated MoDCs (p = 0.002; Figure 3.4B). This indicates that RALDH activity 
responsible for Aldefluor activity in human MoDCs requires the presence of RARα 
signalling during differentiation, and that the activity of these enzymes may be further 
upregulated by exogenous RA.   
Of the three major RALDH isoforms analysed by real-time PCR, only expression of 
ALDH1A2 was enhanced by the addition of RA as compared with control MoDCs 
(Figure 3.4C). This increase did not reach statistical significance across three 
independent experiments, and may indicate a role for post-transcriptional regulation of 
ALDH1A2 in determining overall RALDH2 activity. In contrast, ALDH1A1 expression of 
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MoDCs was significantly suppressed by the presence of exogenous RA (p = 0.002; 
Figure 3.4C). Whilst ALDH1A3 was generally expressed at a significantly lower level 
than the other isoforms, it too was reduced by RA (p = 0.077; Figure 3.4C). Overall, this 
indicates that the enhanced Aldefluor activity of MoDCs grown in the presence of 
exogenous 10 nM RA is the partially the result of enhanced ALDH1A2 expression, with 
a potential additional role for post-translational regulation. Based on reduced 
B 
Figure 3.4: Retinoic acid is both required for and enhances RALDH2-mediated 
Aldefluor activity of human MoDCs. A: CD14+ monocytes were cultured with GM-CSF 
and IL-4 (100 ng/ml) for 7 days to generate MoDCs in the presence of Ro41-5253 (1 μM), 
RA (10 nM) or neither (control). Representative example (n=3) of Aldefluor activity of MoDC 
groups; numbers the proportion of Aldefluorhi cells gating relative to a DEAB control (not 
shown). B: Summary Aldefluor data (n=3). C: ALDH1A expression determined in treated 
MoDC groups by real-time PCR (n=3), expression normalized to GAPDH. Mean values 
displayed + SD except in B (median); one way ANOVA with pair-wise comparison by Tukey 
test; * indicates p-value following log10 transformation of non-normally distributed data.  
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transcription, neither RALDH1 nor RALDH3 are likely to contribute to this enhanced 
activity. 
ALDH1A1 and ALDH1A3 expression were suppressed by the presence of Ro41-5253 
during MoDC differentiation (p = 0.003 and p = 0.03, respectively; Figure 3.4C). 
ALDH1A2 expression was also suppressed, although this did not reach statistical 
significance (Figure 3.4C). This indicates that RARα signalling is required for the 
expression of all major RALDH isoforms in human MoDCs, and that each may 
contribute to the overall Aldefluor activity of these cells as suggested earlier (Figure 
3.3B). However, the effect of RA at a concentration of 10 nM on the expression of 
ALDH1A2 is distinct from its effect on ALDH1A1 and ALDH1A3, suggesting that 
exposure to RA may regulate the balance of ALDH1A isoform expression in human 
DCs. 
3:4.3 RALDH activity and ALDH1A expression of human MoDCs is 
influenced by maturation status 
It has been demonstrated in mice that RALDH activity may be induced in splenic DCs 
by stimulation of TLR1/2 with the bacterial lipoprotein analogue Pam3CSK4 (Lee et al., 
2012). Furthermore, murine intestinal CD103+ DCs display reduced RALDH activity in 
MyD88-/- mice in which signalling through multiple TLRs (as well as IL-1) is suppressed 
(Wang et al., 2011b). Pam3CSK4 also induces ALDH1A2 expression in human MoDCs 
(Wang et al., 2011b). However, the extent to which modulation of RALDH activity 
following TLR stimulation is related to DC maturation status has not been previously 
explored. To address this, Aldefluor/RALDH activity of human MoDCs was assessed 
following overnight culture in the presence or absence of LPS (1 μg/ml). Control 
MoDCs existed in a range of states from immature (HLA-DRlo CD86-) to mature (HLA-
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DRhiCD86+). In contrast, following culture with LPS MoDCs displayed a uniformly 
mature phenotype (Figure 3.5A). LPS-treated MoDCs consistently displayed increased 
levels of Aldefluor/RALDH activity across three independent experiments (Figures 3.5B 
and C). Increased Aldefluor/RALDH activity was associated with a trend towards 
increased expression of both ALDH1A2 and ALDH1A3, with decreased expression of 
ALDH1A1 (Figure 3.5D). Unstimulated MoDCs with a mature phenotype (HLA-
DRhiCD86+) display significantly increased Aldefluor/RALDH activity compared with 
their immature (HLA-DRlo CD86-) counterparts (p = 0.005; Figures 3.5E and F). Overall, 
this indicates that RALDH activity of human MoDCs is largely restricted to subset of 
cells with a mature phenotype. The ability of LPS to increase Aldefluor/RALDH activity 
of MoDCs appears to relate directly to increasing the proportion of cells with this 
phenotype. 
3:4.4  GM-CSF induces RALDH activity in human MoDCs 
It has been demonstrated that the combination of GM-CSF and IL-4 is sufficient to 
induce RALDH activity in splenic DCs in mice (Yokota et al., 2009). GM-CSF alone 
induces significant levels of RALDH activity in non-intestinal DCs in mice following 
administration of adenovirus 5, leading to peripheral induction of α4β7+ CD8+ T cells 
(Ganguly et al., 2011b). The individual contribution of GM-CSF and IL-4 to the 
Aldefluor/RALDH activity of human MoDCs is unknown. To address this, monocytes 
were differentiated either in the presence of both GM-CSF and IL-4 as standard 
(control), or else with GM-CSF or IL-4 alone. Monocytes cultured with IL-4 alone 
displayed very low levels of Aldefluor/RALDH activity (Figures 3.6A and B). In contrast, 
monocytes cultured with GM-CSF alone had significantly elevated Aldefluor/RALDH 
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activity as compared with control MoDCs and monocytes grown with IL-4 (p = 0.018 
and p = 0.008, respectively; Figures 3.6A and B). Overall, this indicates that GM-CSF is 
the principal driving factor behind Aldefluor/RALDH activity in human MoDCs, and that 
IL-4 acts as a negative RALDH factor in this context.   
  
B 
Figure 3.6: GM-CSF alone induces significantly greater levels of Aldefluor activity in 
MoDCs than GM-CSF in combination with IL-4. A: CD14+ monocytes were cultured in 
GM-CSF and IL-4 (Control) or GM-CSF or IL-4 alone (all at 100 ng/ml) for 7 days and 
analysed by Aldefluor assay; representative data (n=3). B: Summary Aldefluor data (n=3); 
median values displayed + SD; one way ANOVA with pair-wise comparison by Tukey test; * 
indicates p-value following log10 transformation of non-normally distributed data. 
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3:5 Discussion 
The primary aim of the work presented in this chapter was to establish the validity of 
the Aldefluor assay in analysis of RALDH activity of human MoDCs, with a view to 
extending this to intestinal DCs. MoDCs were used in these experiments as they could 
be generated under controlled conditions and in quantity sufficient for analysis. They 
displayed an accumulation of the Aldefluor reagent which could be blocked with DEAB 
and competitively inhibited with retinal. Furthermore, cells with increased Aldefluor 
activity had increased expression of all ALDH1A isoforms studied. Overall, this 
indicates a significant overlap between Aldefluor and RALDH activity in human MoDCs.  
The presence of exogenous 10 nM RA throughout differentiation increased the level of 
Aldefluor/RALDH activity of MoDCs upon analysis at day 7. Addition of RA on day 3 of 
differentiation has also been demonstrated to increase Aldefluor activity of human 
MoDCs (Villablanca et al., 2011b). This indicates that the positive feedback loop 
between RA and RALDH enzyme activity is not restricted to an early stage of 
differentiation, but may be amplified throughout this process.  
The mechanism of enhanced Aldefluor/RALDH activity through exogenous RA remains 
unclear. Of the three isoforms studied, only expression of ALDH1A2 was increased by 
this treatment whereas ALDH1A1 and ALDH1A3 were suppressed. This implicates 
RALDH2 activity in this context, though the relatively small increase in ALDH1A2 
expression also suggests post-transcriptional regulation. This has been proposed 
elsewhere to account for a diminishing gradient of Aldefluor/RALDH activity in murine 
intestinal DCs from the proximal to distal intestine, despite relatively stable Aldh1a2 
expression by DCs across the murine intestine (Villablanca et al., 2011b). Furthermore, 
a precedent exists for RA and RARα influencing the post-transcriptional modification of 
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proteins. In the presence of RA, RARα promotes translation of the glutamate receptor 
GluR1 in rat primary hippocampal neurons (Maghsoodi et al., 2008). RA may therefore 
support translation of ALDH1A2 mRNA in human MoDCs. 
The mechanisms regulating RA-mediated transcriptional control of ALDH1A2 remain 
unclear. The murine Aldh1a2 promoter does not contain RARE sites, suggesting that 
transcriptional regulation is indirect and not by direct promoter binding of RARs (Wang 
et al., 2001). Administration of RA has been shown to lead to phosphorylation of the 
MAPK ERK1/2, and this activation is required for the induction of RALDH in murine 
splenic DCs by RA (Villablanca et al., 2011b). In a different context, Rara-/- mice 
(deficient in RARα) display defects in T cell activation and proliferation which 
associates with reduced phosphorylation of ERK1/2 (Hall et al., 2011b). Signalling 
events downstream of ERK1/2 may therefore dictate enhanced ALDH1A2 expression 
following administration of exogenous RA. 
Expression of all ALDH1A isoforms was suppressed in MoDCs by inhibition of RARα 
signalling with Ro41-5253 during MoDC differentiation. This indicates that RA is 
required for expression of RA-generating enzymes and that the estimated 0.2 – 0.5 nM 
RA present in complete medium containing 10% FCS (Kang et al., 2011) is sufficient to 
support this expression. ALDH1A expression may also be supported by low levels of 
RA production by MoDCs in a positive feedback loop. This interpretation is supported 
by the presence of a non-consensus RARE in the human ALDH1A1 promoter that 
recruits RARα/RXRβ which then acts in conjunction with the CCAAT enhancer binding 
protein (C/EBP)-β to promote transcription of ALDH1A1 (Elizondo et al., 2000). 
Interestingly, exogenous RA suppresses binding of C/EBPβ to CCAAT (Elizondo et al., 
2009), providing an explanation for suppression  of  ALDH1A1 in human MoDCs grown 
in the presence of 10 nM RA. Reduced C/EBPβ binding may be the result of reduced 
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transcription and/or the presence of additional proteins such as GADD153 which bind 
to C/EBPβ and reduce its ability to interact with CCAAT sites (Elizondo et al., 2009). 
ALDH1A3 expression may be regulated in a similar manner, as it too was suppressed 
by both Ro41-5253 and RA. The murine Aldh1a2 promoter contains CCAAT sites 
(Wang et al., 2001), but may be regulated by RA within a distinct range of 
concentrations. Regulation of ALDH1A expression by RA also varies between distinct 
cell types. It has been demonstrated that high dose RA (1 μM) significantly enhances 
ALDH1A3 expression in human keratinocytes, whilst ALDH1A1 and ALDH1A2 are 
suppressed (Koenig et al., 2010).  
It is interesting to note that within a single population of MoDCs, Aldefluor/RALDH 
activity was largely limited to cells with a mature phenotype. Whether the upregulation 
of RALDH activity is required for or is simply co-incident with DC maturation is unclear. 
It has been demonstrated that a combination of RA and TNFα is required to mature a 
Langerhans cell (LC)-type DC, a modified MoDC in which TGF-β is present during 
culture (Geissmann et al., 2003). This study also observed that 1 μM retinol induced 
apoptosis in immature but not mature LC-type DCs during two day culture. This may 
indicate that the RALDH activity of mature DCs contributes to metabolism of retinal 
which may otherwise accumulate during this culture period, leading to the apoptosis of 
immature DCs. 
LPS stimulation did not significantly increase the Aldefluor/RALDH activity of human 
MoDCs beyond increasing the proportion of cells with a mature phenotype. Stimulation 
of human MoDCs with the TLR2 ligand Pam3CSK4 increases ALDH1A2, as reported 
elsewhere (Villablanca et al., 2011b), and is consistent with an association with 
maturation-inducing stimulation and upregulation of RALDH activity. Moreover, 
stimulation of murine splenic DCs with LPS, Pam3CSK4 or flagellin enhances 
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expression of Aldh1a2 (Wang et al., 2011b). In contrast with RA-mediated RALDH 
upregulation, this requires the MAPK JNK and not ERK1/2. The extent to which these 
stimulations upregulate RALDH as part of DC maturation is however unclear. 
The significantly enhanced ability of GM-CSF to induce Aldefluor/RALDH activity in 
human monocytes compared with GM-CSF in combination with IL-4 was unexpected, 
as GM-CSF and IL-4 synergistically induce RALDH activity in murine splenic DCs 
(Yokota et al., 2009)  Monocytes cultured in GM-CSF alone differentiate into a 
classically activated or ‘M1’ MФ phenotype (Krausgruber et al., 2011), as opposed to a 
MoDC phenotype. These cells display a pro-inflammatory phenotype characterized by 
high production of TNFα and low amounts of IL-10 in response to microbial stimulation 
(reviewed by Hedl and Abraham, 2013). The relationship between RALDH activity and 
a pro-inflammatory MФ phenotype is explored in detail in Chapter 5. The ability of GM-
CSF to induce RALDH activity human CD14+ monocytes is consistent with GM-CSF-
mediated induction of RALDH activity in peripheral DCs in mice following intra-muscular 
administration of adenovirus type 5 (Ganguly et al., 2011b). This also suggests that 
immunological contexts in which GM-CSF production is induced in humans may lead to 
peripheral induction of DC RALDH activity and the potential induction of gut-homing T 
cell responses from these sites. IL-4 alone was a poor inducer of Aldefluor/RALDH 
activity in human monocytes, and reduced the activity induced by GM-CSF alone. In 
contrast, IL-4 in conjunction with Flt3L induces Aldh1a2 expression in murine bone 
marrow (BM)-derived DCs (Yokota et al., 2009). Furthermore, IL-4 also induces 
Aldh1a2 expression murine BM-derived MФ in conjunction with M-CSF (Broadhurst et 
al., 2012). Thus, the effect of IL-4 on RALDH activity in DCs may be dependent upon 
the context provided by additional cytokines or alternatively this property may be 
specific to IL-4 in the mouse.  
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3:6 Conclusion 
In conclusion, Aldefluor assay is a valid approach for determining RALDH activity in 
human MoDCs. In the next chapter, this methodology is applied to DCs extracted from 
human intestinal mucosa in order to identify which population have RALDH activity and 
to investigate whether this activity is altered in IBD. 
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Chapter 4: Analysis of antigen presenting cell 
retinaldehyde dehydrogenase activity and 
retinoid levels in the healthy human intestine 
and in inflammatory bowel disease 
 
4:1 Chapter summary 
This chapter focuses on determining the distribution of RALDH activity in human 
intestinal antigen presenting cell (APC) subsets in healthy control and IBD patients 
using the Aldefluor assay as validated in Chapter 3. RALDH activity is identified in 
intestinal CD103+ and CD103- DCs, and also CD14+ MФ. This activity derives from 
differential expression of ALDH1A isoforms, with CD14+ MФ distinguished by 
expression of ALDH1A1. RALDH activity of CD103+ DCs is not reduced in IBD patients, 
arguing against a hypothesis that loss of this activity contributes to disease 
pathogenesis. In contrast, this activity is slightly increased in IBD and may therefore 
mediate currently unknown aspects of disease. RALDH activity of CD14+ MФ is 
significantly enhanced in IBD patients. RALDH activity is also observed in non-
haematopoietic cells, including intestinal epithelial cells, which is reduced in IBD 
patients. Preliminary data suggests that net levels of RA are maintained across healthy 
control and CD intestinal mucosa, despite a reduction in the level of mucosal retinol. In 
conclusion, this chapter provides the first detailed analysis of RALDH activity in APC 
subsets in the human intestinal mucosa in health and IBD. It identifies key differences 
between mouse and man which may ultimately provide critical insight into the 
pathogenesis of IBD. 
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4:2 Introduction 
A paradigm has emerged over recent years in which CD103+ DCs play a key role in 
supporting intestinal homeostasis in mice. It is now well established that CD103+ DCs in 
the murine small intestinal lamina propria (SI-LP) have enhanced levels of RALDH 
activity compared with CD103- DCs (Schulz et al., 2009, Denning et al., 2011, 
Jaensson-Gyllenback et al., 2011). This is also true in MLNs (Coombes et al., 2007, 
Yokota et al., 2009, Molenaar et al., 2011, Guilliams et al., 2010) where CD103+ DCs 
are believed to have migrated from the SI-LP via the draining lymphatics (Johansson-
Lindbom et al., 2005, Jaensson et al., 2008). Enhanced RALDH activity is reflected in 
high level expression of Aldh1a2, encoding RALDH2, in CD103+ DCs (Coombes et al., 
2007, Schulz et al., 2009, Yokota et al., 2009, Denning et al., 2011). RALDH activity 
has also been observed in murine colonic LP CD103+ DCs, albeit at lower levels than in 
the SI-LP (Denning et al., 2011, Jaensson-Gyllenback et al., 2011, Villablanca et al., 
2011b). 
Provision of RA by murine CD103+ DCs during lymphocyte activation imprints a ‘gut-
homing’ α4β7+ CCR9+ phenotype on T cells (Iwata et al., 2004, Johansson-Lindbom et 
al., 2005, Jaensson et al., 2008) and similar pathways operate in B cells (Mora et al., 
2006). This allows efficient entry of activated T and B cells into the intestinal mucosa 
from blood circulation. RA derived from CD103+ DCs enhances TGF-β-mediated 
induction of Foxp3+ TREG  (Sun et al., 2007, Coombes et al., 2007) as well as 
suppressing induction of TH17 cells (Mucida et al., 2007). Furthermore, CD103+ DCs 
use RA to drive the differentiation of IgA+ plasma cells from naive B cells (Mora et al., 
2006, Uematsu et al., 2008). 
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Human MLN CD103+ DCs have been shown to be unique in their ability to induce high 
levels of CCR9 expression on naive CD8+ T cells (Jaensson et al., 2008), although 
RALDH activity in these cells has not been addressed. Whilst this indicates a degree of 
overlap between mouse and man, the distribution and role of RALDH activity in human 
intestinal CD103+ and CD103- DCs remain poorly defined.  
Mouse models of IBD indicate that RALDH activity in CD103+ DCs is significantly 
modified under inflammatory conditions. TNFΔARE mice, in which the stability of TNFα 
mRNA is enhanced, develop chronic inflammation of the terminal ileum (TI) with similar 
histology to Crohn’s disease (Kontoyiannis et al., 1999). Expression of Aldh1a2 is 
significantly reduced in CD103+ DCs in the TI LP of TNFΔARE mice by 4 weeks of age, 
and then in the MLN by 20 weeks. This may contribute to inflammation by altering the 
balance of T cell profiles induced by CD103+ DCs in favour of TH17 cells over Foxp3+ 
TREG (Collins et al., 2011). Furthermore, Aldh1a2 expression is significantly reduced in 
MLN CD103+ DCs in the T cell transfer model of colitis (Laffont et al., 2010). CD103+ 
DCs from these mice display a reduced ability to induce Foxp3+ TREG, with enhanced 
induction of both TH1 and TH17 cells. Whether RALDH activity is lost in human CD103+ 
DCs in IBD and the extent to which this contributes to the pathogenesis of disease is 
currently unknown. 
Beyond DCs, RALDH activity has also been identified in CD11b+ CD11c- F4/80+ 
resident MФ in both SI and colonic LP of mice, along with expression of Aldh1a1 
(Denning et al., 2011). In the presence of exogenous TGF-β, these cells induce 
differentiation of naïve CD4+ T cells into Foxp3+ TREG  in vitro which may be inhibited by 
blocking either IL-10 or RA (Denning et al., 2007). They have also been implicated in 
the expansion of Foxp3+ TREG within the LP required for the induction of oral tolerance 
(Hadis et al., 2011). In humans, RALDH activity has not been systematically examined 
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but ALDH1A2 expression has been identified in intestinal CD14+ MФ (Kamada et al., 
2009). These cells are a pro-inflammatory population (Kamada et al., 2008) and 
production of RA by these cells may influence the induction of TH17 cells (Kamada et 
al., 2009). As with DCs, the nature of RALDH activity in human CD14+ DCs is poorly 
defined. 
In this chapter, multi-colour flow cytometry was used to identify CD103+ and CD103- 
DCs as well as CD14+ MФ in lamina propria cells (LPCs) extracted from human 
intestinal mucosa. RALDH activity was assessed in these populations using the 
Aldefluor assay as validated in Chapter 3. Expression of ALHD1A enzyme isoforms 
were assessed in purified cell populations obtained by cell sorting through flow 
cytometry. Furthermore, RALDH activity of these APC subsets was compared across 
healthy control and IBD patients in order to establish whether these are regulated by 
intestinal inflammation. Finally, mucosal levels of RA were analysed in order to 
determine whether observed changes in RALDH activity are sufficient to influence the 
local retinoid environment. Significant changes in RALDH activity in these subsets may 
provide key insights into the pathogenesis of IBD, and ultimately provide fresh 
therapeutic options. 
The hypothesis for this chapter was therefore that RALDH activity is enhanced in 
CD103+ DCs within healthy human intestinal mucosa as compared with either CD103- 
DCs or CD14+ MФ. This would reflect a parallel distribution of RALDH activity as 
observed in the mouse. Furthermore, this activity would be reduced in patients with 
IBD, consistent with both TNFΔARE (Collins et al., 2011) and T cell transfer-mediated 
(Laffont et al., 2010) murine intestinal inflammation. Loss of RALDH activity may lead to 
reduced induction of FOXP3+ TREG and/or a modified ability to induce a gut-homing 
α4β7+ phenotype on naive CD4+ T cells during activation, which may contribute to the 
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pathogenesis of IBD. Loss of RALDH activity may also lead to a reduced overall 
concentration of RA within the intestinal mucosa as implicated in TNFΔARE mice 
(Collins et al., 2011). 
4:3 Aims 
1. Determine which APC populations in human intestinal mucosa have RALDH 
activity 
 
2. Define changes in RALDH activity that occur in IBD 
 
3. Compare retinoid concentrations in healthy and IBD intestinal mucosa 
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4:4 Results 
4:4.1 RALDH activity is detected in multiple human intestinal APC 
subsets 
The ultimate aim of this project was to determine whether alterations in the RALDH 
activity present in human intestinal APCs plays a role in the pathogenesis of IBD and 
whether modification of this pathway has a potential therapeutic role. There is currently 
a significant gap between what is understood in the murine and human intestinal 
immune systems. For any observed differences in RALDH activity in IBD to have 
meaning, extensive characterisation of the distribution and function of RALDH activity in 
human intestinal APCs was therefore required. 
The first step taken was the identification of human intestinal APC subsets via flow 
cytometry. Lamina propria cells (LPCs) were extracted from mucosa derived from 
patients undergoing colonic and/or ileal surgical resection due to cancer or functional 
bowel problems. In the case of cancer patients, there was a significant margin between 
affected areas and tissue used for this research. For the purposes of this study, this 
tissue was classified as healthy. LPCs extracted from collagenase digestion of this 
mucosa were analysed via flow cytometry, with a staining strategy biased towards 
myeloid DCs (Figure 4.1). Leukocytes were first selected as CD45+ cells, and then DCs 
were identified as Lineage- (Lin: CD3, CD14, CD16, CD19, CD20, CD56) HLA-DR+ 
cells. Beyond this, myeloid DCs were identified as CD11c+ and could be further divided 
into CD103+ and CD103- subsets.  
There is ongoing controversy in the murine field as to the DC/macrophage (MФ) nature 
of various intestinal APC subsets, but a clear distinction is the ability of DCs to 
upregulate the chemokine receptor CCR7 during maturation and thereby to migrate into 
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naive T cell areas in the draining MLNs (Jang et al., 2006, Schulz et al., 2009, Rivollier 
et al., 2012). Myeloid DCs analysed immediately following collagenase digestion of 
intestinal mucosa were CCR7- (Figure 4.2A). However, when LPCs were cultured 
overnight at 37 ºC to allow time for DC maturation in 3 independent experiments, the 
vast majority of CD103+ DCs expressed CCR7 (91.9 ± 2.5 %; Figure 4.2B). CD103- 
DCs were also predominantly CCR7+ (65.6 ± 16.3 %), although this represented a 
slightly lower proportion of cells when compared with CD103+ DCs (Figures 4.2C and 
D). Overall these data strongly support the identification of CD103+ DCs as bona fide 
DCs, with a degree of heterogeneity amongst CD103- DCs and the potential inclusion 
of more MФ-like cells. 
 
Figure 4.1: Identification of human intestinal APCs via flow cytometry. LPCs were 
extracted from collagenase-digested colonic and TI resections and APC subsets identified by 
flow cytometry. Gating was focussed on leukocytes (CD45+ cells); DCs were Lin- HLA-DR+ 
and CD11c+ (myeloid cells), CD103+ and CD103- DC subsets were defined by isotype control 
staining (not shown). Lin+ HLA-DR+ cells were also analysed, and defined as CD14+ MФ 
based on expression of CD14, CD33 and CD68. Filled histogram represents antibody 
staining, dotted histogram represents the relevant isotype control; FSC is forward scatter, 
SSC is side-scatter.  
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As stated previously, the flow cytometry staining protocol was designed for the 
identification of human intestinal myeloid DC subsets. A discrete LinbrightHLA-DR+ 
population was however also routinely identified (Figure 4.1). Previous work in the lab 
has attributed CD14 expression to these cells, contributing to the Linbright staining (Bell 
et al., 2001). Strong fluorescence was observed in these cells when labelled with the 
mouse Igγ2a isotype control antibody (control for anti-CD14 staining; Figure 4.1), 
indicating either a significant degree of autofluorescence in the Pacific Blue range of 
the fluorescence spectrum or else high levels of non-specific antibody binding. CD14 
expression was however clearly observed in these cells beyond the isotype control 
staining. Furthermore, these cells also expressed CD33 and CD68 (Figure 4.1). Both 
are widely distributed on myeloid cells, but the presence of CD14 identifies these cells 
as CD14+ MФ.  
A 
Figure 4.2: CD103+ and CD103- DCs upregulate CCR7 during overnight culture, whilst 
CD14+ MФ remain CCR7-. A: LPCs were extracted from collagenase-digested colonic 
biopsies, CCR7 expression was then immediately determined in DCs and CD14+ MФ (as 
defined in Figure 4.1) via flow cytometry. B: LPCs were cultured overnight at 37 ºC in 
complete medium; CCR7 expression was identified in APC subsets (as defined in Figure 
4.1) via flow cytometry; filled histogram represents antibody staining, dotted histogram 
represents the relevant isotype control. The proportion of cells that are CCR7+ is indicated in 
each case. C: Summary data of CCR7 expression on APC subsets following overnight 
culture of LPCs obtained from healthy control biopsies (n=3). Bars indicate median values + 
SD; one way ANOVA with Tukey test; * indicates p-value obtained following log10 
transformation of transformation of non-normally distributed data.   
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As with myeloid DCs, CD14+ MФ analysed immediately following collagenase digestion 
of intestinal mucosa were CCR7- (Figure 4.2A). However, following overnight culture of 
LPCs, the majority of cells remained CCR7- across 3 independent experiments (Figures 
4.2B and C). These data are consistent with CD14+ MФ as a tissue-resident non-
migratory MФ population. Interestingly, a small proportion (5.5 ± 0.8 %) of CD14+ MФ 
were CCR7+ in all experiments following culture, indicating heterogeneity within the 
CD14+ population and the possible existence of CD14+ MФ with DC-like properties.  
In order to characterise RALDH activity amongst these intestinal APC subsets, the 
Aldefluor assay was performed on LPCs and the activity was subsequently attributed to 
each subset via flow cytometry based on the gating strategy as defined in Figure 4.1. 
As seen in Figure 4.3A, CD103+ and CD103- DCs as well as CD14+ MФ possessed 
cells with enhanced Aldefluor/RALDH activity in comparison to the DEAB-inhibited 
controls.  
The distribution of activity in these subsets was similar across 6 healthy control 
samples (Figure 4.3B); with mean values of 18.4, 18.6 and 22.3 % Aldefluor+ cells in 
CD103+ and CD103- DCs and CD14+ MФ, respectively. RALDH activity is enhanced in 
SI-LP CD103+ DCs in mice (Schulz et al., 2009, Denning et al., 2011, Jaensson-
Gyllenback et al., 2011). Paired analysis of CD103+ and CD103- DCs in this study 
however showed no enrichment of Aldefluor/ RALDH activity in human distal intestinal 
CD103+ DCs (Figure 4.3C).  
Analysis of RALDH activity via the Aldefluor assay was then extended to intestinal 
lymphocytes in order to determine whether this was a general feature of human 
intestinal leukocytes. CD19+ B cells possessed low levels of Aldefluor/RALDH activity 
based on a small increase in Aldefluor signal compared with the DEAB control (Figure 
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Figure 4.3: RALDH activity is identified in multiple intestinal APC subsets in healthy 
control patients. A: Aldefluor assay was performed in conjunction with flow cytometry on 
LPCs to identify CD103+ and CD103- DCs and CD14+ MФ from healthy control colon and TI 
resections with enhanced RALDH activity. Aldefluor+ gating was defined in comparison to a 
DEAB-inhibited control reaction (bottom row); a fixed separation was introduced between 
DEAB-inhibited cells and the gate to ensure only cells with enhanced RALDH activity were 
analysed. B: Box and whisker plot depicting the distribution of Aldefluor+ cells in each APC 
subset from healthy control samples (n=6). C: Paired analysis of the proportion of Aldefluor+ 
CD103+ and CD103- DCs from healthy control intestinal mucosa. Lines indicate individual 
experiments, bars represent mean values; paired t-test. SSC is side-scatter.  
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4.4). Approximately 9 % of these cells were Aldefluor+, approximately half the level 
observed in the APC subsets studied. This activity has not previously been identified 
and may be linked to RA-mediated IgA production as observed in mice (Mora et al., 
2006). Very low level levels of Aldefluor/RALDH activity were observed in CD4+ and 
CD8+ T cells (2.3 and 0.7 %, respectively). Overall these data support a more general 
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(CD19+ cells), and CD4+ and CD8+ T cells in LPCs extracted from collagenase-digested 
healthy control colonic biopsies. Aldefluor+ gating was defined in comparison to a DEAB-
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analysed; SSC is side-scatter.  
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role for RALDH activity in human intestinal myeloid APCs than the specific functions 
identified in murine CD103+ DCs.  
Multiple RALDH isoforms have been identified and could be responsible for the 
Aldefluor activity observed in human intestinal APCs. In order to define the specific 
enzymes responsible, human intestinal DCs and CD14+ MФ were sorted by flow 
cytometry for analysis of ALDH1A expression by real-time PCR. The low numbers of 
DCs obtained using this approach presented a significant technical challenge, and no 
ALDH1A isoforms could be detected in CD103+ DCs from a healthy control mucosal 
sample based on approximately 800 sorted cells. Expression of ALDH1A2 and 
ALDH1A3 was however detected in approximately 8500 CD103- DCs from this sample, 
whilst ALDH1A1 was not detected (Figure 4.5). This is consistent with RALDH2 and 
RALDH3 as responsible for the observed Aldefluor activity of CD103- DCs, and 
potentially also of CD103+ DCs. In contrast to CD103- DCs, CD14+ MФ expressed 
significant levels of ALDH1A1, as well as both ALDH1A2 and ALDH1A3 at levels 
comparable with CD103- DCs (Figure 4.5). A similar expression profile was observed in 
Figure 4.5: Human intestinal CD103- DCs and CD14+ MФ have different ALDH1A 
expression profiles. CD103- DCs and CD14+ MФ were sorted from collagenase-digested 
healthy control colonic resection tissue or colonic biopsies (CD14+ MФ only) via flow 
cytometry as Lin- HLA-DR+ (n=1) and CD33+ CD14+ cells (n=7), respectively; ALDH1A 
expression determined by real-time PCR. ALDH1A expression normalized to GAPDH (DCs) 
or GAPDH/RPL30 (CD14+ MФ); mean value displayed + SD; ND is not detected.  
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CD14+ MФ across 7 independent samples, sorted as CD14+ CD33+ cells; the superior 
numbers of CD14+ MФ facilitating sorting and analysis by real-time PCR. Overall, these 
data suggest that distinct profiles of RALDH enzymes drive the observed Aldefluor 
staining in CD14+ MФ and DCs in human intestinal mucosa.  
The overall ability of a cell to produce RA is determined both by the oxidation of retinal 
to RA by RALDH enzyme activity, and the prior oxidation of retinol to retinal by the 
microsomal short chain dehydrogenase/reductase (SDR) family of enzymes (reviewed 
by Napoli, 2012). Expression of the retinol dehydrogenase RDH10 was detected in 
CD103+ and CD103- DCs (Figure 4.6). This expression was approximately 4.5 fold 
higher in CD103+ compared with CD103- DCs in intestinal mucosa from a healthy 
control patient, and is particularly significant considering the low numbers of CD103+ 
DCs obtained through sorting. Furthermore, RDH10 expression was also identified in 
CD14+ MФ (see section 4:4.3, Figure 4.14B). This indicates that all three subsets 
possess the complete enzymatic machinery to convert retinol to RA, and that CD103+ 
DCs may possess an enhanced ability to generate retinal via RDH10 compared with 
their CD103- counterparts, perhaps resulting in increased overall RA output. 
Having identified the presence of RALDH activity in human intestinal DCs and CD14+ 
MФ, the next step was to establish whether this activity was sufficient to influence cell 
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Figure 4.6: Human intestinal DCs express RDH10. 
CD103+ and CD103- DCs were sorted by flow cytometry from 
collagenase-digested healthy control colonic resection tissue 
and RDH10 expression determined by real-time PCR. 
RDH10 expression normalized to GAPDH.  
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function. In order to assess this, DCs were sorted as Lin-HLA-DR+ cells via flow 
cytometry and used to stimulate CFSE-labelled allogeneic naive CD4+ T cells. Naive 
CD4+ T cells alone did not proliferate, remaining CFSEhi. In contrast, a significant 
proportion of CD4+ T cells did proliferate in the presence of sorted DCs and became 
CFSElo (Figure 4.7A). Proliferating cells expressed high levels of α4β7, consistent with 
the provision of RA during T cell activation by the DCs. Due to the low numbers of 
sorted DCs, it was not possible to run multiple co-cultures in which RA signalling was 
blocked. A separate experiment was therefore performed in which naive CD4+ T cells 
were stimulated with ‘walk-out’ cells which are enriched for mature DCs (Bell et al., 
2001) in the presence or absence of the RARα antagonist Ro41-5253 (Apfel et al., 
1992). Walk out cells induced strong proliferation in naive CD4+ T cells as seen by 
CFSE dilution and high levels of α4β7 expression as with sorted DCs (Figure 4.7B). In 
the presence of Ro41-5253 the level of α4β7 expression on proliferating T cells was 
significantly reduced (Figures 4.7B and C), strongly indicating that provision of RA 
during T cell activation is responsible for the induction of α4β7 expression in human T 
cells as seen in the mouse (Iwata et al., 2004). These data support the conclusion that 
the RALDH activity observed in human intestinal DCs generates sufficient RA to allow 
the efficient induction of a gut-homing phenotype on naive CD4+ T cells. 
4:4.2 RALDH activity is not reduced in human intestinal CD103+ DCs in 
IBD 
Having established the presence of RALDH activity in human intestinal CD103+ and 
CD103- DCs and also CD14+ MФ, the next stage was to determine if the level of this 
activity was modified in mucosa derived from IBD patients. To address this, the 
Aldefluor and flow cytometry analysis as described previously in this chapter were 
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applied to LPCs derived from IBD patients undergoing colonic and/or ileal surgical 
resection due to severe inflammation that had resisted therapy. This included patients 
with CD in which either the colon or terminal ileum were affected as well UC in which 
only the colon was affected. As with healthy controls, CD103+ and CD103- DCs as well 
as CD14+ MФ possessed cells with detectable Aldefluor/RALDH activity (Figure 4.8).  
Figure 4.7: Human intestinal DCs induce RA-dependent α4β7 expression on naive CD4+ 
T cells. A: DCs were sorted via flow cytometry as Lin- HLA-DR+ cells from LPCs derived 
from collagenase-digested resected human intestinal mucosa. Following 5 days co-culture 
with CFSE-labelled allogeneic naive CD4+ T cells, α4β7 expression was detected on 
proliferating CFSElo CD4+ T cells via flow cytometry. One example of two independent 
experiments shown; left panel is T cells alone (unstimulated), right panel indicates isotype 
control staining. B: CFSE-labelled naive CD4+ T cells were stimulated with ‘walk out’ cells 
derived from human intestinal biopsies in the presence or absence of the RARα antagonist 
Ro41-5253. MFI of α4β7 on CFSElo cells is depicted. C: Bar chart depicts mean α4β7 MFI + 
SD from two independent ‘walk out’ co-cultures from the same patient; paired t-test.  
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A direct comparison was then made of the proportion of cells within each subset with 
detectable Aldefluor/RALDH activity in healthy control and IBD patients, which were 
separated into ‘inflamed’ and ‘non-inflamed’ samples. Of note, ‘non-inflamed’ in this 
context refers to macroscopically normal mucosa where inflammation was present 
elsewhere in the colon or terminal ileum of the patient. In contrast to two murine models 
of IBD (Collins et al., 2011, Laffont et al., 2010), reduced RALDH activity in human 
intestinal CD103+ DCs in IBD was not observed in this study (Figure 4.9A). 
Furthermore, the average proportion of Aldefluor+ CD103+ DCs was increased in both 
non-inflamed and inflamed IBD compared with healthy control mucosa (27.9, 27.1 and 
18.4 %, respectively), although this difference did not reach statistical significance. The 
trend was more apparent in CD rather than UC samples due to the greater number of 
Figure 4.8: RALDH activity is identified in all APC subsets studied in both CD and UC 
mucosa. Aldefluor assay was performed in conjunction with flow cytometry to identify 
CD103+ and CD103- DCs and CD14+ MФ with enhanced RALDH activity from IBD colon 
and/or ileal surgical resections. Aldefluor+ gating was defined in comparison to a DEAB-
inhibited control reaction (not shown); a fixed separation was introduced between DEAB 
inhibited cells and the gate to ensure only cells with enhanced RALDH activity were 
enumerated. Both examples above derive from inflamed mucosa.  
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CD samples obtained (13 versus 4). Of the 3 inflamed UC samples, none displayed 
enhanced Aldefluor/RALDH activity in CD103+ DCs. The single non-inflamed UC 
sample did however possess high levels of Aldefluor/RALDH activity in CD103+ DCs. 
These data therefore support the conclusion that RALDH activity is maintained or 
possibly enhanced in human intestinal CD103+ DCs in IBD, particularly in CD. 
Increased activity is also observed in non-inflamed areas which may indicate that 
RALDH activity becomes enhanced prior to the onset of overt inflammation.   
As with CD103+ DCs, human intestinal CD103- DCs also did not display reduced 
Aldefluor/RALDH activity in IBD (Figure 4.9B). The proportion of Aldefluor+ CD103- DCs 
was however similar between non-inflamed and inflamed IBD and healthy control 
mucosa (24.1, 21.1 and 18.6 %, respectively) with no indication of an enhancement in 
CD103+ DCs
0
5
10
15
20
25
30
35
40
45
50
0 10 20
%
 A
ld
e
fl
u
o
r+
Healthy InflamedNon
inflamed
IBD
CD103- DCs
0
5
10
15
20
25
30
35
40
45
50
0 10 20
%
 A
ld
e
fl
u
o
r+
Healthy InflamedNon
inflamed
IBD
A B 
Figure 4.9: Human intestinal CD103+ DCs have enhanced RALDH activity in IBD. A: 
Aldefluor and flow cytometry analysis were performed on healthy control (n=6) and non-
inflamed (n=5) and inflamed (n=12) IBD LPCs as described previously in this chapter; 
collated results are shown for CD103+ DCs. B: Collated results shown for CD103- DCs. ● = 
Healthy▲ = CD, ■ = UC; filled symbols are colonic and empty symbols are ileal tissue 
samples; bars represent mean values.  
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IBD samples. This may indicate differential regulation of RALDH activity in human 
intestinal CD103+ and CD103- DCs in health and IBD.  
LPCs derived from an inflamed ileal CD surgical resection were sorted for CD103+ and 
CD103- DCs by flow cytometry in order confirm ALDH1A expression in these subsets in 
IBD. ALDH1A2 expression was observed by real-time PCR in both CD103+ and CD103- 
DCs derived from this sample (Figure 4.10). Expression of ALDH1A1 and ALDH1A3 
were however not detected in either subset. This may indicate that the increased 
RALDH activity of CD103+ DCs in IBD is due to increased expression or alternatively 
modified post-transcriptional regulation of ALDH1A2. Furthermore, RDH10 expression 
was again enhanced approximately 4 fold in CD103+ compared with CD103- DCs 
(Figure 4.11); indicating that enhanced conversion of retinol to retinal by CD103+ DCs is 
preserved in IBD. However further samples would be required to confirm this 
observation.  
The proportion of CD103+ DCs relative to other APC subsets is significantly reduced in 
the inflamed murine intestine (Collins et al., 2012, Laffont et al., 2010). A reduced 
proportion of human CD103+ DCs has also been recently observed in our laboratory in 
an analysis of non-inflamed colonic tissue from CD patients (McCarthy et al., 
manuscript in preparation). A similar trend was observed in the current study with 
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Figure 4.10: ALDH1A2 expression is detected in 
intestinal CD103+ and CD103- DCs in IBD. DC 
subsets were sorted via flow cytometry from LPCs 
derived from surgically resected inflamed CD ileum 
and ALDH1A expression was determined by real-time 
PCR. Expression normalised to GAPDH; ND is not 
detected.  
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relatively fewer colonic CD103+ DCs in IBD patients as a proportion of total myeloid 
DCs (Figure 4.12). This trend was not observed with CD103+ DCs from the TI of IBD 
patients however (data not shown). 
4:4.3 RALDH activity is significantly enhanced in human intestinal CD14+ 
MФ in IBD 
A direct comparison was made of RALDH activity in intestinal CD14+ MФ in healthy 
control and IBD patients. The proportion of Aldefluor+ CD14+ MФ was significantly 
enhanced in LPCs derived from both non-inflamed (p = 0.008) and inflamed IBD (p = 
Figure 4.12: The proportion of human colonic 
CD11c+ DCs that are CD103+ is reduced in IBD. 
Data derived from cells as in Figure 4.9, proportion of 
CD45+ Lin- HLA-DR+ CD11c+ DCs that are CD103+ is 
shown. ● = Healthy, ▲ = CD, ■ = UC; filled symbols 
are colonic and empty symbols are terminal ileal 
tissue samples; bars represent mean values.  
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Figure 4.11: Human intestinal CD103+ DCs have enhanced 
RDH10 expression in IBD. CD103+ and CD103- DCs were 
sorted from collagenase-digested inflamed ileum derived from 
a CD patient via flow cytometry. RDH10 expression 
determined by real-time PCR; expression normalized to 
GAPDH.  
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0.032) compared with healthy control mucosa (49.3, 39.7 and 22.3 %, respectively; 
Figure 4.13), consistent with enhanced RALDH activity. Due to the superior number of 
samples, this relationship was again more apparent in CD than UC, but clearly 
enhanced activity could be seen with both diseases. The proportion of Aldefluor+ CD14+ 
MФ was slightly higher and displayed a reduced degree of variation in non-inflamed 
compared with inflamed mucosa. The increased proportion of Aldefluor CD14+ MФ in 
both non-inflamed and inflamed colonic mucosa of IBD patients compared with healthy 
control mucosa was statistically significant in the absence of data from CD14+ MФ of 
the TI, with P-values of 0.007 and 0.026, respectively (data not shown). 
In order to determine if modified ALDH1A expression was responsible for the increased 
Aldefluor/RALDH activity of CD14+ MФ in IBD, these cells were analysed by real time 
PCR following sorting by flow cytometry. There was a statistically significant (p = 0.035) 
increase in ALDH1A1 expression in CD14+ MФ from inflamed intestinal mucosa of CD 
patients compared with healthy controls (Figure 4.14A). In contrast, expression of 
ALDH1A2 and ALDH1A3 in CD14+ MФ was not significantly different between 
Figure 4.13: Human intestinal CD14+ MФ have 
significantly enhanced RALDH activity in IBD. 
A: Aldefluor and flow cytometry analysis was 
performed on healthy control and IBD LPCs as 
described previously in this Chapter; collated 
results are shown for CD14+ MФ identified as Lin+ 
HLA-DR+ cells. ● = Healthy,▲ = CD, ■ = UC; filled 
symbols are colonic and empty symbols are 
terminal ileal tissue samples; bars represent mean 
values. P-values derived from one way ANOVA 
with Tukey test.  
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Figure 4.14: ALDH1A1 expression is enhanced in human intestinal CD14+ MФ in CD. 
A: CD14+ MФ were sorted by flow cytometry as CD33+ CD14+ cells from healthy control 
and/or inflamed ileal surgical resection or endoscopic biopsies from CD patients. ALDH1A 
isoform expression was determined by real-time PCR; expression normalised to GAPDH and 
RPL30. B: Expression of RDH10 and DHRS9 were determined in the same samples by real-
time PCR; expression normalised to GAPDH and RPL30. ● = Healthy,▲ = CD; filled symbols 
are colonic and empty symbols are ileal tissue samples; bars represent median values 
except for ALDH1A2 (mean); P-values derive from t-tests; * indicates p-value following log10 
transformation of non-normally distributed data. 
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inflamed CD mucosa and healthy controls. This indicates that enhanced transcription of 
ALDH1A1 leads to enhanced RALDH1 activity, contributing to the observed increase in 
Aldefluor activity of CD14+ MФ in CD. 
In contrast with ALDH1A1, no statistically significant differences were observed in the 
levels of RDH10 or DHRS9 expression in CD14+ MФ in inflamed CD and healthy 
control intestinal mucosa (Figure 4.14B) although samples sizes were small. This 
indicates that the ability to oxidise retinol to retinal, at least via RDH10 and DHRS9, is 
unchanged in CD14+ MФ in IBD but that conversion of retinal to RA is potentially 
increased. 
4:4.4 RALDH activity is present in non-haematopoietic cells and is 
reduced in IBD 
Non-haematopoietic cells were excluded from analysis of RALDH activity in APCs by 
gating on CD45+ cells. Significant Aldefluor staining was however observed within the 
CD45- compartment (Figure 4.15A), indicating that non-haematopoietic cells are an 
additional source of RALDH activity within the human intestinal mucosa. The EDTA 
incubation step was omitted when processing biopsies to assess this activity so as to 
avoid the loss of epithelial cells, which were a potential source of the activity. The level 
of Aldefluor staining in colonic CD45- cells was reduced in CD (Figures 4.15B and C), 
and also in a single UC sample derived from a non-inflamed biopsy. This indicates that 
in contrast to human intestinal myeloid APCs, non-haematopoietic cell RALDH activity 
is reduced in IBD. 
Variable expression of HLA-DR was detected on CD45- cells, and expression was 
typically enhanced on cells derived from IBD biopsies (Figures 4.15D and E). 
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D 
Figure 4.15: Human colonic CD45- cells have RALDH activity which is reduced in IBD 
and negatively correlates with HLA-DR expression. A: Aldefluor analysis was performed 
on LPCs following collagenase digestion of colonic biopsies; analysis was focussed on 
CD45- cells, in comparison to a DEAB inhibited control as previously. B: Aldefluor analysis 
was performed on CD45- cells derived from IBD biopsies in addition to healthy controls; 
example from a CD patient shown. C: Collated CD45- Aldefluor data. D: HLA-DR expression 
was detected on CD45- cells, and was increased in cells derived from IBD mucosa. E: 
Collated HLA-DR expression on CD45- cells from healthy control and IBD biopsies. P-value 
derives from ANOVA with Tukey test. F: HLA-DR expression negatively correlates with 
proportion of Aldefluor+ CD45- cells. P-value derived from a Spearman’s rank test, coefficient 
of correlation indicated as R. G: A significant proportion of CD45- cells are epithelial: 
cytokeratin 8/16 measured following permeabilisation of LPCs; filled histogram represents 
antibody staining, dotted histogram represents the relevant isotype control. ● = Healthy,▲ = 
CD, ■ = UC; bars represent mean values.  
 
A 
0
10
20
30
40
50
60
70
80
90
100
0 10 20 30 40
%
 H
L
A
-D
R
+
Healthy Inf lamedNon
inf lamed
p = 0.05
IBD
E G 
100 101 102 103 104 105
Cytokeratin : PE
0
1
0
2
0
3
0
4
0
5
0
6
0
7
0
N
u
m
b
e
r
37.34 %
Cytokeratin 8/16
0 500 1000 1500 2000 2500
FSC-A (x 100)
1
0
0
1
0
1
1
0
2
1
0
3
1
0
4
1
0
5
C
D
4
5
 :
 P
a
c
B
R2
C
D
4
5
FSC
Healthy control
100 101 102 103 104 105
Aldefluor
1
0
0
1
0
1
1
0
2
1
0
3
1
0
4
1
0
5
S
S
C
-A
R4
45.18 %
100 101 102 103 104 105
Aldefluor
1
0
0
1
0
1
1
0
2
1
0
3
1
0
4
1
0
5
S
S
C
-A
R4
Aldefluor
S
S
C
+ DEAB - DEAB
B 
100 101 102 103 104 105
Aldefluor
1
0
0
1
0
1
1
0
2
1
0
3
1
0
4
1
0
5
S
S
C
-A
R9
100 101 102 103 104 105
Aldefluor
1
0
0
1
0
1
1
0
2
1
0
3
1
0
4
1
0
5
S
S
C
-A
R9
17.31 %
+ DEAB - DEABS
S
C
Aldefluor
Crohn’s disease
C 
0
10
20
30
40
50
60
0 10 20 30 40
%
 A
ld
e
fl
u
o
r+
Healthy Inf lamedNon
inf lamed
IBD
0
10
20
30
40
50
60
0 20 40 60 80 100
%
 A
ld
e
fl
u
o
r+
% HLA-DR+
85.42
28.84
75.8
HC
CD
UC
R = -0.647
p = 0.002
F 
100 101 102 103 104 105
HLA-DR : PECy7
1
0
0
1
0
1
1
0
2
1
0
3
1
0
4
1
0
5
S
S
C
-A
R4
100 101 102 103 104 105
HLA-DR : PC7
1
0
0
1
0
1
1
0
2
1
0
3
1
0
4
1
0
5
S
S
C
-A
R6
HLA-DR
Healthy control Crohn’s disease
3.03 %
52.46 %
S
S
C
Chapter 4: RALDH activity in human intestinal APCs and retinoid levels in health and IBD 
174 
 
Furthermore, a significant negative correlation was observed between the proportion of 
HLA-DR expressing cells and overall RALDH activity within the CD45- compartment 
(Figure 4.15F). A significant proportion of the CD45- cells expressed cytokeratin 8 
and/or 16, indicating the presence of intestinal epithelial cells (Moll et al., 1982). This 
indicates that the observed Aldefluor/RALDH activity may at least in part derive from 
colonic epithelial cells. HLA-DR expression is induced on these cells by inflammatory 
cytokines (Pallone et al., 1988), and so overall these data support the conclusion that 
RALDH activity in non haematopoietic cells including epithelial cells is negatively 
regulated by inflammatory signals in IBD.  
4:4.5 Total tissue RA levels are unchanged in IBD compared with healthy 
intestinal mucosa 
Having observed enhanced RALDH activity in CD14+ MФ and CD103+ DCs and 
reduced activity in non-haematopoietic cells in IBD, the next step was to determine the 
impact of these changes on overall tissue RA levels. To address this, intestinal biopsies 
were snap frozen in liquid nitrogen and shipped for analysis to the lab of Maureen Kane 
at the University of Maryland for quantification of retinoids by liquid chromatography 
with tandem mass spectrometry (LC/MS/MS) (Kane et al., 2005). This preliminary 
analysis did not detect significant differences in the tissue levels of RA in biopsies 
derived from healthy control and CD patients (Figure 4.16). The average level of RA 
was approximately 40 pmol/g protein.  
In contrast to RA, the levels of retinol were reduced in CD compared with healthy 
controls, although this difference did not reach statistical significance (Figure 4.16). The 
average level detected in non-inflamed biopsies was approximately halfway between 
healthy control and inflamed biopsies (89.5 compared with 123.8 and 69.9 nmol/g 
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protein, respectively). Furthermore, the storage form of retinol, retinyl ester, was also 
reduced in inflamed CD compared with healthy control biopsies (41.7 and 57.6 nmol/g 
protein), with only a small difference between inflamed and non-inflamed CD biopsies. 
  
Figure 4.16: RA levels are unchanged whilst retinol levels are reduced in colonic 
biopsies in IBD. Colonic biopsies were snap frozen in liquid nitrogen and analysed by 
HPLC-MS/MS (Kane et al., 2005). Retinoids are quantified in each case relative to the mass 
of protein present within the biopsies. Bars indicate mean values; ● = healthy, ▲ = CD.  
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4:5 Discussion 
In this chapter, RALDH activity in human intestinal APCs was characterised using the 
Aldefluor assay as described in Chapter 3. Focussing on both the colon and TI, RALDH 
activity was identified in CD103+ and CD103- DCs, as well as in CD14+ MФ. Activity in 
these subsets varied between individuals, but no single subset displayed enhanced 
levels of activity. RALDH activity was not common to all haematopoietic cells however 
as T cells did not stain in the Aldefluor assay. A small population of B cells stained 
weakly with the Aldefluor reagent but the significance of this low level of potential 
RALDH activity is unclear. 
In the mouse, RALDH activity is particularly enhanced in CD103+ DCs found in the SI-
LP, particularly the duodenum and jejunum (Schulz et al., 2009, Denning et al., 2011, 
Jaensson-Gyllenback et al., 2011), as well as the MLN (Coombes et al., 2007, Yokota 
et al., 2009, Molenaar et al., 2011, Guilliams et al., 2010) which reflects migration of SI-
derived DCs (Johansson-Lindbom et al., 2005, Jaensson et al., 2008). Murine colonic 
and TI CD103+ DCs however have lower levels of RALDH activity (Denning et al., 2011, 
Jaensson-Gyllenback et al., 2011, Villablanca et al., 2011b). The equivalent RALDH 
activity observed in CD103+ and CD103- DCs in this study may be consistent with the 
murine data if the level of activity in these cells is considered basal for myeloid cells in 
the colon and TI LP.  
Enhanced RALDH activity is inferred in human MLN CD103+ DCs based on a 
specialised ability to imprint naive CD8+ T cells with CCR9 expression (Jaensson et al., 
2008). It was not possible to confirm the presence of enhanced RALDH activity in these 
cells as MLN were not available in this study. However, future work in which human 
duodenal or jejunal mucosal CD103+ DCs are characterised would confirm whether 
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RALDH activity is significantly enhanced in human proximal SI-LP.  It remains possible 
that RALDH levels in all cell populations examined in the study could be lower than 
those of cells in the proximal small intestine. 
Real-time PCR indicated that ALDH1A2 expression was responsible for the RALDH 
activity observed in CD103- DCs in the healthy human intestine. This is also likely to be 
the case for CD103+ DCs, as ALDH1A2 was identified in these cells in a sample 
derived from a CD patient. This is consistent with the mouse in which Aldh1a2 
expression is identified in MLN (Coombes et al., 2007) and SI-LP CD103+ DCs (Schulz 
et al., 2009, Yokota et al., 2009). ALDH1A1 expression was not identified in CD103+ or 
CD103- DCs in this study, although may have been present below the limit of detection. 
In the mouse, low levels of Aldh1a1 expression have been observed in SI-LP CD103+ 
CD11b+ DCs and lower levels in CD103+ CD11b- DCs (Denning et al., 2011). Aldh1a1 
was also detected in PP DCs in mice (Iwata et al., 2004), although the gating strategy 
used (MHCII+ CD11c+) is not sufficient to have excluded macrophages (Schulz et al., 
2009). 
In contrast with DCs, ALDH1A1 expression was routinely detected at high levels in 
CD14+ MФ in this study. This is may be the result of upregulation within the intestinal 
mucosa or could be intrinsic to this lineage of cells. Expression was approximately 9 
fold higher than ALDH1A2, whilst ALDH1A3 was also present. ALDH1A expression in 
CD14+ MФ in this study is consistent with their observed RALDH activity. The relative 
contributions of the separate ALDH1A isoforms to the overall RALDH activity of CD14+ 
MФ is unclear at present, although ALDH1A1 is expressed at sufficiently high levels to 
drive at least some of this activity. Interestingly, high levels of Aldh1a1 expression are 
found in murine CD11c- F4/80+ MФ in the SI-LP (Denning et al., 2011). Elevated 
ALDH1A1/Aldh1a1 expression may therefore be common to human and murine 
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monocyte-derived cells. This idea is developed further in Chapter 5, where ALDH1A1 
expression is also identified in human CD14+ blood monocytes. 
This significance of multiple RALDH isoforms expressed simultaneously within CD14+ 
MФ, and why ALDH1A1 expression is not observed in intestinal DCs is unclear. One 
hypothesis is that different RALDH enzymes exist in specific locations within cells, and 
generate distinct intracellular pools of RA (Napoli, 2012). This notion is supported by 
the distribution of RALDH enzymes in rat primary hippocampus astrocytes. RALDH1 is 
located both in the cytosol but also a significant quantity is observed in the nucleus of 
these cells. In contrast, RALDH2 is concentrated within a perinuclear region (Wang et 
al., 2011a). Furthermore, RALDH1, 2 and 3 all make distinct contributions to the overall 
RA output of astrocytes (Wang et al., 2011a). RALDH1, 2 and 3 are also differentially 
expressed in different organs during pre-natal development of mice, indicating that they 
are each involved in distinct contexts where RA generation is required (Niederreither et 
al., 2002). The distribution of RALDH enzymes in human intestinal CD14+ MФ and DCs 
is unknown and could be studied further by immunohistochemistry. 
The substrate specificities of the RALDH enzymes are also distinct. Human RALDH1 
oxidises all-trans, 13-cis and 9-cis retinal with equal efficiency (Bhat and Samaha, 
1999), whilst murine RALDH2 oxidises all-trans retinal with greater efficiency than the 
other isoforms (Gagnon et al., 2002). In contrast, murine RALDH3 catalyses only all-
trans retinal with approximately 10 fold greater efficiency than RALDH1 and RALDH2 
(Sima et al., 2009). Primary rat astrocytes express all three RALDH enzymes, and each 
contributes to the net output of RA (Wang et al., 2011a). RALDH enzymes are also 
differentially regulated by retinoids. RALDH1 in rats is inhibited by cellular retinol 
binding protein (CRBP)-I which is not in association with retinol (apo-CRBP-I), 
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indicating low levels of cellular retinol (Posch et al., 1992). In contrast, RALDH2 in rats 
is not inhibited by apo-CRBP-I (Zhai et al., 2001). 
The ability to produce RA is widely inferred from expression of RALDH enzymes. 
However data in Chapter 6 working with MoDCs suggest that RALDH activity is not 
always indicative of release of functional RA. Therefore, it was important to seek further 
evidence to support RA production by APC populations isolated from intestinal tissue. 
Small cell numbers precluded direct RA measurement therefore an indirect approach 
was adopted. DCs sorted via flow cytometry as Lin- HLA-DR+ cells were able to induce 
α4β7 expression on allogeneic naive CD4+ T cells in this study. Furthermore, in ‘walk 
out’ T cell stimulation cultures induction of α4β7 was shown to be RA-dependent. These 
data indicate that the RALDH activity observed in DCs in this study generates sufficient 
RA for the induction of this ‘gut-homing’ phenotype. An alternative explanation for the 
induction of α4β7 is that DCs pick up RA from the intestinal mucosa and simply transfer 
it to T cells during activation. This is particularly important as only low concentrations 
(0.1 nM in mice) of RA are required to induce α4β7 expression (Iwata et al., 2004). This 
possibility has been addressed directly in the context of murine DCs (Jaensson-
Gyllenback et al., 2011). MLN DCs in this study were unable to induce CCR9 on CD8+ 
T cells where retinol had been removed from the growth medium, either by use of a 
serum-free media (X-Vivo10) or else destruction of retinoids in the media by UV-
irradiation of FCS. The authors concluded that metabolism of retinol to RA by the DCs 
and not simple carryover of RA was required to induce CCR9 expression. Whilst this 
does not confirm that the α4β7 expression induced by sorted intestinal DCs in this study 
is the result of retinol metabolism specifically within DCs, it does provide significant 
supporting evidence. These experiments focussed exclusively on α4β7 expression as 
CCR9 expression was routinely very low or absent on CD4+ T cells following ‘walk out’ 
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stimulation cultures in this study, and even during activation of naive CD4+ T cells in the 
presence of exogenous RA (data not shown). 
Based on a limited number of samples, expression of RDH10 was approximately 4 fold 
enhanced in CD103+ compared with CD103- DCs in this study. RDH10 is a microsomal 
short chain dehydrogenase/reductase (SDR) which exerts significant influence over the 
rate of RA production by catalysing the oxidation of retinol to retinal which is rate-
limiting in the presence of CRBP-I (Napoli, 1986, Wang et al., 2011a). Whether this 
level of enhancement is sufficient to affect the function of CD103+ DCs is unclear. It 
may however indicate that CD103+ DCs possess a superior ability to oxidise retinol to 
retinal and so provide a greater quantity of substrate for RALDH enzymes, ultimately 
resulting in enhanced RA production. The low numbers of CD103+ obtained during cell 
sorting precluded further analysis of the influence of RDH10 on overall RA output. 
However, this would be an interesting area to develop where sufficient material is 
available. Further investigation would be required to both confirm and determine the 
functional significance of this observation. 
Reduced RALDH activity has been reported in CD103+ DCs in both the TNFΔARE 
(Collins et al., 2011) and T cell transfer murine models of IBD (Laffont et al., 2010). In 
this study, RALDH activity in CD103+ DCs was not reduced in IBD patients compared 
with healthy controls. There was instead a trend in which CD103+ DCs displayed 
greater Aldefluor/RALDH activity, although this did not reach statistical significance with 
the relatively small number of samples it was possible to analyse. The majority of 
samples studied were CD, but enhanced RALDH activity was also apparent in the UC 
samples analysed. This was observed in both inflamed and non-inflamed IBD mucosa; 
although importantly in these macroscopically ‘non-inflamed’ samples significant 
inflammation was present elsewhere colon and/or ileum of the patient. This tissue may 
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therefore exist in a ‘pre-inflamed’ state - whether enhanced RALDH activity is observed 
in CD103+ DCs in quiescent IBD remains to be determined. This should be addressed 
directly by studying RALDH activity in CD103+ DCs in IBD patients in remission. 
The enhanced RALDH activity of CD103+ DCs may be the result of increased 
transcription of ALDH1A2, or alternatively post-transcriptional regulation of the ALDH1A 
isoforms already present. As discussed in Chapter 3, RA may boost RALDH activity of 
human MoDCs through post-transcriptional regulation of ALDH1A2 and so a similar 
mechanism could operate in CD103+ DCs. Further analysis would be required to 
understand the mechanism of this increased activity, including expression analysis of a 
large number of samples and also analysis of RALDH2 protein content via 
methodologies including Western blot. 
The contrasting RALDH activity between human and murine CD103+ DCs in health and 
disease may relate to the tissue origin of the DCs in question. In the mouse, high levels 
of RALDH activity accumulate within CD103+ DCs in the SI-LP, possibly due to the 
presence of RA within the tissue inducing a positive feedback loop (Villablanca et al., 
2011b, Molenaar et al., 2011, Jaensson-Gyllenback et al., 2011). Based on BrdU 
labelling experiments, murine CD103+ DCs are known to turnover relatively quickly 
within the LP (Jaensson et al., 2008, Schulz et al., 2009, Laffont et al., 2010). 
Moreover, inflammation enhances CD103+ DC maturation and migration to the draining 
MLN in a CCR7-dependent manner (Schulz et al., 2009). Newly recruited CD103+ DCs 
within the inflamed LP may therefore have insufficient time to accumulate high levels of 
RALDH before undergoing maturation and migration. Furthermore, TNFΔARE mice 
have reduced levels of RA within the TI (Collins et al., 2011), which may further reduce 
RA-mediated induction of RALDH in CD103+ DCs in inflammation. As this study 
focused on more distal areas of the human intestine, it is possible that CD103+ DCs 
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possess only basal levels of RALDH activity common to myeloid cells within this tissue. 
The onset of inflammation would therefore result in migration of these DCs from the LP, 
and replacement by DCs with at least similar levels of RALDH activity.  
The enhanced RALDH activity observed in this study in CD103+ DCs may be related to 
phenotypic differences in DCs in health and IBD. Enhanced expression of CD40 has 
been reported on human intestinal myeloid DCs in CD (Hart et al., 2005). Whilst DCs 
are not fully mature in IBD patients (Bell et al., 2001), this may reflect a slightly 
advanced state of maturation when compared with healthy control patients. RA 
signalling through RARα/RXR has previously been implicated in DC maturation 
(Geissmann et al., 2003), and so a potential explanation is that RALDH activity in 
CD103+ DCs increases as part of or because of DC maturation. To address this 
directly, RALDH activity of CD103+ DCs could be determined via the Aldefluor assay 
following collagenase digestion of intestinal tissue, and then again after 24 hours in 
culture to allow time for maturation. In support of this hypothesis, it was demonstrated 
in Chapter 3 that Aldefluor/RALDH activity of human MoDCs is largely restricted to cells 
displaying a mature phenotype. Furthermore, MLN CD103+ DCs in TNFΔARE mice 
display slightly enhanced levels of Aldh1a2 expression compared with WT mice at 4 
weeks, which is early in the onset of inflammation (Collins et al., 2011). By 20 weeks, 
and at the full onset of inflammation, Aldh1a2 expression in MLN CD103+ DCs is 
significantly reduced. This early enhancement of Aldh1a2 expression may be 
consistent with the arrival of DCs in a more mature state. 
In contrast with CD103+ DCs, enhanced RALDH activity was not as clearly observed in 
CD103- DCs in IBD in this study. This may reflect heterogeneity within the CD103- DC 
gate as suggested by the reduced levels of CCR7 expression on these cells following 
maturation. In this sense, the overall RALDH activity of this subset may be reduced by 
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the presence of cells that are not bona fide DCs when compared with the ‘purer’ 
CD103+ DC population. Alternatively, RALDH activity could be regulated differently in 
CD103+ and CD103- DCs in the context of intestinal inflammation. Other reports have 
identified a CD1c+ subset of DCs in human intestinal mucosa as predominantly CD103- 
(Dillon et al., 2010). The extent of overlap between CD1c+ and CD103- DCs as defined 
here, and whether these cells possess functional RALDH activity should be the subject 
of future study. 
Whether the enhanced RALDH activity of CD103+ DCs would significantly alter the 
function of DCs is unclear. If IBD and healthy control CD103+ DCs ultimately mature to 
the same extent then they would likely have equivalent ability to produce RA and so 
influence naive lymphocytes during activation in lymphoid tissue. If however following 
maturation DCs from IBD patients still have enhanced RALDH activity, then this would 
be more likely to influence the functional outcomes of antigen presentation. It has 
previously been shown that human MLN CD103+ DCs from CD patients induce a 
similar level of CCR9 expression on CD8+ T cells compared with healthy controls 
(Jaensson et al., 2008). This may indicate that overall, the differences in RALDH 
activity observed in CD103+ DCs in this study do not significantly modify the ability of 
these cells to induce RA-dependent responses. Alternatively, enhanced RALDH activity 
of CD103+ DCs may contribute to an observed increase in the proportion of FOXP3+ T 
cells in the colonic mucosa of CD and UC patients  (Wang et al., 2011d).  
Reduced proportions of colonic CD103+ DCs may be attributed to migration into the 
draining lymphatics, or may simply be relative to influx of CD103- DCs. In the 
TNFΔARE model of IBD the proportion of ileal CD103+ DCs is reduced during 
inflammation (Collins et al., 2011). It remains unclear why a similar reduction is not 
observed in the TI samples used in this study. This may relate to the presence of 
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lymphoid tissue including PPs in the TI which are less frequent in the large intestine 
(reviewed by Day and Morson, 2003). The dynamics of DC migration and recruitment 
may be distinct in such tissue under the influence of inflammation. Overall therefore, 
the study would be further improved by increasing sample numbers to allow for a more 
systematic comparison of RALDH activity in CD103+ DCs in healthy control and IBD 
patients with a more defined colonic/TI distinction. Taken further, the various colonic 
segments (ascending, transverse, descending, sigmoid) could be analysed separately 
to indicate how RALDH activity is modified along the intestinal tract in greater 
resolution.    
In addition to CD103+ DCs, this study identified significantly enhanced RALDH activity 
in CD14+ MФ in IBD patients compared with healthy controls. This appears to be due at 
least in part to enhanced expression of ALDH1A1. An earlier report identified equivalent 
ALDH1A2 expression in CD14+ MФ in healthy control and CD patients (Kamada et al., 
2009) which was also observed in this study. However, the Kamada study did not 
measure ALDH1A1 expression and so it is unclear to what extent it was increased 
within their patient group.  
The Kamada study also identified significantly reduced expression of RDH10 in CD14+ 
MФ in CD patients compared with healthy controls (Kamada et al., 2009). However, the 
work presented in this thesis identified no statistically significant difference in RDH10 
expression between the two groups. The reason for this discrepancy is unclear, though 
may relate to the particular purification methods employed. In the study by Kamada et 
al, CD14+ MФ were enriched from LPMCs with CD14+ microbeads before being 
subjected RNA extraction and real-time PCR. In contrast, in this thesis, CD14+ MФ 
were sorted by flow cytometry as CD33+ CD14+ cells which may have given a purer 
population and so more accurate results for RDH10 expression. 
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As with CD103+ DCs, the role of RDH10 in determining overall RA output of human 
intestinal CD14+ MФ has not been properly addressed and warrants further attention. 
The origins and functional significance of enhanced RALDH activity in human intestinal 
CD14+ MФ in IBD are addressed in Chapter 5. 
This study identified the non-haematopoietic compartment (identified as CD45- cells), 
including epithelial cells, as an additional source of RALDH activity in the human 
intestinal mucosa. RA signalling through RAR/RXR has previously been implicated in 
the maintenance of epithelial tight junctions and contributes to the integrity of the 
epithelial barrier (Osanai et al., 2007). Furthermore, mice maintained on a vitamin A 
deficient diet display significant alterations in small intestinal epithelial physiology 
including shortened villi, atrophy and goblet cell hyperplasia (Cha et al., 2010).  
The level of RALDH activity of CD45- cells was reduced in IBD compared with healthy 
controls in this study. This is consistent with reports that expression of ALDH1A1 is 
significantly down regulated in colonic epithelial cells in CD (Iliev et al., 2009). In 
addition, a statistically significant negative correlation was identified between Aldefluor 
staining and HLA-DR expression on colonic CD45- cells in this study. It has been 
previously observed that HLA-DR expression is significantly enhanced on human 
colonic epithelial cells in active IBD compared with healthy controls (Fais et al., 1987). 
Furthermore, culturing epithelial cells for 24 hours in the presence of IFNγ in vitro 
induces significant increases in HLA-DR expression (Pallone et al., 1988). It is likely 
that a significant fraction of the CD45- Aldefluor/RALDH activity is driven by the 
epithelial cells identified within this population by cytokeratin staining but this could not 
be tested directly because the cell permeabilisation required for epithelial identification 
was not compatible with the Aldefluor assay. It is therefore possible that non-epithelial 
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stromal cells also contribute to this RALDH activity, with reduced overall activity in the 
presence of inflammation. 
The functional significance of this is currently unclear. It has been suggested that small 
intestinal epithelial-derived RA plays an important role in conditioning intestinal DCs by 
inducing RALDH activity in mice (McDonald et al., 2012) as well as inducing regulatory 
properties including the ability to induce of FOXP3+ TREG  in humans (Iliev et al., 2009). 
The observed increase in RALDH activity in CD103+ DCs in this study suggests that the 
loss of RALDH activity in colonic epithelial cells does not impact on human colonic DCs 
in this way, at least at the level of RALDH activity. Whether or not this is also the case 
in the small intestine remains to be determined. 
Based on increased RALDH activity in CD103+ DCs and decreased activity in and 
CD45- cells, it was interesting to note that the overall tissue levels of RA were 
equivalent between healthy controls and CD patients. Whilst this is based on a limited 
number of samples, it contrasts directly with the TNFΔARE mouse model of IBD in 
which RA levels in the TI are significantly reduced compared with WT mice (Collins et 
al., 2011). The average level of RA including all samples was approximately 42.4 
pmol/g protein, or 2.6 pmol/g tissue. This compares with a value of 5 pmol/g tissue 
detected in the mouse colon using an identical approach (Villablanca et al., 2011b). 
Whether this difference in the levels of tissue RA between species is sufficient to 
influence intestinal immunology is unclear. Reduced levels of tissue RA in humans may 
even explain why CD103+ DCs do not display enhanced RALDH activity in this study. 
Whilst RA levels were unchanged, levels of retinol did however appear to be reduced in 
CD patients. Approximately 44 nmol/g protein or 7 nmol/g tissue of retinol were 
detected in healthy control biopsies, compared with 1 nmol/g tissue in mice (Villablanca 
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et al., 2011b). Interestingly, mice and humans have similar levels of serum retinol with 
0.81 nmol/ml in mice (Kane et al., 2005) and approximately 1 to 2 nmol/ml in humans 
(Olmedilla et al., 1997). The mechanism and functional significance of a reduction in 
retinol in the colonic mucosa of CD patients is unclear. It has been previously 
demonstrated that serum retinol levels are reduced in active CD and UC patients 
compared with healthy controls, and was attributed primarily to reduced levels of serum 
retinol binding protein (Janczewska et al., 1991). This study also showed that serum 
retinol levels return to normal in inactive disease. Reduced retinol concentration within 
the colonic mucosa of active CD patients therefore may be the result of reduced 
circulating levels of retinol. Furthermore, the intermediate level of mucosal retinol may 
result from elevated serum retinol associated with inactive disease. This highlights a 
close association between serum and mucosal retinol levels in the large intestinal 
mucosa. Villus-associated enterocytes in the small intestine display specialized 
expression of CRBP-II, consistent with a key role in uptake of dietary retinol (Li and 
Norris, 1996). It would therefore be of interest to determine the relationship between 
serum and mucosal retinol levels in the small intestine of IBD patients. 
Despite a reduced level of retinol in large intestinal mucosa of active CD patients, levels 
of RA were similar between these two states. This may suggest that retinoid 
metabolism is shifted within the large intestinal mucosa in CD in order to maintain 
overall levels of RA. This would therefore suggest that net RALDH activity is increased 
in the intestinal mucosa in IBD, compensating for reduced levels of serum retinol. RA 
contributes to immune responses in mice in part as an accessory factor e.g. in 
promoting inflammation in the presence of IL-15 (DePaolo et al., 2011) or favouring 
induction of Foxp3+ TREG in the presence of TGF-β (Coombes et al., 2007, Sun et al., 
2007, Mucida et al., 2007). RA may therefore influence ongoing immune responses 
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within human intestinal mucosa through supporting the activities of the varying cytokine 
landscape associated with IBD, without a significant change in overall RA levels 
between healthy controls and IBD patients. 
4:6 Conclusion 
In conclusion, this chapter has demonstrated for the first time the presence of RALDH 
activity in CD103+ and CD103- DCs as well as CD14+ MФ in distal human intestinal 
mucosa. This activity stems from ALDH1A2 and ALDH1A3 expression in DCs, but 
predominantly ALDH1A1 expression in CD14+ MФ. Furthermore, DCs display an ability 
to induce high levels of α4β7 expression on naive CD4+ T cells, consistent with 
functional RALDH. Contrary to expectation, RALDH activity is not reduced in CD103+ 
DCs in IBD and displays a slight increase in activity which is not observed in CD103- 
DCs. The hypothesis that loss of RALDH activity in human intestinal CD103+ DCs 
contributes to the pathogenesis of IBD is therefore not supported. In addition, RALDH 
activity is significantly enhanced in CD14+ MФ in IBD patients. RALDH activity in the 
non-haematopoietic compartment, including epithelial cells, correlates negatively with 
inflammation and is reduced in IBD patients. The overall concentration of RA within the 
intestinal mucosa is similar in CD and healthy control patients, despite an apparent 
reduction in mucosa retinol levels in CD. In Chapter 5, attention will turn to the origins 
and functions of enhanced RALDH activity of CD14+ MФ in the pathogenesis of IBD. 
Chapter 5: Origins and function of RALDH activity in CD14+ MФ in IBD 
189 
 
Chapter 5: Analysis of the origins and function of 
enhanced RALDH activity in human intestinal 
CD14+ MФ in IBD  
 
5:1 Chapter summary 
This chapter focuses on determining the origins and function of enhanced RALDH 
activity in human intestinal CD14+ MФ in IBD reported in Chapter 4. Analysis of 
Aldefluor/RALDH activity in CD14+ blood monocytes, precursors to CD14+ MФ, 
indicates that RALDH activity is acquired in this lineage prior to arrival in the intestinal 
mucosa but may be locally upregulated within the distal intestine of IBD patients. 
Furthermore, enhanced expression of MN1 suggests that differentiation of CD14+ 
monocytes is altered in IBD; blood monocytes in patients may exist in an earlier state of 
differentiation compared with their healthy control counterparts. An in vitro system of 
monocyte differentiation indicates that RA plays an important role in the differentiation 
of an inflammatory MФ phenotype and that RALDH activity in MФ themselves may 
contribute to this process. This observation indicates that in IBD one potential role of 
RALDH activity in human intestinal CD14+ MФ is related to promotion of differentiation 
toward an ‘inflammatory’ rather than a steady state-associated phenotype.  
5:2 Introduction 
It was established in Chapter 4 that human intestinal CD14+ MФ possess RALDH 
activity which is significantly enhanced in IBD patients compared with healthy controls. 
However, the origin of this activity and how it influences cellular function of CD14+ MФ 
within the intestinal mucosa remain unclear. Human intestinal CD14+ MФ are implicated 
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in the pathogenesis of IBD based on a pro-inflammatory profile. They produce TNFα 
and IL-6 following microbial stimulation (Kamada et al., 2008), both of which are 
present at increased concentration in CD and UC (reviewed by Strober and Fuss, 
2011). CD14+ MФ are sensitive to stimulation through IgG-antigen complexes due to 
surface expression of CD64 (FcγR1). This induces TNFα and IL-1β production and is 
important as CD and UC are associated with an increased proportion of LP IgG+ 
plasma cells (Uo et al., 2012). Disease-specific features of CD14+ MФ have also been 
identified. In CD, these cells produce significantly greater quantities of IL-23 as 
compared with their UC or healthy control counterparts. This promotes IFNγ production 
by intestinal LP T and NK cells (Kamada et al., 2008, Takayama et al., 2010). A 
significantly increased proportion of intestinal MФ display the pro-inflammatory CD14+ 
phenotype in IBD patients (Grimm et al., 1995a, Kamada et al., 2008, Tamoutounour et 
al., 2012, Bain et al., 2013). In contrast, the majority of resident intestinal MФ in healthy 
control patients are CD14- and do not produce pro-inflammatory cytokines in response 
to microbial stimulation. They are however able to efficiently phagocytose and kill 
intracellular bacteria (Smythies et al., 2005). Limited responsiveness to microbial 
stimulation is the result of a combination of low expression of surface receptors e.g. 
CD14, as well as suppression of NF-κB signalling (Smythies et al., 2010).  
A parallel of the human intestinal CD14+ and CD14- MФ system has been reported in 
mice; however the subsets are not distinguished by CD14 expression. In the steady 
state, CX3CR1hi MФ display an anti-inflammatory profile and constitutively produce IL-
10 which is enhanced following microbial stimulation. In models of intestinal 
inflammation however, there is an accumulation of a heterogeneous population of 
CX3CR1int cells described as inflammatory MФ (Bain et al., 2013, Tamoutounour et al., 
2012) and DCs (Rivollier et al., 2012, Zigmond et al., 2012). They display increased 
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production of IL-6, IL-1β and iNOS (Weber et al., 2011b, Zigmond et al., 2012). Both 
the CX3CR1hi and CX3CR1int populations represent alternative differentiation fates of 
Ly6Chi monocytes (Bain et al., 2013, Tamoutounour et al., 2012, Rivollier et al., 2012, 
Zigmond et al., 2012).  
A similar system is likely to operate in humans as CD14+ blood monocytes are linked 
with both intestinal CD14+ and CD14- MФ phenotypes. Culturing CD14+ monocytes in 
vitro with intestinal stromal cell conditioned medium induces a phenotype closely 
resembling intestinal CD14- MФ (Smythies et al., 2005). This phenotype includes 
significantly reduced responsiveness to microbial stimulation alongside maintained 
phagocytic and bactericidal activity (Smythies et al., 2005). Furthermore, intestinal 
CD14+ MФ and CD14+ blood monocytes share features beyond CD14 expression 
including expression of CD64, CD11c (Smythies et al., 2005, Kamada et al., 2008, Bain 
et al., 2013) and the production of reactive oxygen species (Hausmann et al., 2001). 
The uptake of labelled monocytes into inflamed intestinal mucosa of IBD patients from 
circulation has also been demonstrated (Grimm et al., 1995b).  
It has been proposed that monocytes enter the human intestinal mucosa in the steady 
by chemotaxis towards IL-8 and TGF-β, produced by stromal cells within the LP 
(Smythies et al., 2006). In CD and UC there is a significant increase in the expression 
of a range of chemokines including IL-8 and CCL2 (monocyte chemoattractant protein 
[MCP]-1) within the intestinal mucosa which induces high levels of monocyte 
recruitment (Reinecker et al., 1995, Grimm et al., 1996, Banks et al., 2003). 
Furthermore, CCL2 has also been implicated in promoting a pro-inflammatory CD14+ 
MФ phenotype in IBD (Spoettl et al., 2006). The elevated proportion of CD14+ MФ in 
IBD therefore likely reflects accumulation of CD14+ monocytes which then fail to 
undergo differentiation into the steady state resident CD14- MФ phenotype. 
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The enhanced RALDH activity of CD14+ MФ in IBD may therefore be related to the pro-
inflammatory profile of these cells. RA significantly influences the differentiation of 
myeloid cells (Breitman et al., 1980). High dose RA is prescribed in the treatment of 
acute promyelocytic leukaemia (APL) where it induces the differentiation of myeloid 
progenitor cells (Degos and Wang, 2001). It is therefore hypothesised that RA 
production by CD14+ MФ through RALDH activity plays a role in determining the 
differentiation fate of CD14+ monocytes, favouring development of the pro-inflammatory 
CD14+ MФ phenotype.      
Murine SI-LP CD103+ DCs possess enhanced RALDH activity which is absent in 
circulating preDCs (Jaensson-Gyllenback et al., 2011). By analogy, it is therefore 
hypothesised that the enhanced RALDH activity of human intestinal CD14+ MФ 
develops following entry of these cells into the intestinal mucosa and is not apparent in 
circulating CD14+ monocytes. This question is addressed in the first part of this chapter 
by analysis of RALDH activity in CD14+ monocytes of healthy control and IBD patients. 
This then allows a direct comparison between RALDH activity of CD14+ monocyte and 
MФ in these groups.  
5:3 Aims 
1. Determine whether RALDH activity of CD14+ MФ is acquired within the intestinal 
mucosa and whether it is locally enhanced in IBD patients  by studying RALDH 
activity in CD14+ blood monocytes 
 
2. Determine whether RALDH activity and RA generation play a role in the 
differentiation of inflammatory macrophages 
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5:4 Results 
5:4.1 Enhanced RALDH activity of CD14+ MФ in IBD is acquired following 
entry of monocytes into the intestinal mucosa 
It was observed in Chapter 4 that the Aldefluor/RALDH activity of CD14+ MФ is 
enhanced in IBD compared with healthy control patients. However, the origins of this 
enhanced activity were unknown. Intestinal CD14+ MФ derive from circulating CD14+ 
blood monocytes (Grimm et al., 1995b). Enhanced RALDH activity of intestinal CD14+ 
MФ in IBD may therefore develop within the intestinal mucosa in response to local 
mediators, or alternatively may already be present within CD14+ monocytes in 
circulation. In order to distinguish between these possibilities, RALDH activity of CD14+ 
blood monocytes in healthy control and IBD patients was analysed. 
CD14+ monocytes were identified in PBMCs by flow cytometry on the basis of forward 
and side-scatter and CD14 expression (Figure 5.1A). Following the Aldefluor assay, 
approximately 25 % of CD14+ monocytes from healthy controls displayed Aldefluor 
activity that was inhibited in the presence of DEAB (Figure 5.1A). Furthermore, real-
time PCR analysis of immuno-magnetically sorted CD14+ monocytes identified 
prominent expression of ALDH1A1 in these cells (Figure 5.1B). In contrast, ALDH1A2 
was expressed at approximately 1000 fold reduced levels as compared with ALDH1A1, 
whilst ALDH1A3 was routinely below the limit of detection (Figure 5.1B). Therefore 
CD14+ monocytes from healthy controls, in common with the intestinal CD14+ MФ, 
display Aldefluor/RALDH activity which associates with ALDH1A1 expression.  
CD14+ monocytes from IBD patients also displayed Aldefluor/RALDH activity, with a 
similar profile of ALDH1A expression (Figure 5.1B). However, a significantly reduced 
proportion of CD14+ monocytes from IBD patients were Aldelfuor+ as compared with 
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Figure 5.1: Aldefluor/RALDH activity is present in human CD14+ blood monocytes and 
is upregulated following entry into the intestinal mucosa in IBD. A: Aldefluor assay was 
performed on PBMCs and activity was determined in CD14+ monocytes by gating on cells in 
the monocyte region of the FSC vs. SSC plot, then on CD14+ cells (filled histogram) as 
defined in comparison with matched mouse IgG2a isotype control (dotted histogram). 
Aldefluor+ cells were defined in relation to a DEAB-inhibited control reaction as previously, 
with a fixed separation introduced in the gating to ensure only significantly Aldefluor+ cells 
were analysed. B: CD14+ monocytes were immuno-magnetically purified from PBMCs from 
healthy control (n=7) and IBD patients (n=14) with CD14 microbeads; ALDH1A expression 
was determined by real-time PCR. Expression normalized to GAPDH; bars indicate mean 
values + SD, ND is not detected. Continued on next page... 
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their healthy control counterparts (p=0.04; Figure 5.1C). This was associated with a 
trend towards reduced ALDH1A1 expression in CD14+ monocytes in IBD patients, 
although this difference did not reach statistical significance (p=0.062; Figure 5.1D). 
When compared directly, there was a clear and statistically significant upregulation of 
Aldefluor/RALDH activity within CD14+ MФ from IBD patients compared with their 
monocyte precursors (Figure 5.1E). In contrast, the level of RALDH activity did not 
differ between monocytes and CD14+ MФ from healthy controls. This strongly indicates 
that CD14+ monocytes enter the intestinal mucosa in both healthy control and IBD 
patients with basal RALDH activity. Whilst in healthy controls this level of activity is 
maintained, Aldefluor/RALDH activity of CD14+ monocytes becomes significantly 
enhanced following entry into the intestinal mucosa in IBD.  
Real-time PCR identified expression of the retinol dehydrogenase enzymes RDH10 
and DHRS9 in CD14+ blood monocytes, with no statistically significant difference in 
expression between these cells in healthy controls and IBD patients (Figure 5.2). An 
additional retinol dehydrogenase, RDH16, was also expressed by CD14+ monocytes at 
levels approximately 100 fold lower than either RDH10 or DHRS9. Furthermore, 
RDH16 was expressed at significantly lower levels in CD14+ monocytes from IBD 
patients compared with their healthy control counterparts (p=0.028; Figure 5.2). Overall 
...Continued from previous page. C: Summary Aldefluor activity of CD14+ blood monocytes 
for healthy controls (n=6) and IBD patients (n=5); bars indicate mean values, p-value from a 
t-test. D: Comparison of ALDH1A1 expression of purified CD14+ monocytes between healthy 
control (n=7) and IBD patients (n=14). Expression normalized to GAPDH; bars indicate mean 
values, p-value from a t-test, ● = Healthy ▲ = CD, ■ = UC; black and grey shapes for IBD 
samples indicate active and quiescent disease, respectively. E: Comparison of Aldefluor 
activity of CD14+ monocytes as in Figure 5.1C and CD14+ MФ as in Figure 4.13; NI and I are 
non-inflamed and inflamed, respectively; bars indicate mean values + SD; p-values derive 
from One Way ANOVA with pair-wise comparisons by Tukey test.  
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this indicates that in addition to RALDH activity, CD14+ monocytes enter the intestinal 
mucosa with ability to oxidise retinol to retinal in both healthy control and IBD patients.   
The oncogene MN1 suppresses expression of RARα-regulated genes in 
haematopoietic cells (Meester-Smoor et al., 2008, Kandilci and Grosveld, 2009). It was 
therefore speculated that modified expression of MN1 may have been responsible for 
the reduced RDH16 and trend towards reduced ALDH1A1 expression in CD14+ 
monocytes from IBD patients. Indeed, MN1 expression was significantly higher in 
CD14+ monocytes from IBD patients compared with those from healthy controls 
(p=0.006; Figure 5.3). Overall, these data suggest the presence of significant 
differences in the phenotype of CD14+ monocytes between healthy control and IBD 
patients. These differences may influence the upregulation of RALDH activity in CD14+ 
MФ in the intestinal mucosa of IBD patients. 
 
Figure 5.2: CD14+ monocytes from healthy control and IBD patients express multiple 
retinol dehydrogenase enzymes. Expression of RDH10, DHRS9 and RDH16 was 
determined in immuno-magnetically purified CD14+ monocytes by real-time PCR from 
healthy controls (RDH10: n=5; DHRS9/RDH16: n=7) and IBD patients (RDH11: n=5; 
DHRS9/RDH16: n=14). Expression normalized to GAPDH; bars indicate mean values, P-
values from t-tests, ● = Healthy▲ = CD, ■ = UC; black and grey shapes for IBD samples 
indicate active and quiescent disease, respectively.  
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5:4.2 RALDH activity in CD14+ MФ may contribute to an inflammatory 
phenotype 
The functional significance of enhanced RALDH activity in CD14+ MФ in IBD remained 
unclear. Based on an association between RA and myeloid cell differentiation 
(Breitman et al., 1980), it was hypothesised that the RALDH activity of CD14+ MФ 
provides RA required to promote differentiation into the CD14+ as opposed to the CD14- 
MФ phenotype. An in vitro system was established to test this hypothesis. 
It was observed in Chapter 3 that human CD14+ blood monocytes cultured in the 
presence of GM-CSF for 7 days developed high levels of Aldefluor/RALDH activity. 
Furthermore, GM-CSF induces the differentiation of human monocytes into pro-
inflammatory MФ which produce cytokines including TNFα, IL-23 and IL-6 in response 
to stimulation with LPS (Verreck et al., 2004). Based on this pro-inflammatory cytokine 
profile and the observed RALDH activity, the in vitro differentiation of monocytes with 
GM-CSF was therefore used as a model to study the role of RALDH activity in human 
intestinal CD14+ MФ.  
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Figure 5.3: CD14+ monocytes from IBD patients express 
enhanced levels of MN1 compared with CD14+ 
monocytes from healthy controls. Expression of MN1 was 
determined in CD14+ monocytes immuno-magnetically 
purified CD14+ monocytes by real-time PCR from healthy 
controls (n=5) and IBD patients (n=8). Expression 
normalized to GAPDH; bars indicate mean values, p-values 
from t-tests, ● = Healthy▲ = CD, ■ = UC; black and grey 
shapes for IBD samples indicate active and quiescent 
disease, respectively.  
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It was hypothesised that the RA produced by RALDH activity during MФ differentiation 
would be required for the development of a pro-inflammatory phenotype. Consistent 
with the results in Chapter 3, CD14+ blood monocytes cultured in GM-CSF for 7 days 
developed high levels of Aldefluor/RALDH activity (Figure 5.4A). Aldefluor/RALDH 
activity in these in vitro-derived MФ was significantly greater than that observed in 
freshly isolated CD14+ monocytes from healthy control individuals (p=0.007; Figure 
5.4C). Furthermore, Aldefluor/RALDH activity was significantly inhibited by inclusion of 
the RARα antagonist Ro41-5253 throughout monocyte differentiation (Figures 5.4A and 
B). The ALDH1A expression profile of the DMSO-treated MФ was similar to CD14+ 
monocytes, with predominant expression of ALDH1A1 (Figure 5.4D). Finally, MФ grown 
in the presence of Ro41-5253 displayed a significant reduction in the level of ALDH1A1 
expression (p<0.001; Figure 5.4E). Overall, this confirms that CD14+ monocytes 
cultured with GM-CSF develop significant levels of Aldefluor/RALDH activity which 
closely associates with ALDH1A1 expression and is suppressed in the absence of 
RARα signalling. This is consistent with a model where RALDH activity generates RA, 
which then acts in a positive feedback loop to enhance RALDH activity further. 
Following 6 day culture of CD14+ monocytes with GM-CSF, the majority of cells 
remained CD14+. In contrast, a significantly reduced proportion were CD14+ when 
cultured with GM-CSF in the presence of Ro41-5253 (p<0.001; Figures 5.5A and B). 
Furthermore, Ro41-5253-treated MФ which remained CD14+ displayed significantly 
increased Aldefluor/RALDH activity compared with their CD14- counterparts (p=0.018; 
Figure 5.5C). This observation demonstrates an association between loss of RALDH 
activity and CD14 expression at the single cell level and indicates that RA plays an 
important role in maintaining CD14 expression in human MФ. RALDH activity may 
therefore provide an important source of RA for this process. In addition to modified 
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expression of CD14, the overall level of HLA-DR expression was also reduced in MФ 
treated with Ro41-5253 (p=0.007; Figures 5.5A and B).  
Having established a clear association between the loss of RALDH activity and surface 
CD14 expression, the next step was to establish whether this was also related to a 
reduced pro-inflammatory phenotype. To address this, Ro41-5253 and DMSO-treated 
Figure 5.4: GM-CSF induces Aldefluor/RALDH activity in human CD14+ monocytes 
which is suppressed in the absence of RARα signalling. A: CD14+ monocytes were 
cultured in GM-CSF (100 ng/ml) for 6 days in the presence of Ro41-5253 (1 μM) or 
concentration-matched DMSO (vehicle control) and analysed by Aldefluor assay. Gating 
defined relative to DEAB-inhibited control (not shown); per cent Aldefluorhi cells indicated in 
each case. B: Summary Aldefluor activity of MФ treated with Ro41-5253 or DMSO (n=5). C: 
Comparison of Aldefluor activity of MФ (treated with DMSO; as in Figure 5.4B) with healthy 
control CD14+ monocytes (as in Figure 5.1C). D: CD14+ monocytes from healthy controls 
were immuno-magnetically purified using CD14 microbeads and ALDH1A expression profile 
determined by real-time PCR. E: Summary ALDH1A1 expression data of MФ treated with 
Ro41-5253 and DMSO (vehicle control). Expression normalized to RPL30, bars indicate 
mean values + SD; p-values derive from paired t-tests, except Figure 5.4C (t-test).  
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MФ were stimulated with LPS for 4.5 hours and the accumulation of intracellular TNFα 
was determined by intracellular flow cytometry. Neither group produced significant 
TNFα in absence of stimulation. However, following LPS stimulation the majority of 
DMSO-treated MФ were TNFα+ (90.6 ± 5.9 %; Figure 5.6A). In contrast, a significantly 
reduced proportion of Ro41-5253-treated MФ were TNFα+ (29.6 ± 18.7 %; p=0.003; 
Figures 5.6A and B). Whilst the proportion of MФ producing IL-10 following LPS 
stimulation was considerably lower than that of TNFα, there was also a trend towards 
reduced IL-10 production by Ro41-5253-treated MФ (p=0.079; Figure 5.6C).  
The reduced production of TNFα by Ro41-5253-treated MФ could have been the result 
of diminished cell viability. To address this, the proportion of cells that were both 
negative for the dead cell marker 7-aminoactinomycin (7-AAD) and large enough (by 
Figure 5.5: RARα signalling during inflammatory MФ 
differentiation is required for the maintenance of CD14 
expression. A: CD14+ monocytes were cultured in GM-CSF 
(100 ng/ml) for 6 days in the presence of Ro41-5253 (1 μM) or 
concentration-matched DMSO (vehicle control) and CD14 and 
HLA-DR expression determined by flow cytometry; positive 
staining was defined in relation to isotype control antibody 
staining (not shown). B: Summary data for proportion of CD14+ 
(n=6) and HLA-DR MFI (n=5) for Ro41-5253 and DMSO-treated 
MФ. C: Aldefluor activity of CD14+ and CD14- Ro41-5253-
treated MФ (n=5). Bars indicate mean values; p-values derive 
from paired t-tests.  
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forward scatter) to exclude cellular debris was compared between the MФ groups 
(Figure 5.6D). No significant difference could be identified the level of cell viability 
between DMSO and Ro41-5253-treated MФ (Figures 5.6D and E). Overall, this 
Figure 5.6: RARα signalling during human inflammatory MФ differentiation is 
required for the ability to produce TNFα in response to LPS stimulation. A: CD14+ 
monocytes were cultured in GM-CSF (100 ng/ml) for 6 days in the presence of Ro41-5253 
(1 μM) or concentration-matched DMSO (vehicle control) and then cultured in the presence 
or absence of LPS (1 μg/ml) for 4.5 hours, and TNFα production determined by intracellular 
flow cytometry; proportion of TNFα+ cells indicated in each case. B: Summary data for 
intracellular TNFα (n=4) as in Figure 5.5A. C: Summary data for intracellular IL-10 (n=4) 
determined as for TNFα in Figure 5.5A. D: Viability of Ro41-5253 and DMSO-treated MФ as 
defined by lack of 7-AAD staining and sufficient forward scatter (FSC) to exclude cellular 
debris; proportion of viable cells noted. E: Summary viability data for Ro41-5253 and 
DMSO-treated MФ (n=5); bars indicate mean values + SD; P-values derive from paired t-
tests.  
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indicates that RA signalling through RARα is required during the differentiation of 
human inflammatory MФ in vitro for the development of RALDH activity, maintenance of 
CD14 expression and ability to produce TNFα in response to LPS. RALDH activity may 
therefore contribute to this process through the provision of RA. This is consistent with 
a role for RALDH activity in human intestinal CD14+ MФ in the development of a pro-
inflammatory phenotype in IBD. 
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5:5 Discussion 
The first aim of this chapter was to establish the origin of enhanced RALDH activity in 
CD14+ MФ in IBD. As intestinal CD14+ MФ derive from circulating CD14+ monocytes 
(Grimm et al., 1995b), the first step was to determine whether enhanced RALDH 
activity was intrinsic to CD14+ monocytes in IBD patients or else followed entry of these 
cells into the intestinal mucosa. Basal levels of Aldefluor/RALDH activity were observed 
in CD14+ monocytes from both healthy control and IBD patients, indicating that 
monocytes enter the distal human intestinal mucosa with RALDH activity which is then 
selectively upregulated in IBD patients. Furthermore, expression of RDH10 and DHRS9 
by CD14+ monocytes indicates that these cells enter the intestinal mucosa with the 
complete enzymatic machinery to produce RA from retinol. 
The ALDH1A expression profile of CD14+ monocytes from both healthy control and IBD 
patients was dominated by ALDH1A1, with approximately 1000 fold lower expression of 
ALDH1A2 and ALDH1A3 below the limit of detection. As seen in Chapter 4, ALDH1A1 
was also the predominant ALDH1A isoform in intestinal CD14+ MФ but was not 
detected in intestinal DCs. This is consistent with a direct precursor-product relationship 
between human CD14+ monocytes and intestinal CD14+ MФ but not between CD14+ 
monocytes and intestinal DCs. Furthermore, it has been demonstrated that murine SI-
LP CX3CR1hi MФ in the steady state and CX3CR1int inflammatory MФ in models of IBD 
derive from Ly6Chi monocytes (Bain et al., 2013, Tamoutounour et al., 2012, Rivollier et 
al., 2012, Zigmond et al., 2012) whereas CD103+ DCs derive from committed DC 
progenitors (Bogunovic et al., 2009). ALDH1A1 expression may therefore act as a 
marker of monocyte-derived cells in the human intestinal mucosa. 
Chapter 5: Origins and function of RALDH activity in CD14+ MФ in IBD 
204 
 
CD14+ monocytes from IBD patients displayed significantly reduced Aldefluor/RALDH 
activity compared with their counterparts in healthy controls. The functional significance 
and the mechanism behind this observation however remain unclear. RALDH1 in rats is 
inhibited by apo-CRBP-I, which is an indicator of low cellular retinol concentration 
(Posch et al., 1992). In addition, serum retinol is reduced in IBD patients (Janczewska 
et al., 1991). Theoretically this could lead to reduced pairing of retinol and CRBP-I in 
CD14+ monocytes and therefore inhibition of RALDH1, reducing overall 
Aldefluor/RALDH activity. Alternatively, reduced activity could be the result of the 
observed trend towards reduced ALDH1A1 expression in CD14+ monocytes in IBD 
patients.  
The role of RALDH1 activity in human CD14+ monocytes is unclear. As discussed in 
Chapter 3, the Aldefluor assay was originally developed for the identification and 
isolation of viable haematopoietic stem cells (HSCs) on the basis of ALDH activity and 
low side scatter (Storms et al., 1999). As monocytes ultimately derive from HSCs 
following a differentiation process within the bone marrow (Auffray et al., 2009), the 
RALDH1 activity observed in monocytes may be preserved from an earlier stage of 
differentiation. There are indications in mice that Aldh1a1 expression and ALDH activity 
in HSCs are linked with a promotion of myeloid versus lymphoid differentiation (Rice et 
al., 2008, Storms et al., 2005). This suggests that the RALDH activity of CD14+ 
monocytes is the result of a process favouring monocyte differentiation. However, it has 
been also observed that Aldh1a1-/- mice display no defects in the differentiation of 
myeloid or lymphoid cells (Levi et al., 2009), which may indicate redundancy in the 
provision of RA by RALDH enzymes during myeloid cell differentiation. 
Reduced expression of ALDH1A1 in human CD14+ MФ may therefore indicate 
important differences in the differentiation of these cells in IBD patients. Consistent with 
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this hypothesis, CD14+ monocytes expressed significantly greater levels of MN1 than 
their healthy control counterparts. Differentiation of human CD34+ bone marrow HSCs 
to either CD14+ monocytes or CD15+ granulocytes associates with a significant 
downregulation of MN1 (Kandilci and Grosveld, 2009). Furthermore, MN1 
overexpression is observed in some forms of acute myeloid leukaemia (AML) where it 
promotes proliferation as opposed to differentiation of myeloid progenitors (Grosveld, 
2007). Therefore, elevated MN1 expression by CD14+ monocytes in IBD may indicate 
reduced differentiation of these cells. MN1 can both promote and repress transcription 
of RAR-regulated genes including DHRS9 when overexpressed in a pro-monocytic cell 
line (Meester-Smoor et al., 2008). Based on the requirement for RARα signalling in 
ALDH1A1 expression as observed in both this Chapter and Chapter 3, elevated MN1 
expression could be responsible for the trend towards suppressed ALDH1A1 
expression in CD14+ monocytes in IBD.  
Overexpression of Mn1 in murine bone marrow cells leads to an accumulation of 
committed myeloid progenitors (CMPs) with suppressed expression of both Csf1r 
(CD115) and Csf2r (CD116), the receptors for M-CSF and GM-CSF, respectively 
(Kandilci et al., 2013). Circulating monocytes and granulocytes in IBD patients have 
significantly reduced expression of CD116 but not CD115 (Goldstein et al., 2011). 
Whilst the mechanism behind this differential expression is unknown, it may relate to 
the modified MN1 expression observed here. Finally, monocyte-derived MФ from CD 
patients display reduced responses to TLR stimulation which may relate to a reduced 
level of differentiation (Smith et al., 2009, Sewell et al., 2012).  
As observed in Chapter 4, intestinal CD14+ MФ in IBD patients express significantly 
greater levels of ALDH1A1 as compared with their healthy control counterparts. This 
likely contributes to the increased overall Aldefluor/RALDH activity of these cells in IBD. 
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However, comparison of the ALDH1A profiles of CD14+ monocytes and intestinal 
CD14+ MФ from both healthy controls and IBD patients identifies an increased 
prominence of ALDH1A2 and ALDH1A3 expression within intestinal CD14+ MФ. Each 
of these enzyme isoforms may therefore contribute to the net Aldefluor/RALDH activity 
of CD14+ MФ. Furthermore, post-transcriptional regulation of ALDH1A expression may 
also play a significant role in determining the ability of CD14+ MФ to generate RA within 
the intestinal mucosa.  
As demonstrated in both this Chapter and Chapter 3, GM-CSF is a potent inducer of 
RALDH activity in human CD14+ monocytes. This is therefore a candidate for the 
upregulation of RALDH activity in human intestinal CD14+ MФ in IBD. Consistent with 
this hypothesis, GM-CSF is present at a significantly increased concentration in the 
colonic mucosa of both CD and UC patients compared with healthy controls (Ina et al., 
1999). As discussed earlier, the GM-CSF receptor (CD116) is expressed at a 
significantly lower level on both granulocytes and monocytes from IBD patients 
(Goldstein et al., 2011). This indicates a modified relationship between CD14+ 
monocytes and GM-CSF signalling in IBD patients and healthy controls. Whether 
reduced expression of CD116 influences the differentiation of CD14+ monocytes 
following entry into the intestinal mucosa is unclear. Moreover, the extent to which 
CD14+ MФ upregulate CD116 expression within the mucosa and whether this 
modulates RALDH activity is unknown, and warrants further attention.  
An alternative candidate for the upregulation of RALDH activity in CD14+ MФ in IBD is 
RA itself. In the mouse, exposure of murine CD103+ DCs to RA is directly responsible 
for upregulation of Aldh1a2 expression and RALDH activity (Villablanca et al., 2011b, 
Jaensson-Gyllenback et al., 2011). Furthermore, the presence of exogenous RA 
enhances the RALDH activity of human MoDCs as demonstrated in Chapter 3. 
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However, the level of RA present within the intestinal mucosa of IBD and healthy 
control patients was very similar, as demonstrated in Chapter 4. This indicates that 
whilst RA is likely to be required for the upregulation of RALDH activity in CD14+ MФ in 
IBD, it is unlikely to be the principal driver of the enhancement of this activity in IBD. 
RALDH activity of human MoDCs is enhanced following exposure to various TLR 
ligands (Villablanca et al., 2011b, Wang et al., 2011b). As demonstrated in Chapter 3, 
stimulation of human MoDCs with LPS also induced a slight increase in RALDH activity 
which was due to an increase in the proportion of cells with a mature phenotype. The 
increased RALDH activity of CD14+ MФ in IBD may therefore be due to exposure to an 
array of microbial products not present in healthy control patients. This is consistent 
with the increased intestinal permeability associated both CD and UC (reviewed by 
Baumgart and Sandborn, 2012, Ordas et al., 2012). 
It was hypothesized that the upregulation of RALDH activity by human intestinal CD14+ 
MФ in IBD patients was associated with the differentiation of CD14+ monocytes 
following entry into the intestinal mucosa. This view was suggested by the established 
role of RA in cellular differentiation, including the differentiation of myeloid cells (Zhang 
et al., 2000). An in vitro system was developed to address this possibility. 
Culture of CD14+ monocytes from healthy controls in the presence of GM-CSF 
generated cells with multiple features shared with intestinal CD14+ MФ in IBD patients. 
These included enhanced Aldefluor/RALDH activity and maintained expression of 
CD14, as demonstrated in this Chapter, as well as a uniform ability to produce TNFα in 
response to LPS stimulation (Verreck et al., 2004). In order to determine the role of RA 
production in this system, cells were cultured in the presence of the RARα antagonist 
Ro41-5253 (Apfel et al., 1992) throughout differentiation. This resulted in significantly 
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reduced Aldefluor/RALDH activity alongside suppressed ALDH1A1 expression. 
Furthermore, expression of CD14 and the ability to produce TNFα following LPS 
stimulation were also significantly reduced. The ability of Ro41-5253 to significantly 
influence the GM-CSF-mediated differentiation of blood CD14+ monocytes is consistent 
with the constitutively high level expression of RARα and a key heterodimeric partner 
RXRα in these cells as observed elsewhere (Fritsche et al., 2000, Szatmari et al., 
2006). 
The generation of pro-inflammatory CD14+ and less inflammatory CD14- MФ in this 
system mirrors intestinal CD14+ and resident CD14- MФ phenotypes. It also establishes 
a clear association between RALDH activity and a pro-inflammatory MФ phenotype. 
However, a limitation of this system is that Ro41-5253 suppresses the signalling of both 
RA generated by RALDH during MФ differentiation as well as RA endogenous to the 
cell culture media. Further experiments are therefore required to distinguish the specific 
contribution of RALDH-derived RA to this process. The system could be developed by 
culturing CD14+ monocytes with GM-CSF in the presence of DEAB to inhibit RALDH 
activity throughout differentiation. Alternatively, ALDH1A1 expression could be 
suppressed artificially using siRNA technology. 
The in vitro MФ differentiation system identified a clear role for RARα in the 
maintenance of CD14 expression. The requirement of RARα signalling for the 
expression of both ALDH1A1 and CD14 may be related to the transcription factor 
C/EBPβ, which is also implicated in the expression of these genes (Pan et al., 1999, 
Elizondo et al., 2009). Furthermore C/EBPβ plays a key role in the differentiation of 
monocytes into MФ in mouse and man reviewed by Huber et al., 2012). It is therefore 
hypothesised that inhibition of RARα signalling during the differentiation of CD14+ 
monocytes leads to a reduction in C/EBPβ activity and subsequently a loss of CD14 
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expression. The elevated Aldefluor/RALDH activity of CD14+ compared with CD14- 
Ro41-5253-treated MФ is consistent with a link between RA production and signalling 
and retention of CD14 expression. 
The reduced production of TNFα following stimulation of Ro41-5253-treated MФ with 
LPS may simply reflect reduced sensitivity based on the lack of surface CD14 
expression, which could be addressed through stimulation of these cells through 
alternative TLR ligands. Alternatively, this could reflect a more general suppression of 
inflammatory activity as observed with intestinal CD14- MФ (Smythies et al., 2005). 
C/EBPβ promotes NF-κB signalling in mice through reduced transcription of IκBα, an 
inhibitor of the nuclear translocation of NF-κB (Cappello et al., 2009). Furthermore, 
Cebpb-/- mice are more sensitive to bacterial infections including Listeria 
monocytogenes (Tanaka et al., 1995). C/EBPβ has also been shown to bind to the 
human TNFα promoter directly (Pope et al., 1994). C/EBPβ may therefore also play a 
key role in the differentiation of CD14+ MФ within the intestinal mucosa in IBD. It has 
been demonstrated that C/EBPβ regulates FcγR-mediated inflammatory responses to 
IgG-antigen immune complexes in murine MФ (Yan et al., 2012). Human CD14+ MФ 
are also stimulated in the presence of IgG immune complexes, producing TNFα and IL-
1β (Uo et al., 2012).  
Overall, this is consistent with a role for C/EBPβ in the differentiation of human 
inflammatory CD14+ MФ in vitro. Modulation of C/EBPβ activity during this process by 
inhibition of RARα signalling would provide a novel insight into this process. There is 
currently limited evidence of a direct link between RARα and C/EBPβ expression. One 
study showed that RA induces C/EBPβ expression and activity in acute promyelocytic 
leukaemia, but only in the presence of the PML-RARα fusion protein as opposed to 
conventional RARα (Duprez et al., 2003). 
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It was recently reported that Aldh1a2 expression and RALDH2 activity are significantly 
upregulated in MФ in the livers of mice infected with the helminth Schistosoma mansoni 
(Broadhurst et al., 2012). Interestingly, this was associated with an alternatively 
activated MФ phenotype, typified by expression of arginase1, Ym1 and FIZZ1. 
Furthermore, in vitamin A-deficient mice there was a significantly reduced TH2 response 
in the liver indicated by reduced presence of the cytokines IL-4, IL-5 and IL-13, as well 
as diminished eosinophil granuloma formation. The upregulation of Aldh1a2 could be 
replicated in bone-marrow derived MФ with IL-4. Collectively, these data indicate that in 
the mouse, upregulation of Aldh1a2 in MФ is associated with an effective TH2 response 
in S. mansoni infection. Whether the upregulation of this activity is required for the 
differentiation of these MФ, i.e. an ‘intrinsic’ role for RA in this case, is unclear. This 
does however indicate that RALDH activity is an important component of monocyte 
differentiation in a range of different contexts. 
An important alternative role for RALDH activity in human intestinal CD14+ MФ may be 
in influencing mucosal T cell responses. It has been demonstrated CD14+ MФ  
efficiently activate naive CD4+ T cells and primarily induce IFNγ production associated 
with a TH1 response (Kamada et al., 2009). The lack of CCR7 expression by CD14+ 
observed in Chapter 4 suggests that these cells are unlikely to encounter naive T cells 
within draining lymphoid tissue. However they are likely to interact with local 
effector/memory T cell subsets within the intestinal mucosa. The nature of this 
interaction and how it may be influenced by the RALDH activity of intestinal CD14+ MФ 
in IBD is an important area for future study. T cells within the intestinal mucosa of mice 
display a significant degree of plasticity which may allow effector responses to be 
context-specific (reviewed by Zhou et al., 2009). In this way, Foxp3+ TREG may switch 
phenotype to TH17 cells in the presence of proinflammatory cytokines including IL-6 
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(Yang et al., 2008c). RA produced by human intestinal CD14+ MФ may therefore 
influence such plasticity, perhaps stabilising the FOXP3+ TREG phenotype. The elevated 
proportions of Foxp3+ TREG observed in the intestinal mucosa of CD and UC patients 
compared with healthy controls may be consistent with local provision of RA by CD14+ 
MФ within these sites (Makita et al., 2004, Maul et al., 2005, Uhlig et al., 2006). 
5:6 Conclusion 
In conclusion, this chapter has demonstrated that circulating CD14+ monocytes in 
healthy controls and IBD patients have basal levels of RALDH activity which is further 
enhanced following entry into the distal intestinal mucosa of IBD patients but not 
healthy controls. It also demonstrates a key role for RA in the differentiation of 
inflammatory MФ in vitro, including maintenance of expression of CD14 and production 
of TNFα in response to LPS stimulation. Overall, this is consistent with a role for 
enhanced RALDH activity in CD14+ MФ in the provision of RA required for the 
differentiation into this phenotype as opposed to the CD14- MФ associated with the 
steady state. Understanding the factors that influence the fate of CD14+ monocytes in 
the intestinal mucosa in IBD may provide new therapeutic options in the treatment of 
IBD. In particular, treating CD14+ monocytes so that they adopt the steady state 
resident CD14- phenotype within the context of inflammatory mediators in the mucosa 
of IBD patients may help to clear ongoing microbial presence without the production of 
inflammatory cytokines and so restore intestinal homeostasis.  
Chapter 6: Influence of human intestinal soluble factors on DC RALDH activity 
212 
 
Chapter 6: Analysis of the influence of human intestine-
derived soluble factors on RALDH expression 
and activity in DCs  
 
6:1 Chapter summary 
This chapter focuses on determining the influence that soluble factors within the 
intestinal mucosa of healthy control and IBD patients exert on the RALDH activity of 
human MoDCs. This is particularly important in light of observations in Chapter 4 that 
the RALDH activity of CD103+ DCs and CD14+ MФ is increased in IBD. Contrary to 
expectation, intestinal biopsy-derived conditioned medium (CM) is suppressive of 
RALDH activity in MoDCs, at least partially due to the presence of PGE2. Nonetheless, 
MoDCs grown in the presence of inflamed IBD intestinal biopsy-derived CM possess an 
enhanced ability to induce α4β7 on CD4+ T cells as compared with non-inflamed IBD 
biopsy-derived CM treated MoDCs. This effect is independent of RALDH activity and 
has important implications in how the ability of APCs within the intestinal mucosa of IBD 
patients to propagate RA signalling in T cells and in particular how the induction of a 
‘gut-homing’ α4β7 phenotype is influenced in the context of inflammation. 
6:2 Introduction 
In Chapter 4 it was observed that human intestinal CD103+ DCs from IBD patients 
possess enhanced levels of activity in the Aldefluor assay compared with healthy 
controls. Although this difference did not reach statistical significance, it indicated that 
contrary to expectation such cells possess enhanced rather than suppressed RALDH 
activity in IBD. This was supported by the expression of ALDH1A2 as observed by real-
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time PCR of CD103+ DCs purified from a CD patient. Due to the low numbers of DCs 
and the paucity of suitable tissue this approach could not be taken further within the 
time-frame of this project. In order to circumvent these limitations, an in vitro system 
was established and is the focus of this chapter. 
It was hypothesized that factors responsible for modifying RALDH activity of CD103+ 
DCs in IBD would be present as soluble mediators within the tissue. One method to 
collect such soluble factors is to culture intestinal biopsies in complete medium to 
generate a biopsy-conditioned medium (CM). The duration of this culture (6 hours) 
represents a balance between sufficient time to collect significant quantities of 
cytokines and other soluble mediators in the medium against excessive levels of cell 
death within the biopsy leading to an increasingly artificial cytokine profile. 
Differentiation of DCs in the presence of this intestinal biopsy CM therefore allows the 
influence of soluble factors in healthy control or IBD intestinal mucosa on RALDH 
activity of DCs to be studied. 
MoDCs were used as a substitute for CD103+ DCs in this system as they could be 
reliably generated under control conditions and in sufficient quantities for analysis of 
function. Moreover, as discussed in Chapter 3, it was already established that they 
possessed Aldefluor activity that could be directly linked with RALDH activity. This 
would mean that any modification of RALDH activity by CM could be clearly identified. 
The overall influence of intestinal biopsy-conditioned medium (CM) on MoDC RALDH 
activity may be the result of a balance between factors that enhance or decrease 
RALDH expression or activity. Well established factors that induce or enhance RALDH 
activity include RA, acting in a positive feedback loop as observed in Chapter 3 and 
elsewhere (Villablanca et al., 2011b, Molenaar et al., 2011). GM-CSF has been shown 
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to induce RALDH activity in murine DCs (Ganguly et al., 2011b) and in combination 
with IL-4 (Yokota et al., 2009), as observed in Chapters 3 and 5 of this thesis. 
Stimulation of murine splenic DCs with the TLR2 agonists Pam3CSK4 and zymosan 
also induce Aldh1a2 expression and RALDH activity (Wang et al., 2011c, Manicassamy 
et al., 2009). Moreover, Pam3CSK4 also stimulates RALDH activity in human MoDCs 
(Villablanca et al., 2011b).  
Prostaglandin E2 (PGE2) was recently identified as a negative RALDH factor in both 
murine and human MoDCs (Stock et al., 2011). PGE2 was shown to stimulate 
production of cyclic adenosine monophosphate (cAMP), which in turn activates 
inducible cAMP early repressor (ICER). This then directly inhibits expression of 
Aldh1a2 and so suppresses RALDH activity. PGE2 is known to play a wide range of 
roles within the intestine, including influencing motility and secretions (Stenson, 2007). 
Prostaglandins are produced by cyclooxygenase (COX) enzymes found within the 
intestinal epithelium from arachidonic acid. COX-1 is constitutively expressed within the 
human intestinal epithelium in the crypt regions, whilst COX-2 expression is induced in 
the epithelium in both colon cancer and IBD. This upregulation may be mediated by IL-
1β, TNFα and LPS (Stenson, 2007). 
The ability of intestinal DCs to imprint an α4β7+ CCR9+ ‘gut-homing’ phenotype on the 
CD4+ T cells they activate is dependent upon RA (Iwata et al., 2004). Expression of 
α4β7 allows lymphocytes to interact with mucosal addressin cell adhesion molecule-1 
(MAdCAM-1) which is expressed constitutively on vascular endothelial cells in the 
intestine. Furthermore, CCR9 expression allows lymphocytes to respond to CCL25, 
which in the gastro-intestinal tract is expressed primarily by small intestinal epithelial 
cells in the mouse and becomes trapped on vascular endothelial cells (Sigmundsdottir 
and Butcher, 2008, Agace, 2010). RA has also been shown to suppress induction of E-
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selectin ligands on T cells in mice, which are required for migration into non-intestinal 
sites including the skin during inflammation (Iwata et al., 2004). The human equivalent 
is cutaneous lymphocyte antigen (CLA), a P-selectin glycoprotein-1 core which is post-
translationally modified by α(1,3)-fucosyltransferase VII (Fuhlbrigge et al., 1997). 
The close association between provision of RA during naive CD4+ T cell activation and 
the induction of an α4β7+ CCR9+ phenotype therefore provides a functional assay in 
which the impact of modified RALDH activity in intestinal biopsy CM-treated MoDCs 
may be assessed. The overall hypothesis for this system is that treatment of human 
MoDCs with CM derived from healthy control and IBD patients will recapitulate the 
slightly enhanced levels of RALDH activity in CD103+ DCs and the significantly 
enhanced RALDH activity of CD14+ MФ in IBD. This would lead to an increased 
generation of RA, which in turn will lead to enhanced induction of α4β7 and CCR9 on 
naive CD4+ T cells with suppression of CLA expression during antigen presentation. 
6:3 Aims 
 
1. Determine  impact of CM derived from intestinal biopsies of healthy control and  
IBD patients on RALDH activity in MoDCs 
 
2. Identify factors within CM responsible for modified RALDH activity in MoDCs 
 
3. Assess impact of CM treatment on RALDH-dependent induction of α4β7 and 
CCR9 on naive CD4+ T cells by MoDCs 
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6:4 Results 
6:4.1 Intestinal biopsy conditioned medium suppresses RALDH activity 
of human MoDCs 
As discussed in Chapter 3, human blood CD14+ monocytes cultured in GM-CSF and IL-
4 differentiate into MoDCs with RALDH activity detectable by Aldefluor assay and 
consistent with their expression of ALDH1A2. When cultured with CFSE-labelled naive 
CD4+ T cells, MoDCs were capable of activating and inducing proliferation of T cells as 
indicated by alterations in scatter profile (Figure 6.1A) as well as CFSE dilution (Figure 
6.1B). This observation confirms that the MoDCs grown in vitro possessed naive T cell 
stimulatory capacity, a key feature of DCs.  
In order to understand the influence of the intestinal mucosal environment on RALDH 
activity of MoDCs, these cells were differentiated in the presence of intestinal biopsy-
conditioned medium (CM) at 20 % v/v. To generate CM, intestinal biopsies were 
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Figure 6.1: Monocyte-derived DCs activate 
naïve CD4 T cells. CD14+ monocytes were 
cultured in GM-CSF and IL-4 (100 ng/ml) for 7 
days then co-cultured with CFSE-labelled naive 
CD4+ T cells for 5 days at a ratio of 1:10. A: 
Proliferation of CD4+ T cells is evident in 
alteration in forward (FSC) and side-scatter 
(SSC) profiles. B: Proliferating cells display 
‘diluted’ CFSE signal as each subsequent 
generation of cells inherits half CFSE present in 
the parent cell. Percent ‘CFSElo’ cells shown; 
representative example (n=20). 
 
Chapter 6: Influence of human intestinal soluble factors on DC RALDH activity 
217 
 
collected from patients undergoing endoscopy and cultured in complete medium for 6 
hours at 37 ºC. CM-treated MoDCs displayed consistently reduced Aldefluor activity 
compared with non-conditioned MoDCs (Figures 6.2A and B). This reduction was seen 
with CM generated from both healthy control and from both non-inflamed and inflamed 
mucosa from IBD patients (Figure 6.2A). Due to considerable variation in the level of 
Aldefluor activity within non-conditioned MoDCs, a relative Aldefluor activity was 
determined by dividing the proportion of Aldefluorhi CM-treated MoDCs by the 
proportion of Aldefluorhi untreated (‘non-conditioned’) MoDCs in parallel cultures. 
Comparison of relative Aldefluor activities indicated that CM derived from healthy 
control and IBD patients significantly suppressed Aldefluor activity of human MoDCs, 
but there were no statistically significant differences between the different CM groups 
(Figure 6.2C). Furthermore, similar suppression of RALDH activity was observed with 
CM derived from both CD and UC patients (Figure 6.2C). 
Consistent with the Aldefluor data, CM-treated MoDCs displayed reduced expression of 
ALDH1A2, with no statistically significant separation between different CM groups 
(Figure 6.3). This is consistent with CM suppressing RALDH2 activity through down-
regulation of ALDH1A2 expression. ALDH1A1 expression displayed more variation, 
with expression suppressed in three of four CM-treated MoDCs tested, but enhanced in 
one sample (Figure 6.3). This is consistent with data in Chapter 3 that indicates 
ALDH1A2 expression correlates more strongly than ALDH1A1 expression with 
Aldefluor activity of human MoDCs. 
Suppression of ALDH1A2 expression and Aldefluor activity by CM strongly suggested 
that RALDH2 activity was reduced, and that therefore output of RA by the cells would 
also be diminished. To confirm this, non-conditioned and CM-treated MoDCs were 
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cultured in serum-free medium (X-VIVO 10) in the presence or absence of all-trans 
retinal (100 nM) for 4 hours and RA was measured in the supernatants directly by high 
performance liquid chromatography with tandem mass spectrometry (LC/MS/MS). RA 
was detected in the supernatant of non-conditioned MoDCs cultured in the presence of 
retinal (mean concentration 0.32 pmol/ml). However, a significantly reduced 
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Figure 6.2: Human intestinal biopsy-derived CM suppresses Aldefluor activity of 
MoDCs. A: CD14+ monocytes were cultured with GM-CSF and IL-4 (100 ng/ml) in the 
presence (‘+CM) or absence (‘Unconditioned’) of intestinal biopsy derived-CM, with Aldefluor 
analysis performed on day 7. Gate defines Aldefluorhi cells relative to a DEAB-inhibited 
control (not depicted); calculation of relative Aldefluor activity is shown. Note the variation in 
Aldefluor activity in unconditioned MoDCs between different experiments. B: Summary data 
of median proportion of Aldefluorhi unconditioned and CM-treated MoDCs + SD (n=30); p-
value derives from a paired t-test. C: Summary data depicting relative Aldefluor activity of 
individual CM-treated MoDCs; HC is healthy control, NI is non-inflamed, I is inflamed; ● = 
HC, ▲ = CD, ■ = UC, filled and empty shapes depict CM derived from colonic and ileal 
biopsies, respectively; bars indicate median values.  
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concentration of RA was detected in the supernatant of CM-treated MoDCs (mean 
concentration 0.17 pmol/ml; Figure 6.4), consistent with reduced RALDH activity in 
these cells. Notably, RA was undetectable in supernatants in absence of exogenous 
retinal. RA was detected in medium only control wells at approximately 0.1 pmol/ml (0.1 
nM) in the presence of retinal (Figure 6.4), but was below the limit of detection without 
retinal. This indicates that a small fraction of retinal spontaneously oxidises to retinoic 
acid in culture or else the commercial preparation contains trace amounts of RA.  
Overall, these data indicate that the human intestinal mucosa contains soluble 
mediators which act as negative regulators of RALDH activity in MoDCs. Contrary to 
expectation, the enhanced RALDH activity of CD103+ DCs and CD14+ MФ in IBD was 
not observed in this system. 
Figure 6.3: Human intestinal biopsy-derived CM suppresses ALDH1A2 expression in 
MoDCs. CD14+ monocytes were cultured in GM-CSF and IL-4 (100 ng/ml) in the presence or 
absence of intestinal biopsy derived-CM and ALDH1A expression determined by real-time 
PCR on day 7. ALDH1A1 and ALDH1A2 expression in CM-treated MoDCs, normalized to 
GAPDH using 2-ΔCt then expressed relative to unconditioned MoDCs. HC is healthy control 
(n=4), NI is non-inflamed (n=4), I is inflamed (n=4); ● = HC, ▲ = CD, ■ = UC, filled and 
empty shapes depict CM derived from colonic and ileal biopsies, respectively; bars indicate 
median values.  
Figure 1.6: Migration of naive T cells and effector T cells into intestinal tissue. Upper 
panel: Naive T cells express L-selectin which interacts with sialyl-LewisX residues expressed 
o  high endothelial venules (HEVs) in PPs and MLNs, as ell as with glycans of MAdCAM-1, 
leading to tethering and rolling along the endothelium. Low expression of α4β7 by naive T 
cells contributes to tethering through interaction with MAdCAM-1 (not shown).Signalling by 
CCL21 present on HEVs through CCR7 on naive T cells induces activation of the αLβ2 
integrin of naive T cells and increases affinity of this integrin for HEV-associated ICAM-1, 
bringing the cell to a stop. Transendothelial migration then transports the naive T cell to the 
interior of the tissue in a process which remains poorly understood. Lower panel: Naive T 
cells activated in GALT express high levels of α4β7 which is sufficient to interact with 
MAdCAM-1 on vascular endothelial cells in the intestinal mucosa and induce tethering and 
rolling behaviour. Signalling of CCL25 through CCR9 promotes recruitment of lymphocytes 
to the small intestinal mucosa, and may act through modulation of α4β7-MAdCAM-1 
interactions. 
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As discussed in Chapters 2 and 5, GM-CSF is a potent inducer of RALDH activity in 
human CD14+ blood monocytes. A possible mechanism of the suppression of RALDH 
activity by CM was therefore modification of GM-CSF signalling in these cells. 
Interaction between GM-CSF and its receptor leads, through a series of intermediate 
steps, to the phosphorylation of tyrosine residues on signal transducers and activators 
of transcription (STAT)-5 (Mui et al., 1995). STAT5 is then directed into the nucleus 
where it influences transcription of a wide range of genes. An experiment was therefore 
performed to determine if GM-CSF induced reduced levels of STAT5 phosphorylation 
in monocytes during MoDC differentiation cultures when in the presence of biopsy CM. 
Peak pSTAT5 MFI was observed at 1 hour and was reduced at both 4 and 24 hours of 
culture (Figure 6.5). However, no differences in pSTAT5 MFI were apparent between 
untreated and CM-treated MoDCs. This indicates that early GM-CSF signalling events 
are not disturbed by the presence of CM, and that suppression of RALDH activity 
occurs either downstream of this point or is independent of the GM-CSF/STAT5 
signaling pathway. 
Figure 6.4: Human intestinal biopsy CM suppresses 
ability of MoDCs to generate RA in the presence of 
retinal. CD14+ monocytes were cultured with GM-CSF and 
IL-4 (100 ng/ml) in the presence or absence of intestinal 
biopsy-derived CM, then cultured on day 7 for 4 hours in 
the presence of retinal (100 nM); RA was quantified in 
supernatants by HPLC with MS/MS in the lab of Maureen 
Kane, University of Maryland, Baltimore. Cultures 
performed in triplicate, mean values displayed + SD; p-
values derive from One Way ANOVA, with pair-wise 
comparisons by Tukey Test.  
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6:4.2 Prostaglandin E2 contributes to suppression of RALDH activity by 
intestinal biopsy CM 
During the course of these experiments it was reported that PGE2 acts as a negative 
regulator of RALDH activity in both human and murine MoDCs (Stock et al., 2011), and 
it was suggested that PGE2 generation in tissues such as the skin inhibit RALDH 
expression and DC imprinting of gut tropism at these sites. Stock et al did not examine 
the role of PGE2 in the human intestine but their work suggested it was a potential a 
mediator present within intestinal biopsy CM responsible for the suppression of RALDH 
activity observed in our system. In order to address this, MoDCs were grown in the 
presence or absence of the PGE2 receptor antagonist AH6809, which targets the E-
prostanoid (EP)1 and EP2 receptors (Jones et al., 2009). As expected, there was 
suppression of Aldefluor activity within MoDCs treated with intestinal biopsy CM, 
consistent with a loss of RALDH activity. However, when MoDCs were cultured with 
both CM and AH6809, there was partial restoration of Aldefluor activity (Figure 6.6A), 
Figure 6.5: STAT5 phosphorylation in MoDCs by GM-CSF is unaltered in the presence 
of intestinal biopsy-derived CM. CD14+ monocytes were cultured with GM-CSF and IL-4 
(100 ng/ml) in the presence or absence of intestinal biopsy-derived CM and were fixed at 
time points shown in PFA (4 %) and permeabilised in methanol (70 %). pSTAT5 MFI was 
determined by intracellular flow cytometry. 
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indicating that PGE2 signalling is involved in the suppression of RALDH activity in this 
system. AH6809 was able to partially restore Aldefluor activity suppressed by a range 
of CM, including those derived from healthy control and IBD biopsies (Figure 6.6B). 
This suggests that PGE2 is present and is able to influence RALDH activity within DCs 
in the context of healthy and IBD intestinal mucosa. Overall, AH6809 had no significant 
effect on the Aldefluor activity of non-conditioned MoDCs (Figures 6.6A and B). In one 
of three independent experiments however, the Aldefluor activity of non-conditioned 
MoDCs was increased in the presence of AH6809. This indicates that in this particular 
experiment, inhibition of endogenous PGE2 as opposed to intestinal biopsy-derived 
PGE2 cannot be excluded as the mechanism behind the partial restoration of Aldefluor 
activity in CM-treated MoDCs cultured with AH6809. 
A 
Figure 6.6: PGE2 in human intestinal biopsy-derived CM is partially responsible for 
suppressed RALDH activity in CM-treated MoDCs. A: CD14+ monocytes were cultured in 
GM-CSF and IL-4 (100 ng/ml) for 7 days in the presence or absence of intestinal biopsy CM 
and either the PGE2 EP1/EP2 receptor antagonist AH6809 (10 μM) or DMSO (vehicle 
control). Aldefluor analysis was performed on day 7; gate defines Aldefluorhi cells relative to 
a DEAB-inhibited control (not depicted). B: Summary data of 3 independent experiments; 
mean Aldefluor activity relative to DMSO control depicted + SD where replicate data for a 
particular CM exists. Non-cond. refers to non-conditioned MoDCs.  
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Assuming a role for PGE2 in the downregulation of RALDH activity by CM, it was 
unclear whether PGE2 was present in CM itself, or whether production of PGE2 was 
induced within MoDCs by factors present in CM. To address this, MoDCs were grown 
in the presence of CM and indomethacin, an inhibitor of cyclooxygenase (COX)-1 and 
COX-2 which generate the PGE2 precursor PGH2 from arachidonic acid (Nakata et al., 
1981). Indomethacin did not restore Aldefluor activity suppressed by a healthy control, 
non-inflamed or inflamed IBD biopsy-derived CM (Figures 6.7A and B). This strongly 
suggests that PGE2 present within the CM itself rather than induced PGE2 production is 
partially responsible for suppression of RALDH activity of MoDCs in this system. 
 
A 
Figure 6.7: PGE2 production induced by human intestinal biopsy-derived CM is not 
responsible for suppressed RALDH activity in CM-treated MoDCs. A: CD14+ monocytes 
were cultured in GM-CSF and IL-4 (100 ng/ml) for 7 days in the presence or absence of 
intestinal biopsy CM and either the COX inhibitor indomethacin (1 μM) or DMSO (vehicle 
control). Aldefluor analysis was performed on day 7; gate defines Aldefluorhi cells relative to 
a DEAB-inhibited control (not depicted). B: Data from a single experiment in which 3 
independent CM were tested; mean Aldefluor activity relative to DMSO control depicted. 
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6:4.3 Inflamed IBD biopsy CM significantly alters the differentiation of 
MoDCs 
It has been observed elsewhere that inclusion of PGE2 with CD14+ monocyte and GM-
CSF/IL-4 cultures significantly alters the phenotype of human MoDCs (Kalinski et al., 
1997). This includes a failure to both downregulate CD14 and to upregulate CD1a, an 
MHC class I-like molecule involved in presentation of endogenous and pathogen-
derived lipid antigens (Brigl and Brenner, 2004).  Based on PGE2-mediated 
suppression of RALDH activity in CM-treated MoDCs, it was therefore hypothesized 
that surface phenotype would also be modified. Indeed, MoDCs grown in the presence 
of intestinal biopsy CM displayed increased retention of CD14, with reduced 
upregulation of CD1a (Figure 6.8A). Furthermore, MoDCs treated with CM derived from 
both non-inflamed and inflamed biopsies from IBD patients had significantly reduced 
expression of CD1a compared with CM derived from healthy controls (Figure 6.8B). 
There was a further trend in which inflamed CM-treated MoDCs had reduced CD1a 
expression compared with non-inflamed CM-treated MoDCs, although this did not 
reach statistical significance (Figure 6.8B). In addition, inflamed CM-treated MoDCs 
had significantly elevated expression of CD14 compared with both non-inflamed and 
healthy control CM-treated MoDCs (Figure 6.8C). These data indicate that factors 
present within intestinal biopsy CM influence MoDC differentiation in a manner 
consistent with the published effects of PGE2.  
6:4.4 Inflamed IBD biopsy CM enhances ability of MoDCs to induce α4β7 
expression in naive CD4+ T cells 
Based on the presence of RALDH activity within non-conditioned MoDCs, and the 
demonstrated ability to produce measurable levels of RA in the presence of exogenous 
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A 
Figure 6.8: Inflamed IBD biopsy-derived CM significantly alters the differentiation of 
MoDCs. A: CD14+ monocytes were cultured in GM-CSF and IL-4 (100 ng/ml) for 7 days in 
the presence or absence of intestinal biopsy CM and surface phenotype was analyzed by 
flow cytometry on day 7; representative data. B: Summary data of relative CD1a expression 
based on ratio of CD1a MFI for CM-treated MoDCs to non-conditioned MoDCs in parallel 
culture. C: Summary data of relative CD14 expression based on ratio of CD14MFI for CM-
treated MoDCs to non-conditioned MoDCs in parallel culture. Each symbol represents an 
individual CM-treated MoDC; HC (n=7) is healthy control, NI (n=10) is non inflamed IBD and 
I (n=11) is inflamed IBD biopsy-derived CM; ● = Healthy, ▲ = CD, ■ = UC; filled symbols are 
colonic and empty symbols are ileal tissue samples; bars represent mean values in B and 
median values in C; p-values derived from one way ANOVA with  pair-wise comparison by 
Tukey test; statistical analysis of C follows log10 transformation.  
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retinal, it was presumed that these cells would induce RA-dependent induction of α4β7 
and CCR9 expression during the activation of naive CD4+ T cells. Indeed, following 5 
days co-culture of MoDCs and CFSE-labelled naive CD4+ T cells, a significant fraction 
of proliferating CFSElo CD4+ T cells were β7+ compared with isotype control-labelled 
cells (Figures 6.9A and B). These experiments were performed using a monoclonal 
antibody to β7 alone as opposed to α4β7 as the necessary antibody (Act-1) was not 
available at this point. However, subsequent experiments confirmed a close association 
between β7 and α4β7 expression on proliferating CD4+ T cells when stimulated by 
MoDCs (Figures 6.10A and B), demonstrating that β7 is sufficient as a surrogate marker 
for α4β7 expression in this context. The induction of α4β7 by MoDCs was suppressed in 
the presence of the RARα antagonist Ro41-5253 (Apfel et al., 1992), demonstrating the 
requirement for RARα signalling in this induction. Furthermore, the presence of 
exogenous RA (10 nM) enhanced induction of α4β7 (Figures 6.10A and B). In contrast, 
MoDCs did not induce CCR9 expression on proliferating CD4+ T cells (Figures 6.9C 
and D).  
Based on reduced RALDH activity and therefore a presumed reduced ability to make 
RA, it was hypothesized that CM-treated MoDCs would induce lower levels of α4β7 
expression on proliferating CD4+ T cells compared with their non-conditioned MoDC 
counterparts. However, naïve CD4+ T cells activated by CM-treated MoDCs displayed 
no defects in β7 induction. Indeed, CD4+ T cells activated by some CM-treated MoDCs 
expressed more β7 than T cells activated in parallel by non-conditioned MoDCs 
(Figures 6.11A and B). 
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It was observed that β7 expression increased with successive T cell divisions (Figure 
6.11 B), as has been noted elsewhere (Stagg et al., 2002, Johansson-Lindbom et al., 
2003, Sheasley-O'Neill et al., 2007, Jaensson et al., 2008). The extent of T cell 
proliferation was therefore a potential confounding influence on the level of β7 induction. 
Figure 6.9: Activation by human MoDCs results in increased α4β7 expression by 
allogeneic CD4+ T cells. A: CD14+ monocytes were cultured in GM-CSF and IL-4 (100 
ng/ml) for 7 days in the presence or absence of intestinal biopsy CM and then co-cultured 
with CFSE-labelled naive CD4+ T cells at a ratio of 1:10 and β7 expression analysed on 
proliferating CFSElo cells by flow cytometry. Successive divisions were gated on the basis of 
CFSE dilution as indicated. B: β7 MFI was determined at each cell division and compared to 
cells stained with the rat IgG2a isotype control antibody as indicated. C: In parallel cultures, 
CCR9 expression was determined on proliferating CD4+ T cells. D: CCR9 MFI at successive 
divisions compared with the mouse IgG2a isotype control antibody as in B.  
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To control for this possibility, β7 MFI was measured at a fixed point (division 6 as 
identified by CFSE dilution) in all experiments, and the effect of DC conditioning was 
determined by calculating, at this fixed point, the ratio of β7 MFI on CD4+ T cells 
activated by CM-treated MoDCs to β7 MFI on CD4+ T cells activated by non-conditioned 
MoDCs (Figure 6.11B). This analysis identified significantly increased induction of β7 
expression on CD4+ T cells activated by inflamed compared with non-inflamed IBD CM-
treated MoDCs (Figure 6.11C). This represented a median fold increase in β7 MFI over 
unstimulated MoDCs of 1.6 for inflamed CM-MoDCs compared with 0.9 for non-
inflamed CM-treated MoDCs. This increase in β7 was observed with MoDCs 
conditioned with CM derived from both CD and UC patients (Figure 6.11C). For healthy 
control CM-MoDCs, the median fold increase in β7 MFI over non-conditioned MoDC 
was intermediate at 1.3. As expected, there was no correlation between the level of 
Aldefluor activity of CM-treated MoDCs and the relative induction of β7 on proliferating 
Figure 6.10: β7 is an effective surrogate marker for α4β7 in MoDC-naive CD4+ T cell co-
cultures. A: CD14+ monocytes were cultured in GM-CSF and IL-4 (100 ng/ml) for 7 days in 
the presence or absence of intestinal biopsy CM and then co-cultured with CFSE-labelled 
naive CD4+ T cells at a ratio of 1:10 in the presence of RA (10 nM) or Ro41-5253 (1 μM) for 
5 days, then β7 or α4β7 expression on CFSElo cells determined by flow cytometry. B: β7 and 
α4β7 MFI for the different treatment groups were correlated.  
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CD4+ T cells (Figure 6.11D). This indicates that despite equivalent suppression of 
 
Figure 6.11: Inflamed IBD intestinal biopsy CM-treated MoDCs induce significantly 
greater levels of β7 on CD4+ T cells than non-inflamed IBD CM-treated MoDCs. A: 
CD14+ monocytes were cultured in GM-CSF and IL-4 (100 ng/ml) for 7 days in the presence 
or absence of intestinal biopsy CM and then co-cultured with CFSE-labelled naive CD4+ T 
cells at a ratio of 1:10 for 5 days and β7 expression was determined on CFSElo cells by flow 
cytometry. B: β7 MFI at successive cell divisions was determined for the different CM-treated 
MoDC-naive CD4+ T cell co-cultures; β7 MFI at division 6 is indicated; calculation of relative 
β7 expression at division 6 displayed. C: Summary data of relative β7 expression of CD4+ T 
cells at division 6 following co-culture with intestinal biopsy-derived CM-treated MoDCs; HC 
(n=10) is healthy control, NI (n=12) is non inflamed IBD and I (n=14) is inflamed IBD biopsy-
derived CM; ● = Healthy, ▲ = CD, ■ = UC; filled and empty symbols are CM derived from 
colonic and TI biopsies, respectively; bars represent median values; p-value derives from 
one way ANOVA with pair-wise comparison by Tukey test following log10 transformation of 
data. D: Correlation between relative β7 expression of CD4+ T cells at division 6 and relative 
Aldefluor activity of match intestinal biopsy CM-treated MoDCs; p-value derives from a 
Spearman Rank Order Correlation.  
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RALDH activity across the range of CM sub-groups, differences exist in their ability to 
influence the induction of α4β7 by MoDCs, in particular between inflamed and non-
inflamed IBD CM. 
Murine E-selectin ligand induction is negatively regulated by RA (Iwata et al., 2004). To 
confirm the reciprocal induction of the human equivalent, cutaneous lymphocyte 
antigen (CLA), and α4β7 by RA in humans, naive CD4+ T cells were stimulated with 
activation beads (coated with anti-CD2, CD3 and CD28) in the presence of various 
concentrations of RA and the RARα antagonist Ro41-5253. As expected, increasing 
the concentration of RA to 10 nM led to greater induction of β7 on proliferating CD4+ T 
cells which was suppressed in the presence of Ro41-5253 (Figure 6.12). Furthermore, 
Ro41-5253 also suppressed the induction of β7 in the absence of exogenous RA. In 
contrast, increasing the concentration of RA suppressed the induction of CLA, which 
could be inhibited by Ro41-5253 at lower concentrations of RA (0.1 and 2 nM). In 
contrast with β7, Ro41-5253 enhanced induction of CLA in the absence of exogenous 
RA (Figure 6.12).     
 
Figure 6.12: RA enhances α4β7 but suppresses CLA expression during the activation 
of naive CD4+ T cells. A: CFSE-labelled naive CD4+ T cells were stimulated with 
microbeads coated with anti-CD2/CD3/CD28 for 5 days in varying concentrations of RA and 
Ro41-5253 as indicated; β7 and CLA MFI were determined on CFSElo cells.  
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The induction of increased levels of α4β7 on proliferating CD4+ T cells by inflamed 
compared with non-inflamed IBD CM-MoDCs was consistent with elevated levels of RA 
signalling in the inflamed IBD CM MoDC-T cell co-cultures. Based on the reciprocal 
regulation of α4β7 and CLA expression on CD4+ T cells by RA as confirmed above, it 
was hypothesised that inflamed IBD CM-MoDCs would therefore induce less CLA on 
proliferating CD4+ T cells as compared with non-inflamed IBD CM-MoDCs. Non-
conditioned MoDCs induced expression of CLA on a small proportion of proliferating 
CD4+ T cells (Figures 6.13A and B). The influence of CM treatment of MoDCs on 
induction of CLA expression by CD4+ T cells was variable. However, suppression of 
CLA was observed in a number of experiments, consistent with enhanced RA signalling 
(Figures 6.13C and D).  
CLA expression increased with successive T cell divisions (Figure 6.13B), and so a 
relative CLA expression level was determined in the same manner as for β7 to allow 
comparison between experiments. Overall, the pattern of CLA induction by healthy, 
non-inflamed and inflamed IBD CM MoDCs was reciprocal to that of β7. Specifically, 
there was a trend towards lower expression of CLA when naive CD4+ T cells were 
activated by inflamed CM-treated MoDCs than when the T cells were activated by non-
inflamed IBD CM-treated MoDCs, although this did not reach statistical significance 
(Figure 6.13E). Levels of CLA suppression by healthy and inflamed IBD CM-treated 
MoDCs were similar. Overall, this suggests that soluble factors within inflamed but not 
non-inflamed IBD mucosa are able to enhance induction α4β7 at the expense of CLA 
expression on CD4+ T cells by MoDCs, independently of RALDH activity. 
It remained unclear as to why induction of α4β7 on proliferating CD4+ T cells should be 
independent of RALDH activity in MoDCs. Based on the inability of MoDCs to produce 
detectable levels of RA in the absence of exogenous retinal (Figure 6.4), it was 
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hypothesized that the RALDH activity in MoDCs was unable to generate sufficient RA 
to influence β7 expression. To address this possibility, MoDCs were compared directly 
Figure 6.13: Inflamed IBD intestinal biopsy CM-treated MoDCs induce lower levels of 
CLA on CD4+ T cells than non-inflamed IBD CM-treated MoDCs. A: CD14+ monocytes 
were cultured in GM-CSF and IL-4 (100 ng/ml) for 7 days in the presence or absence of 
intestinal biopsy CM and then co-cultured with CFSE-labelled naive CD4+ T cells at a ratio of 
1:10 and CLA expression analysed on proliferating CFSElo cells by flow cytometry. 
Successive divisions were gated on the basis of CFSE dilution as indicated. B: CLA MFI 
was determined at each cell division and compared to cells stained with the rat IgM isotype 
control antibody as indicated. C: Example of differential induction of CLA on proliferating 
CD4+ T cells by non-conditioned and CM-treated MoDCs. D: CLA MFI on proliferating CD4+ 
T cells activated by non-conditioned and CM-treated MoDCs at successive divisions. E: 
Summary data comparing relative CLA expression (calculated as for β7) in CM-treated 
MoDCs; HC (n=8) is healthy control, NI (n=10) is non inflamed IBD and I (n=12) is inflamed 
IBD biopsy-derived CM; ● = Healthy, ▲ = CD, ■ = UC; filled and empty symbols are CM 
derived from colonic and TI biopsies, respectively; bars represent median values; p-value 
derives from one way ANOVA.  
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with ‘walk out’ cells obtained from colonic biopsies that induce significant levels of α4β7 
on proliferating CD4+ T cells, as observed in Chapter 4. In a parallel co-culture 
experiment, ‘walk out’ cells induced a substantially greater level of β7 expression on 
proliferating CD4+ T cells as compared with that induced by non-conditioned MoDCs 
(Figures 6.14A and B). This indicates that the level of α4β7 induction by MoDCs is 
relatively low compared with intestinal APCs, and is consistent with low or absent RA 
production by the RALDH enzymes present in these cells. Both MoDCs and ‘walk out’ 
cells induced low levels of CLA, whilst neither induced CCR9 expression on CD4+ T 
cells (Figure 6.14A). 
An alternative hypothesis to explain differential induction of β7 expression on CD4+ T 
cells by CM-treated MoDCs independent of RALDH activity was a modified ability to 
oxidise retinol present in serum to retinal, the RALDH substrate. The oxidation of retinol 
to retinal is rate-limiting in the presence of CRBP-I for the overall production of RA 
(reviewed by Napoli, 2012). Equivalent levels of retinol (2.5 nmol/ml; 2.5 μM) were 
detected in all CM tested by HPLC MS/MS (Figure 6.15), indicating that MoDCs were 
not exposed to different levels of retinol depending on the CM group. Expression of 
RDH10 and DHRS9 was determined in CM-treated MoDCs by real-time PCR to assess 
the influence of CM-treatment on expression of these retinol oxidising enzymes. As with 
ALDH1A2 (Figure 6.3), RDH10 expression was suppressed by healthy control, non-
inflamed and inflamed IBD CM to approximately 50 % of the level observed in non-
conditioned MoDCs (Figure 6.16). In contrast, DHRS9 expression was suppressed by 
some but not all CM tested. Of particular interest was a trend in which DHRS9 
expression was suppressed in three of four non-inflamed CM-treated MoDCs tested, 
whilst both healthy and inflamed IBD CM-treated MoDCs had similar distributions of 
DHRS9 expression (Figure 6.16). These levels of expression match the distribution of 
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β7 induction in CD4+ T cells, although differences do not reach statistical significance. 
Overall, these data may indicate that the ability of MoDCs to oxidise the available 
retinol to retinal via DHRS9 expression is a key determinant of overall RA output and 
induction of α4β7 in CD4+ T cells.  
In addition to retinol, some CM contained detectable levels of RA (Figure 6.15). 
Therefore, an alternative hypothesis explaining the in induction of β7 in CD4+ T cells 
stimulated by inflamed and non-inflamed IBD CM-treated MoDCs may have related to 
Figure 6.14: ‘Walk out’ cells derived from colonic biopsies induce substantially greater 
levels of α4β7 on CD4+ T cells than MoDCs. A: CD14+ monocytes were cultured in GM-
CSF and IL-4 (100 ng/ml) for 7 days in the presence or absence of intestinal biopsy CM and 
then co-cultured with CFSE-labelled naive CD4+ T cells at a ratio of 1:10. ‘Walk out’ cells 
derived from colonic biopsies were also co-cultured with naive CD4+ T cells at a ratio of 1:4 
for 5 days and expression of α4β7, CCR9 and CLA determined on proliferating CFSElo cells 
by flow cytometry. B: β7 MFI was determined at successive CD4+ T cell divisions; MFI at 
division 6 is indicated.  
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‘carry-over’ of RA directly from the biopsy into CM. Levels of RA in CM derived from 
five healthy control biopsies were too low to be reliably quantified by this approach. RA 
was detected in both inflamed and non-inflamed biopsy CM, at an average level of 0.02 
pmol/ml (20 pM; Figure 6.15). However, there were no apparent differences between 
inflamed and non-inflamed RA levels. Together with the very low levels detected, this 
indicates that ‘carry-over’ of RA directly from the biopsies into CM is unlikely to be 
responsible for the differences in induction of β7 by inflamed and non-inflamed IBD CM-
treated MoDCs. 
The inhibition of β7 induction on CD4+ T cells by MoDCs in the presence of Ro41-5253 
(Figures 6.10A and B and Figure 6.12) strongly implicated RARα signalling in this 
process. The level of RARA expression (encoding RARα) in proliferating CD4+ T cells 
was therefore a further potential source of differential induction of β7 expression. To 
address this hypothesis, naive CD4+ T cells were stimulated with non-conditioned 
MoDCs and MoDCs treated with an inflamed CM that lead to a 2 fold increase in β7 MFI 
Figure 6.15: Variable concentrations of retinoids detected in intestinal biopsy-derived 
CM. Intestinal biopsy CM were analyzed by HPLC MS/MS for the presence of all-trans RA 
and all-trans retinol in the lab of Maureen Kane, University of Maryland, Baltimore; HC (n=5) 
is healthy control, NI (n=5) is non inflamed IBD and I (n=6) is inflamed IBD biopsy-derived 
CM; ● = Healthy, ▲ = CD, ■ = UC; filled and empty symbols are CM derived from colonic 
and TI biopsies, respectively; bars represent median values.  
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at division 6 (data not shown). Proliferating CD4+ T cells (CFSElo) were sorted by flow 
cytometry and RARA expression was quantified by real-time PCR. The expression of 
RARA was identical in CD4+ T cells stimulated by both non-conditioned MoDCs and 
inflamed CM-treated MoDCs (Figure 6.17). This indicates that at the level of 
transcription, RARα is not modified during CD4+ T cell activation by CM-treated 
MoDCs. Modulation of RARα expression is therefore unlikely to explain differential 
induction of β7 expression on CD4+ T cells by CM-treated MoDCs. 
Figure 6.16: Intestinal biopsy-derived CM suppresses RDH10 expression in MoDCs 
but has variable effects on DHRS9 expression. CD14+ monocytes were cultured in GM-
CSF and IL-4 (100 ng/ml) for 7 days in the presence or absence of intestinal biopsy CM then 
RDH10 and DHRS9 expression was determined by real-time PCR; expression normalized to 
GAPDH using 2-ΔCt then expressed relative to unconditioned MoDCs; HC is healthy control 
(n=4), NI is non-inflamed (n=4), I is inflamed (n=4); ● = HC, ▲ = CD, ■ = UC, filled and 
empty shapes depict CM derived from colonic and ileal biopsies, respectively; bars indicate 
mean and median values for RDH10 and DHRS9, respectively.  
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As previously stated, expression of β7 was noted at a particular division to control for 
the effect of additional divisions boosting perceived levels. However, a high overall level 
of proliferation may indicate strong signalling through the T cell receptor which itself 
could influence α4β7 induction (Svensson et al., 2008). Indeed, a positive correlation 
was detected between the overall level of T cell proliferation and the relative expression 
of β7 at division 6 (Figure 6.18A). Whilst this correlation was highly statistically 
significant, the coefficient of correlation was low at 0.432, indicating a weak correlation. 
Systematic changes in the overall level of proliferation were not likely to have 
influenced the level of β7 induction however as no statistically significant differences 
were observed in proliferation levels across healthy, inflamed and non-inflamed IBD 
CM-treated MoDC T cell stimulations (Figure 6.18B). Overall therefore, human MoDCs 
generated in the presence of inflamed intestinal biopsy-derived CM display an 
increased ability to induce α4β7 expression on allogeneic CD4+ T cells compared with 
non-inflamed IBD biopsy-derived CM-treated MoDCs. This effect is RALDH-
independent, but the mechanism remains undefined. 
 
Figure 6.17: Expression of RARA is similar in CD4+ T 
cells stimulated by non-conditioned and CM-treated 
MoDCs. CFSE-labelled naive CD4+ T cells were co-cultured 
with non-conditioned MoDCs or MoDCs differentiated in the 
presence of a CM which had enhanced the ability of MoDCs 
to induce β7 by 2 fold in other experiments; proliferating 
CFSElo cells were sorted by flow cytometry and RARA 
expression was determined by real-time PCR relative to 
GAPDH by the 2-ΔCt method and normalized to expression in 
CD4+ T cells stimulated by non-conditioned MoDCs.  
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Figure 6.18: No system differences observed in the ability of CM-treated MoDCs to 
induce proliferation of naive CD4+ T cells. A: Relative β7 expression of CD4+ T cells at 
division 6 was correlated against the relative level of proliferation in the co-culture (% CFSElo 
cells in CM-MoDC-T cell co-cultures relative to %CFSElo cells in non-conditioned MoDC-T 
cell co-cultures); p-value derives from Spearman Rank Order Correlation. B: Relative level of 
CD4+ T cell proliferation following activation with CM-treated MoDCs, calculated as in A; HC 
is healthy control (n=10), NI is non-inflamed (n=12), I is inflamed (n=14); ● = HC, ▲ = CD, ■ 
= UC, filled and empty shapes depict CM derived from colonic and ileal biopsies, 
respectively; bars indicate mean values; p-value derives from a one way ANOVA.  
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6:5 Discussion 
This chapter aimed to understand how soluble mediators within human intestinal 
mucosa influence the RALDH activity of DCs. It was observed that such factors exerted 
negative regulation on RALDH activity and ALDH1A2 expression in MoDCs when 
included from the start of culture, and that this effect was apparent regardless of 
whether the original biopsies were derived from healthy control or IBD patients. These 
findings indicate that some DCs in the intestinal mucosa may operate in an 
environment where there is default suppression of GM-CSF-induced RALDH activity. 
Whether this suppression also applies to other populations of DC or other pathways of 
RALDH induction within the human intestine remains to be determined.  
The identity of one major source of negative RALDH regulation in intestinal biopsy-
derived CM was PGE2, which was identified by others during the course of this work as 
suppressive for DC RALDH activity in both mice and humans (Stock et al., 2011). 
Accordingly, CM-treated MoDCs grown in the presence of the PGE2 receptor 
antagonist AH6809 displayed at least partial restoration of Aldefluor activity, consistent 
with restored RALDH activity. AH6809 is a selective antagonist for EP1 and EP2 
receptors, whilst at higher concentrations (300 μM) can antagonise PGD2 and 
thromboxane (TBX) receptors (Jones et al., 2009, Keery and Lumley, 1988).  As neither 
PGD2, TBX nor the EP1-selective agonist (D1-004) suppress RALDH activity in human 
MoDCs (Stock et al., 2011), it is therefore likely that AH6809 restores RALDH activity in 
this system through antagonism of PGE2-EP2 interactions. Furthermore, inhibition of 
COX enzymes during MoDC differentiation with indomethacin had no restorative effect 
on RALDH activity, strongly suggesting that PGE2 derived from CM and not induction of 
PGE2 synthesis in MoDCs was responsible for this effect. It is unclear whether a 
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greater concentration of AH6809 would lead to further restoration of RALDH activity, or 
whether additional negative factors are present in CM. 
This inhibitory effect of CM and the role of PGE2 could be explored further by analysing 
ALDH1A expression by real-time PCR following AH6809-mediated restoration of 
Aldefluor activity in CM-treated MoDCs. In addition, the ability of these cells to convert 
retinal to RA could be analysed by HPLC MS/MS as used later in this Chapter. This 
would confirm that restored Aldefluor activity closely matches a restoration of RALDH 
activity. 
The inflamed intestinal mucosa of UC patients contains a higher concentration of PGE2 
than is found in the mucosa of healthy controls (Sharon et al., 1978, Carty et al., 2000). 
As noted earlier, COX-1 is constitutively expressed within the human intestinal 
epithelium, whilst COX-2 expression is induced in the epithelium in IBD in response to 
inflammatory mediators such as IL-1β, TNFα and LPS (Stenson, 2007). Furthermore, 
expression of microsomal PGE synthase-1 (mPGES-1), which specifically generates 
PGE2 from PGH2, is enhanced in inflamed colonic epithelium of both CD and UC 
patients (Subbaramaiah et al., 2004). This coincides with reduced expression of 15-
hydroxyprostaglandin dehydrogenase (15-PGDH), which metabolises PGE2 in IBD 
patients (Subbaramaiah et al., 2004). It would therefore be anticipated that if PGE2 is 
the principal agent of negative regulation of RALDH, there should be a greater degree 
of RALDH suppression in MoDCs by CM derived from inflamed IBD compared with 
healthy control biopsies. There are multiple possibilities as to why this is not the case. 
The RALDH activity of MoDCs may be particularly sensitive to suppression, in which 
case the system lacks the sensitivity to detect more subtle differences in PGE2 
concentration present in CM. There is evidence in mice of constitutive COX-2 
expression and production of PGE2 in small intestinal stromal cells (Newberry et al., 
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1999, Newberry et al., 2001) which is not influenced by a range of inflammatory stimuli 
including LPS, TNFα, IL-1β, IFNγ and IL-12. Assuming this is present in the human 
intestine, and alongside known constitutive COX-1 activity (Stenson, 2007), PGE2 in 
CM derived from healthy control biopsies may be sufficient to suppress a large 
proportion of MoDC RALDH activity. 
An alternative explanation may relate to the way in which CM is generated. PGE2 is 
known to mediate epithelial responses to injury, including the enhancement of epithelial 
proliferation (Stenson, 2007). COX enzyme activity may be induced in intestinal 
biopsies during the 6 hour culture period in which CM is generated, in response to 
detection of ‘epithelial injury’ associated with biopsy collection. This would boost the 
levels of PGE2 in the CM and may therefore mask background levels of PGE2 that are 
found within the intestinal mucosa across health and disease. This possibility could be 
addressed in future work by blocking PGE2 synthesis during the 6 hour culture period 
with the COX inhibitor indomethacin. This would prevent the generation of PGE2 in 
response to ‘epithelial injury’, allowing only background PGE2 to influence RALDH 
activity in MoDCs. This would provide an important insight into how PGE2 influences 
RALDH activity in human intestinal DCs in health and IBD. This work could be further 
developed by determining whether the PGE2 in CM is epithelial-derived. This could be 
done by generating CM from biopsies in which the epithelium has been removed by 
EDTA treatment and in parallel with biopsies in which the epithelium is intact. 
The proposed mechanism by which PGE2 suppresses RALDH activity in MoDCs is 
based on elevation of intracellular levels of cyclic adenosine monophosphate (cAMP) 
(Stock et al., 2011). This effect is mediated specifically by the E-prostanoid (EP)-2 
receptor, and stimulates inducible cAMP early repressor (ICER) which directly inhibits 
transcription of Aldh1a2. A direct effect on ALDH1A2 expression such as this would 
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operate independently of GM-CSF signalling which may explain why levels of p-STAT5 
were similar in MoDC cultures irrespective of exposure to CM. Stock et al. also 
demonstrated that MLN DCs in mice with high RALDH activity expressed very low 
levels of EP2, whereas DCs in the same site with low RALDH activity expressed far 
higher levels of EP2. This indicates that sensitivity to PGE2 via EP2 expression may be 
a key determinant of whether DCs are likely to respond to PGE2 in this way. This raises 
an important question of the extent to which MoDCs will behave like other intestinal DC 
populations, including CD103+ DCs, in response to these soluble mediators. It is 
interesting to note that the distribution of relative Aldefluor activities across MoDCs 
treated with healthy, non-inflamed and inflamed IBD CM resembles more closely the 
Aldefluor activities of ex vivo CD103- rather than CD103+ DCs derived from equivalent 
contexts as discussed in Chapter 4. It would be interesting to compare EP2 expression 
across the different human intestinal DC subsets to determine whether differences in 
the ability to respond to PGE2  could explain the distinct influence of inflammation on the 
RALDH activity of CD103+ and CD103- DCs. One hypothesis is that CD103+ DCs 
express lower EP2 levels and signals that promote RALDH activity in IBD encounter 
less resistance from PGE2 signalling. 
Beyond negative regulation of RALDH activity in CM-treated MoDCs, PGE2 may have 
also contributed to the modified surface phenotype of these cells. The retention of 
CD14 expression and the failure to upregulate CD1a is consistent with effects observed 
with PGE2 treatment elsewhere (Kalinski et al., 1997). This altered differentiation could 
be interpreted as a failure of monocytes to differentiate. However, CM-treated MoDCs 
displayed no defect in their ability to induce T cell proliferation which suggests that key 
DC properties remain intact. This is also consistent with PGE2-treated MoDCs (Kalinski 
et al., 1997).  The significantly increased retention of CD14 and failure to upregulate 
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CD1a in inflamed CM compared with non-inflamed and healthy control CM-treated 
MoDCs is also consistent with a greater concentration of PGE2 present in the CM. This 
would support the argument that the RALDH activity of MoDCs is too sensitive to 
suppression to detect subtle increases in PGE2 concentration, whereas CD14 
expression for instance is not. It would therefore be informative to analyse the surface 
phenotype of MoDCs grown in the presence of intestinal biopsy-derived CM in the 
presence or absence of AH6809. 
Beyond PGE2, other factors potentially present in CM have been shown to influence 
MoDC differentiation in a similar manner.  Inclusion of TLR ligands including LPS, 
which is likely to be present in CM, during MoDC differentiation leads to retention of 
CD14 and failure to upregulate CD1a (Bartz et al., 2006). The proposed mechanism is 
an upregulation of suppressor of cytokine signalling (SOCS)-1 and -3, which 
suppresses the ability of GM-CSF to signal through p-STAT5. There are a few key 
differences to note here however. MoDCs differentiated in the presence of LPS are 
poor activators of allogeneic naive CD4+ T cells compared with untreated MoDCs (Bartz 
et al., 2006). In contrast, CM-treated MoDCs displayed no defect in their ability to 
induce T cell proliferation; with a 1.3 fold mean increase over proliferation induced by 
non-conditioned MoDCs. The ability of CM-treated MoDCs to stimulate naive CD4+ T 
cells is consistent with differentiation into a viable MoDC phenotype. Furthermore, in a 
preliminary experiment there was very little difference observed in the MFI of p-STAT5 
in CM-treated and non-conditioned MoDCs. This suggests that whilst the overall 
CD14+CD1a- phenotype appears to be similar, inhibition of GM-CSF signalling by early 
induction of SOCS1 or SOCS3 is not responsible here. 
The upregulation of CD1a occurs throughout MoDC differentiation, and may be blocked 
at any point by addition of an inflammatory cytokine cocktail (Gogolak et al., 2007). This 
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cocktail includes PGE2 alongside TNFα, IL-1β, IL-6. The relative contributions of each 
cytokine to this overall effect is however unclear. Intestinal biopsy-derived CM are likely 
to contain a wide range of mediators beyond PGE2, and so further experiments are 
required to determine whether PGE2 is the primary mediator of modified CD14/CD1a 
expression by CM-treated MoDCs. This would include determining if AH6809 can at 
least partially restore a ‘non-conditioned’ MoDC phenotype to these cells, as observed 
with RALDH activity. Importantly, MoDCs differentiated in the presence of intestinal 
biopsy-derived CM and neutralising antibodies to TNFα or IL-6 displayed severely 
reduced cell viability, precluding this approach as a means of identifying a role for these 
cytokines in the suppression of RALDH activity in MoDCs. This suggests that low levels 
of these cytokines are required for the survival and differentiation of MoDCs in vitro. 
MoDCs grown in the presence of inflamed IBD intestinal biopsy-derived CM possessed 
a significantly enhanced ability to imprint naive CD4+ T cells with α4β7 expression as 
compared with the ability of non-inflamed IBD CM-treated MoDCs to induce α4β7. This 
would be predicted to lead in vivo to an increased proportion of CD4+ T cells with a ‘gut-
homing’ phenotype when activated by DCs migrating into lymphoid tissue from inflamed 
mucosal areas. This would produce superior interactions between α4β7 and endothelial 
MAdCAM-1 throughout the gastrointestinal tract, and would in turn bias intestinal T cell 
populations in favour of antigen specificities associated with the inflamed mucosa. This 
process could be associated with the dissemination of inflammation to distinct sites in 
the intestinal mucosa. CD103+ DCs sorted from MLNs draining the inflamed TI of CD 
patients induce similar levels of α4β7 and CCR9 expression on naive CD8+ T cells as 
compared with those derived from healthy controls (Jaensson et al., 2008). However 
this work did not address how DC subsets migrating from the inflamed and non-
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inflamed intestinal mucosa may differ in their ability to induce these ‘gut-homing’ 
markers.  
 The mechanism of enhanced induction of α4β7 on CD4+ T cells by inflamed compared 
with non-inflamed IBD CM-treated MoDCs is independent of effects on RALDH activity, 
but ultimately remains undefined. Irrespective of the underlying mechanism, this finding 
is important as it may suggest that factors within the inflamed human intestinal mucosa 
influence the ability of DCs to induce RA signalling in T cells during activation, with or 
without the presence of additional RA. The loss of RALDH activity in MoDCs following 
differentiation in the presence of intestinal biopsy CM and the maintained ability to 
induce α4β7 on CD4+ T cells implies that despite ALDH1A expression and the presence 
of RALDH activity (Chapter 3), non-conditioned MoDCs do not produce sufficient RA to 
influence α4β7 expression. Indeed, RA was only detectable in the supernatant of non-
conditioned MoDCs following the addition of exogenous retinal suggesting that the 
availability of RALDH substrate may be limiting for RA generation. Supernatant of CM-
treated MoDCs cultured in the presence of exogenous retinal contained a significantly 
reduced concentration of RA, consistent with suppression of RALDH activity. Induction 
of α4β7 on CD4+ T activated by MoDC was nonetheless dependent upon RA, most likely 
derived from the cell culture serum. Indeed, anti-CD2/CD3/CD28 bead-activated CD4+ 
T cells also upregulated α4β7 and this effect was inhibited in the presence of Ro41-
5253. It has been estimated that approximately 0.2 – 0.5 nM (0.2 – 0.5 pmoles/ml) RA 
is present in complete medium containing 10 % FCS (Kang et al., 2011). In the 
experiments reported in this study, no CM contained more than 0.01 pmoles/ml RA (the 
limit of detection) but it should be noted that  RA is unstable (Napoli, 2012) and so may 
be degraded during CM generation. Addition of exogenous RA to T cell stimulation 
cultures did lead to further increases in α4β7, confirming the potential for further integrin 
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expression when concentrations of the retinoid are increased. Ideally, CM-MoDC and 
naive CD4+ T cell co-cultures should be carried out in serum-free medium to remove 
the RA contribution from serum. However, this was not possible as naive CD4+ T cells 
proliferated poorly where these co-cultures were attempted. 
The oxidation of retinol to retinal is rate limiting in the production of RA in the presence 
of CRBP-I (reviewed by Napoli, 2012). This step may therefore provide a key control 
point in the output of RA by MoDCs (Napoli, 1986). Indeed, RA generation by MoDCs 
was only detectable when the cultures were supplemented with exogenous retinal. 
Expression by MoDCs of a number of enzymes capable of oxidising retinal to retinal 
was confirmed. The expression of RDH10 by MoDCs was suppressed by all CM tested, 
indicating similar regulation of transcription as ALDH1A2 which may be mediated by 
PGE2 directly. In contrast, DHRS9 expression was more varied following CM treatment, 
with some CM-treated MoDCs displaying enhanced expression of DHRS9 compared 
with non-conditioned MoDCs. This could indicate a differential relationship between 
DHRS9 expression and PGE2 as compared with RDH10 or ALDH1A2. It was observed 
in two samples in Chapter 4 that RDH10 expression was enhanced in human intestinal 
CD103+ compared with CD103- DCs. This could enhance the ability of CD103+ DCs to 
produce RA through enhanced production of retinal. A similar system may therefore 
operate in CM-treated MoDCs in relation to expression of DHRS9. If the rate of retinal 
oxidation is faster than retinol oxidation, then reduced RALDH activity of CM-treated 
MoDCs would not significantly reduce overall RA output as this will be closely 
associated with the rate of retinol oxidation. Detailed kinetic analysis of RDH10 and 
DHRS9 activities are not currently available. This information will illustrate the potential 
contributions of these enzymes to the generation of RA in this system. Furthermore, it 
is important to note that post-transcriptional regulation could play a key role in 
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determining the activities of these enzymes. Collectively these data suggest that further 
investigation of the role played by regulation of retinal generation in the generation of 
RA by immune cells is merited. Future work could assess the influence of modified 
DHRS9 expression on the output of RA by CM-treated MoDCs by culturing cells with 
known differences in DHRS9 expression in the presence of varying concentrations of 
retinol and analysing RA in the culture supernatants. This could be developed by 
analysing the output of RA following knock-down of DHRS9 expression by MoDCs by 
siRNA treatment. 
 ‘Walk out’ cells derived from colonic biopsies displayed a significantly increased ability 
to induce α4β7 expression on CD4+ T cells compared with non-conditioned MoDCs. 
Interestingly, neither walk out cells nor MoDCs could induce CCR9 expression on CD4+ 
T cells however, indicating that additional factors are required for the induction of this 
chemokine receptor. The addition of exogenous RA during CD4+ T cell activation also 
did not result in CCR9 expression (data not shown), suggesting that additional factors 
may be required. In mice, transient TCR stimulation is required in addition to high levels 
of RA for efficient CCR9 induction on CD4+ and CD8+ T cells (Ohoka et al., 2011). It is 
possible that walk out cultures did not meet these TCR stimulation criteria. 
Alternatively, CCR9 induction is more commonly observed in murine CD8+ as opposed 
to CD4+ T cells (Svensson et al., 2002), and induction of CCR9 by human intestinal 
CD103+ DCs in CD patients focussed only on CD8+ T cells (Jaensson et al., 2008). The 
inability of ‘walk out’ cells to induce CCR9 on CD4+ T cells may therefore be related to 
the nature of the T cell itself. Moreover, CCR9 is associated with homing to the small 
intestinal mucosa and epithelium (reviewed by Agace, 2006, Sigmundsdottir and 
Butcher, 2008), and so ‘walk out’ cells derived from the proximal small intestine may 
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display an ability to induce CCR9 expression on CD4+ and CD8+ T cells by delivery 
additional signal that are currently undefined. 
It was recently determined that RA-mediated induction of α4β7 and CCR9 induction in 
mice requires additional transcription factors such as basic leucine zipper transcription 
factor, ATF-like (BATF) that direct acetylation of histones and binding of RARα to gene 
promoters (Wang et al., 2013). A distinct possibility is therefore that inflamed and non-
inflamed IBD CM-treated MoDCs influence expression of such accessory factors that 
influence the overall level of RARα signalling and induction of α4β7. The mechanisms by 
which DC could influence T cell expression of these transcription factors are currently 
unknown. Preliminary data in this chapter also suggested that this effect is not 
mediated through modification of RARA expression. However, this does not rule out a 
role for differential post-transcriptional regulation of RARα in proliferating T cells. 
Human MoDCs express high levels of RARA mRNA with low levels of RARα protein 
relative to CD14+ monocytes (Fritsche et al., 2000). Inflamed biopsy CM-treated 
MoDCs could potentially induce a greater level of RARα protein in allogeneic CD4+ T 
cells than their non-inflamed CM-treated MoDC counterparts. 
The presence of detectable RA in IBD but not healthy biopsy-derived CM does not 
explain differences in α4β7 induction by CM-treated MoDCs. It is however interesting in 
the light of fact that no differences were detected in RA concentration of intestinal 
biopsies derived from healthy control and IBD patients in Chapter 4. This may indicate 
that RA is generated by cells within biopsies during the 6 hour culture period, and to a 
greater extent in those derived from IBD patients. This may relate to a modified 
damage response in IBD, and could further implicate RA in intestinal homeostasis. 
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6:6 Conclusion 
In conclusion, this Chapter has demonstrated that differentiation of human MoDCs in 
the presence of conditioned medium generated using intestinal biopsies from healthy 
control patients does not recapitulate the slightly enhanced RALDH activity of human 
intestinal CD103+ DCs or significantly enhanced RALDH activity of CD14+ MФ as 
observed in Chapter 4. However, it reveals a novel mechanism where soluble factors in 
the inflamed intestinal mucosa of IBD patients confer upon MoDCs an enhanced ability 
to imprint CD4+ T cells with α4β7 expression as compared with factors derived from the 
non-inflamed mucosa of IBD patients. This is independent of MoDC RALDH activity, as 
CM from all patient groups suppressed RALDH activity which was partially mediated by 
PGE2. The enhanced ability of inflamed IBD CM-treated MoDCs to imprint naive CD4+ 
T cells with α4β7 suggests a novel pathway in the pathogenesis of IBD whereby APCs 
in the inflamed mucosa have an increased ability to imprint a ‘gut-homing’ phenotype 
on responding T cells. This may lead to an increased proportion of the intestinal T cell 
pool with antigen-specificities biased towards inflamed intestinal mucosa-associated 
antigen. Lymphocyte migration into the intestinal mucosa is an active area of 
development in the treatment of IBD (Villablanca et al., 2011a). Understanding how 
inflammation influences the induction of lymphocyte gut homing by intestinal DCs may 
provide further insight into the pathogenesis of disease. 
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Chapter 7:  Final discussion and future work 
The work presented in this thesis aimed to identify APC subsets capable of RA 
generation in the distal human intestine, determine whether this production is altered in 
patients with IBD, and identify how such change might contribute to disease 
pathogenesis.  
The overall picture that emerges from this work is that human CD103+ DCs within distal 
intestinal mucosa have RALDH activity in the steady state associated with ALDH1A2 
expression, and that this activity may be slightly increased during chronic intestinal 
inflammation in CD and UC patients. RALDH activity is also increased in CD103+ DCs 
in macroscopically non-inflamed intestinal mucosa of active IBD patients, which 
suggests that this increase may occur prior to the onset of overt inflammation or 
perhaps that this activity could locally restrain inflammatory processes. Whilst the 
immunological basis of IBD remains incompletely understood, the hypothesis that loss 
of RALDH activity in human intestinal CD103+ DCs is involved in the pathogenesis of 
IBD is not supported by these data.  
Beyond human intestinal CD103+ DCs, CD103- DCs and CD14+ MФ also display 
RALDH activity. CD14+ MФ within both the macroscopically inflamed and non-inflamed 
intestinal mucosa of active IBD patients display profoundly increased levels of RALDH 
activity which is associated with increased expression of ALDH1A1. The intestinal 
CD14+ MФ phenotype with elevated RALDH activity may be recapitulated by culturing 
CD14+ monocytes from healthy controls in GM-CSF. Such CD14+ MФ rapidly generate 
TNFα in response to LPS stimulation in vitro, and so reflect the proposed pro-
inflammatory nature of intestinal CD14+ MФ (Kamada et al., 2009). Blocking RARα 
signalling during this differentiation process fundamentally alters the MФ phenotype, 
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with loss of surface CD14, reduced RALDH activity and ALDH1A1 expression, and 
reduced ability to produce TNFα following LPS stimulation. ALDH1A1-associated 
RALDH activity was also observed in blood CD14+ monocytes from both healthy 
controls and IBD patients. Taken together, this data supports a model whereby blood 
CD14+ monocytes enter the intestinal mucosa with RALDH activity which, in patients 
with active IBD, is then selectively upregulated within the mucosa as part of a 
differentiation process that generates pro-inflammatory CD14+ MФ (see Figure 7.1). An 
alternative interpretation is that in IBD there is selective recruitment of blood CD14+ 
monocytes with greater levels of RALDH activity, leading to an overall increase in the 
proportion of intestinal CD14+ MФ with this activity. It would therefore be of interest to 
determine the chemokine receptor (e.g. CCR2) expression of CD14+ blood monocytes 
with varying levels of RALDH activity in future experiments, to determine whether 
RALDH activity associates with increased migratory capacity. Within the intestinal 
mucosa, CD14+ MФ may then contribute to the pathogenesis of IBD through production 
of a range of pro-inflammatory cytokines including TNFα and IL-23 in response to 
microbial stimulation (Kamada et al., 2008). At present, it is unknown if the elevated 
RALDH activity of intestinal CD14+ MФ generates sufficient RA to influence cell 
differentiation, or if this RALDH activity is the consequence of a process which is 
generating inflammatory CD14+ MФ in IBD and which is also dependent on RARα 
signalling. Further experiments are required to distinguish these possibilities, in 
particular the differentiation of blood CD14+ monocytes in the presence of DEAB to 
inhibit RALDH activity throughout GM-CSF-mediated differentiation in vitro. 
Alternatively, ALDH1A1 expression could be suppressed by siRNA to specifically limit 
the influence of this RA-generating enzyme. 
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The preliminary analysis in this thesis indicates that the overall levels of RA are not 
significantly different in the mucosa of CD patients, which suggests that changes in 
RALDH activity within APC populations are not sufficient to affect the overall levels of 
RA present within the mucosa. However, the RALDH activity of stromal and epithelial 
cells is slightly reduced in IBD, consistent with reduced ALDH1A1 expression in CD 
epithelial cells (Iliev et al., 2009). This may indicate that varying levels of RALDH 
activity in different cell compartments maintain an overall homeostasis of RA levels. 
This does not however rule out significant local variations in RA production and 
signalling at the cellular level. RA is regarded as an important morphogen capable of 
diffusing through tissues and influencing gene expression in a concentration-dependent 
Figure 7.1: Proposed role of RALDH activity in promoting differentiation of human 
CD14+ monocytes into CD14+ MФ in IBD. Circulating blood CD14+ monocytes have low 
levels of RALDH activity. Upon entering the intestinal mucosa in healthy controls (upper 
panel), RALDH activity remains basal and monocytes differentiate into the resident intestinal 
CD14-/lo MФ phenotype. In contrast, CD14+ monocytes enter the intestinal mucosa of IBD 
patients (lower panel) and upregulate RALDH activity. RARα signalling promotes retention of 
CD14 expression and differentiation into a pro-inflammatory CD14+ MФ phenotype. 
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manner (reviewed by Niederreither and Dolle, 2008). Thus local RA concentration in a 
particular microanatomical location may be more relevant than overall tissue levels. 
The data presented in Chapters 3 and 6 demonstrate that the Aldefluor assay provides 
a clear indication of the level of RALDH activity present within human DCs. However, it 
is also apparent that the loss of RALDH activity associated with differentiation of 
MoDCs in the presence of human intestinal biopsy-derived conditioned medium does 
not reduce the ability of these cells to induce RARα-dependent expression of α4β7 by 
allogeneic CD4+ T cells. Therefore, the presence of RALDH activity alone is not 
necessarily sufficient to generate high enough levels of RA to influence neighbouring 
cells. For this reason, care is required when interpreting the presence of RALDH 
activity in cells. The overall output of RA may be determined by the ability of cells to 
generate retinal from retinol by the activity of microsomal retinol dehydrogenase 
enzymes including RDH10. Whilst the expression of such enzymes may be confirmed 
by real-time PCR and protein analysis, an equivalent Aldefluor assay that directly 
monitors the ability of cells to oxidise retinol to retinal is not currently available. A further 
important consideration is the ability of cells to oxidise RA to inactive metabolites 
through the activity of CYP26 enzymes. In development, spatial and temporal 
regulation of CYP26 enzymes controls RA responsiveness (Hernandez et al., 2007) . A 
study published late in the preparation of this thesis identified a weak association 
between a polymorphism in CYP26B1 and CD, possibly leading to reduced RA 
catabolism and therefore increased RA signalling (Fransén et al., 2013). The overall 
output of RA is therefore likely to involve a complex range of factors, of which RALDH 
activity is only one component.    
The trend towards increased RALDH activity in human intestinal CD103+ DCs contrasts 
with data from the TNFΔARE and T cell transfer models of colitis in which RALDH 
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activity of MLN CD103+ DCs is reduced during inflammation (Laffont et al., 2010, 
Collins et al., 2011). This may result from the fact that tissue used in this project derived 
predominantly from the distal human intestine, i.e. the colon and TI, whilst MLN CD103+ 
DCs are likely to have drained from the SI mucosa where CD103+ DCs display the 
greatest levels of RALDH activity (Villablanca et al., 2011b, Schulz et al., 2009).  
CD103+ DCs within proximal human intestine e.g. the jejunum may display greater 
levels of RALDH activity which may play a role in diseases such as Coeliac disease 
which affect the small intestinal mucosa (reviewed by Marsh, 1992). However, CD103+ 
DCs in the inflamed TI mucosa of TNFΔARE mice also express significantly reduced 
levels of Aldh1a2 compared with WT mice (Collins et al., 2011), suggesting that if the 
loss of RALDH activity in mice and humans in intestinal DCs during inflammation was 
shared between species, loss of RALDH activity should have been apparent in the 
present study. Whilst the need to group TI and colonic samples due to the low number 
of samples available during the study is a clear limitation, there is little difference in the 
RALDH activity of murine colonic and TI DCs (Villablanca et al., 2011b). As discussed 
above however, it is important to note that RALDH activity alone may not completely 
determine the overall RA output and so a range of additional factors including retinol 
oxidation and RA metabolism need to be considered in future work. A report published 
late during the preparation of this thesis identified increased Aldefluor activity in CD11c+ 
cells in the colonic mucosa of DSS-treated mice (Mielke et al., 2013). As the CD11c+ 
compartment is likely to contain both DCs and MФ populations, this supports the 
conclusion that RALDH activity in murine intestinal APCs is enhanced under certain 
inflammatory conditions, as in the present study. 
Beyond a potential role in the differentiation of CD14+ MФ within the intestinal mucosa 
of IBD patients, the effect of increased RA production by CD14+ MФ on neighbouring 
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cells and how this might affect disease pathogenesis remains unclear. It may exert 
protective roles including stimulation of local γδ T cells and innate lymphoid cells to 
produce IL-22 as observed in mice (Mielke et al., 2013). IL-22 induces production of  
the antimicrobial peptides RegIIIγ and RegIIIβ in murine colonic epithelial cells during 
acute bacterial infection (Zheng et al., 2008), and plays a key role in STAT3-mediated 
epithelial wound healing during DSS colitis (Pickert et al., 2009).  IL-22 is not detectable 
in the steady state human intestinal mucosa, but is observed in UC and at greater 
levels of CD patients (Andoh et al., 2005). Such a protective role for RA generation may 
be consistent with the presence of enhanced RALDH activity in CD14+ MФ in the non-
inflamed intestinal mucosa of active IBD patients. This may be part of a process in 
which inflammation is being actively restrained within these mucosal areas. The extent 
to which the macroscopically non-inflamed mucosa of such patients matches that of 
patients in remission is unclear, and it would be of interest to compare the RALDH 
activity of CD14+ MФ in these different tissues. RA produced by CD14+ MФ may also 
exert different functions in non-inflamed and inflamed tissue, depending on the 
presence of additional cytokines. This is observed in mice where RA in the presence of 
IL-15 supports IL-12p70 production by intestinal DCs and reduces their ability to induce 
Foxp3+ TREG (DePaolo et al., 2011). 
The model described above proposes that the failure of blood CD14+ monocytes 
entering the steady state intestinal mucosa to upregulate RALDH activity leads to 
differentiation into CD14- resident MФ. Currently, human intestinal resident MФ are 
identified as CD14- (Smythies et al., 2005) or alternatively CD14lo (Bain et al., 2013), 
depending on techniques used to isolate and identify these cells. Understanding the 
role of RALDH activity in the differentiation of blood CD14+ monocytes into different MФ 
phenotypes will require a better mechanistic understanding of this process. 
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Furthermore, the in vitro system of CD14+ MФ differentiation outlined in Chapter 5 is 
limited in that it is removed from the physiological setting. These issues may be 
addressed by the development of a new model system in which cell trace (e.g. CFSE) 
labelled blood CD14+ monocytes are cultured in the presence of autologous intestinal 
biopsy-derived LPCs from healthy controls and IBD patients. This would allow the 
differentiation of these cells to be monitored in a more physiological setting over several 
days, as well as identifying the point at which RALDH activity becomes upregulated 
during this process. The influence of factors such as GM-CSF and RA signalling on this 
differentiation process could therefore be monitored with the use of specific monoclonal 
antibodies and inhibitors.  
Ly6Chi monocytes entering acutely inflamed intestinal mucosa during Toxoplasmosis 
gondii infection of mice produce PGE2 which suppresses neutrophil activation and 
therefore prevents excessive tissue damage (Grainger et al., 2013). Human blood 
CD14+ monocytes also produce PGE2 following stimulation with LPS (Grainger et al., 
2013). It is likely therefore that human blood CD14+ monocytes entering the intestinal 
mucosa possess the ability to generate PGE2. Whether CD14+ MФ continue to produce 
PGE2 in IBD and how this influences neighbouring cells including neutrophils remains 
to be determined. PGE2 suppresses RALDH activity of human MoDCs through 
suppression of ALDH1A2 expression (Stock et al., 2011). As observed in Chapter 6, 
PGE2 is an important factor in the suppression of ALDH1A2-associated RALDH activity 
in human MoDCs by intestinal biopsy-conditioned medium. Whether the elevation of 
RALDH activity in human intestinal CD14+ MФ in IBD is related to alterations in PGE2 
production or signalling by these cells within the diseased mucosa remains to be 
determined. 
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The mechanism behind the increased ability of human MoDCs grown in the presence 
of inflamed intestinal biopsy-conditioned medium to induce α4β7 on proliferating CD4+ T 
cells remains undefined. It is possible that this effect is mediated by unknown factors 
acting in synergy with RA. If DCs within inflamed intestinal mucosa are able to imprint 
an increased level of α4β7 this may result in a population of effector T cells specific for 
antigen associated with the inflamed intestinal mucosa with a selective advantage in 
their ability to home into the gut mucosa through interaction with endothelial MAdCAM-
1. Identifying factors acting in synergy with RA to induce α4β7 in the context of intestinal 
inflammation may provide an additional therapeutic target by which the imprinting of T 
cells with inflammatory potential is selectively inhibited, whilst that of other T cells 
associated with antigen derived from non-inflamed areas may remain unaffected. 
Understanding phenotype differences between blood CD14+ monocytes in healthy 
controls and IBD patients is likely to be a key area for future research. In particular, 
monocyte-derived MФ in CD produce significantly reduced levels of pro-inflammatory 
cytokines in response to microbial stimulation in CD patients (Smith et al., 2009, Sewell 
et al., 2012), which may result in defective innate clearance of encroaching bacteria 
within the intestinal mucosa. The present study identified significantly increased 
expression of the oncogene MN1 in blood CD14+ monocytes in IBD patients compared 
with healthy controls. The differentiation of human CD34+ bone marrow HSCs to either 
CD14+ monocytes or CD15+ granulocytes associates with a significant downregulation 
of MN1 (Kandilci and Grosveld, 2009). This indicates that monocytes circulate in IBD in 
a more immature state of differentiation, potentially through modulations in the 
haematopoiesis program within the bone marrow in response to inflammatory signals 
as observed in mice (reviewed by (King and Goodell, 2011). Consistent with this view, it 
is well established that inflammation associates with increased production and release 
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of immature monocytes from the bone marrow into circulation in humans (Meuret et al., 
1974). Moreover, the T cell transfer model of colitis associates with a significant 
expansion in the number of granulocyte/macrophage progenitors (GMPs) in the bone 
marrow, spleen, and also within the inflamed colonic mucosa (Griseri et al., 2012), 
consistent with peripheral circulation of immature progenitor cell populations. Forced 
expression of MN1 in primary human HSCs inhibits differentiation into monocytes and 
granulocytes in vitro (Kandilci and Grosveld, 2009). Following confirmation of the 
overexpression of MN1 in blood CD14+ monocytes in IBD patients in a larger study, it 
will be of interest to determine the effect of suppressing MN1 through siRNA on the 
ability of monocytes to produce pro-inflammatory cytokines in response to microbial 
stimulation. This could also be applied to monocytes used in the ex vivo intestinal 
differentiation model outlined above to determine if it leads to modified induction of 
RALDH activity and differentiation into distinct MФ subsets. Finally, it would be of 
interest to determine whether MN1 expression is modified in blood CD14+ monocytes of 
first degree relatives of IBD patients which possess an ‘at risk’ phenotype for 
developing disease (reviewed by Hedin et al., 2012). This may help to determine 
whether alterations in haematopoiesis predispose patients to the onset of disease, and 
whether these changes are an important early component of disease pathogenesis. 
Overall, this thesis has demonstrated that the loss of RALDH activity of CD103+ DCs in 
IBD is unlikely to contribute to the pathogenesis of IBD. However, it implicates RALDH 
in the differentiation of CD14+ MФ in the intestinal mucosa of IBD patients. Modulating 
this differentiation so as to favour the non-inflammatory resident MФ phenotype may 
provide a novel therapeutic approach in the treatment of IBD. 
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Appendix:  Summary patient data 
Chapter 4 
 
HC (%) CD (%) UC (%) 
Number of subjects 32 34 7 
Male 21 (66) 18 (53) 3 (43) 
Female 11 (34) 16 (47) 4 (57) 
Average age (years) 57.6 25.9 38.3 
    Tissue samples 32 40 8 
Colon 31 (96.9) 31 (78) 7 (88) 
TI 1 (3.1) 9 (22) 1 (12) 
    Active disease 
   Number of subjects 
 
27 4 
Number of samples 
 
33 5 
Colon (inflamed) 
 
17 4 
Colon (non-inflamed) 
 
7 0 
TI (inflamed) 
 
6 0 
TI (non-inflamed) 
 
3 1 
    Inactive disease 
   Number of subjects 
 
7 3 
Number of samples 
 
7 3 
Colon 
 
7 3 
TI 
 
0 0 
    Medication 
   AZA N.D. 14 (41) 1 (14) 
Anti TNFα N.D. 9 (26) 0 (0) 
MTX N.D. 2 (6) 1 (14) 
5-asa N.D. 4 (12) 2 (29) 
Steroids N.D. 7 (21) 2 (29) 
6-MP N.D. 4 (12) 0 (0) 
 
Several IBD patients were receiving combination therapies at the time of tissue 
collection. N.D. = no data, AZA = azathioprine, anti-TNFα includes both infliximab and 
adalimumab, MTX = methotrexate, 5-asa = 5 aminosalicylic acid (mesalazine), 6-MP = 
6 mercaptopurine. 
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Chapter 5 
 
HC (%) CD (%) UC (%) 
Number of subjects 7 10 4 
Male 4 (57) 4 (40) 1 
Female 3 (43) 6 (60) 3 
Average age (years) 31.4 20.9 
 
    Active disease 
   Number of samples 
 
6 3 
    Inactive disease 
   Number of samples 
 
4 1 
    Medication 
   AZA 
 
8 (80) 3 (75) 
Anti TNFα 
 
3 (30) 0 (0) 
MTX 
 
0 (0) 1 (25) 
5-asa 
 
1 (10) 1 (25) 
Steroids 
 
0 (0) 0 (0) 
6-MP 
 
0 (0) 0 (0) 
 
Samples used in Chapter 5 were exclusively for the analysis of blood CD14+ 
monocytes.  
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Chapter 6 
 
HC (%) CD (%) UC (%) 
Number of subjects 10 10 7 
Male 8 (80) 7 (70) 4 (57) 
Female 2 (20) 3 (30) 3 (43) 
Average age (years) 52.9 30.4 31.0 
    Tissue samples 12 16 9 
Colon 10 (83) 13 (81) 8 (89) 
TI 2 (17) 3 (19) 1 (11) 
    Active disease 
   Number of subjects 
 
9 5 
Number of samples 
 
15 7 
Colon (inflamed) 
 
7 5 
Colon (non-inflamed) 
 
5 1 
TI (inflamed) 
 
2 0 
TI (non-inflamed) 
 
1 1 
    Inactive disease 
   Number of subjects 
 
1 2 
Number of samples 
 
1 2 
Colon 
 
1 2 
TI 
 
0 0 
    Medication 
   AZA 
 
2 (20) 3 (43) 
Anti TNFα 
 
1 (10) 1 (14) 
MTX 
 
0 (0) 0 (0) 
5-asa 
 
1 (10) 5 (71) 
Steroids 
 
3 (30) 2 (29) 
6-MP 
 
0 (0) 0 (0) 
 
 
 
